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Bryostatin 1 is a complex natural product isolated from the marine bryozon 
Bugula neritina by Pettit and coworkers whose structure was reported in 1982. This 
highly oxygenated macrolide has complex and unprecedented architectural features. In 
addition, bryostatin 1 has exhibited a remarkable biological profile including anticancer 
activity, synergetic effect with other anticancer agents, reversal of multidrug resistance, 
stimulation of the immune system, improvement of learning and memory, 
neuroprotection after stroke, reduction of amyloid plaque formation, and activity against 
HIV. The anticancer activity of bryostatin 1 has resulted in some 80 phase I and II 
clinical trials and a clinical trial against Alzheimer’s disease is underway. 
 Despite having potential as a therapeutic drug, the availability of bryosatin 1 from 
natural as well as other sources is extremely limited. Synthesis of simplified analogues of 
bryostatin 1 provides an alternative way to solve the supply problem. With an aim of 
practical synthesis of simplified bryostatin 1 analogues, our group started the study of 
structure activity relationship of bryostatin 1 using a newly discovered pyran annulation 
methodology. 
The work presented in this dissertation focuses on the synthesis, computational 
study and biological evaluation of bryostatin 1 analogues modified in the A and B ring 
region. Specifically, the role of three substituents in the A and B ring region has been  
iv 
 
investigated by synthesizing C30-decarbomethoxy bryostatin 1, C9-deoxy bryostatin 1 and 
a C8-gemdimethyl analogue. This study suggested that these three groups do not by 
themselves serve as functional switches between the PMA versus bryostatin 1 like 
activity of bryostatin analogues. Moreover, analogues with more polar groups in the A, B 
ring region tend to behave like bryostatin 1 as opposed to PMA and vice versa.  
 In addition to bryostatin analogues, the first total synthesis of bryostatin 1 was 
accomplished in 30 steps for longest linear sequence from commercially available 
starting material. The synthesis involved a highly convergent union of fully 
functionalized A and C rings by pyran annulation. The route developed to bryostatin 1 is 
also applicable for the synthesis of bryostatin 7, bryostatin 9 and bryostatin 15 as well as 
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In 1968, Pettit and coworkers detected that the extracts of marine bryozoans 
Bugula neritina had anticancer properties towards murine P388 lymphocytic leukemia 
cells.
1
 After a large scale collection of the organism from the Gulf of Mexico and a 
bioassay guided fractionation of the animal extract, the active agent was identified as 
bryostatin 1, whose chemical structure was determined in 1982.
2
 
The bryozoan Bugula neritina is a filter feeder animal which forms mosslike 
colonies and is known to attach to ship hulls. Although bryostatin 1 was initially thought 
to be derived from Bugula neritina, it has been recently proposed that the symbiotic 
bacterium Endobugula sertula is the true source of the bryostatins.
3
 The study revealed 
that bryostatins were highly concentrated on the larvae and are believed to act as an 
antifeedant providing chemical defense for the larvae of Bugula neritina against 
predation. On the other hand, the larvae of the Bugula neritiana provide a suitable 
medium for the growth of the bacteria.
4
 Since the original isolation of bryostatin 1, 
nineteen other structurally related members have been isolated and characterized (Figure 
1.1).
5
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of a twenty-membered macrolactone with eleven stereocenters and three embedded pyran 
rings, also known as the A-, B- and C-rings. The A- and C-rings of most bryostatins 
contain a hemiketal moiety whereas the B- and C-rings have an exocyclic ,-
unsaturated methyl esters. While all bryostatins have a gem-dimethyl group at C8 and C18 
positions, most of the bryostatins differ from each other at the C7 and C20 positions on the 
A- and C-rings, respectively. Except bryostatin 2, which has a free hydroxyl group at the 
C7 position, all the bryostatins have esters at the C7 position. Similarly, most of the 
bryostatins also have an ester at the C20 position except bryostatins 10, 11, 18 and 20, 
which have no substituents at C7 position. Some members of the family such as 
bryostatin 3, 19 and 20 have a more functionalized C-ring characterized by the presence 
of a five membered lactone fused with the pyran ring.  Bryostatins 16 and 17, on the 
other hand, have less functionalized C-rings in which C19 and C20 functionality has been 
replaced with a glycal moiety. An additional variation is that the exocyclic methyl enoate 
in C-ring of bryostatins 17 and 18 have E geometry whereas all other bryostatins have Z 
geometry. Structurally different from the bryostatins, neristatin is another member of the 
family, which has a rearranged/oxidixed C-ring.
5 
Among all bryostatins, bryostatin 1 is 
the most abundant in nature and the most studied member of the family. 
 
The Biological Activity of Bryostatins 
Since the first detection of its ability to inhibit the growth of the murine P388 
lymphocytic leukemia cells, a number of studies have been carried out using bryostatin 1 
as an anticancer agent. It has been found from these studies that bryostatin 1 is a highly 
potent anticancer agent that inhibits the growth of various human cancer cell lines at 
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remarkably low concentrations. As a result, bryostatin is in roughly 80 phase I and II 
human clinical trials as an anticancer chemotherapeutic agent.
 
Data from the clinical trials 
have verified that bryostatin 1 is extremely potent anticancer drug requiring only about 1 
mg of the drug over a course of 8 weeks treatment. By comparison, a similar 8-week 
treatment would require about 2.6 grams of Taxol. Despite being highly active, bryostatin 
1 is quite well tolerated by humans, the only side effect being myalgia muscle pain or due 
to dose limiting toxicity. In addition to being used as a single chemotheraupetic agent, 
bryostatin 1 has exhibited impressive synergetic effects when used in combination with 
other well established oncolytic agents such as paclitaxel, vincristine, cisplatin and 
gemcitibine.
6
 In contrast to most anticancer drugs, which suppress the immune system, 
bryostatin 1 has been shown to stimulate the immune system.
7
 More recently, Chauhan 
and coworkers have shown that bryostatin 1 inhibits latent HIV infection in the 
lymphocytes indicating that bryostatin 1 has potential application in the context of 
acquired immune deficiency syndrome (AIDS).
8
 Stimulation of the immune system by 
bryostatin 1 is believed to occur by promotion of T-cell proliferation.  
Besides anticancer and immune-stimulant activity, another important biological 
activity of bryostatin 1 is its ability to affect neurological activity. Recent studies by 
Alkon and co-workers have shown that bryostatin 1 improves the learning and memory in 
animal models such as snails, rats and rabbits.
9
 In a separate study, bryostatin 1 has been 
shown to reduce the formation of amyloid plaques, a key indicator of Alzheimer‟s 
disease, in transgenic mice.
10
 Both of these studies indicate that bryostatin 1 has potential 
for the treatment of Alzheimer‟s disease and a human clinical trial is in progress.11 In 
addition, bryosatin 1 has recently been found to possesses neurorepair activity. In 
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particular, bryostatin was able to reverse neural damage and restore spatial memory and 
learning in mice with ischemia/hypoxia induced stroke. 12 
The mode of action by which bryostatin 1 elicits these interesting biological 
activities is still under investigation; however, parts of these effects are believed to arise 
due binding of the bryostatin 1 to protein kinase C (PKC) and activating the enzyme. 
Bryostatin 1 binds with PKC with nanomolar affinity (Ki = 1.35 nM).
13
 Protein kinase C 
is a family of kinases, that regulate various inter- and intracellular signal transduction 
processes through the phosphorylation of serine and threonine residues of substrate 
proteins. Physiologically, PKC is known to have an important role in various cellular 
processes such as proliferation, differentiation, motility, inflammation, and apoptosis. 
Irregularities in PKC signaling are linked to diseases such as cancer, diabetes, 
autoimmune disease, neurological disorders and cardiovascular diseases.
14
  
PKC is comprised of a group of 10 isozymes that are divided into three categories 
based on the cofactors required for their activation (Figure 1.2).
15
 The conventional 
isozymes (α, βI, βII, γ) are activated by phosphatidyliserine (PS), diacylglycerol (DAG) 
and Ca
+, whereas the novel isozymes (δ, ε, ε/L, ζ) are activated only by PS and DAG. On 
the other hand, atypical isozymes (δ, η/λ) are activated only by PS. Only the conventional 
PKCs (cPKCs) and novel PKCs (nPKCs) are capable of binding with the ligands such as 
bryostatin, DAG, and phorbol esters. All the PKC isozymes contain an N-terminal 
regulatory domain and C-terminal catalytic domain connected by a proteolytic region. 
The catalytic domain, which is highly conserved among various isozymes, is responsible 




Figure 1.2. Schematic Representation of PKC Family 
 
 
autoinhibitory pseudosubstrate region and a membrane targeting C region. While the 
pseudosubstrate region is common to all PKCs, the membrane targeting C region varies 
in each class of PKCs. The conventional PKCs have a cystine rich C1 (C1A and C1B) 
domain which binds to DAG and a calcium-binding C2 region. It is important to note that 
the C1 domain is present in other proteins such as RasGRP, chimaerins and Munc 13 and 
some of the biological activities of bryostatins are thought to be mediated by these 
proteins as well.
16
 In the case the of nPKCs, not only are the C domains switched, but the 
C2 domain is inactive. In contrast to both cPKCs and nPKCs, the aPKCs do not have any 
C2 domain and the C1 domain is inactive.  
The mechanism of PKC activation consists of two major events: (i) conversion of 
the newly synthesized PKC into its mature catalytically competent form by 
phosphorylation of the catalytic kinase domain and (ii) binding of a ligand (DAG, 
phorbol esters or bryostatin) to the regulatory domain (Figure 1.3).
17 
The newly 




Figure 1.3. Schematic Representation of PKC Downregulation 
 
 
Transphosphorylation by the phosphatidylinositol-dependent protein kinase 1(PDK-1) 
converts the PKC into its mature form. The mature PKC then undergoes two 
phosphorylation events. First autophosphorylation of the serine/threonine residues on the 
kinase domain is responsible for turning the PKC into its catalytically competent 
conformation whereas the second autophosphorylation releases the protein in the cytosol. 
The fully phosphorylated free floating PKC is inactive because the pseudosubstrate in the 
regulatory domain occupies the substrate binding site in the catalytic domain. On the 
other hand, certain stimuli cause the hydrolysis of the phosphatidylinositol 4,5 
biphosphate into inositol triphosphate and DAG causing the release of  Ca
2+
 from an 
intracellular organelle. Binding of the Ca
2+
 to the C2 region of PKC increase its affinity 
for negatively charged lipids and the PKCs translocate to the cell membrane. Once 
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associated with the cell membrane, the C1 domain of PKC binds with DAG which 
increases the hydrophobic surface and ensures a tight membrane association. The strong 
lipid association of PKC results in a conformational change releasing the pseudosubstrate 
region from the catalytic domain and thus fully activating the enzyme. In addition to 
endogenous ligands, PKC is also able to bind with external ligands like phorbol ester and 
bryostatins. Once fully activated, the enzyme begins its catalytic activity by binding and 
phosphorylating specific protein substrates rendering its biological activity. Ultimately, 
PKC is dephosporylated by membrane bound alkaline phosphatases, which convert it into 
catalytically inactive form. The inactive PKC is then degraded via ubiquitination 
resulting in down regulation.  
In addition to diacylglycerols, which are endogenous activators of PKC, 
chemically very different structures such as phorbol esters (phorbol 12-myristate 13-
acetate PMA, Ki = 0.55 nM) and bryostatins are high affinity competitive ligands for 
PKC.
18
 Unlike DAGs, which are relatively unstable under physiological conditions and 
are degraded quickly, bryosatin and PMA are rather robust to degradation. This causes 
the long term activation of PKC ultimately leading to its downregulation.
19
 Although 
both phorbol esters and bryostatins bind to PKC and cause its activation, the resulting 
biological effect of these ligands is different and unique.
20
 Bryostatin 1 induces only a 
few of the responses exhibited by phorbol esters. Moreover, bryostatin blocks those 
responses which it does not induce itself or those induced by the phorbol ester. One of the 
most important examples of such antagonism is that phorbol esters are tumor promoters 





mechanism by which phorbol esters and bryostatins exhibit such antagonism is not yet 
understood. 
 
Development of Analogues of Bryostatin 1 
Because of their diverse biological activities, bryostatins present an excellent lead 
for therapeutic development. However these natural products are extremely scarce in 
nature and not readily available. The largest isolation of the bryostatins from 1300 kg of 
Bugula neritina provided only 18 grams of bryostatin 1 with a yield of 0.0013%.
22
 This 
material is being used for all the biological and clinical studies to date. The isolation of 
bryostatins from such a nonrenewable source is not viable for long term purposes and has 
serious ecological consequences. Attempts to aquaculture the organism Bubula neritina 
in an artificial environment by CalBiomarine Technologies were not cost effective due to 
low production of bryostatins and the company ultimately stopped its operation.
23
 Since 
the discovery of symbiotic bacteria Endobugula sertula as the true source of the 
bryostatins, effort has been devoted to culture the bacteria. Unfortunately, the symbiotic 
bacterium has proven difficult to grow in the absence of its host.
24
 Another potential 
method of producing bryostatins is via a biosynthetic route which involves cloning of the 
genetic code for bryostatin from the source organism and transplanting and 
overexpressing it in a suitable host. Studies in this area are underway and have so far 
been able to identifiy and isolate the putative bryostatin gene cluster form Endobugula 
sertula.
25 Even if successful, this would afford a rather “bare bones” bryopyran dubbed 
“bryostatin zero”, and not (even) one of the more highly oxidized natural bryostatins. On 
the other hand, the impressive biological activity coupled with challenging structure and 
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low natural abundance of bryostatins have attracted a number of groups towards their 
total synthesis. This has resulted in the total synthesis of bryostatins 7, 2 and 3 by the 
Masamune, Evans and Yamamura groups respectively.
26,27,28
 However due to the large 
size and complex nature of these natural products, these total syntheses required more 
than 70 chemical steps and were not able to provide clinically relevant quantities of 
material. Very recently, a relatively concise synthesis of the simpler and less well studied 
bryostatin 16 has been reported by Trost and coworkers but provided less than a 
milligram of the final product.
29
 
The restricted availability of bryostatins both naturally and synthetically has 
affected its further development as therapeutic agent. Bryostatin 1 is not produced by 
nature as an optimized therapeutic drug, but rather as a means of chemical defense. 
However, bryostatins can serve as a lead for the development of more clinically useful 
drugs. Optimization of such a lead structure involves careful modifications of the parent 
compound generating simpler analogues which retain or exceed the biological properties 
of the parent compound. Moreover, such simplification would allow the practical 
preparation of the analogues in a more efficient manner. Prior to any modification of the 
lead compound, it is necessary to identify the critical structural elements responsible for 
the desired biological activity. 
The fact that DAGs, phorbol esters and bryostatins bind to the same site of the 
PKC led to the hypothesis that they may share a common pharmacophoric region (Figure 
1.4). Studies based on this hypothesis were carried out under a collaborative effort among 
the Wender, Pettit and Blumberg groups using computational and chemical studies of 
these PKC activators.
30




Figure 1.4. Pharmacophores of Some PKC Activators 
 
 
of tumor promoting activity required the presence of a long chain hydrocarbon at C12/C13 
alcohol and free hydroxyl groups at C4 and C9. A comparison of the spatial coordinates of 
the lowest energy conformations of (S)-1,2-diacyl-sn-glycerol to the X-ray crystal 
structure of PMA showed that the two carbonyl and alcohol oxygen of the DAG 
correlated with that of C4, C9 and C20 oxygen atoms of PMA. A similar comparison 
between the crystal structure of PMA and of bryostatin 1 revealed a close relationship 
between the C4, C9 and C20 oxygen atoms and the C1 carbonyl, C19 and C26 alcohol of 
bryostatin 1, respectively. Mapping of such interatomic distance thus suggested that the 
requirement of C1-C19-C26 heterotriad was necessary for biological activity.  
Next, a comparison of the PKC binding affinity of the bryostatins 1-11 revealed 
that that substitution at C7 and C20 only moderately changed the binding affinity (Figure 
1.5). On the other hand, bryostatin 16 and 17, which lack the C19-C20 oxidation, had 
binding affinity 80 to 130 times less than that of bryostatin 1 indicating that this region is 











the hydrogenation or epoxidation of the C13-C30 olefin of the bryostatins had affinity 
compared to that of natural products whereas hydrogenation of the both C13-C30 and C21-
C34 olefins significantly reduced the binding affinity. Removal of the unsaturation from 
the side chain did not have much effect in the binding affinity. Finally inversion or 
acetylation of the C26 stereochemistry significantly diminished the binding affinity. These 
studies thus supported the hypothesis from the computational studies that C19-C26 region 
of bryosatin 1 is important for the binding with PKCs. 
Results from the computational studies taken together with the SAR obtained 
from the binding affinity of the natural product as well as the semisynthetic analogues 
indicated that the southern C-ring region of the bryostatin 1 binds with the PKC. It was 
also hypothesized that the northern A-B-ring region as well as the hydrocarbon chain on 
the C-ring hold the pharmacophoric southern region in a rigid conformation providing a 
proper orientation for binding with PKC. The two regions were then coined by Wender as 
“spacer domain” and “recognition domain” for A-B-ring and C-ring regions, respectively. 
 
Wender‟s Design of Bryosatin Analogues 
 Based on pharmacophore model mentioned above, Wender and coworkers have 
designed and synthesized analogue 1.1 in which all of the functional groups on the A and 
B-rings have been eliminated (Figure 1.6).
31 
Moreover, the B-ring pyran is replaced by a 
cyclic acetal for the ease of synthesis. The other difference between this analogue and 
bryostatin 1 is removal of unsaturation from the side chain on the C-ring. Their design of 
lead analogue 1.1 is shown in Figure 1.6 where the macrolactone was envisioned to form 




Figure 1.6. Wender's Retrosynthesis of Bryostatin Analogue 1.1 
 
 
domain carboxylic acid 1.1. The esterification would be followed by an acid catalyzed 
transacetalization that would form B-ring and the macrolactone as well remove the 
protecting groups.  
   The first generation synthesis of the recognition domain 1.2 commenced with 
benzyl protection of commercially available (R) methyl lactate (Figure 1.7). Half 
reduction of the methyl ester to the aldehyde followed by a 1,2 chelation controlled 
allylation installed the C25 stereocenter. The newly formed alcohol was protected as 
aPMB ether and the olefin was cleaved to an aldehyde using ozonolysis. In a separate set  
of reactions, ketone 1.8 was prepared in three steps from commercially available 




Figure 1.7. Wender's Synthesis of Recognition Domain 1.2 
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provided the corresponding aldol adduct which was oxidized to a ketone 1.9. The 
addition of the dienolate of diketone 1.9 to aldehyde 1.6 followed by dehydration 
provided a 1:1 mixture of pyranones 1.10, which were separated using silica gel column 
chromatography. The desired -isomer was subjected to Luche reduction.  
Epoxidation/methanolysis of the glycal followed by selective benzyl protection of the 
least sterically hindered alcohol and oxidation of the remaining C20 alcohol provided the 
ketone 1.11. Deoxygenation of the benzyl ester provided the ketone which was subjected 
to an aldol reaction with methyl glyoxylate. The resulting aldol adduct was mesylated, 
and elimination of the mesylate using DBU provided the ,-unsaturated methyl ester 
1.12 as a single isomer. A Luche reduction of the C20 ketone followed by Yamaguchi 
esterification with octanioc acid installed the side chain on the C-ring. The removal of the 
TBS protecting group and subsequent oxidation of the alcohol provided aldehyde 1.13. 
Addition of allyl-BEt2 followed by acetylation of the resulting alcohol provided 
inconsequential mixture of acetates. Oxidative cleavage of the terminal olefin using 
OsO4/Pb(OAc)4 followed by DBU mediated elimination installed the ,-unsaturated 
aldehyde. The PMB group was removed under oxidative conditions and hydrolysis of the 
methylketal completed the synthesis of recognition domain 1.2 in 25 steps (longest linear 
sequence). 
   In order to synthesize the spacer domain 1.3 (Figure 1.8), the bisolefin 1.15 was 
converted into a triol by ozonolysis and in situ reduction presence of a Chiral catalyst 
providing the pyranone 1.17 as 2:1 mixture of diastereomers in favor of the desired 
isomer. Luche reduction of the ketone gave a -alcohol which was converted into a vinyl 





Figure 1.8. Wender's Completion of First Generation of Bryostatin Analogue 
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aldehyde 1.18. Hydrogenolysis of the olefin, followed by Brown asymmetric allylation 
installed the C3 stereocenter. The alcohol was protected as a TBS ether and oxidative 
cleavage of the olefin followed by oxidation of the resulting aldehyde to a carboxylic acid 
completed the synthesis of the spacer domain 1.3.  
   Once both the spacer and the recognition domains were ready, the coupling of the 
carboxylic acid 1.3 with the alcohol 1.2 was accomplished using a Yamaguchi 
esterification. Removal of the TES group followed by treatment of the enal 1.20 with 
Amberlyst-15 acidic resin formed the B-ring acetal as single diastereomer. Removal of 
the benzyl protecting groups furnished the analogue 1.1 in 29 longest linear steps. 
   Biological evaluation of this analogue was carried out by measuring the binding 
affinity with the PKC mixtures isolated from rat brain. As suggested by the 
pharmacophoric model, the analogue 1.1 displayed high binding affinity (3.4 nM). In 
addition, the analogue 1.1 also showed 1.8-170 ng/mL growth inhibitory effect against 
several human cancer cell lines.  
   Wender‟s second generation analogue differed from the analogue 1.1 in just one 
position, i.e., the absence of C27 methyl group in the recognition domain.
32
 This methyl 
group was deleted to ease the synthesis of the recognition domain. The second generation 
synthesis of the C-ring was accomplished in 18 steps from the diol 1.21 (Figure 1.9). 
   Monoprotection of the diol, oxidation, Grignard addition and alcohol oxidation 
provided the keto-aldehyde 1.22. The C23 stereocenter was installed using Keck 
asymmetric allylation providing the homoallylic alcohol in good yield and excellent 
enantioselectivity.
2
 Dehydrative cyclization of the keto-alcohol followed by an 





Figure 1.9. Wender's Synthesis of Second Generation of Bryostatin Analogue 
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to ketone 1.24. The methyl enoate moiety was then installed using a aldol condensation 
with methyl glyoxylate. Reduction of the ketone under Luche condition followed by 
esterification with octanoic acid installed the saturated C20 side chain. A two carbon 
homologation of the aldehyde furnished the ,-unsaturated aldehyde 1.37. Sharpless 
asymmetric dihydroxylation of the terminal olefin provided a 2.5:1 mixture of diols 
favoring the desired isomer which were separated after the hydrolysis of the C19 
methylketal and TBS protection of the primary alcohol. This completed the second 
generation synthesis of the “recognition domain” 1.28.  
   With this new recognition domain, the coupling of the carboxylic acid 1.3 with 
the alcohol 1.28 was accomplished using Yamaguchi esterification (Figure 1.9). 
Treatment of the ester with HF in pyridine formed the B-ring acetal as well as removed 
the protecting groups furnishing the analogue 1.29 in 19 longest linear steps. Biological 
evaluation of analogue 1.29 was carried out similarly to analogue 1.1. Although the 
binding affinity of this analogue was originally reported to be 0.25 nM, a more recent 
paper by Wender and coworkers report that the binding affinity is actually 3.1 nM.
33
  
   In addition to these analogues, Wender and coworkers have synthesized a number 
of other bryostatin analogues (Figure 1.10).
34
 Some representative analogues are shown 
in Figure 1.10 and for detailed chemical and biological descriptions, interested readers 
are referred to the review.
35
 
   Several interesting observations were made from the biological evaluation of 
these analogues. Starting from the C3 position, absence of the hydroxyl group or 
inversion of the stereochemistry at this position dramatically reduces the binding affinity 












without the macrocyclic structure have severely low affinity, but the analogues with 
macrocyclic structure exhibited high binding affinity. Substitution of the B-ring acetal at 
the C13 position or its contraction to a five membered acetal does not affect the affinity. 
On the C-ring, removal of C20-C21 unsaturation has a severe effect. Incorporation of bulky 
esters on the C21-C34 segment significantly decreases the binding affinity.  
 
Keck‟s Design of Bryostatin Analogues 
   The discovery of ever growing unique and interesting biological activities of 
bryostatins coupled with its limited natural abundance and challenging architecture had 
attracted our group towards the total synthesis of bryostatins and their analogues. The 
polyacetate-polypropionate nature of bryostatins provides an excellent opportunity for the 
application of the methodologies developed in our lab over the past years. The synthesis 
of simpler analogues of the bryostatin 1 not only enabled us to explore the SAR of these 
highly complex compounds, but also served as a model for the total synthesis of the 
natural product itself.  
   Our efforts directed towards the synthesis of bryostatin 1 has resulted in the 
development of a new reaction called “pyran annulation” which allows for the rapid 
asymmetric assembly of cis-2,6-dialkyl-4 methylene pyrans, a structural motif common 
to the B-ring of the bryostatins.
36
 The reaction involves the construction of a -
hydroxyallyl silane 1.48 via CAA reaction of an aldehyde 1.46 with trimethylsilyl 
methylallylstannane 1.47 (Figure 1.11). Treatment of such a silane 1.48 and aldehyde  
23 
 
Figure 1.11. Pyran Annulation Methodology 
 
 
1.49 with TMSOTf results the formation of the 2,6-disubstituted 4-methylene pyran 1.50. 
Figure 1.11 shows the application of this methodology in the construction of bispyran 
compound 1.53 as demonstrated previously by Dr. Jonathan Covel from our group. 
   If A- and B-rings of bryostatin 1 is simply spacer domain as suggested by 
Wender, replacement of the highly functionalized A-B-rings of the bryostatin 1 by 
bispyran 1.53 would result a bryopyran analogues with biological activity comparable to 
that of bryostatin 1. In addition, application of the pyran annulation methodology should 
allow the synthesis of simplified analogues in a rapid manner. With this concept, our 
group started the synthesis of bryostatin analogues in which the A- and B-rings would be 
simplified to the exo-methylene pyrans as in 1.53. 
24 
 
   This approach towards the synthesis of bryostatin analogues was initiated by Dr. 
Anh Truong (Figure 1.12).
37
 Using a sequential pyran annulation approach, Dr. Truong 
was able to synthesize bryopyran analogue 1.62. Biological evaluation of the analogue 
1.62 in terms of binding affinity was carried out by Dr. Peter M. Blumberg from NIH. 
The analogue 1.62 was found to have a inhibitory dissociation constant (Ki) of 546 nM 




Figure 1.12. Dr. Anh Truong's Synthesis of Bryostatin Analogue 1.62  
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binding affinity towards PKC than does bryostatin 1 (Ki = 1.35 nM)This study 
suggested that lack of functional groups in the C-ring of the analogue 1.62 might be 
responsible for such decrease in the binding affinity. 
   At this point, Dr. Carina Sanchez took the intermediate 1.61 (Figure 1.13) and 
fully functionalized the C-ring. This involved the protection of the C3 alcohol with TBS 




Figure 1.13. Dr. Carina Sanchez's Synthesis of Bryostatin Analogue Carina 1 
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   Elimination of the aldol adduct gave ,-unsturated keto ester and the ketone was 
reduced under Luche conditions. Esterification of the resulting alcohol with benzyoic 
anhydride followed by global deprotection completed the analogue “Carina-1” .38 This 
analogue has similar substituent at C21 position and a different ster in C20 position 
compared to C-ring of bryostatin 1. The binding affinity of Carina-1 (Ki = 1.35 nM) was 
found similar to that of bryostatin 1 indicating the necessity of the C20 and C21 functional 
groups. Although analogue Carina-1 has binding affinity comparable to that of bryostatin 
1, it does not truly reflect its biological function. This is because bryostatins and PMA 
both bind competitively to the same C1 domain of the PKC with different end results. 
Bryostatin 1 is not a tumor promoter whereas PMA is. Thus, it was necessary to 
determine whether Carina-1 behaves like bryostatin or not. Biological function of the 
Carina-1 was determined using U937 human leukemia cell line. This cell line exhibits 
different behavior towards PMA and bryostatin 1. For example, PMA induces attachment 
and inhibits the proliferation of U937 cells in dose dependent manner whereas bryostatin 
has little effect.
39
 Moreover, bryostatin blocks the effect of the PMA in dose dependent 
manner. When Carina-1 was tested using these assays (Figure 1.14), it displayed activity 
similar to PMA indicating that it mimicked the biological activity of PMA despite being a 
close structural analogue of bryostatin 1.  
   The difference between bryostatin 1 and Carina-1 lies in five positions, three 
positions on the A-ring and one each on the B- and C-rings (Figure 1.15). Since Carina-1 
behaves like tumor promoting PMA, these five groups alone or in combination must be 
responsible for such a switch in biological function. Thus, we directed our study to 
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Figure 1.15. Difference Between Bryostatin 1 and Carina-1 
 
 
analogues varying in these positions.  
   From the synthetic point of view, it seemed more reasonable to determine the role 
of C21 ester first since this would require only a minor modification on the existing route. 
Using a more convergent and improved pyran annulation approach, Matthew B. Kraft 
and Wei Li from our group synthesized three analogues with different side chains at the 
C20 position (Figure 1.16).
40
 All of these analogues were found to have binding affinity 
slightly better than bryostatin 1 indicating the tolerance of different ester side chains at 
C20 position. Further biological activity in terms of function was carried out using U937 
proliferation and attachment assays as mentioned before (Figure 1.17). To our surprise, 
Merle 23 also behaved similar to PMA but different from bryostatin 1 in these two 
assays. Since bryostatin 1 and Merle 23 differ only at four positions on the A and B 
region, this region must somehow be responsible for PMA like activity of Merle 23. If 



















Figure 1.17: Proliferation (top) and attachment (bottom) of U937 cells by Merle 23 
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Wender, Merle 23 would behave like bryostatin 1.  
    With the information from the biological studies of these analogues, we set out to 
determine the role of different substitutions on the A and B-rings of the bryostatin 1. 
 
Synthesis of C30-Decarbomethoxy Bryostatin 1 
   Bryostatin 1 and its simplified analogue Merle 23 differ from each other just at 
four positions (C7, C8, C7 and C13) on the A- and B-ring region. It is thus proposed that 
these four positions are responsible for the PMA like activity of Merle 23 as opposed to 
that of bryostatin 1. In order to determine the substitution crucial for the switch of the 
biological effect, we decided to systematically remove one group at a time from the 
bryostatin 1 structure at these four positions and observe the corresponding biological 
effect. From a synthetic point of view, it seemed most logical to first remove the distant 
substitution on the B-ring among all four positions. Thus, removal of the carbomethoxy 
group from the C30 position on the B-ring would lead an analogue that would differ from 
bryostatin 1 just at one position and the role of this substituent could be determined. If the 
substitution on this positiosn has no effect on the end biological effect, then the role of 
other position on the A-ring would be investigated. 
 
Retrosynthesis 
   Figure 1.17 shows retrosynthetic plan for the synthesis of C30-decarbomethoxy 
bryostatin 1. We envisioned installing the unsaturation on the C21 and C22 positions 
through a late stage functionalization of C-ring of a tricyclecycle such as 1.67. The B-ring 
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Figure 1.17 Retrosynthesis of C30-decarbomethoxy Bryostatin 1 
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1.68 with the aldehyde 1.69. The highly convergent union of these two fragments of 
almost equal complexity would not only construct the B-ring in a very convergent 
manner, but would also install the two stereocenters around the B-ring pyran. The 
flexibility of this methodology is such that the coupling partners could be reversed with 
A-ring as silane and C-ring as aldehyde. The latter methodology has been successfully 
applied in the total synthesis of bryostatin analogues mentioned before.
38
 The other 
termins of these pieces would be coupled by Yamaguchi esterification.  
   Our design of the A-ring aldehyde 1.69 is based on Lewis acid mediated substrate 
controlled nucleophilic additions in order to create the necessary stereocenters. The A-
ring of the bryostatin could be formed by the ketalization of a keto-alcohol derived from 
an acyclic precursor such as 1.70 (Figure 1.18). The acyclic fragment 1.70 has a C3-C5-C7 
anti stereotriad which allows us to apply our 1,3 chelation controlled addition 
methodology. Thus, a series of chelation controlled additions of the nucleopliles on either 
side of the C5 stereocenter would create the C3 and C7 stereoenters. One such nucleophile 
is stannane 1.71 which when added to the aldehyde 1.72 would not only create the C7 
stereocenter but also install the gem-dimethyl group. This is particularly interesting 
because most previous bryostatin analogue syntheses are built around a gem-dimethhyl 
group brought in from a simple starting material. In addition, the use of such a 
functionalized stannane would make the synthesis of A-ring itself highly convergent. The 
C5 stereocenter would be installed by another chelation controlled addition of the 
thioketene acetal 1.75 on aldehyde 1.74. The crucial C5 stereocenter would be installed by 




Figure 1.18. Retrosynthesis of A-ring Aldehyde 1.69 
 
 
The -hydroxy allylsilane functionality of the C-ring was envisioned to come 
from a CAA reaction of trimethylsilylmethallyl stannane on aldehyde 1.76 (Figure 1.19). 
The -unsaturated aldehyde would be formed by a HWE olefination of the aldehyde 
derived from olefin 1.77. The gem-dimethyl group could be installed by a prenylation of 
aldehyde 1.78. A hydroformylation of the olefin 1.79 would install the aldehyde handle. 




Figure 1.19: Retrosynthesis of C-ring Silane 1.68 
 
 
from a series of chelation controlled addition of allylstanne to the aldehyde derived from 
the commercially available lactate 1.80. It is important to note that most of the 
stereocenters on the C-ring would be derived from a single stereocenter present in the 
lactate 1.80 exhibiting a highly substrate controlled synthesis.  
 
Synthesis of A-ring Aldehyde  
The synthesis of the A-ring aldehyde 1.69 commenced with the preparation of C1-
C7 fragment 1.72 (Figure 1.20).
41
 Monoprotection of the commercially available 1,3-
propane diol followed by Swern oxidation generated the aldehyde 1.83.
42











asymmetric allylation reaction on aldehyde 1.83 proceeded with excellent yield and 
enantioselectivity providing the homoallylic alcohol 1.84.
43
 The newly generated C5 
stereocenter was later used for the chelation controlled addition reactions on both sides to 
generate the C3 and C7 stereocenters. The free alcohol was protected as a PMB ether 
under acidic conditions as basic condition led to extensive 1,3 migration of the silyl 
protecting group resulting in an inseparable mixture of products. The BPS protecting 
group was then removed using TBAF and the resulting alcohol was oxidized to an 
aldehyde using the Parikh-Doering reaction.
44 
It was found that aldehyde 1.74 was prone 
to -elimination of the PMB group if old bottles of SO3py were used or if the reaction 
temperature was increased above 0 °C. The aldehyde 1.74 was used next for the first 
chelation controlled Mukaiyama aldol reaction that would generate the C3 stereocenter.
 
Use of Lewis acids like MgBr2OEt2 or BF3OEt2 resulted in only moderate 
diastereoselectivity and yield. However the application of 2.5 equivalent of Ti(Cl)2(Oi-
Pr)2 in toluene provided the desired product with high diastereoselectivity. After the 
successful establishment of the C3 stereocenter, the resulting alcohol was protected as its 
BPS ether. A two-step oxidative cleavage of the olefin was found to be superior to 
ozonolysis and generated aldehyde 1.72 in nearly quantitative yield. 
The synthesis of the stannane 1.93 was addressed next (Figure 1.21). A 
vinylogous alkylation of the lithium enolate of commercially available ethyl 2,2-
dimethylacrylate with TBS protected 2-iodoethanol provided the desired product in good 
yield.
 
The olefin was then migrated to the more thermodynamically favored α,β- 
unsaturated position using KOtBu.  It was necessary to rigorously exclude oxygen during 
the isomerization in order to prevent any oxidation of the potassium enolate.
45
 Full  
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Figure 1.21. Synthesis of Stanne 1.71 
 
 
reduction of ester 1.92 using DIBAL-H provided the allylic alcohol 1.93. Conversion of 
the alcohol to the corresponding chloride, bromide or mesylate provided the desired 
products which were unstable for isolation and purification. Thus the conversion of the 
alcohol into a mesylate at –78°C followed by in situ displacement with tributyltinlithiate 
provided the desired allylstannane 1.71 in a 70% yield.
 
   With aldehyde 1.72 and stannane 1.71 in hand, the crucial chelation controlled 
addition reaction was attempted (Figure 1.22). According to our previous observations, 
such an addition reaction would need a strong Lewis acid.
46
 Thus activation of the 
aldehyde 1.72 by precomplexation with Me2AlCl in toluene at –78 °C followed by slow 







 It was extremely important to maintain the 
chelation time at 5 min  in order to avoid the formation of a secondary alcohol byproduct 




Figure 1.22: Completion of the A-ring Aldehyde 1.69 
 
 
   After the successful installation of the gem-dimethyl group as well as the C7 
stereocenter, the newly formed alcohol was converted into the acetate which is present in 
the natural product. Removal of the PMB group under oxidative conditions using 
buffered DDQ provided the alcohol. The alcohol proved to be unstable for long term 
storage as it underwent lactonization with the terminal thioester. Ozonolysis of the olefin 
followed by reductive work-up yielded the hemiketal 1.96 in 91% yield. The hemiketal 
1.96 was found prone to equilibrate to the corresponding keto-alcohol. Such equilibration 
40 
 
with the open chain compound was more deleterious in the present context due to 
lactonization of the resulting alcohol with the thiolester carbonyl. Thus, treatment of the 
hemiketal with acidic methanol converted the unstable hemiketal into the more stable 
methylketal as well as removing the TBS group in a single operation. The primary 
alcohol was then subsequently oxidized to aldehyde 1.69 by using Parikh-Doering 
conditions to generate the A-ring subunit 1.69 in a 94% yield. 
   During the preparation of the aldehyde 1.69, it was observed that the aldehyde 
decomposed significantly when it was not purified right after reaction workup (Figure 
1.23). Moreover, overnight NMR using CDCl3 also led to the decomposition of the 
material. Mass spectrometric analysis of the byproduct indicated the presence -
unsaturated aldehyde 1.97 as well as the lactone 1.98. The presence of such byproducts 
was not too surprising since CDCl3 is known to contain small amount of DCl/D2O which 
could catalyze the hydrolysis/elimination of the methoxy group. No such decomposition 
was observed when the aldehyde was purified immediately after the reaction and CDCl3 
was neutralized by passing through activated Al2O3. However, attempted conversion of 




Figure 1.23. Some of the Byproducts from Decomposition of Aldehyde 1.69 
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Such acid lability of the methyl ketal was very concerning regarding the potential 
use of aldehyde 1.69 in a pyran annulation reaction. In order to examine if the aldehyde 
1.69 would survive in a Lewis acid mediated reaction, we subjected it to a pyran 
annulation reaction with the simple -hydroxyallyl silane 1.99. To our delight, the 
reaction provided the bicyclic compound in 85% yield as a single diastereomer (Figure 
1.24). Diagnostic NOE transfers from the C11 proton to the C15 and C9 methoxy protons 
proved the expected stereochemistry about the newly formed B-ring. This reaction thus 
confirmed the validity of the aldehyde 1.69 as a suitable substrate for the pyran 
annulation with an even more complex C-ring -hydroxy allylsilane 1.68 as proposed in 
the retrosynthetic analysis. In addition, the bicyclic compound 1.100 itself could be 








Synthesis of the C-Ring Silane  
 The route for preparation of the olefin 1.77 needed for the C-ring was developed 
by Dr. Anh Truong and scaled up for the present synthesis by another graduate student, 
Jeffrey C. Stephens from our group (Figure 1.25).
37
 Briefly, a BOM protection of 
commercially available R-isobutyl lactate followed by half reduction of the ester using 
DIBAL-H provided the aldehyde 1.102 in excellent yield. A 1,2-chelation controlled 
allylation
48
 installed the C25 stereocenter providing a single alcohol isomer and the 
resulting alcohol was protected as a PMB ether.
 
Ozonolysis of the olefin furnished the 
aldehyde 1.105 which was used for a 1,3 chelation
49 
controlled allylation to set the C23 
stereocenter. The allylation provided a 5:1 mixture of diastereomeric alcohols in 
quantitative yield in favor of the desired isomer. The alcohol isomers were found to be 
inseparable. However, when the alcohol was protected with TBS group, the mixture of 
alcohols could be easily separated using silica gel flash column chromatography. Thus 
both C25 and C23 stereocenters were installed using substrate mediated chelation 
controlled additions reactions using C27 stereocenter One carbon homologation of the 
olefin 1.79 using Buchwald hydroformylation
50
 provided the aldehyde 1.78 as a single 
linear formylated product.The gem-dimethyl group was installed by the addition of a 
prenyl indium reagent to the corresponding aldehyde which provided an inconsequential 
mixture of alcohol diastereomers. Oxidation of the alcohols using Parikh-Doering 
conditions completed the synthesis of C16-C27 fragment.
44 
Thus the synthesis of the C16-
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Further functionalizaton of the olefin 1.77 involved ozonolysis with reductive 
workup providing aldehyde 1.110, which was found to be unstable for chromatographic 
isolation (Figure 1.26). Therefore the crude aldehyde 1.110 was subjected to a Horner-
Wadsworth-Emmons olefination with a thiolester phosphate reagent which resulted in the 
formation of a single geometric isomer of the -unsaturated thioester 1.111 in good 
yield.
54




Figure 1.26. Synthesis of C-ring Silane 1.68 
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glycal 1.112. It should be noted that long term storage of the glycal in benzene resulted in 
partial decomposition resulting from the hydration of the dihydropyran. However, such 
decomposition could be avoided if the glycal was stored neat. A half reduction of the 
thioester using DIBAL-H provided the aldehyde 1.76 in good yield.  
With aldehyde 1.76 in hand, installation of the -hydroxyallyl silane functionality 
was attempted. This involved a CAA reaction of aldehyde 1.26 with 
trimethylsilylmethylallyl stannane 1.113.
52
 Although successfully used by Dr. Anh 
Truong in the synthesis of simple bryopyran analogues, this CAA reaction was found to 
be poorly reproducible. Even with the use of a super-stoichiometric amount of the 
catalyst, the reaction provided only 5:1 mixture of diastereomers at C15 in a very low 
yield. We believe that the low reactivity of this aldehyde in CAA reaction is both steric 
and electronic in origin. The more delocalized -unsaturated aldehydes are typically 
less reactive towards the nucleophilic addition of stannane reagents 1.111 in CAA. This 
particular aldehyde is comparatively more complex and much more sterically hindered 
for both the activation by the catalyst and addition of the nucleophile in the CAA 
reaction. 
As attempts to form the silane 1.68 in a stereoselective manner were unsuccessful, 
we focused our attention towards an alternative solution (Figure 1.27). One potential way 
to this solve this problem would be to set the C15 alcohol stereocenter by the reduction of 
the corresponding ketone. Such -unsaturated ketones are known to be good substrates 
for the CBS reduction or Noyori‟s BINAL-H reduction. In order to prepare the ketone, 
the aldehyde 1.76 was heated at reflux with trimethylsilyl methylallyl stannane in toluene 




Figure 1.27. Alternative Synthesis of C-ring Silane 1.68 
 
 
that the relatively unstable glycal was found to be robust enough for this reaction. The 
diastereomeric mixture of alcohol was oxidized to the corresponding ketone using a 
Parikh-Doering oxidation. As expected, the ketone 1.114 was found not to be very stable 
for long term storage. It was also necessary to immediately purify the ketone right after 




Although the reaction provided the alcohol in good yield, the diastereoselectivity 
was only 3:1 at -78 °C. The selectivity could be increased to 5:1 at -100°C, but the yield 
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dropped to 50%. Moreover, it was found to be really difficult to keep the reaction 
temperature at -100 °C even for few h using the conventional cooling bath. With little 
success using the BINAL-H reagent, application of Corey-Bakchi-Shibata (CBS) reagent 
was attempted next.
54
 However the conventional method of running the CBS reduction 
by mixing the ketone with the CBS reagent and BH3•DMS at -78 °C provided a complex 
mixture of products presumably due to the hydroboration and/or reduction of the olefins. 
However, when the reaction was performed sequentially by first pre-complexing the 
BH3•DMS with the CBS reagent at 0 °C followed by the slow addition of the ketone at -
40 °C, the reaction provided the desired alcohol as a single diastereomer in good yield. 
The absolute stereochemistry at the C15 position was determined using Mosher ester 
analysis.
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 This oxidation-reduction sequence easily provided multigram quantities of the 
silane 1.68 for coupling with aldehyde 1.69. 
 
Completion of C30-Decarbomethoxy Bryostatin 1 (Merle 28) 
 With both fragments in hand, the A-ring aldehyde 1.69 and C-ring silane 1.68 
were subjected to the crucial pyran annulation reaction (Figure 1.28). This reaction 
provided the desired tricyclic compound 1.115 in a 58% yield. Although the yield was 
moderate, this advanced pyran annulation furnished the tricyclic carbon skeleton of the 
bryostatin analogue. The majority of the byproduct was O-TMS protected silane and 
unreacted A-ring aldehyde which could be recovered without appreciable loss. The O-
TMS byproduct could be easily converted into the desired silane 1.69 by stirring with 
PPTS/MeOH at 0 °C. It should be pointed out that monitoring this pyran annulation 




Figure 1.28. Coupling of A- and C-rings Using Pyran Annulation 
 
 
the TLC spotter and decomposition took place. In addition, it is necessary to run the 
pyran annulation under anhydrous condition. The presence of any moisture leads to the 
purple colored reaction mixture and low yields. 
 Because of the moderate yield of the pyran annulation reaction, several conditions  
were examined to improve the yield. Increase of temperature, increase/decrease of 
reaction concentration, and precomplexation of the aldehyde with TMSOTf did not have 
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any positive impact on the outcome of the reaction. Use of other Lewis acids such as 
TBSOTf or TESOTf did not provide any product. Since the aldehyde 1.69 provided 
thebispyran 1.100 in high yield with a model silane (Figure 1.24), the moderate yield of 
this reaction could be attributed to the relatively complex nature of silane 1.68 making its 
accessibility to aldehyde 1.69 difficult due to severe steric congestion around the 
aldehyde.  
With the tricyclic carbon skeleton of the analogue in hand, we turned our attention 
towards the functionalization of the C-ring (Figure 1.29). This involved the 
chemoselective epoxidation of the glycal using MMPP and in situ opening of it by 
methanol to provide methoxy alcohol 1.116. Attempts to carry out this transformation 
using m-CPBA gave low yield presumably due to the oxidation of the thioester sulfur. 
The inconsequential mixture of crude alcohols was then oxidized using TPAP/NMO 
providing the ketone 1.117.
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 Further functionalization of the C- ring required the 
installation of the -unsaturated methyl ester at the C21 position. This was 
accomplished by a two step process involving an aldol reaction of the ketone with 
methylglyoxylate followed by its dehydration (Figure 1.29). Initial experiments showed 
that three equivalents of LDA were needed for the reaction to go to completion. 
Surprisingly, in addition to the desired aldol adduct 1.119, the reaction also provided the 
bis-adduct 1.118 in which the aldol reaction took place at C7 acetate. This side reaction at 
the C7 acetate could be avoided by using only one equivalent of base but the yield of 
desired product did not increase above 50%. However, the unreacted ketone starting 
material was recovered quantitatively and was recycled. Elimination of the aldol adduct 




Figure 1.29 Functionalization of the C-ring 





.. ",.O,M,J H OBPSOPMB 
o Me '''OBOM 
1.119 HO C02Me 
49% 
COl, DMAP, (iPr)2NEI, 
• 
OAe 
NaBH4' CeCI3· 7H20, 
• 
• COStBu 






Me 0"" I Me ""OBOM 
~O C02Me 
1.122 











unsaturated ester as single isomer. It is interesting to note that any C-ring intermediates 
that have this type of keto-ester functionality were bright yellow in color (vide infra) and 
all of them proved to be unstable for long term storage. However, the decomposition 
could be reduced by storing the olefin 1.120 in the dark. Luch reduction
57
 of ketone 1.120 
set the C20 stereocenter providing the alcohol 1.121 which also proved to be unstable for 
chromatographic separation. The bryostatin side chain was thus installed by an immediate 
esterification of the alcohol with the octadienoic anhydride. 
With all the necessary functional groups present in compound 1.122, the next step 
would be the preparation of the seco acid for macrolactonization (Figure 1.30). 
Unfortunately the hydrolysis of the thioester to reveal the carboxylic acid was found to be 
problematic. Use of conventional procedures employing LiOH/H2O2 resulted in a 
complex mixture of products due to competitive hydrolysis of various esters. Other 
conditions such as basic aq. AgNO3 partially hydrolyzed and/or eliminated the C9 
methylketal. Use of Hg(OCOCF3)2  resulted in the oxymercuration of the various olefins 
leading to a complex mixture. In order to prevent the loss of this valuable material while 
attempting hydrolysis reaction, a model study was devised with a simple thioester (Figure 
1.31). The thioester 1.89 was inert to hydrolysis with LiOH/H2O2 even at room 
temperature for several h. In contrast, when the thiolester 1.88 with a free alcohol group 
at the C3 position was subjected to the same reaction condition, the reaction was complete 
within 15 min. The rapidity of this hydrolysis is likely because of the lack of steric 
hindrance imposed by BPS group and due to the activation of the ester carbonyl by an 
intramolecular H-bonding with the -alcohol. When these reaction conditions were 





Figure 1.30. Synthesis of the Carboxylic Acid 
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Figure 1.31. Model Hydrolysis of Thioester 
 
 
smoothly providing the hydroxyacid 1.125. Stirring of the compound 1.125 with TESCl 
protected both alcohol and the carboxylic acid which upon workup and column 
chromatography removed the TES ester providing the carboxylic acid 1.126 in good 
yield.  
In order to prepare the seco acid, the PMB group was removed using DDQ 
(Figure 1.32). This reaction needed to be monitored carefully since DDQ competitively 
deprotected the TES group. If the reaction is allowed to go longer than 2 h at 0 °C, there 
was complete TES deprotection resulting into the formation of an extremely polar 
dihydroxy acid which was impossible to separate from the DDQ byproduct. With the 
seco acid 1.127 in hand, the macrocycle was closed using the Yamaguchi reaction 
providing the protected analogue 1.128.
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 A global deprotection using LiBF4 hydrolyzed 
two methylketals, and removed a BOM and a TES group providing the C30 
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Biological Evaluation of C30-Decarbomethoxy Bryostatin 1 
The biological evaluation of Merle 28 was carried out by Dr. Peter M. Blumberg 
at National Cancer Institute, NIH at Bethesda, Maryland.  
1. Binding affinity of Merle 28. The first assay involved the determination of 
potency of Merle 28 by measuring its binding affinity to PKC-. This assay is an 
important first step in determining whether simplified analogues retain similar potency to 
that of the natural product or not. The potency of Merle 28 was tested by measuring its 
binding ability to the PKC- expressed as inhibitory dissociation constant (Ki). The 
smaller the dissociation constant, the higher the binding affinity and the higher the 
potency. The determination of Ki was done by a competitive binding assay of Merele 28 
with the bound [20-3H]phorbol 12,13-dibutyrate (PDBu) from mouse recombinant 
isozyme PKC-α. The assay revealed that Merle 28 had higher binding affinity (Ki = 0.52 
± 0.06 nM average of three experiments) to that of bryostatin 1 (Ki = 1.35 nM). This 
result suggested that C30 carbomethoxy group of bryostatin 1 has a little less effect on the 
binding affinity with PKC-.  
2. Determination of the biological function. Bryostatin is one of the high affinity 
ligands for PKC. Other PKC ligands are phorbol esters and natural activators such as 
DAGs. Although phorbol esers are high affinity PKC ligands, in contrast to bryostatins, 
they are tumor promoters. Thus, the high binding affinity of a ligand does not necessarily 
reflect anything about biological function. Therefore, it is extremely important to 
differentiate various ligands of PKC in terms of their function. The biological function of 
these ligands can be determined by observing their behavior towards certain cells using 
various assays. Two such assays are the proliferation and attachment of U937 human 
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lymphoma cells which are used to determine whether a PKC ligand is likely a tumor 
promoter or not. These assays are used to differentiate the functional antagonism 
exhibited by the various PKC ligands such as bryostatin and phorbol ester. In the 
attachment assay, the tumor promoting PMA induces attachment of U937 cells in a dose 
dependent manner while nontumor promoting bryostatin 1 shows a much diminished 
effect. In addition, when both bryostatin and PMA are administered together, bryostatin 1 
antagonizes and blocks the effect of the phorbol ester in a dose dependent manner. 
When the analogue Merle 28 was subjected to the attachment assay (Figure 1.33), 
it induced attachment similar to that of bryostatin 1 and different from that of PMA. 




Figure 1.33. Attachment of U937 Cells by Merle 28  
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moderate concentration and lower attachment at lowest and highest concentrations. It is 
clear from the graph that Merle 28 displays the dose-dependent biphasic response 
characteristic of bryostatin 1. Moreover, when Merle 28 and PMA were administered 
together, Merle 28 blocked the effect of PMA exactly similar to that of bryostatin 1.Thus, 
from the attachment assay, it can be concluded that Merle 28 behaves like bryostatin 1 
and is a functional antagonist of PMA.  
In the proliferation assay (Figure 1.34.), PMA is strongly antiproliferative 
whereas bryostatin is weakly antiproliferative. Similar to the attachment assay, bryostatin  
1 blocks the effect of PMA in a dose dependent manner when both agents are tested 




Figure 1.34. Proliferation of U937 Cells by Merle 28 
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Moreover, both bryostatin and Merle 28 share similar biphasic behavior which is absent 
with PMA. In addition, Merle 28 blocks the effect of the PMA in a dose dependent 
manner which is a characteristic feature of bryostatin. Even though Merle 28 has binding 
affinity comparable to that of  bryostatin 1, it lost some potency compared to bryostatin 1 
in both the cell attachment and proliferation assays. This can be observed by slight 
increase in the attachment, decrease in the proliferation as well as  decreased blockage of 
the effect of PMA by Merle 28 compared to that by bryostain 1.   
From study of the biological evaluation of Merle 28, it is clear that the absence of 
C30 carbomethoxy group does not decrease the binding affinity towards PKC. In terms 
of function, this group is not necessary for bryostatin like biological activity. Thus, it can 
be concluded from these two assays that Merle 28, which is a very close structural 
analogue of bryostatin, is also a functional analogue of it. Since the C30 carbomethoxy 
group is not needed for bryostatin like biological activity, this reduces the complexity of 
analogue design by one level. Thus Merle 28 can act as lead in preparing simplified B-
ring analogues that retain bryostatin 1 like biological activity.
 
 
As mentioned earlier, Merle 23 chemically differs from bryostatin 1 in four 
positions but biologically behaves like PMA. The effect of one of such positions, the C30 
carbomethoxy group, is addressed with the synthesis and biological evaluation of Merle 
28.
60 
Since Merle 28 differs from Merle 23 in three positions on the A-ring (Figure 1.35), 
these three position must be largly responsible for the bryo like biological activity of the 
former as opposed to the latter one. The effect of the C7 acetate group was studied by 
another graduate student Wei Li from our group who prepared bryostatin analogue Merle 
27 with an acetate in the C7 position (Figure 1.36) 
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Figure 1.37. Proliferation and Attachment of U937 Cells by Merle 27 
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of this analogue revealed that it behaved like PMA in attachment and proliferation using 
U937 cell line indicating that the C7 acetate is not alone responsible for bryo like biology. 
Thus the potential positions responsible for PMA/bryo-like behavior of these analogues is 
finally reduced to two positions, the C8 gem-dimethyl group and C9 hydroxyl group. 
 
Synthesis of C9-Deoxy Bryostatin 1 (Merle 30) 
With the information that C8 and C9 positions could be responsible for this 
unusual biological phenomenon, we focussed our attention towards the chemical 
synthesis and biological study of analogues in which one of these two position were 
adressed. We thought that the C9 hydroxyl group could likely be crucial for the 
PMA/bryo switch in bioactivity. This hydroxyl group had been labile during the synthesis 
of the Merle 28 even when  protected as methylketal group. The unusual reactivity of this 
group comes from its tendency to form an oxocarbenium ion in acidic medium. The 
oxocarbenium ion is can be attacked by various nucleophiles including water. We 
thought a similar phenomenon could be possible in a biological system as well. The 
oxocarbenium ion being attacked by a nucleophilic protein residue could form a covalent 
bond between the protein and the A-ring pyran which could lead to bryo-like behavior. 
Since this functional group is absent in Merle 23 and Merle 27, it seemed to be a possible 
explanation for the PMA like activity of these analogues.  
 
Computational Study of C9-Deoxy Bryostatin 1 
In addition to the chemical observation, there were some computational studies of 
bryostatin 1 with the C1 domain of PKC which indicated that C9 hydroxyl group could  
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play a critical role in determining the biological activity. One such model is proposed by 
Itai and coworkers in which they mention a H-bond between the C9 OH and the carbonyl 
of methionine 239.
62
 In addition, we also conducted the docking studies of bryostatin 1 
and C9 deoxy bryostatin 1 with the C1b domain of PKC The computational studies 
were conducted by Dr. Megan Peach from the NIH. In order to do the docking study, a 
global energy minimum of bryostatin 1 and its C9 deoxy analogue was calculated which 
resulted in a conformation identical to that of the bryostatin 1 crystal structure. The 
optimized model indicated that an intramolecular H-bonding array similar to one 
observed in the X-ray structure of bryostatin 1 (Figure 1.38) was maintained.  
In the next step, the lowest energy conformations of both bryostatin 1 and C9 
deoxybryostatin 1 were docked into the protein which revealed that binding of both of 
these ligands to the C1 domain does not affect their conformations. It was observed from 
the docking that the A and B-rings of both ligands lie above the binding site in close 
proximity to the lipid bilayar. In addition to intramolecular H-bonding, both of these 
ligands make similar H-bonds with PKC residues. Three of these H-bonds are similar in 
both ligands; (1) a weak H-bond between the C1 ester oxygen and the NH of Gln 257, (2) 
a bifurcated H-bonding between the C26 hydroxyl and the NH of Thr 242 and carbonyl of 
Leu 251; and (3) an H-bond between the C34 carbonyl and the NH of Gly 253. Similar to 
the model proposed by Itai, there exists a fourth H-bond between C9 hydroxyl of 
bryostatin 1 and the carbonyl of Met 239. This H-bonding is absent in C9 deoxy 
bryostatin and more importantly in the phorbol ester compounds suggesting that 





























Figure 1.38: Space Filling Model for the Docking of Bryostatin 1  
and C9-Deoxy Bryostatin 1 to PKC C1 Domain 
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 With this information in hand, we planned to check our hypothesis that the C9 
hydroxyl group might act as molecular switch for biological activity. This required the 
chemical synthesis of C9 deoxy bryostatin 1 and its biological evaluation. Since the target 
compound C9 deoxy bryostatin 1 differs from bryostatin 1 in just one position, we 
initially thought of doing a relay synthesis using bryostatin 1 as the starting material. This 
would require a selective deoxygenation of the C9 hemiketal in the presence of C19 
hemiketal. Such selective deoxygenation could possibly be carried out since the C19 
hemiketal is more sterically hindered and electronically deactivated compared to the C9 
hemiketal. The latter is so labile that it was one of the biggest challenges during the 
synthesis of Merle 28. Moreover, the Masamune group had observed that when the C20 
ester is acetate, the hydrolysis of the C19 methylketal could not be carried out. With this 
information in hand, we planned to use natural bryostatin 1 as starting material for this 
synthesis. The synthesis would require several milligrams of bryostatin 1. Unfortunately, 
the extremely high cost of bryostatin 1 (ca US $2000 per mg), due to its scarcity, 
prevented us from executing this plan.  
 The total synthesis of C9 deoxy bryostatin commenced from the advanced 
intermediate 1.117 which had been prepared during the total synthesis of Merle 28 
(Figure 1.39). As mentioned earlier, we observed that the C9 methyl ketal was more 
reactive than the C19 ketal towards acid mediated hydrolysis. The advantage of this 
difference in reactivity was utilized in the deoxygenation of the former methylketal. Thus 
when the bisketal 1.117 was treated with TMSOTf and triethyl silane, the reaction 
provided compound 1.131 as a single regio-and stereo-isomer. The relative 











and C5 protons. With the successful deoxygenation, the functionalzation of the B-ring 
was attempted next. Since B-ring already has an olefin handle, a cross metathesis with 
methyl acrylate was attempted to install the C13-eneoate. The reaction was found 
completely regioselective towards the exocyclic olefin but unfortunately provided 
unseparable 1:1 mixture of E:Z isomers in poor yield. Since the olefin is almost 
symmetrical and does not have enough steric bias towards metathesis reaction, an 
improvement to this reaction would be the introduction of external chirality by using 
asymmetric metathesis catalyst. But such asymmetric metathesis catalysts are still in the 
process of development and have not been commercialized yet.  
Since cross metathesis failed to selectively install the enoate moiety on the B-ring, 
an alternative solution to this problem was sought. Previous bryostatin syntheses have 
utilized a modified asymmetric Horner-Wadsworth-Emmons reaction using Fuji‟s chiral 
BINOL phosphanate to install this moiety.
27,64
 Thus it was thought that we could employ 
the same reagent to install the ester on the B-ring. This would require a regioselective 
oxidative cleavage of the B-ring olefin in the presence of the C16-C17 olefin. Even though 
these two olefins are similar electronically, they seem to be in very different steric 
environment as C16-C17 is more sterically hindered environment due to an adjacent gem-
dimethyl group.  
When the bisolefin 1.117 was treated with OsO4, we were surprised to find that 
both of the olefins reacted with the reagent (Figure 1.40). Attempts to differentiate these 
two olefins during osmylation by lowering the temperature or carefully monitoring the 
reaction while using stoichiometric OsO4 failed. Although the C16-C17 olefin seems to be 











dimensional structure of the molecule which could be ultimately responsible for such a 
low discrepancy during osmylation reaction. With no success in differentiating the 
olefins, the next reagent to try was ozone. At first, we were little skeptical about using 
ozone regarding as it is more reactive than osmium tetroxide. Thus theoretically ozone 
would be less selective for these two olefins if the selectivity depended on the reactivity 
of the reagent. This was the case when the ozonolysis was done using an ozone stream. 
But we were delighted to find that when the bisolefin 1.117 was slowly treated with a 
solution of ozone in CH2Cl2, the reaction was found to be regioselective and provided the 
bisketone 1.136 after reductive workup. It is interesting to note that although both olefins 
of the substrate 1.117 reacted with OsO4, when this reaction was later carried out on 
macrolactone substrate, only the exocyclic olefin reacted with OsO4. This supports our 
hypothesis that the two olefins are much more differentiable when they are present in a 
macrolactone. When bisketone 1.136 was subjected to an asymmetric HWE reaction, the 
reaction once again provided 1.35:1 mixture of Z:E olefins which could not be separated. 
However, the reaction provided only one regioisomer indicating that C20 ketone is less 
reactive towards this reaction presumably due to steric overcrowding and electronic 
deactivation because of adjacent pyran and methylketal oxygen functionalities. 
 When similar asymmetric HWE olefination reactions on the B-ring were 
examined in previous bryostatins syntheses, it was found that the reaction gave the best 
selectivity in the macrocyclic compounds.
27,28
 With this information in hand, the 
substrate 1.117 was advanced towards the macrocycle (Figure 1.41). The PMB group was 
removed under standard oxidative conditions providing the alcohol in excellent yield. 




Figure 1.41. Functionalization of the B-ring 
 
 
pleased to find that that m-CPBA did not react with the C16-C17 olefin nor did it cause any 
Baeyer-Villiger oxidation of the ketones on the B and C-rings.
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 Yamaguchi 
macrolactonization of the seco acid provided the macrolactone 1.137 in good yield. When 
the bisketone 1.137 was subjected to an asymmetric HWE reaction, the reaction provided 
the desired compound 1.139 as a single regioisomer and a 4:1 mixture of Z:E isomer. The 
desired Z isomer could be separated from the mixture using preparative thin layer 
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chromatography. The expected stereochemistry of the Z olefin was verified by observing 
a NOE interaction between the C30 proton and the equatorial proton on C12.   
 The next step in the synthesis is the functionalization of the C-ring (Figure 1.42). 
would cause elimination of the adduct and install ,-unsaturated ester at C21 position 
resulting a bright yellow enoate. But treatment of the aldol adduct with acetic anhydride 
resulted in no such product formation. Instead, the reaction led to the formation of a 
 
 
Figure 1.42. Attempted Functionalization of the C-ring 
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different compound which turned out to be the acetate of the aldol adduct on C7 acetate. 
The exclusive formation of such undesired adduct was surprising because the same 
reaction using one equivalent of LDA provided only the desired product for compound 
1.117. It is very likely that the lack of steric hindrance imposed by methoxy group at C9 
position led the LDA to attack at C7 position preferentially over the C21 position. When 
the undesired product 1.143 was treated with potassium carbonate in methanol, alcohol 
1.144 was generated quantitatively, which could be converted back into the starting 
material. The stability of the macrolactone ester in this reaction led us to assume that an 
aldol reaction involving K2CO3/MeOH could be used to install the enoate on the C-ring. 
This reaction, which involves K2CO3/MeOH and the methyl acetal of methyl glyoxylate, 
has been successfully used for a similar reaction in simpler substrates.
32 
When ketone 
1.139 was stirred with K2CO3/MeOH and the methyl acetal of methylglyoxylate, the 
reaction provided the aldol adduct 1.145 in which the acetate on the C7 position was 
removed (Figure 1.43). Heating of this crude aldol adduct with acetic anhydride and 
DMAP in pyridine dehydrated the aldol adduct as well as reinstalled the C7 acetate. The 
C20 stereocenter was installed by reducing the corresponding ketone under Luche 
conditions providing an unstable alcohol as a 4:1 mixture of diastereomers. The crude 
alcohol was subjected to esterification with octadieonic anhydride which installed the 
bryostatin side chain. The undesired minor diastereomer from the Luche reduction was 
removed at this point using a preparative thin layer chromatography. Removal of the BPS 















An interesting observation was made during global deprotection of macrocycle 
1.147 (Figure 1.44). When compound 1.147 was subjected to deprotection using LiBF4, a 
new spot in the TLC appeared after 1 h which was less polar than starting material. This 
was surprising since the deprotection of 1.147 would give free alcohols which would 
make the compound more polar. Observation of the crude NMR of this compound 
showed all protecting groups were gone except the BOM group. This abnormal behavior 
of compound 1.148 is believed to be the result of the multiple intramolecular hydrogen 
bonds in the molecule. It has been observed in the crystal structure of bryostatin 1 that 
there are two intramolecular H-bonds. The first one is the C19-OH with the C3-OH and 
the second one is proton of the C3-OH making a bifurcated H-bonding with the pyran 
oxygens of the A and B-rings of bryostatin. Since the BOM-compound is highly 
analogous to bryostatin 1, similar H-bonding can be expected. Thus the H-bonds tied the 




Figure 1.44. Observation of Unexpected Polarity 
74 
 
the resulting final compound was more polar than both the fully protected and the BOM-
protected compounds.  
 
Biologial Evaluation of C9-Deoxy Bryostatin 1 
 Similar to Merle 28, the biological evaluation of Merle 30 began by evaluating its 
binding ability with PKC. From the binding assay, Merle 30 was found to have an 
inhibitory dissociation constant (Ki = 0.38 nM) comparable to that of bryostatin 1 (Ki = 
1.35 nM). This suggested that the absence of H-bonding between the C9-OH and Met 239 
of PKC does not affect its binding ability. According to the computational study and 
chemical observation, the molecule is held by three intramolecular H-bonds even in the 
absence of C9-OH. Thus the presence or absence of the C9-OH does not change the 
conformation of Merle 30. Since bryostatin is extensively bound to the C1 domain of 
PKC which involves four H-bonding interactions and various other nonspecific 
interactions, the loss of binding due to the C9-OH hydrogen bond might have been 
counterbalanced by an increase in nonbonding interaction due to the increase in the 
hydrophobicity of the A, B-ring region.  
 The second part of the biological investigation involved the determination of the 
function of Merle 30 with respect to PMA. This was again carried by proliferation and 
attachment cell assays using the U937 cell line. It appears from the attachment assay that 
Merle 30 induced cell attachment similar to bryostatin 1 but to a slightly larger extent 
(Figure 1.45). Similar to Bryostatin 1, Merle 30 exhibited the biphasic behavior and 
blocked the effect of PMA in dose dependent manner. In addition, it was shown to 




Figure 1.45. Attachment of U937 Cells by Merle 30 
 
 
In the second assay, the proliferation caused by Merle 30 is very different from 
that caused by PMA and very similar to bryostatin 1 (Figure 1.46). In both of the assays, 
Merle 30 blocked the effect of PMA in dose dependent manner. Thus these assays 
suggested that Merle 30 functions like bryostatin and not like PMA. In order to determine 
whether the functional behavior exhibited by these analogues is general or not, another 
assay was carried out using LNCaP cell line. These are androgen-sensitive human 
prostate cancer cell lines widely used in various onological studies.
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 Similar to the U937 
cell line, these cells also give different responses to PMA and bryostatin, PMA is strongly 




Figure 1.46. Proliferation of U937 Cells by Merle 30 
 
 
PMA which it itself does not exhibit.  
As seen from the proliferation assay using LNCaP cells (Figure 1.47), Merle 30 
shows response similar to that of bryostatin and different from that of PMA. Moreover it 
also blocks the effect of PMA in dose dependent manner, a characteristic behavior of 
bryostatin 1. Another assay involving LNCaP cell is the effect of these ligands in the 
secretion of tumor necrosis factor  (TNF). TNF is a immunomodulating protein 
produced mostly by immune cells and induces inflammatory response. Phorbol esters 
such as PMA induce the production of  TNF whereas bryostatin has little effect and it 




Figure 1.47. Proliferation of LNCaP Cells by Merle 30 
  
 
induces the highest secretion of TNF in a biphasic manner whereas bryostatin 1 has 
little effect. Moreover bryo blocks the effect of PMA in a dose dependent manner. It is 
seen from the assay that Merle 30  has little effect on the secretion of TNF and more 
importantly blocks the secretion caused by PMA when both agents are applied together 
(Figure 1.48). This clearly suggests the bryostatin like nature of Merle 30. Even though 
Merle 30 is very similar to bryostatin 1 in both of these assays; it also has a small PMA 
like character shown by small increase in attachment of the U937 cells, decrease in the 
proliferation of both U937 and LNCaP cells as well as small increase in the secretion of 
TNF 
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Figure 1.48. Secretion of TNF- from LNCaP Cells by Merle 30 
 
 
From the study of the biological activity of various bryostatin analogues it was 
assumed that two groups on the A-ring could be responsible for the bryostatin like 
activity exhibited by these analogues, the C8 gem-dimethyl group and the C9 hydroxyl 
group (Figure 1.49). The C9 hydroxyl group was thought to contribute more in the 
biological response both due to its chemical reactivity and ability to H-bond with the C1 
domain of PKC. It is clear from the study of Merle 30 that the absence of C9 hydroxyl 
group has very little affect in its binding ability to PKC. Moreover, the biological 
through the function of the Merle 30 is not much affected by the absence of C9 hydroxyl  
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group. Thus by chemical synthesis and biological evaluation of various analogues, we 
have determined the role of various functional groups. Firstly, the biological data from 
Merle 23 showed that A and B-rings are responsible for the bryostatin like biology. Merle 
28 revealed that the ester functional group on the B-ring was not important indicating that 
substitution on the A-ring was critical. Among the three groups on the A-ring; C7 acetate, 
C8 gem-dimethyl group and C9 hydroxyl group, the biological results from Merle 27 
suggested that C7 acetate was not critical. This left gem-dimethyl group on C8 and and C9 
hydroxyl group. From the study of Merle 30, it was revealed that C9 was not the 
molecular switch of bryostatin-phorbol biology. This leaves the gem-dimethyl group 
which could be potentially responsible for the bryostatin like response of these analogues. 
It is interesting to note that of the all analogous prepared and tested for biological activity 
from our group so far, those devoid of the gem-dimethyl group behave like phorbol esters 
whereas those with the gem-dimethyl group behave like bryostatin 1.  
It has been observed from the study of the C1 domain of PKC that its top face 
interacts with the lipid bilayer.
15
 When the C1 domain binds with the ligands such as 
bryostatin and phorbol ester, it changes the surface characteristics of the top face and thus 
leads to a change in its interactions with the lipid bilayer. Our modeling of bryostatin 1 
with the C1 domain of PKC also suggests that binding of bryostatin 1 significantly 
changes the polarity of lipid binding surface, and thus might result in a change in its 
interactions with the lipid bilayer. Among the four groups in the A and B-ring of 
bryostatin 1, which are absent in phorbol like analogue Merle 23, carbomethoxy group, 
C9 alcohol and C7 acetate are oxygenated and more polar. The C8 gem-dimethyl group is 
hydrophobic, and one of the unique structural features of bryostatins. Since binding of 
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bryostatin 1 with the C1 domain changes its interaction with the lipid bilayer, the 
presence or absence of polar/nonpolar group on bryostatin would make a significant 
contribution towards this interaction. Such change in the polarity of the ligand could 
ultimately be responsible for the switch in the phorbol-bryostatin like biological activity 
of the analogues of bryostatin.  
 
Synthesis of C8-Gem-dimethyl Analogue (Merle 32) 
From the observation of the biological profile of analogues so far studied, it 
seemed logical that the gem-dimethyl group could be critical in defining the biological 
activity. The effect of this group could be tested by synthesizing the analogue with only 
the gem-dimethyl group on the A-ring or one with all the substituent but the gem-
dimethyl group on the A-ring. The former would serve as positive control whereas the 
latter would serve as a negative control. Moreover, the ideal chemical structure would be 
one which could be compared directly with the closest phorbol-like bryostatin analogue 
and is preferably different from it only at the gem-dimethyl group. Such an analogue 
would be Merle 32 (Figure 1.49) which has a gem-dimethyl group at the C8 position and 
differs only at one position from the previously studied phorbol like analogue Merle 23. 
Synthetically, it seemed more reasonable to use the existing intermediate and 
route to synthesize this analogue. This would avoid the time and cost involved in 
developing a separate route to synthesize and test this analogue.  The synthesis 
commenced from compound 1.131 which was synthesized enroute to C9-deoxy bryostatin 
1. The synthesis would follow essentially the same route as that of Merle 30 with the 
substitution of the acetate on C7 position with an exo-methylene group. We envisioned 
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that hydrolysis of the C7 ester would reveal an alcohol which could be oxidized to a 
ketone. The ketone could then be converted to olefin using an olefination reaction. 
Among all the reactions in the sequence, we were most concerned about the crucial 
olefination reaction. This is because the ketone is adjacent to a sterically demanding gem-
dimethyl group. Proximity of such a severely bulky group would make the approach of 
the reagent very difficult and lead to side reactions in a complex substrate. With this 
potential problem in mind, we first decided to test the viability of the olefination reaction 
on a model substrate. The synthesis of model substrate 1.151 commenced from the 
previously synthesized intermediate 1.149 (Figure 1.50). Deoxygenation of the 




Figure 1.50. Model Olefination Study 
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compound 1.150. A transesterification using K2CO3/MeOH removed the C7 acetate and 
converted the C1 thioester into a methyl oxoester. The free alcohol was oxidized to a 
ketone using TPAP/NMP providing the model substrate 1.151 in excellent yield over 4 
steps. With 1.151 in hand, we decided to first investigate the use of the Petasis reagent in 
the olefination reaction.
68 
Although the Petasis reagent is also known to react with ester 
carbonyls, the reactivity can usually be controlled by increasing/decreasing the 
temperature of reaction. The choice of the Petasis reagent as opposed to the Wittig 
reagent was made based on the previous observation that C1 ester compounds with a BPS 
group on the C3 position were prone to -elimination in Wittig reaction conditions.
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Moreover, a ketone such as 1.151 is in an extremely hindered environment and the Wittig 
reagent is known to be sensitive towards steric factors. An alternative but similar to 
Petasis reagent would be Tebbe‟s reagent.70 Here we were concerned about the lower 
reactivity and higher Lewis acidity of the reagent, especially in the context of a complex 
intermediate. In the event, when ketone 1.151 was subjected to Petasis olefination 
conditions, the reaction provided the olefin 1.152 in good yield. 
 With the success of the model olefination reaction, the synthesis of Merle 32 
commenced from the previously synthesized intermediate 1.131 (Figure 1.51). The PMB 
group was removed under standard conditions providing alcohol 1.153 in excellent yield. 
Hydrolysis of the thioester was achieved using mCPBA in THF/H2O. During this 
hydrolysis, the thioester was stirred with mCPBA in THF/H2O at 0 °C for 1 h, and then at 
room temperature for 2.5 h. It was necessary to stop the reaction after 3.5 h in order to 
prevent the epoxidation of the B-ring olefin. Although both the product and the byproduct 
























DDQ, pH 7 buffer 



















• THF/tol, DMAP, 
40 'C 81% 





from the mixture by silica gel column chromatography using 30% ethyl acetate in 
hexanes. With the seco acid in hand, a Yamaguchi reaction provided the macrolactone 
1.157 in good yield. 
The next step in the synthesis would involve the functionalization of the C-ring 
through an aldol reaction reaction with methyl glyoxylate. Experience from previous 
analogue syntheses had shown that the aldol reaction could not be done on the C-ring 
with the C7 acetate still present in the molecule. Aldol condensation using the 
K2CO3/MeOH was another alternative but that would remove the C7 acetate. Therefore a 
cleaner route was devised in which the C7 acetate was removed using K2CO3/MeOH and 
the resulting alcohol was protected as TES ether (Figure 1.52). An aldol reaction of the 
ketone 1.157 using LDA and freshly prepared methyl glyoxylate provided the aldol 
adduct 1.158 as a mixture of diastereomers. Elimination of the crude aldol adduct to the 
desired -keto ,-unsaturated ester 1.159 was accomplished by stirring the adduct with 
acetic anhydride and DMAP. It was necessary to keep the elimination reaction at room 
temperature to avoid the deprotection of the TES group. The C20 stereocenter was set by 
Luche reduction of ketone 1.159, and the alcohol was immediately esterified with 2,4-
octadieonic anhydride. Removal of the TES group under standard conditions followed by 
Dess-Martin oxidation of the resulting alcohol provided the ketone 1.161 in excellent 
yield.  
When the ketone 1.161 was subjected to the Petasis olefination reaction, no 
desired product was formed (Figure 1.53). Instead, the reaction provided a complex 
mixture of byproducts which could not be isolated and identified. The failure of this 














Figure 1.53. Olefination Study 
 
 
concerned about -elimination of the model ketone 1.151 under basic condition, we were 
prompted to try a Wittig reaction on it. We were pleased to find that the Wittig 
olefination on the model ketone 1.151 actually worked. It was proved to be extremely 
important to stop the reaction at 15 min in order to avoid decomposition of the desired 
product and other side reactions. When the reaction was stopped at 15 min, a 78% 
isolated yield of the desired alkene was realized. When this olefination condition was 
applied to the advanced substrate 1.161, the reaction provided the desired olefin 1.162 
(Figure 1.54). Removal of BPS ether with HF•py followed by global deprotection then 




Figure 1.54. Completion of Merle 32 
 
 
Biological Evaluation of C8-Gem-dimethyl Analogue 
Merle 32 was submitted for the biological evaluation involving its binding affinity 
to PKC- and function in terms of bryostatin-phorbol like activity. From the binding 
assay, the inhibitory dissociation constant (Ki) was found to be 1.08 nM. This suggested 
that the presence of the gem-dimethyl group does not affect the binding affinity towards 
PKC-. 
Further biological activity in terms of function was carried out by proliferation 
and attachment assays in U937 cell lines (Figure 1.55) . The proliferation assay involving 





Figure 1.55. Proliferation (top) and Attachment (bottom) of U937 Cells 
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seen with PMA and much different from bryostatin. Moreover, unlike the previous 
bryostatin 1 like analogues, Merle 32 was not able to block the effect of PMA when it 
was administered together with bryostatin 1. In the attachment assay, Merle 32 induced 
attachment similar to that of PMA and was not able to block the effect of PMA. Both of 
these assays involving the U937 cell line showed that Merle 32 is a functional antagonist 
of bryostatin 1.  
In order to verify that the PMA like behavior displayed by Merle 32 in the U937 
cell line was more general, it was tested using another cell line. In the proliferation assay 
using LNCaP cell line, the analogue again gave results similar to PMA (Figure 1.56). 
When Merle 32 was subjected to the attachment assay, once again, it behaved like PMA. 
In both of these assays involving LNCaP cells, Merle 32 was unable to block the effect of 
PMA in a dose dependent manner.  
From all four assays involving both U937 and LNCaP cell lines, it is clear that the 
Merle 32 behaves like PMA. If the gem-dimethyl group was the group solely responsible 
for determining the bryo-like character, which might be inferred by the chemical and 
biological evaluation of the previous analogous, Merle 32 would have behaved like 
bryostatin 1. This result suggests that this is not the case and it can be said that there is no 
single group in the A-B region of bryostatin 1 that is singly responsible for switching 
between bryostatinand phorbol ester biological function. 
 
Comparison of Various Bryostatin Analogues 
 The bryostatin analogues mentioned above have close structural relationships 















Proliferat ion of LNCaP cells 
Attachment of LNCaP cells 
--• PIM (0.1. I. 10. 100. IOOO Ml) 
• 81,0' · " IO. I. I. I O. IOO. I OOO Ml) 
• _ n lO. I. O.3. I.), 10. lO. 100. 300. 1000. 5000nMj 
• l OO MIPIM . Btyo_ 1 (I . 10. 100. lOOOMlj 
.'OOMlPIM._n(I. l o. I OO. IOOOnM) 
92 
 
only a few positions, they have different biological properties. For example some 
analogues mimic the biological profile of bryostatin and are its agonists while others are 
antagonists. Even among the analogues which are functionally similar, their potency in 
functional responce is different. One of the goals of synthesizing various bryostatin 
analogues is to study the structure activity relationships and to ultimately optimize an 
analogue with respect to biological activity. Thus it is important to compare these 
analogues not only with the natural product, but also among themselves in terms of their 
biological activity.  
Comparison of Merle 28 and Merle 30. As mentioned earlier, two of the 
analogues Merle 28 and Merle 30 are very close structural analogues of bryostatin 1. 
Merle 28 differs from bryostatin 1 at only one position. This analogue is devoid of the 
C30 carbomethoxy group present in the natural product. The other analogue Merle 30 
lacks the C9 hydroxyl group of bryoststin 1. When these analogues were tested for their 
binding affinity, both of them were found to have high binding affinity to PKC. In fact, 
they have higher (Merle 28, Ki = 0.52 nM, Merle 30 Ki = 0.38 nM binding affinity than 
bryostatin 1 (Ki = 1.35 nM) for purified PKC. In order to determine the bryo or phorbol 
like behavior, both of these analogues were compared in cell proliferation and attachment 
assays using the U937 cell line (Figure 1.57). In the proliferation assay, both of these 
analogues showed proliferation similar to bryostatin but different from that of PMA. In 
the attachment assay, they both induced the attachment characteristic of bryostatin 1. The 
biological behavior of these analogues was further tested in their ability to secret TNF 
in LNCaP cell lines (Figure 1.58). This assay revealed that both Merle 28 and 30 were 






Figure 1.57. Comparison of Merle 28 and Merle 30 
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Figure 1.58. Comparison of Merle 28 and Merle 30 
 
 
like biological profile of these analogues.  
One interesting observation was made when the secretion of TNF- by various 
bryostatin analogues was measured in the presence of Lactacystin. Lactacystin is a 
proteasome inhibitor which prevents the down-regulation of PKC. When the bryostatin 
analogues were tested with the proteasome inhibitor Lactacystin, the level of secreted 
TNF-was significantly increased (Figure 1.59). This suggests that analogues which 






Figure 1.59. Reversal of the Biological Activity of Bryostatin Like Analogues 
 
 
presence of lactacystin. The reason(s) for such switch in the biological effect is under 
investigation. Although both Merle 28 and Merle 30 were found to have similar higher 
binding affinity for PKCto that of bryostatin 1, they were found to be slightly less 
potent than bryostatin 1 during attachment and proliferation assays. This can be seen by 
the larger decrease in the proliferation and greater attachment of the U937 cells by both 
of these analogues (Figure 1.57). Between the two analogues, Merle 30 is slightly less 
potent than Merle 28. Such difference in the potency of the same compound in two 
different assays suggests that binding affinity and resulting biological function are 
different things.  
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Comparison of Merle 30 and Merle 32. Another comparison was made between 
Merle 30 and Merle 32. Merle 30 differs from bryostatin 1 at just one position whereas 
Merle 32 differs at three positions. As mentioned earlier, Merle 32 was prepared in order 
to reveal the role of the gem-dimethyl group on the A-ring. Merle 30 was found to be 
functional analogue of bryostatin 1, whereas Merle 32 was like PMA from the 
proliferation and attachment of the U937 and LNCaP cell lines. The biological function 
of these two analogous was further investigated using the MV4-11 cell line. The MV4-11 
cell line is a human leukemia cell line that also exhibits differential response to various 
PKC ligands such as bryostatin and PMA. Both analogues were subjected to the 
proliferation and attachment assays. It is observed from the attachment assay that Merle 
30 resulted in the attachment of the MV4-11 cell line similar to bryostatin 1 whereas the 
response shown by Merle 32 was like that of PMA (Figure 1.60). Moreover, Merle 30 is 
able to block the effect of PMA in dose dependent manner whereas Merle 32 is not able 
to do so. In the proliferation assay, Merle 30 seems to have an effect intermediate 
between bryostatin 1 and PMA but Merle 32 is very similar to PMA. In this assay, Merle 
30 is not able to block the effect of PMA as effectively as byrostatin 1. This suggests the 
dual nature of Merle 30 in some assays suggesting that Merle 30 is predominantly 
bryostatin 1 like but in some assays, it weakly resembles PMA. 
Both of these compounds were further investigated in another human leukemia 
cell line, K562.
71
 A proliferation assay involving this cell line suggested that Merle 32 
behaves like PMA whereas Merle 30 displayes predominantly bryostatin 1 like character 
with little inclination towards PMA (Figure 1.61). Both of these assays involving MV4-
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Figure 1.61. Comparison of Merle 30 and Merle 32 
 
 
U937 and LNCaP cell lines that Merle 32 gave response similar to bryostatin 1 whereas 
Merle 30 is similar to PMA.  
Comparison of Merle 23 and Merle 32. The comparison of Merle 32 is with 
another analogue Merle 23 which behaves like phorbol ester. The difference between 
these two analogues is at just one point, i.e., the presence of gem-dimethyl group on the 
A-ring of Merle 32. One of the reasons for synthesizing Merle 32 was that it could be 
most logically compared with Merle 23 the role of the gem-dimethyl group could be 
revealed. When these two analogues were compared in the cell attachment and 
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proliferation assays using the U939 cell line, both of them caused the attachment and 
proliferation of cells similar to PMA and thus behaved exactly similar to PMA (Figure 
1.62). Neither analogue were able to block the effect of PMA in dose dependent manner, 
a response characteristic of bryostatin. In fact Merle 23 displayed more PMA like 
response than Merle 32 in the attachment assay by inducing higher attachment of the 
U937 cells. This suggested that the presence or absence of the gem-dimethyl group on the 
C8 position does not reverse the PMA-bryo like response.  
Comparison of Merle 28 and Merle 32. A final comparison was made between the 
most bryostatin like analogue Merle 28 and PMA like Merle 32 (Figure 1.63). The results 
showed that these two compounds behaved opposite to each other in terms of their PMA 
or bryo like character, Merle 28 was similar to bryostatin 1 whereas Merle 32 was just 
like PMA.   
Translocation of PKC by bryostatin analogues. In addition to the cell attachment 
and proliferation assays, the biological behavior of various bryostatin analogues was also 
determined by examining the translocation of PKC by these compounds. As mentioned 
earlier, bryostatin is one of the potent exogeneous activators of PKC and most of the 
biological functions of the enzyme are attributed to its activation by various ligands. In 
addition to the endogenous activators such as DAG, PKC is also activated by a wide 
variety of nonendogenous ligands such as bryostatin and phorbol esters. It has been 
mentioned before that PKC activation and its translocation are related processes. The 
inactivated PKC is freely floating in the cytosol. Once PKC is activated by binding with a 
ligand such as bryostatin or PMA, its binding affinity with the lipid bilayer increases and 





Figure 1.62. Comparison of Merle 23 and Merle 32 
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pseudosubstrate is removed from the substrate binding site of PKC leading to the 
phosphorylation of the target protein. It has been shown by Blumberg and coworkers that 
the pattern of translocation of PKC by various ligands is different.72 Tumor promoters 
such as phorbol esters induce the translocation of PKC primarily to the plasma 
membrane. Bryostatin 1, a nontumor promoter, on the other hand, caused translocation of 
PKC primarily to the nuclear membrane. This opposite behavior of PMA and bryostatin 
towards PKC translocation thus serves as a tool to identify the PMA versus bryostatin 
like character of PKC ligands. The translocation of the PKC can be monitored in real 
time using PKC-green fluorescence protein (GFP) conjugate.  
 The preliminary results of PKC translocation assay in LNCaP cell using various 
bryostatin analogues is shown in Figure 1.64. It can be observed from the figure that 
PMA shows strong membrane fluorescence due to the translocation of PKC leaving the 
cytosol almost empty. In contrast, bryostatin 1 shows no plasma membrane staining, 
some nuclear membrane and mostly cytoplasmic staining. A similar type of staining 
behavior is shown by Merle 28 indicating that biological function of Merle 28 is more 
similar to that of bryostatin but very different from that of PMA. On the other hand, 
Merle 30 shows more cell membrane staining than Merle 28 and bryostatin indicating its 
intermediate behavior which is also observed in the cell proliferation assay involving the 
MV4-11 cell line. In the case of Merle 23 and Merle 32, both show strong plasma 
membrane staining which is comparable to that of PMA indicating their PMA like nature. 
The observations made using translocation the assay are entirely consistent with the 
biological behavior shown by these analogues in the cell proliferation and attachment 




Figure 1.64. Translocation of Endogenous PKC- After 2 hr Treatment of LNCaP Cells 
 
 
functional analogue of bryostatin 1 whereas Merle 23 and Merle 32, although both 
structurally similar to bryostatin 1, antagonize its effect and are functional analogues of 
PMA. Merle 30, on the other hand, shows more intermediate behavior between bryostatin  
and PMA. 
The biological studies of various analogues using different assays revealed some 
interesting structure activity relationship of these compounds. Although all of these 
analogues have the basic bryostatin structure, their function varies from tumor promoting 
PMA to nontumor promoting bryostatin. Chemically, these analogues differ from each 
other only in the A-B-ring region. There are four different groups on the A-B region, C7 
acetate, C8 gem-dimethyl, C9 hydroxyl and C30 methyl ester. Three of the four groups are 
oxygen containing polar groups whereas the gem-dimethyl is more hydrophobic. Some 
analogues such as Merle 28 and Merle 30 have only one less polar group compared to 
bryostatin 1. Other compounds like Merle 23 and Merle 32 have all three polar groups 
removed from the A-B-ring region. It seems that the larger the number of polar groups on 
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the A-B-rings, the more bryostatin like the analogue is and vice versa.  For example 
Merle 28, which has three polar groups (C7 acetate, C9 hydroxyl and C30 methyl ester), 
behaves like bryostatin 1 whereas Merle 32 in which all three polar groups are removed 
behaves like PMA. Between Merle 23 and Merle 32, everything is the same except the 
latter has an extra gem-dimethyl group on the A-ring which would make the A-B-ring 
region less polar. This suggests that Merle 32 would be more PMA like than Merle 23. In 
fact the opposite is true; the attachment assay using U937 cell shows that Merle 23 is 
more PMA like than Merle 32 (Figure 1.65). This anomaly could arise due to the steric 
factor imposed by the extra gem-dimethyl group on Merle 32 that would make the 




Figure 1.65. Comparison of Analogue Behavior on U937 Cell Line 
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When Merle 30 and Merle 28 are compared in terms of their A-B-ring polarity, 
Merle 30 has more polar group removed (assuming that a hydroxyl group is more polar 
than an ester group). Thus Merle 30 behaves less bryostatin 1 like and more PMA like 
than Merle 28 in the assays involving proliferation and attachment of various cell lines as 
well as the translocation assays. The polarity of a compound can be tentatively measured 
by calculating their ClogP values. The ClogP values of the A-B-ring region of various 
analogues and bryostatin are shown in Figure 1.66 calculated using ChemDraw. It is seen 
from the figure that the lower the ClogP value, the more bryostatin like activity and vice 
versa. Thus polarity can give a rough estimate of PMA-bryostatin like activity although 




In order to systematically study the structure activity relationship of bryostatin 1, 
three bryostatin analogues were prepared using the pyran annulation chemistry. Two of 
these analogues Merle 28 and Merle 30 differed from bryostatin at just one point, Merle 
28 is C30-decarbomethoxy bryostatin 1 whereas Merle 30 is C9-deoxy bryostatin 1. The 
third analogue Merle 32 differs from PMA-like analogue Merle 23 at just the C8 position 
with an additional gem-dimethyl group. The biological evaluation of these analogues was 
carried out in terms of their binding affinity towards PKC- their function in several 
differential assays using human cell lines. All these analogues showed binding affinity 
comparable to that of bryostatin 1 for PKC- indicating that substitution at these three 
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function revealed that Merle 28 and Merle 30 behave like bryostatin where Merle 32 was 
like PMA. These studies suggested that the C30 carbomethoxy group, C9-OH or C8 gem-
dimethyl group do not alone switch the PMA versus bryostatin like activity. Thus the role 
of the three out of the four groups on the A-B region of the bryostatin 1 has been 
explored. A combination of four groups on the A-B-ring region (C7 acetate, C8 gem-
dimethyl, C9-OH, and C30 carbomethoxy) is ultimately responsible for the switch of PMA 
versus bryostatin like biology. The exact contributions of these groups have not been 
determined yet. However from the study of currently available analogues, it can be said 
that a combination that makes the A-B-ring region more hydrophilic leads to bryostatin 1 
like behavior whereas the analogues with more lipophilic A-B-ring regions tend to 
behave like PMA. 
 
Experimental Section 
General Experimental Procedures, Materials, and Instrumentation 
Solvents were purified according to the guidelines in Purification of Common 
Laboratory Chemicals (Perrin, Armarego, and Perrin, Pergamon: Oxford, 1966).
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Diisopropylamine, diisopropylethylamine, pyridine, triethylamine, EtOAc, MeOH, and 
CH2Cl2 were distilled from CaH2.  The titer of n-BuLi was determined by the method of 
Eastham and Watson.
74
 All other reagents were used without further purification.  Yields 
were calculated for material judged homogenous by thin layer chromatography and 
nuclear magnetic resonance (NMR).  Thin layer chromatography was performed on 
Merck Kieselgel 60 Å F254 plates or Silicycle 60Å F254 eluting with the solvent indicated, 
visualized by a 254 nm UV lamp, and stained with an ethanolic solution of 12-
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molybdophosphoric acid, or 4-anisaldehyde.  Flash column chromatography was 
performed with Silicycle Flash Silica Gel 40 – 63 µm or Silicycle Flash Silica Gel 60 – 
200 µm, slurry packed with 1% EtOAc/hexanes in glass columns. Preparative thin layer 
chromatography was performed on Silicycle 60Å F254 20 cm × 20 cm × 250 μm plates. 
Glassware for reactions was oven dried at 125 C and cooled under a dry nitrogen 
atmosphere prior to use.  Liquid reagents and solvents were introduced by oven dried 
syringes through septum-sealed flasks under a nitrogen atmosphere.  Nuclear magnetic 
resonance spectra were acquired at 500 MHz for 
1
H and 125 MHz for 
13
C.  Chemical 
shifts for proton nuclear magnetic resonance (
1
H NMR) spectra are reported in parts per 
million relative to the signal of relative to the signal of residual CHCl3 at 7.27 ppm.  
Chemical shifts for proton nuclear magnetic resonance (
1
H NMR) spectra are reported in 
parts per million relative to the signal residual C6D6 at 7.16 ppm or CDCl3 at 7.27 ppm .  
Chemicals shifts for carbon nuclear magnetic resonance (
13
C NMR and DEPT) spectra 
are reported in parts per million relative to the center line of the C6D6 triplet at 128.39 
ppm. Chemical shifts of the unprotonated carbons („C‟) for DEPT spectra were obtained 
by comparison with the 
13
C NMR spectrum.  The abbreviations s, d, apd, dd, ddd, dddd, t, 
td, tt, q, dq, and m stand for the resonance multiplicity singlet, doublet, apparent doublet, 
doublet of doublets, doublet of doublet of doublets, doublet of doublet of doublet of 
doublets, triplet, triplet of doublets, triplet of triplets, quartet, doublet of quartets, and 
multiplet, respectively.  Optical rotations (Na D line) were obtained using a microcell 
with 1 dm path length.  Specific rotations ([] , Unit: °cm2/g) are based on the equation 
 = (100·)/(l·c) and are reported as unit-less numbers where the concentration c is in 
g/l00 mL and the path length l is in decimeters.  Mass spectrometry was performed at the 
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mass spectrometry facility of the Department of Chemistry at The University of Utah on 
a double focusing high resolution mass spectrometer or at the mass spectrometry facility 
of the Department of Chemistry at the University of California, Riverside on an LCTOF 
mass spectrometer.  Compounds were named using using ChemDraw 12.0. 
 
Experimental Procedures and Analytical Data for Merle 28  
 Preparation of 3-(tert-butyl-diphenyl-silanyloxy)-propan-1-ol 
(1.81). To the 1,3-propanediol (8.3 g, 109.16 mmol, 3 equiv), triethylamine (7.6 mL, 
54.58 mmol, 1.5 equiv) and CH2Cl2 (200 ml) in a 500 ml flask at 0 C was added tert-
butyl(chloro)diphenylsilane (10.0 g, 36.8 mmol, 1 equiv), dropwise via syringe. The 
reaction was allowed to proceed for 12 h. The reaction was concentrated under reduced 
pressure and diluted with 30% EtOAc/Hexane (200 ml) and water (50 ml). Layers were 
separated and the organic layer was washed with brine (2 ml), dried over MgSO4, 
filtered and concentrated under reduced pressure. Flash column chromatography of the 
crude product with 15% EtOAc/Hexane gave the desired product (8.25 g, 72% yield) as a 
white crystalline solid: mp = 40 C, Rf = 0.37 (25% EtOAc/hexanes); 500 MHz 
1
H NMR 
(CDCl3) 7.70 – 7.68 (m, 4H), 7.46 – 7.39 (m, 6H), 3.87 – 3.84 (m, 4H), 2.36 (s, 1H), 
1.82 (J = 5.67 Hz, 2H), 1.07 (s, 9H); 125 MHz 
13
C NMR (CDCl3) 135.7, 133.4, 129.9, 
127.9, 63.5, 62.2, 34.4, 27.0, 19.3. 
 Preparation of 3-(tert-butyl-diphenyl-silanyloxy)-propion 
aldehyde (1.82). The stirring solution of oxalyl chloride (16.6 mL, 190.9 mmol, 1.5 
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equiv) and CH2Cl2 (500 mL) in a 1000 mL round bottom flask, was cooled to -78 C and 
the mixture was allowed to stir for 10 min. Dimethyl sulfoxide (27.1 mL, 381.9 mmol, 3 
equiv) was then added slowly via syringe to the reaction mixture and stirred for 10 min. 
The alcohol 1.81 (40.0 g, 127.3 mmol, 1 equiv) in 100 ml CH2Cl2 was cannulated to the 
reaction mixture slowly and an additional 10 ml CH2Cl2 was used for rinse. The reaction 
mixture stirred for 45 min at -78 C and triethylamine (88.7 mL, 636.5 mmol, 5 equiv) 
was added via syringe to the reaction mixture. The reaction was allowed to proceed for 1 
h and was allowed to warm up to 0 C. The reaction was quenched by adding 100 ml 
saturated NaHCO3 solution and 20% EtOAc/hexanes (200 ml). The layers were separated 
and organic layer was washed with brine (2  50 mL), water (2  50 ml), dried over 
MgSO4, filtered, and concentrated under reduced pressure to give the crude product as a 
yellow oil. The crude product was purified by flash column chromatography with 10% 
EtOAc/hexanes which gave aldehyde 1.82 (38.1 g, 96% yield) as colorless oil: Rf = 0.40 
(30% EtOAc/hexanes); 500 MHz 
1
H NMR (CDCl3) 9.84 (t, J = 2.19 Hz, 1H), 7.70 – 
7.68 (m, 4H), 7.48 – 7.40 (m, 6H), 4.05 (t, J = 6.22 Hz, 2H) 2.63 (td, J = 6.2, 2.1 Hz, 
2H), 1.07 (s, 9H); 125 MHz 
13
C NMR (CDCl3) 202.0, 135.7, 133.4, 130.0, 127.0, 58.5, 
46.6, 27.0, 19.38.  
           Preparation of (3S)-1-(tert-butyl-diphenyl-silanyloxy)-hex-5-
en-3-ol (1.84). To 1000 mL round bottom flask was added a magnetic stir bar, oven dried 
4 Å molecular sieves (51.2 g, 400 mg/mmol aldehyde), and CH2Cl2 (500 mL).  To the 
stirring solution, was added (S)-BINOL (7.33 g, 25.60 mmol, 0.2 equiv) in one portion, a 
1.0215 M solution of Ti(OiPr)4 (12.5 mL, 12.8 mmol, 0.1 equiv) in CH2Cl2 via syringe, 
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and a freshly prepared 0.1 M solution of TFA (8.9 mL, 0.89 mmol, 0.007 equiv) in 
CH2Cl2.  The reaction mixture was heated at reflux (~40 C) for 1 h, and then allowed to 
cool to rt.  Aldehyde 1.82 (40.0 g, 128.0 mmol, 1.0 equiv), in CH2Cl2 (7 mL), was added 
to the reaction flask via cannula.  An additional CH2Cl2 (5 mL) was for rinsing remaining 
aldehyde.  The mixture was stirred for 0.5 h at rt, cooled to -78 C and allyltributyltin 
(63.57 g, 192.0 mmol, 1.5 equiv) was added dropwise via syringe to the stirring mixture 
down the inside of the reaction flask.  The reaction mixture was stirred for an additional 
15 min at -78 C then kept in a -20 C freezer where it was briefly agitated every 24 h.  
After 5 days, the reaction mixture was filtered over a pad of Celite
®
 into a stirring 
saturated aqueous NaHCO3 solution (300 mL). The slurry was diluted with CH2Cl2 (200 
mL) and the resulting mixture was stirred for 1 h and the layers were separated. The 
aqueous layer was extracted with CH2Cl2 (2  100 mL). The combined organic layers 
were washed with brine (2  100 mL), dried over MgSO4, filtered, and concentrated 
under reduced pressure to give the crude product as red oil.  Flash column 
chromatography of the crude product with 5% EtOAc/hexanes gave homoallyic alcohol 
1.84 (40.16 g, 90% yield) as colorless oil: Rf = 0.46 (25% EtOAc/hexanes); 500 MHz 
1
H 
NMR (CDCl3) 7.70 – 7.69 (m, 4H), 7.47 – 7.40 (m, 6H), 5.87 (dddd, J = 17.2, 9.8, 6.9, 
6.9 Hz, 1H), 5.16 – 5.12 (m, 2H), 4.01 – 4.3.96 (m, 1H), 3.93 – 3.83 (m, 2H), 3.23 (d, J = 
2.4 Hz, 1H), 2.33 – 2.24 (m, 2H), 1.79 – 1.67 (m, 2H), 1.07 (s, 9H); 125 MHz 13C NMR 
(CDCl3) 135.7, 135.1, 130.0, 130.0, 129.9, 117.5, 71.0, 63.4, 42.1, 38.0, 27.0, 19.2; 
Assay of enantiomeric excess: HPLC (Chiralcel OD-H 25 cm column, 2.5% 
iPrOH/hexanes; 0.5 mL/min); tr (major) = 8.13 min, tr (minor) = 8.92 min; 93% ee. 
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 Preparation of tert-butyl-[(3S)-(4-methoxy-benzyloxy)-hex-
5-enyl-oxy]-diphenylsilane (1.85). To a stirring solution of alcohol 1.84 (26.32 g, 74.65 
mmol, 1.0 equiv) in CH2Cl2 (149 mL) in a 500 mL round bottom flask, was added freshly 
prepared 4-methoxybenzyl trichloroacetimidate (31.52 g, 111.97 mmol, 1.2 equiv). To 
the mixture was then added (±)-camphor-10-sulfonic acid (1.73 g, 7.465 mmol, 0.1 
equiv) in one portion.  The reaction was allowed to proceed for 12 h at rt, after which 
time TLC analysis indicated almost complete consumption of starting material.  The 
reaction mixture was concentrated under reduced pressure, diluted with 20% 
EtOAc/hexanes (200 mL), filtered over a pad of Celite
®
, and concentrated under reduced 
pressure to give a red slurry.  The crude product was purified by flash column 
chromatography eluting with 5% EtOAc/hexanes which gave PMB ether 1.85 (27.8 g, 
79% yield) as colorless oil: Rf = 0.45 (20% EtOAc/hexanes); 500 MHz 
1
H NMR (CDCl3) 
7.71 – 7.68 (m, 4H), 7.47 – 7.39 (m, 6H), 7.24 – 7.22 (m, 2H), 6.87 – 6.86 (m, 2H), 
5.87 (dddd, J = 17.2, 9.8, 6.9, 6.9 Hz, 1H), 5.13 – 5.08 (m, 2H), 4.47 (ABq, J = 10.9 Hz, 
 = 54.9 Hz, 2H), 3.88 – 3.83 (m, 1H), 3.81 (s, 3H), 3.80 – 3.73 (m, 2H), 2.35 (t, J = 6.0 
Hz, 2H), 1.82 – 1.78 (m, 2H), 1.09 (s, 9H); 125 MHz 13C NMR (CDCl3) 159.24, 
135.77, 135.11, 134.13, 134.11, 131.15, 129.76, 129.48, 127.83, 117.15, 113.91, 75.28, 
71.02, 60.73, 55.46, 38.75, 37.23, 27.11, 19.42. 
 Preparation of (S)-3-(4-methoxy-benzyloxy)-hex-5-en-1-ol 
(1.86).  To a stirring solution of BPS ether1.85 (3.58 g, 7.54 mmol, 1.0 equiv) and THF 
(50 mL) in a 250 mL round bottom flask, at rt, was added a 1.0 M solution of 
tetrabutylammonium fluoride (9.42 mL, 9.42 mmol, 1.25 equiv) in THF, dropwise via 
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syringe.  The reaction was allowed to proceed for 12 h at rt, after which the reaction 
mixture was concentrated under reduced pressure. The crude product was purified by 
flash column chromatography with 10% EtOAc/hexanes (400 mL), 25% EtOAc/hexanes 
(250 mL), and 50% EtOAc/hexanes (250 ml) which gave primary alcohol 1.86 (1.72 g, 
97% yield) as colorless oil: Rf = 0.23 (50% EtOAc/hexanes); 500 MHz 
1
H NMR (CDCl3) 
7.27 – 7.25 (m, 2H), 6.89 – 6.87 (m, 2H), 5.82 (dddd, 17.2, 9.8, 6.9, 6.9 Hz, 1 H), 5.13 
– 5.08 (m, 2H), 4.50 (ABq, J = 11.5 Hz,  = 81.7 Hz, 2H), 3.79 (s, 3H), 3.79 – 3.67 (m, 
3H), 2.60 (s, 1H), 2.44 – 2.39 (m, 1H), 2.37 – 2.31(m, 1H), 1.81 – 1.71 (m, 2H); 125 
MHz 
13
C NMR (CDCl3) 159.39, 134.42, 130.46, 129.58, 117.62, 114.01, 77.51, 70.82, 
60.72, 55.39, 38.21, 36.14;  
 Preparation of (S)-3-(4-methoxy-benzyloxy)-hex-5-enal 
(1.74).  To a stirring solution of alcohol 1.86 (5.0 g, 21.15 mmol, 1.0 equiv) and CH2Cl2 
(211 mL) in a 500 mL round bottom flask, at -5 C, was added freshly distilled N,N-
diisopropylethylamine (26.6 mL g, 148.10 mmol, 7.0 equiv), dropwise via syringe.  After 
10 min at -10 C, dimethyl sulfoxide (15.7 mL, 221.58 mmol, 10.0 equiv) was added to 
the reaction mixture via syringe and the solution was allowed to stir for an additional 10 
min.  Sulfur trioxide pyridine complex (13.47 g, 84.63 mmol, 4.0 equiv) was then added 
in one portion.  The reaction was allowed to proceed for 30 min at -5 C, was quenched 
by transferring the reaction mixture to a stirring saturated aqueous NaHCO3 solution.  
The reaction mixture was then concentrated under reduced pressure; diluted with 25% 
EtOAc/hexanes (200 mL), and the layers were separated.  The aqueous phase was 
extracted with 25% EtOAc/hexanes (4  50 mL).  The combined organic layers were 
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washed with brine (2  50 mL), dried over MgSO4, filtered, and concentrated under 
reduced pressure to give the crude product as a pale yellow oil. The crude product was 
purified by flash column chromatography with 10% EtOAc/hexanes which gave aldehyde 
1.84 (4.2 g, 85% yield) as colorless oil: Rf = 0.42 (40% EtOAc/hexanes); 500 MHz 
1
H 
NMR (CDCl3) 9.74 (t, J = 2.44 Hz, 1H), 7.25 – 7.23 (m, 2H), 6.87 – 6.86 (m, 2H), 5.81 
(dddd, J = 16.9, 9.9, 7.3, 7.3 Hz, 1H), 5.14 – 5.13 (m, 1H), 5.11 (s, 1H), 4.49 (ABq, J = 
10.9 Hz,  = 47.8 Hz, 2H), 4.03 – 3.98 (m, 1H), 3.77 (s, 3H), 2.66 (ddd, J = 16.6, 7.8, 
2.4 Hz, 1H), 2.55 (ddd, J = 16.6, 4.8, 1.9 Hz, 1H), 2.45 – 2.40 (m, 1H), 2.38 – 2.33 (m, 
1H); 125 MHz 
13
C NMR (CDCl3) 201.33, 159.28, 133.65, 130.19, 129.36, 118.17, 
113.82, 73.30, 70.87, 55.22, 47.98, 38.31;  
 Preparation of (3R, 5S)-3-hydroxy-5-(4-methoxy-
benzyloxy)-oct-7-enethioic acid S-tert-butyl ester (1.88). To a stirring solution of 
aldehyde 1.74 (3.98 g, 16.98 mmol, 1.0 equiv) and toluene (169 mL) in a 250 mL round 
bottom flask, at -78 C, was added a freshly prepared 1.0 M solution of TiCl2(OiPr)2 
(42.4 mL, 42.4 mmol, 2.5 equiv) dropwise via syringe.  The resulting yellow solution was 
allowed to stir for 15 min, followed by dropwise addition of thioketene acetal 1.74 (9.03 
g, 44.16 mmol, 2.6 equiv), in toluene (5 mL), down the inside of the reaction flask over a 
5 min period.  After 3 h, at -78 C, the reaction was quenched by transferring directly into 
a vigorously stirring mixture of CH2Cl2 (200 mL) and pH 7.0 phosphate buffer (100 mL).  
The layers were separated and the aqueous layer was extracted with CH2Cl2 (2  50 mL).  
The combined organic layers were washed with a saturated aqueous NH4Cl solution (2  
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100 mL), brine (2  100 mL), dried over MgSO4, filtered, and concentrated under 
reduced pressure to give a pale yellow oil.  The crude product was purified by flash 
column chromatography with 10% EtOAc/hexanes which gave -hydroxy thiol ester 1.88 
(5.79 g, 93% yield) as colorless oil: Rf = 0.42 (25% EtOAc/hexanes); 500 MHz 
1
H NMR 
(CDCl3) 7.27 – 7.26 (m, 2H), 6.88 – 6.86 (m, 2H), 5.79 (dddd, J = 17.0, 10.2, 6.8, 6.8 
Hz, 1H), 5.11 – 5.06 (m, 2H), 4.50 (ABq, J = 10.7 Hz,  = 69.9 Hz, 2H), 4.29 – 4.28 
(m, 1H), 3.79 (s, 3H), 3.79 – 3.76 (m, 1H), 3.18 (s, 1H), 2.60 – 2.58 (m, 2H), 2.43 – 2.38 
(m, 1H), 2.35 (ddd, J = 14.0, 7.0, 7.0 Hz, 1H), 1.67 – 1.56 (m, 2H), 1.46 (s, 9H); 125 
MHz 
13
C NMR (CDCl3) 200.0, 159.4, 134.4, 130.5, 129.6, 117.6, 114.0, 75.4, 71.2, 
65.9, 55.4, 51.5, 48.5, 40.2, 38.3, 29.9.   
 Preparation of (3R, 5S)-3-(tert-butyl-diphenyl-
silanyloxy)-5-(4-methoxy-benzyloxy)-oct-7-enethioic acid S-tert-butyl ester (1.89). To 
a stirring solution of a -hydroxy thiol ester 1.88 (1.00 g, 2.72 mmol, 1.0 equiv), 
imidazole (0.55 g, 8.18 mmol, 3.0 equiv), and DMF (9.0 mL) in a 15 mL round bottom 
flask, at rt, was added tert-butyl(chloro)diphenylsilane (0.89 g, 3.27 mmol, 1.2 equiv) via 
syringe.  The reaction was allowed to proceed for 24 h, and was quenched by adding a 
mixture of 10% EtOAc/hexanes (100 mL) and H2O (10 mL) in a rb flask. The layers 
were separated and the organic layer was washed with brine (2  mL), dried over 
MgSO4, filtered, and concentrated under reduced pressure.  The crude product was 
purified by flash column chromatography with 5% EtOAc/hexanes which gave silyl ether 




H NMR (CDCl3) 7.71 – 7.67 (m, 4H), 7.42 – 7.34 (m, 6H), 7.11 – 7.09 (m, 2H), 6.82 – 
6.81 (m, 2H), 5.58 (dddd, J = 17.5, 10.7, 7.3, 7.3 Hz, 1H), 4.96 – 4.92 (m, 2H), 4.38 (tt, J 
= 6.3, 5.8 Hz, 1H), 4.28 (d, J = 10.74 Hz, 1H), 4.02 (d, J = 10.7 Hz, 1H), 3.79 (s, 3H), 
3.35 – 3.31 (m, 1H), 2.71 (dd, J = 14.6, 6.3 Hz, 1H), 2.65 (dd, J = 14.6, 6.6 Hz, 1H),  
2.11 – 2.02 (m, 2H), 1.76 (ddd, J = 14.3, 8.4, 5.9 Hz, 1H), 1.66 (ddd, J = 14.3, 6.2, 3.9 
Hz, 1H), 1.42 (s, 9H), 1.03 (s, 9H);  125 MHz 
13
C NMR (CDCl3) 197.9, 159.1, 136.1, 
136.1, 134.0, 134.5, 134.2, 131.0, 129.8, 129.7, 129.3, 127.8, 127.7, 117.2, 113.8, 75.7, 
70.2, 69.1, 55.4, 53.0, 48.1, 42.4, 38.5, 29.9, 27.1, 19.6.  
  Preparation of (3R, 5S)-3-(tert-butyl-diphenyl-
silanyloxy)-5-(4-methoxy-benzyloxy)-oct-7-oxo-heptanethioic acid S-tert-butyl ester 
(1.72).  To a stirring solution of olefin 1.89 (3.0 g, 4.95 mmol, 1.0 equiv), THF (23 mL), 
t-butanol (22.5 mL), and H2O (4.5 mL) in a 100 mL round bottom flask, was added 4-
methylmorpholine N-oxide (726 mg, 3.19 mmol, 1.25 equiv) in one portion.  A 0.078 M 
solution of OsO4 (3.14 mL, 0.247 mmol, 0.05 equiv) in THF was added dropwise, via 
syringe.  The reaction was allowed to proceed for 12 h, and was quenched by addition of 
sodium metabisulfite (Na2S2O5) in one portion and the mixture was stirred for 1 h, during 
which time color changed from yellow to dark brown.  The reaction mixture was diluted 
with H2O (50 mL), EtOAc (200 mL), and the layers were separated. The aqueous layer 
was extracted with EtOAc (2  50 mL).  The combined organic layers were washed with 
brine (2  25 mL), dried over MgSO4, filtered, concentrated under reduced pressure give 
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crude diol 1.90 (3.22 g) as a thick paste that was taken directly onto the next reaction 
without further purification.  
To a stirring solution of crude diol 1.90 (3.22 g, approx. 5.03 mmol, 1.0 equiv) 
and benzene (50 mL), at rt, was added Pb(OAc)4 (2.34 g, 5.29 mmol, 1.05 equiv) in five 
portions over 10 min.  After 2 h, the reaction mixture was diluted with hexanes (200 mL), 
filtered over a pad of Celite
®
 and Na2SO4, and concentrated under reduced pressure to 
yield crude aldehyde. The crude product was purified by flash column chromatography 
with 10% EtOAc/hexanes which gave aldehyde 1.72 (2.91 g, 95% yield over 2 steps) as a 
viscous colorless oil: Rf = 0.40 (20% EtOAc/hexanes); 500 MHz 
1
H NMR (CDCl3) 
9.54 (s, 1H), 7.74 – 7.70 (m, 4H), 7.46 – 7.37 (m, 6H), 7.11 – 7.09 (m, 2H), 6.84 – 6.83 
(m, 2H), 4.44 (tt, J = 5.8, 5.6 Hz, 1H), 4.20 ABq, J = 10.7 Hz,  = 42.6 Hz, 2H), 3.84 – 
3.82 (m, 1H), 3.80 (s, 3H), 2.73 (dd, J = 14.6, 5.8 Hz, 1H), 2.64 (dd, J = 14.6, 6.3 Hz, 
1H), 2.34 (ddd, J = 16.1, 6.3, 1.9 Hz, 1H), 2.27 (ddd, J = 16.5, 4.9, 2.3 Hz, 1H), 1.97 
(ddd, J = 13.6, 6.8, 6.8 Hz, 1H), 1.65 (ddd, J = 14.1, 5.8, 5.8 Hz, 1H), 1.44 (s, 9H), 1.06 
(s, 9H); 125 MHz 
13
C NMR (CDCl3) 201.0, 197.6, 159.3, 136.1, 136.0, 133.8, 133.6, 
130.2, 130.0, 129.9, 129.4, 127.8, 113.8, 71.3, 70.6, 68.4, 55.4, 52.5, 48.5, 48.2, 42.7, 
29.9, 27.1, 27.1, 19.5.  
 Preparation of tert-butyl-(2-iodo-ethoxy)-dimethyl silane (1.74).  
To the commercially available 2-iodoethanol (20.0g, 116.29 mmol, 1.0 equiv) in a 500 ml 
flask were added CH2Cl2 (233 ml) and imidazole (23.75 g, 348.87 mmol, 3 equiv). To 
this solution was then added TBSCl (18.4g, 122.1 mmol, 1.05 equiv) in one portion. The 
mixture was stirred at room temperature for 24 hr after which it was diluted with 250 ml 
of hexane and 100 ml of water. The layers were separated and the organic layer was 
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washed with brine (2 ml), dried over MgSO4, concentrated under reduced pressure. 
Flash column chromatography with 2% EtOAc/Hexane gave the desired compound 
(32.63 g, 98% yield) as colorless oil; Rf = 0.40 (2.5% EtOAc/hexanes); 500 MHz 
1
H 
NMR (CDCl3) 3.84 (t, J = 6.9, 2H), 3.20 (t, J = 7.3, 2H), 0.91 (s, 9H), 0.09 (s, 6H); 125 
MHz 
13
C NMR (CDCl3) 64.4, 26.0, 18.53, 7.2, -4.9. 
 Preparation of 2-[-tert-butyl-dimethyl-silanyloxy-ethyl]-3-
methyl-but-3-enoic acid ethyl ester (1.91). To a flame dried 500 ml flask was added 
diisopropylamine (6.6 mL, 46.8 mmol, 1.1 equiv) in THF (229 ml) and the mixture was 
cooled to 0 C. To the solution was added a solution of n-BuLi in hexanes (17.3 ml of 
2.48 M, 42.91 mmol, 1.1 equiv) dropwise via syringe. The pale yellow solution was 
stirred at 0 C for 30 min and cooled to -78 C. Ethyl 2, 2-dimethyl acrylate (5.0 g, 39 
mmol, 1 equiv) was then added dropwise via syringe to the reaction mixture. After 30 
min, a solution of iodide 1.74 (11.16 g, 39 mmol, 1 equiv) in THF (5 ml) was added 
dropwise to the reaction mixture via cannula. The reaction was allowed to proceed for 12 
hr during which time the -78 C bath came to rt. The reaction was quenched by the 
addition of saturated aqueous NH4Cl solution (50 mL) and the mixture was diluted with 
100 ml of water and 200 ml of ether. The layers were separated and aqueous layer was 
extracted with diethyl ether (2 ml). The combined organic layers were washed with 
brine (2 ml), dried over MgSO4, filtered, and concentrated under reduced pressure. 
Purification was accomplished by flash column chromatographed with 1% EtOAc/hexane 
(1 liter), 2.5% EtOAc/hexane (1 liter), and 3.5% EtOAC/hexane (1 liter) to give the 
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desired product (8.95 g, 80% yield) as a colorless oil. Rf = 0.40 (5% EtOAc/hexanes); 
500 MHz 
1
H NMR (CDCl3) 4.90 (m, 1H), 4.89 (m, 1H), 4.14 (dq, J = 7.3, 3.6 Hz, 2H), 
3.59 (t, J = 6.2 Hz, 2H), 3.25 (t, J = 7.6 Hz, 2H), 2.06 (dddd, J = 13.9, 8.1, 6.2, 6.2 Hz, 
1H), 1.75 (s, 3H), 1.25 (t, J = 6.9 Hz, 3H), 0.89 (s, 9H), 0.04 (s, 6H),); 125 MHz 
13
C 
NMR (CDCl3) 173.8, 142.6, 113.9, 60.8, 60.7, 49.4, 33.2, 26.1, 20.5, 18.5, 14.3, -5.1, -
5.2.  
 Preparation of 2-[2-(tert-Butyl-dimethyl-silanyloxy)-ethyl]-
3-methyl-but-2-enoic acid ethyl ester (1.92). An oven-dried 25 mL round bottom flask 
was charged with alkene 1.91 (1.0 g, 3.49 mmol, 1.0 equiv) a magnetic stir bar, and then 
was purged with N2 for 15 min.  THF (7 mL), which was purged with N2 for 30 min, was 
added to the reaction flask via Gastight
®
 syringe. After cooling the mixture to 0 C, 
potassium tert-butoxide (0.391 g, 3.49 mmol, 1.0 equiv), was added to the mixture in one 
portion under the stream of N2. The reaction was allowed to proceed for 2 h at 0 C in 
which time TLC showed the completion of the reaction. The reaction was quenched by 
transferring into a flask that contained a stirring mixture of a saturated aqueous NH4Cl 
solution (25 mL) and Et2O (100 mL).  The layers were separated and the organic layer 
was washed with brine (2  20 mL), dried over MgSO4, filtered, and concentrated under 
reduced pressure. Purification was accomplished using flash column chromatography, 
eluting with 5% EtOAc/hexanes, providing ester 1.92 (0.952 g, 95% yield) as a colorless 
oil: Rf = 0.31 (10% EtOAc/hexanes); 300 MHz 
1
H NMR (CDCl3) 4.18 (q, J = 7.0 Hz, 
2H), 3.64 (t, J = 6.8 2H), 2.56 (t, J = 7.3 Hz, 2H), 2.00 (s, 3H), 1.85 (s, 3H), 1.30 (t, J = 
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6.7 Hz, 3H), 0.89 (s, 9H), 0.05 (s, 6H); 125 MHz 
13
C NMR (CDCl3) 
  
 Preparation of 2-[2-(tert-butyl-dimethyl-silanyloxy)-3-
methylbut-2-en-1-ol (1.93). To a stirring solution of the ester 1.92 (1.0 g, 3.49 mmol, 1 
equiv) in CH2Cl2 (35 ml) in a 100 ml flask at 0 C was added a solution of 
diisobutylaluminium hydride (8.72 ml of 0.1M, 8.72 mmol, 2.5 equiv) in CH2Cl2 
dropwise via syringe. The mixture was allowed to proceed for 2 h at 0 C at which time 
TLC showed the completion of the reaction. The reaction was quenched by dropwise 
addition of water and the mixture was transferred to a flask that contained a vigorously 
stirring solution of CH2Cl2 (25 ml) and saturated aqueous solution of potassium sodium 
(25 ml). The mixture was stirred vigorously for overnight and the layers were separated. 
The aqueous layer was extracted with CH2Cl2 (2 ml). The combined organic layers 
were washed with brine (2 x 20 ml), dried over MgSO4, concentrated under reduced 
pressure. Purification was accomplished using flash column chromatography, eluting 
with 10% EtOAc/hexanes, providing allylic alcohol (721 mg, 91% yield) as a pale yellow 
oil: Rf = 0.35 (20% EtOAc/hexanes); 500 MHz 
1
H NMR (CDCl3) 4.10 (d, J = 5.6 Hz, 
2H), 3.70 (t, J = 5.7 Hz, 2H), 3.24 (t, J = 5.6 Hz, 1H), 2.42 (t, J = 5.95 Hz, 2H), 1.76 (s, 
3H), 1.1.70 (s, 3H), 0.90 (s, 9H), 0.08 (s, 6H); 125 MHz 
13




  Preparation of tert-butyl-dimethyl-(3-methyl-tributyl-
stannanyl-methyl-pent-enyloxy)-silane (1.71). To a stirring solution of allylic alcohol 
1.93 (1.62 g, 7.54 mmol, 1.0 equiv) in THF (7 mL) in a flame-dried 50 mL round bottom 
flask, at -78 C, was added a solution of n-BuLi (3.38 mL of 2.45 M, 8.3 mmol, 1.1 
equiv) in hexanes dropwise via syringe.  The resulting yellow solution was stirred for 15 
min at -78 C.  Separately, to a stirring solution of diisopropylamine (2.6 mL, 18.9 mmol, 
1.1 equiv) and THF (7 mL) in a 25 mL round bottom flask, at 0 C, was added a solution 
of n-BuLi (6.5 mL of 2.45 M, 15.85 mmol, 2.1 equiv) in hexanes dropwise via syringe.  
After 45 min, tributyltin hydride (4.4 mL, 15.09 mmol, 1.0 equiv) was added via syringe 
to the freshly prepared LDA solution.  After 15 min, methanesulfonyl chloride (1.1 g, 
7.54 mmol, 1.0 equiv) was added to the lithium alkoxide solution at -78 C. After 1.25 h, 
the Bu3SnLi solution was added dropwise to the reaction flask via cannula.  An additional 
THF (1 mL) rinse was used to transfer Bu3SnLi residue.  The reaction was allowed to 
proceed for 2 h at -78 C, then for an additional 12 h during which time the -78 C bath 
expired to reach rt. The reaction mixture was quenched by adding water (15 ml), diluted 
with 10% EtOAc/hexanes (150 mL) and layers separated. The organic layer was washed 
with brine (2  10 mL), dried over MgSO4, filtered, and concentrated under reduced 
pressure.  Purification was accomplished by flash column chromatography with hexanes 
providing allyl stannane 1.71 (2.81 g, 71% yield) as a colorless oil: Rf = 0.20 (hexanes); 
500 MHz 
1
H NMR (CDCl3) 3.62 (t, J = 8.0 Hz, 2H), 2.20 (t, J = 7.6 Hz, 2H), 1.72 (s, 
1H), 1.67 (s, 3H), 1.59 (s, 3H), 1.51 – 1.44 (m, 6H), 1.34 – 1.27 (m, 6H), 0.91 (s, 9H), 
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0.90 – 0.88 (m, 9H), 0.85 – 0.82 (m, 6H), 0.07 (s, 3H); 125 MHz 13C NMR (CDCl3) 

 Preparation of 11-(tert-butyl-dimethyl-silanyloxy)-
3-(tert-butyl-diphenyl-silanyloxy)-7-hydroxy-5-(4-methoxy-benzyloxy)-8,8-dimethyl-
9-methylene-undecanethioic acid S-tert-Butyl ester (1.94). To a stirring solution of 
aldehyde 1.72 (300 mg, 0.49 mmol, 1.0 equiv) in toluene (4 mL) in a 15 mL round 
bottom flask, at -78 C, was added a freshly prepared solution of Me2AlCl (823 L of 3.0 
M, 2.47 mmol, 5.0 equiv) in toluene dropwise via syringe.  The solution was stirred for 5 
min at -78 C, then stannane 1.71 (332.0 mg, 0.642 mmol, 1.3 equiv) in toluene (900 L) 
was added dropwise, via syringe, down the inside of the reaction flask.  The reaction was 
allowed to proceed for 2 h at -78 C, and then quenched by transferring into a vigorously 
stirring mixture of a saturated aqueous potassium sodium tartrate solution (25 mL) and 
20% EtOAc/hexanes (50 mL). The resulting mixture was allowed to stir for 2 h and then 
the layers were separated.  The aqueous layer was extracted with 20% EtOAc/hexanes (2 
 25 mL). The combined organic layers were washed with brine (2  20 mL), dried over 
Na2SO4, filtered, and concentrated under reduced pressure to give the crude product as a 
pale yellow oil.  Purification was accomplished by flash column chromatography eluting 
with 5% EtOAc/hexanes providing coupled product 1.94 (315 mg, 76% yield) as a single 
diastereomer by NMR; Rf = 0.58 (25% EtOAc/hexanes); 500 MHz 
1
H NMR (CDCl3) 
7.73 – 7.69 (m, 4H), 7.44 – 7.36 (m, 6H), 7.13 – 7.12 (m, 2H), 6.83 – 6.81 (m, 2H), 
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4.97(s, 1H), 4.90 (s, 1H), 4.31 ( quin, J=5.9 Hz, 1H), 4.21 (ABq, J = 11.6 Hz,  = 50.0 
Hz, 2H), 3.80 – 3.75 (m, 2H), 3,79 (s, 3H), 3.68 (d, J = 9.5 Hz, 1H), 3.64 – 3.59 (m, 1H), 
2.69 (dd, J = 14.6, 5.8 Hz, 1H), 2.63 (dd, J = 14.6, 5.8 Hz, 1H), 2.40 (d, J = 2.93 Hz, 1H), 
2.28 ( ddd, J= 15.0, 7.3, 7.3 Hz, 1H), 2.22 ( ddd, J= 15.0, 6.2, 6.2 Hz, 1H), 1.94 (td, J = 
13.9, 6.6 Hz, 1H), 1.57 (td, J = 13.9, 5.6 Hz, 1H), 1.44 (s, 9H), 1.26 – 1.16 (m, 2H), 1.04 
(s, 9H), 0.94 (s, 3H), 0.90 (s, 9H), 0.87 (s, 3H), 0.10 (s, 3H), 0.06 (s, 3H); 125 MHz 
13
C 
NMR (CDCl3) 197.8, 159.2, 151.8, 136.1, 136.1, 134.1, 133.9, 130.9, 129.9, 129.8, 
129.5, 127.8, 113.8, 111.2, 74.4, 71.6, 71.0, 68.9, 63.5, 55.4, 52.3, 48.1, 43.8, 42.6, 35.5, 
34.0, 30.0, 27.1, 26.2, 22.7, 21.5, 19.5, 18.6, -5.0, -5.1. 
 Preparation of acetic acid 1-[4-(tert-butyl-
dimethyl-silanyloxy)-1,1-dimethyl-2 methylene-butyl]-5-(tert-butyl-diphenyl-
silanyloxy)-6-tert-butylsulfanylcarbonyl-3- -(4-methoxy-benzyloxy)-hexyl ester. To a 
stirring solution of alcohol 1.94 (300 mg, 0.359 mmol, 1.0 equiv), DMAP (4.0 mg, 0.035 
mmol, 0.1 equiv) in CH2Cl2 (3.6 mL) in a 10 mL round bottom flask at rt, was added a 
premixed solution of triethylamine (150 µL, 0.718 mmol, 3.0 equiv) and acetic anhydride 
(67 µL, 0.718 mmol, 2.0 equiv) dropwise via syringe.  TLC analysis after 24 h indicated 
completion of reaction. The reaction was diluted with 20% EtOAc/hexanes (50 mL), 
washed with sat. NaHCO3 solution (2 25 mL), brine (2 25 mL), dried over MgSO4, 
filtered and concentrated under reduced pressure to give the crude product as a pale 
yellow oil.  Purification was accomplished by flash column chromatography eluting with 
5% EtOAc/hexanes providing acylated product (307 mg, 98% yield) as a colorless oil: Rf 
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= 0.40 (10% EtOAc/hexanes); 500 MHz 
1
H NMR (CDCl3) 7.71 – 7.67 (m, 4H), 7.44 – 
7.35 (m, 6H), 7.20– 7.19 (m, 2H), 6.84 – 6.82 (m, 2H), 5.27 (d, J = 10.25 Hz, 1H), 4.89 
(s, 1H), 4.82 (s, 1H), 4.24 (quin, J=5.8 Hz, 1H), 4.20 (ABq, J = 10.2 Hz,  = 29.0 Hz, 
2H), 3.80 (s, 3H), 3.65 (t, J = 7.3 Hz, 2H), 3.24 – 3.19 (m, 1H), 2.66 (dd, J = 14.6, 6.3 
Hz, 1H), 2.56 (dd, J = 14.1, 5.8 Hz, 1H), 2.29 (ddd, J= 15.0, 7.3, 7.3 Hz, 1H), 2.23 ( ddd, 
J= 15.0, 6.2, 6.2 Hz, 1H), 1.99 (s, 3H), 1.97 – 1.90 (m, 1H), 1.52 – 1.46 (m, 1H), 1.43 (s, 
9H), 1.32 – 1.17 (m, 2H), 1.04 (s, 9H), 0.95 (s, 3H), 0.93 (s, 3H), 0.89 (s, 9H), 0.03 (s, 
6H); 125 MHz 
13
C NMR (CDCl3) 197.7, 170.8, 159.1, 150.8, 136.1, 136.0, 133.9, 
131.0, 129.9, 129.9, 129.6, 127.8, 113.7, 111.1, 74.6, 73.4, 71.3, 68.7, 63.3, 55.4, 52.3, 
48.2, 43.4, 42.8, 35.8, 34.7, 29.9, 27.1, 26.1, 24.1, 22.8, 21.6, 21.3, 19.5, 18.5, -5.0, -5.0. 
 Preparation of 1-[4-(tert-butyl-dimethyl-
silanyloxy)-1,1-dimethyl-2 methylene-butyl]-5-(tert-butyl-diphenyl-silanyloxy)-6-tert-
butylsulfanylcarbonyl-3- hydroxy-hexyl ester (1.95). To a stirring solution of PMB 
ether mentioned above (881 mg, 1.005 mmol, 1.0 equiv) in CH2Cl2 (7 mL), and pH 7.0 
phosphate buffer (3 mL) in a 25 mL round bottom flask, at rt, was added 2,3-dichloro-
5,6-dicyano-1,4-benzoquinone (456 mg, 2.01 mmol, 2.0 equiv) in one portion. After 2 h 





, and Na2SO4 (2 cm each). The filtrate was concentrated under reduced 
pressure to give the crude product as a pale yellow oil. Purification was accomplished by 
flash column chromatography eluting with 5% EtOAc/hexanes providing alcohol 1.95 





NMR (CDCl3) 7.70 – 7.67 (m, 4H), 7.45 – 7.38 (m, 6H), 5.06(dd, J = 11.4, 1.5 Hz, 1H), 
4.93(s, 1H), 4.85 (s, 1H), 4.41 – 4.36 (m, 1H), 3.74 (dddd, J = 17.9, 9.9, 7.0, 7.0 Hz, 2H), 
3.47 (t, J = 7.8 Hz, 2H), 2.63 – 2.61 (m, 3H), 2.24 (t, J = 7.3 Hz, 2H),  1.93 (s, 3H), 1.60 
(ddd, J = 14.3, 9.2, 4.0 Hz, 1H), 1.55 (ddd, J = 14.3, 8.1, 2.6 Hz, 1H), 1.45 – 1.23 (m, 
2H), 1.40 (s, 9H), 1.03 (s, 9H), 1.01(s, 3H), 1.01(s, 3H), 0.90 (s, 9H), 0.06 (s, 6H), 125 
MHz 
13
C NMR (CDCl3) 197.7, 172.2, 150.6, 136.1, 136.0, 133.8, 133.8, 129.9, 129.9, 
127.9, 127.8, 111.3, 75.3, 68.5, 63.8, 63.3, 52.5, 48.1, 44.4, 42.9, 38.1, 34.7, 29.9, 27.1, 
26.1, 24.0, 21.0, 19.6, 18.5, -5.0, -5.0. 
 Preparation of 2-[2-(tert-butyl-dimethyl-
silanyloxy)-ethyl]-6-[2-(tert-butyl-diphenyl-silanyloxy)-3-tert-butylsulfanylcarbonyl-
propyl]-2-3,3-dimethyl-tetrahydro-pyran-4-yl ester (1.96). To a stirring solution of 
alkene 1.95 (571 mg, 0.754 mmol, 1.0 equiv) in CH2Cl2 (15.0 mL) in a 25 mL round 
bottom flask, at -78 C, was bubbled a steady stream of ozone for 5 min. The solution 
color changed to light blue. The ozone stream was stopped and the excess O3 was 
removed by passing a stream of N2. The reaction mixture was concentrated under reduced 
pressure, dimethyl methyl sulfide (20 mL) was added and the resulting solution was 
stirred for 12 h. The solution was concentrated under reduced pressure to give the crude 
product. Purification was accomplished by flash column chromatography eluting with 5% 
EtOAc/hexanes providing cyclic hemiketal 1.96 (486 mg, 85% yield) as a colorless oil. 
Rf = 0.55 (20% EtOAc/hexanes); 500 MHz 
1
H NMR (CDCl3) 7.72 – 7.68 (m, 4H), 7.43 
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– 7.36 (m, 6H), 5.22 (s, 1H), 5.06 (dd, J = 11.7, 4.8 Hz 1H), 4.30 (dddd, J = 10.2, 5.3, 
5.3, 5.3, 1H), 4.17 (ddd, J = 12.1, 10.3, 1.8 Hz, 1H), 3.80 (dddd, J = 11.7, 7.3, 4.4, 2.9 
Hz, 1H), 3.73 (ddd, J = 10.3, 4.0, 2.9, 1H), 2.69 (d, J = 5.8 Hz, 2H), 2.01 (s, 3H), 1.91–
1.85 (m, 1H), 1.72 (td, J = 14.1, 7.8 Hz, 1H), 1.58 – 1.41 (m, 3H), 1.44 (s, 9H), 1.36 
(ddd, J = 12.1, 4.8, 2.9 Hz, 1H), 1.03 (s, 9H), 0.91(s, 3H), 0.89 (s, 9H), 0.83 (s, 3H), 0.09 
(s, 3H), 0.09 (s, 3H), 125 MHz 
13
C NMR (CDCl3) 197.9, 170.5, 136.1, 136.0, 134.6, 
129.8, 129.7, 127.7, 127.7, 102.2, 73.4, 69.3, 64.3, 60.2, 52.4, 48.0, 43.8, 41.3, 34.0, 33.5, 
30.0, 27.1, 26.0, 21.3, 21.1, 19.6, 18.2, 16.8, -5.2, -5.3. 
 Preparation of acetic acid 6-[2-(tert-butyl-diphenyl-
silanyloxy)-3-tert-butylsulfanylcarbonyl-propyl]-2-(2-hydroxy-ethyl)-2methoxy-3,3-
dimethyl-tetrahydro-pyran-4-yl ester). To a stirring solution of TBS ether 1.96 (0.42 g, 
0.553 mmol, 1.0 equiv) and MeOH (5.5 mL) in a 10 mL round bottom flask, at rt, was 
added (±)-camphor-10-sulfonic acid (32 mg, 0.138 mmol, 0.25 equiv) in one portion.  
The reaction mixture was allowed to proceed for 1.5 h, after which time TLC analysis 
indicated completion of reaction. The reaction mixture was quenched by pouring the 
reaction mixture into a mixture of saturated aqueous NaHCO3 solution (50 mL) and 50% 
EtOAc/hexanes (100 mL).  The resulting layers were separated and the aqueous layer was 
extracted with 50% EtOAc/hexanes (2  25 mL). The combined organic layers were 
washed with brine (20 mL), dried over MgSO4, filtered, and concentrated under reduced 
pressure.  Purification was accomplished by flash column chromatography eluting with 
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15% EtOAc/hexanes providing cyclic methyl ketal (312 mg, 86%) as a colorless oil: Rf = 
0.18 (30% EtOAc/hexanes); 500 MHz 
1
H NMR (CDCl3) 7.73 – 7.64 (m, 4H), 7.46 – 
7.36 (m, 6H), 5.05(dd, J = 11.7, 4.7 Hz, 1H), 4.27 (q, J = 5.9, 1H), 3.68 – 3.58 (m, 2H), 
3.47 (dddd, J = 11.7, 7.3, 4.0, 4.0 Hz, 1H), 2.97 (s, 3H), 2.72 (dd, J = 14.2, 5.8 Hz, 1H), 
2.62 (dd, J = 14.6, 6.2 Hz, 1H), 2.32 (t, J = 6.2 Hz, 1H), 2.06 – 1.96 (m, 1H), 2.02 (s, 
3H), 1.83 – 1.72 (m, 2H), 1.53 – 1.41 (m 2H), 1.43 (s, 9H), 1.13 –1.10 (m, 1H),  1.03 (s, 
9H), 0.90 (s, 3H), 0.82 (s, 3H), 125 MHz 
13
C NMR (CDCl3) 198.0, 170.7, 136.1, 136.0, 
134.0, 133.9, 130.0, 130.0, 127.9, 127.9, 104.9, 73.4, 68.8, 66.0, 59.7, 52.6, 48.6, 48.4, , 
43.9, 42.0, 34.7, 32.9, 29.9, 27.1, 21.4, 20.5, 19.5, 17.3. 
 Preparation of acetic acid 6-[2-(tert-butyl-diphenyl-
silanyloxy)-3-tert-butylsulfanylcarbonyl-propyl]-2-methoxy-3,3-dimethyl-2-(2-oxo-
ethyl)-tetrahydro-pyran-4-yl ester (1.69). To a stirring solution of alcohol from above 
reaction (183 mg, 0.277 mmol, 1.0 equiv) in CH2Cl2 (9.2 mL) in a 25 mL round bottom 
flask under an atmosphere of N2, at -5 C, was added freshly distilled N,N-
diisopropylethylamine (634  µL, 1.939 mmol, 7 equiv), dropwise via syringe.  After 10 
min at -5 C, dimethyl sulfoxide (160 µL, 2.77 mmol, 10.0 equiv) was added to the 
reaction mixture via syringe and the solution was allowed to stir for an additional 10 min.  
Sulfur trioxide pyridine complex (176 mg, 1.18 mmol, 4.0 equiv) was then added in one 
portion.  The reaction was allowed to proceed for 1 h at -5 C, and the reaction was 
diluted with 20% EtOAc/hexanes (100 mL) and quenched by pouring into saturated 
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aqueous NaHCO3 solution (50 ml).  The layers were separated and the aqueous phase was 
extracted with 20% EtOAc/hexanes (2 25 mL).  The combined organic layers were 
washed with brine (2  25 mL), dried over MgSO4, filtered, and concentrated under 
reduced pressure to give the crude product. Purification was accomplished by flash 
column chromatography eluting with 10% EtOAc/hexanes providing aldehyde 1.69 (170 
mg, 94% yield) as colorless oil: Rf = 0.55 (25% EtOAc/hexanes); 500 MHz 
1
H NMR 
(CDCl3) t, J = 2.9 Hz, 1H), 7.70 – 7.65 (m, 4H), 7.46 – 7.36 (m, 6H), 5.02(dd, J 
= 11.7, 4.8 Hz, 1H), 4.27 (q, J = 6.3, 1H), 3.68 – 3.58 (m, 1H), 3.47 (dddd, J = 11.7, 7.8, 
4.3, 4.3 Hz, 1H), 2.97 (s, 3H), 2.72 (dd, J = 14.1, 6.3 Hz, 1H), 2.62 (dd, J = 14.1, 6.3 Hz, 
1H), 2.32 (t, J = 3.4 Hz, 1H), 2.06 – 1.96 (m, 1H), 2.02 (s, 3H), 1.83 – 1.72 (m, 2H), 1.53 
– 1.41 (m 2H), 1.43 (s, 9H), 1.13 –1.10 (m, 1H),  1.03 (s, 9H), 0.90(s, 3H), 0.82 (s, 3H), 
125 MHz 
13
C NMR (CDCl3) 198.0, 170.7, 136.1, 136.0, 134.0, 133.9, 130.0, 130.0, 
127.9, 127.9, 104.9, 73.4, 68.8, 66.0, 59.7, 52.6, 48.6, 48.4, , 43.9, 42.0, 34.7, 32.9, 29.9, 
27.1, 21.4, 20.5, 19.5, 17.3.  
 Preparation of acetic acid 2-(6-
benzyloxymethyl-4-methylene-tetrahydro-pyran-2-ylmethyl)-6-[2-(tert-butyl-
diphenyl-silanyloxy)-3-tert-butyl sulfanylcarbonyl-propyl]-2-methoxy-3, 3-dimethyl-
tetrahydro-pyran-4-yl ester (1.100). To a stirring solution of aldehyde 1.69 (19.0 mg, 
0.029 mmol, 1.0 equiv) in Et2O (0.414 mL) in a 5 ml reaction vial, under N2 at –78 C, 
was added hydroxyl allylsilane 1.99 (8.8 mg, 0.0319 mmol, 1.1 equiv, in 0.05 ml Et2O) 
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via syringe and the mixture was stirred for 10 min. A solution of TMSOTf in Et2O (0.034 
ml of 1.014 M, 0.0348 mmol, 1.2 equiv) was then added dropwise via syringe. The 
reaction was allowed to proceed for 5 h at –78 C. The reaction mixture was then 
quenched at –78 C by the addition of Hunig‟s base (0.05 ml) and stirred for 10 min. The 
reaction was warmed to 0 C and again quenched by the addition of saturated aqueous 
NaHCO3 solution (3 mL). The reaction was diluted with 25 ml of 25% EtOAc in 
hexanes. The layers were separated and the aqueous layer was extracted with 25% EtOAc 
in hexanes (2  10 mL). The combined organic layers were washed with brine (2  10 
mL), dried over Na2SO4, filtered and concentrated under reduced pressure. Purification 
was accomplished by flash column chromatography on a 1  25 cm column, eluting with 
5% EtOAc/hexanes, collecting 3 mL fractions.  The product containing fractions (30-41) 
were combined and concentrated under reduced pressure to give 1.100  (21 mg, 85% 
yield) as a colorless viscous oil; Rf = 0.48 (20% EtOAc/hexanes); []
20
D = + 21 (c = 1.15, 
CHCl3); 500 MHz 
1
HNMR (CDCl3) δ 7.70-7.66 (m, 4H), 7.43-7.34 (m, 11H), 4.97 (dd, J 
= 11.7, 5.12 Hz, 1H), 4.72 (s, 2H), 4.59 (s, 2H), 4.26 (dddd, J = 10.98, 3.84, 3.84, 3.84 
Hz, 1H), 3.59-3.42 (m, 4H), 3.19 (dddd, J = 11.23, 7.29, 3.84, 3.81, 1H), 2.95 (s, 3H), 
2.75(dd, J = 15.05, 4.76 Hz, 1H), 2.71 (dd, J = 14.83, 7.12 Hz, 1H), 2.27-2.18 (m, 2H), 
2.0 (s, 3H), 2.04-1.88 (m, 4H), 1.69-1.64 (m, 2H), 1.45 (s, 9H), 1.32-1.26 ( m, 2H), 1.03 ( 
s, 9H), 0.90 (s, 3H), 0.84 (s, 3H); 125 MHz 
13
C NMR (CDCl3) δ 198.2, 170.7, 144.5, 
138.7, 136.1, 136.0, 134.4, 133.6, 129.9, 129.8, 128.5, 127.8, 127.78, 127.72, 127.6, 
109.1, 104.0, 77.5, 75.0, 73.8, 73.5, 73.4, 69.5, 66.0, 53.2, 48.3, 48.1, 43.7, 42.3, 42.0, 
39.2, 37.2, 32.8, 30.0, 27.1, 21.4, 20.7, 19.5, 16.8; IR ( thin film) 2958, 2933, 2895, 2859, 
1742, 1682, 1455, 1428, 1365, 1245, 1111, 892, 822, 612,  703 cm
-1
 ; HRMS (EI+) calcd 
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for C49H68O8SSi 844.4404, found 844.4432. Verification of C11-C15 stereochemistry: 
Following NOE interaction proved the expected stereochemistry about the A and the B-
ring. 
 Preparation of (9S,11R,12R,E)-S-ethyl 12-
((benzyloxy)methoxy)-9-((tert-butyldimethylsilyl)oxy)-11-((4-methoxybenzyl)oxy)-
4,4-dimethyl-5-oxotridec-2-enethioate (1.111): To a stirring solution of alkene 1.77 
(500 mg, 0.81 mmol, 1.0 equiv.) in 20:1 EtOAc/ MeOH (16 mL), in a 50 mL rb flask, at -
78 °C was added NaHCO3 (320 mg, 8.15 mmol, 10.0 equiv).  A steady stream of O3 was 
bubbled through the reaction mixture until a light blue color developed.  TLC showed the 
completion of the reaction. The excess O3 was removed by bubbling O2 through the 
mixture until the light blue color faded. A solution of PPh3 (320 mg, 1.2 mmol, 1.5 
equiv.) in CH2Cl2 (2 mL) was added to the reaction mixture, and the reaction mixture was 
slowly warmed to rt and stirred for 12 h.  The solids were removed by filtration, and the 
solution was concentrated under reduced pressure.  The resulting yellow oil was taken-up 
in 10% Et2O/ pentane (20 mL) in a 50 mL rb flask, and placed in a -20 °C freezer for 6 h 
during which the triphenylphosphine oxide precipitate was formed. The white precipitate 
was removed by filtration, and rinsed with 10 mL of ice cold 1% Et2O/ pentane. The 
solvent was removed under reduced pressure to yield crude aldehyde as a light yellow oil, 
which was taken on to the next step without further purification. 
 To a stirring solution of S-ethyl 2-(diethoxyphosphoryl)ethanethioate (430 mg, 
1.7 mmol, 2.2 equiv) in THF (3 mL) in a 10 mL rb flask at 0 °C, was added NaH (43 mg, 
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1.7 mmol, 2.2 equiv.) slowly over 10 min.  The reaction mixture was stirred at 0 °C for 
an additional 30 min, and a solution of crude aldehyde in THF (1 mL) was added 
dropwise to the reaction mixture slowly via cannula and rinsed with THF (0.5 mL). 
Stirring continued at 0 °C for an addition 2 h after which the reaction was quenched by 
adding EtOAc (15mL) and a saturated aqueous NH4Cl solution (20 mL). The phases were 
separated and the aqueous phase was extracted with EtOAc (3 x 20 mL). The combined 
organic phases were washed with brine (25 mL), dried over Na2SO4, filtered and 
concentrated under reduced pressure.  Purification was accomplished using flash column 
chromatography eluting with 10% EtOAc/ hexanes. The product containing fractions 
were combined and concentrated under reduced pressure to provide thiolester 1.111 (481 
g, 84% over 2 steps) as a clear colorless oil: Rf = 0.51 (20% EtOAc/ hexanes);  500 MHz 
1
H NMR (CDCl3) δ 7.36-7.23 (m, 7H), 6.95 (d, J = 15.9 Hz, 1H), 6.88-6.85 (m, 2H), 6.13 
(d, J = 15.9 Hz, 1H), 4.81 (d, J = 7.3 Hz, 1H), 4.79 (d, J = 7.3 Hz, 1H), 4.66 (d, J = 12.0 
Hz, 1H), 4.60 (d, J = 11.6 Hz, 1H), 4.59 (d, J = 10.7 Hz, 1H), 4.44 (d, J = 10.7 Hz, 1H), 
4.51 (qd, J = 6.4, 4.7 Hz, 1H), 3.89 (m, 1H), 3.80 (s, 3H), 3.64 (ddd, J = 9.4, 4.5, 2.3 Hz, 
1H), 2.97 (q, J = 7.4 Hz, 2H), 2.41(m, 2H), 1.68 (ddd, J = 15.1, 8.5, 2.6 Hz, 1H), 1.60-
1.53 (m, 3H), 1.45-1.40 (m, 2H), 1.29 (t, J = 7.5 Hz, 3H), 1.27 (s, 6H), 1.18 (d, J = 6.4 
Hz, 3H), 0.88 (s, 9H), 0.04 (s, 3H), 0.04 (s, 3H);  125 MHz 
13
C NMR (CDCl3) δ 210.5, 
189.9, 159.2, 147.2, 138.1, 131.0, 129.2, 128.5(x2), 127.9, 127.7, 127.6, 113.8, 93.3, 
78.1, 72.9, 72.0, 69.5, 69.4, 55.3, 50.5, 38.5, 37.7, 37.3, 26.1, 23.5, 23.4, 19.1, 18.2, 15.1, 
14.8, -3.6, -4.2; 125 MHz DEPT 
13
C NMR (CDCl3) CH3 δ 55.3, 26.0, 23.5, 15.1, 14.8, -
3.6, -4.2; CH2 δ 93.2, 71.9, 69.4, 38.5, 37.7, 37.3, 23.4, 19.1; CH1 δ 147.2, 129.2, 128.5, 
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127.9, 127.7, 127.6, 113.8, 78.1, 72.8, 69.5; CH0 δ 210.5, 189.9, 159.2, 138.1, 131.0, 
50.5, 18.2. 
 Preparation of (E)-S-ethyl 4-((S)-2-
((2R,3R)-3-((benzyloxy) methoxy)-2-((4-methoxybenzyl)oxy)butyl)-3,4-dihydro-2H-
pyran-6-yl)-4-methylpent-2-enethioate (1.112):  To a stirring solution of thiolester 
1.111 (102 mg, 0.14 mmol, 1.0 equiv.) in 20:1 CH3CN/ H2O (3 mL), in a plastic bottle at 
0 °C, was added pyridine (480 µL, 0.3 M) and aqueous HF solution (48%, 0.1 mL).  The 
solution was stirred at 0 °C for 30 min and warmed to rt after which it was brought to rt. 
After 30 min at rt, an additional 0.1 mL of aqueous HF solution (48%) was added every h 
until TLC analysis indicated complete consumption of the starting material.  The reaction 
was quenched by slowly pipetting the reaction mixture into a mixture of saturated 
aqueous NaHCO3 solution (25 mL) and EtOAc (25 mL). The phases were separated and 
the aqueous phase was extracted three times with EtOAc (3 x 25 mL). The combined 
organic phases were washed saturated aqueous CuSO4 solution (2 x 25 mL), and with 
brine (2 x 25 mL). The combined organic phases were dried with Na2SO4, filtered and 
concentrated to provide the crude intermediate alcohol as clear light yellow oil.  This 
crude material was carried on to the next step without further purification. 
 To a stirring solution of the previously described intermediate crude alcohol in 
benzene (3 mL) in a 15mL rb flask equipped with a condenser and Dean-Stark trap, was 
added CSA (2 mg, 0.007 mmol, 0.05 equiv.).  The solution was heated to reflux for 1 h 
and allowed to cool to room temperature.  The reaction mixture was quenched with 
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pyridine (0.1 mL), and the solvent was removed under reduced pressure.  This material 
was immediately purified using flash column chromatography on a 1 x 10 cm silica gel 
column, eluting with 5% EtOAc/ hexanes, collecting 5 mL fractions. The product 
containing fractions (15-42) were combined and concentrated under reduced pressure to 
yield pure dihydropyran 1.112 (73 mg, 88% over 2 steps) as a clear colorless oil:  Rf = 
0.48 (20% EtOAc/ hexanes);  500 MHz 
1
H NMR (CDCl3) δ 7.36-7.35 (m, 4H), 7.33-7.27 
(m, 1H), 7.24 (d, J = 8.6 Hz, 2H), 6.97 (d, J = 15.9 Hz, 1H), 6.85 (d, J = 8.6 Hz, 1H), 
6.08 (d, J = 15.9 Hz, 1H), 4.83 (d, J = 6.9 Hz, 1H), 4.81 (d, J = 6.9 Hz, 1H), 4.66-4.58 
(m, 4H), 4.48 (d, J = 11.1 Hz, 1H), 4.02-3.93 (m, 2H), 3.84-3.78 (m, 4H), 2.88 (q, J = 7.4 
Hz, 2H), 2.12-2.04 (m, 1H), 2.01-1.95 (m, 1H), 1.81-1.74 (m, 2H), 1.63-1.56 (m, 1H), 
1.54-1.46 (m, 1H), 1.23-1.19 (m, 12H);  125 MHz 
13
C NMR (CDCl3) δ 190.5, 159.3, 
157.0, 151.9, 138.1, 131.0, 129.6, 128.5 (x2), 128.0, 127.8, 125.7, 113.9, 94.5, 93.7, 77.7, 
73.8, 73.6, 71.9, 69.5, 55.4, 41.4, 36.2, 28.2, 25.2, 25.1, 23.2, 20.5, 15.5, 14.9; 125 MHz 
DEPT 
13
C NMR (CDCl3)  CH3 δ 55.4, 25.2, 25.1, 15.5, 14.9; CH2 δ 93.5, 73.6, 69.5, 
36.2, 28.1, 23.2, 20.5; CH δ 151.9, 129.6, 128.5, 128.0, 127.8, 125.7, 113.9, 94.5, 77.7, 
73.8, 71.9; CH0 δ 190.5, 159.3, 157.0, 138.1, 131.0, 41.4. 
  Preparation of (E)-4-((S)-2-((2R,3R)-3-
((benzyloxy)methoxy)-2-((4-methoxybenzyl)oxy)butyl)-3,4-dihydro-2H-pyran-6-yl)-
4-methylpent-2-enal (1.76): To a stirring solution of thioester 1.112  (457 mg, 0.803 
mmol,  1 equiv.) in CH2Cl2 (8 mL) at - 78 
o
C was added a solution of DIBAL-H in 
CH2Cl2 (5.5 mL of 1.0 M, 1.1 mmol, 3 equiv.) dropwise over a period of 30 min.  This 
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mixture was stirred at -78 
o
C for 1.5 h then EtOAc (2 mL) was added dropwise over 10 
min.  The solution was stirred for 15 min, and then quenched by the addition of saturated 
aqueous Rochelle salt (5 mL) dropwise.  The cold bath was removed, and the mixture 
was stirred vigorously for 3 h at ambient temperature. The layers were separated and the 
aqueous layer was extracted with EtOAc (3 x 20 mL). The combined organic layers were 
washed with brine (2 x 20 mL), dried over Na2SO4, filtered, and concentrated under 
reduced pressure. The residue was purified via flash column chromatography, eluting 
with 10% EtOAc/hexanes collecting 4 mL fractions. The product containing fractions 
(35-80) were collected and concentrated under reduced pressure to provide -
unsaturated aldehyde 1.76 (327 mg, 80%) as a colorless oil: Rf = 0.54 (30% 
EtOAc/hexanes); 500 MHz 
1
H NMR (CDCl3) 9.47 (d, J = 7.8 Hz, 1H), 7.37 – 7.23 (m, 
8H), 6.87 – 6.83 (m, 4H), 6.10 (dd, J = 16.1, 7.81 Hz, 1H), 4.81 (ABq,  = 10.7 Hz, 
2H), 4.62 – 4.60 (m, 4H), 4.46 (d, J = 10.7 Hz, 1H), 4.05 – 3.94 (m, 2H), 3.80 – 3.75 (m, 
1H), 3.79 (s, 3H), 2.13 - 2.06 (m,1H), 2.03 – 1.97 (m, 1H), 1.83 – 1.76 (m, 2H), 1.64 – 
1.58 (m, 1H), 1.55 – 1.47 (m, 1H), 1.25 (d, J = 3.4 Hz, 6H), 1.20 (d, J = 6.3 Hz, 3H); 125 
MHz 
13
C NMR (CDCl3) 194.5, 165.5, 159.3, 156.6, 138.0, 130.8, 129.7, 129.4, 128.5, 
127.9, 127.7 113.9, 94.7, 93.5, 77.5, 73.5, 73.2, 72.0, 69.5, 55.3, 42.0, 35.1, 28.0, 25.2, 
25.0, 20.4, 15.4; 125 MHz DEPT 
13
C NMR (CDCl3)  CH3 δ 55.3, 25.2, 25.1, 15.4; CH2 δ 
93.4, 73.2, 69.5, 35.9, 28.0, 20.4; CH δ 194.5, 165.5, 129.7, 129.4, 128.5, 127.9, 113.9, 




 Preparation of (E)-7-((S)-2-((2R,3R)-3-
((benzyloxy)methoxy)-2-((4-methoxybenzyl)oxy)butyl)-3,4-dihydro-2H-pyran-6-yl)-
7-methyl-2-((trimethylsilyl)methyl) octa-1,5-dien-4-ol (1.113):  To a solution of 
aldehyde 1.76  (625 mg, 1.22 mmol,  1 equiv.) in toluene (12 mL) in a 25 mL rb flask 
was added a trimethyl(2-((tributylstannyl)methyl)allyl)silane via syringe. The mixture 
was heated to reflux at 120 
o
C for 24 h in which TLC showed the completion of reaction. 
The reaction mixture was allowed to cool to rt and the solvent was removed under 
reduced pressure. Purification was accomplished using flash column chromatography 
with a 3 x 18 cm silica gel column, eluting with 10% EtOAc/hexanes, collecting 6 mL 
fractions. The product containing fractions (51-115) were combined and concentrated 
under reduced pressure to provide alcohol 1.113 (702 mg, 90%) as 1:1 mixture of 
diastereomers as colorless oil.  Rf = 0.57 (30% EtOAc/hexanes);   
20
D  +21.2 (c = 
1.03, EtOAc); 500 MHz 
1
H NMR (C6D6) δ 7.38-7.08 (m, 7H), 6.82-6.80 (m, 2H), 6.04 
(dd, J = 15.6, 6.3 Hz, 1H), 5.67 (dd, J  = 15.6, 5.8 Hz, 1H), 4.83-4.70 (m, 4H), 4.67-4.6 
(m, 4H), 4.29-4.4.05 (m, 4H), 3.30 (s, 3H), 2.59-2.50 (m, 2H), 2.29-2.15 (m, 2H), 2.02-
1.83 (m, 5H), 1.76-1.71 (m, 1H), 1.64-1.38 (m, 5H), 1.33 (dd, J = 8.7, 2.4 Hz, 6H), 1.23 
(dd, J = 6.3 Hz, 4H), 0.00 (s, 9H); 125 MHz 
13
C NMR (C6D6) δ 160.0 (x2), 159.7, 159.6, 
144.9, 139.2, 138.8, 138.7, 132.1 (x2), 130.4 (x2), 129.9, 129.8, 128.9, 128.0, 114.4, 
111.0, 110.9, 93.8 (x2), 78.2, 78.1, 74.0, 73.9, 73.6, 73.5, 72.4 (2), 71.0, 70.8, 69.8, 69.7, 
55.1, 47.8, 41.1 (x2), 36.3 (x2), 28.8 (x2), 27.3 (x2), 26.7 (x2), 26.5, 21.0 (x2), 15.5 (x2), 
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-0.9; 125 MHz DEPT 
13
C NMR (C6D6) CH3 δ 55.1, 27.7, 26.5, 15.5, 0.93; CH2 δ 111.0, 
93.8, 73.5, 69.7, 47.8, 47.7, 36.3, 36.2, 28.8, 27.3, 21.0; CH1 δ 138.8 (x2), 130.4, 129.9, 
129.8, 128.0, 114.4, 111.0, 93.8, 78.1, 74.0, 73.9, 72.4, 71.0, 70.8, 69.7; IR (neat) 2959, 
2858, 1738, 1606, 1513, 1461, 1427, 1365, 1247, 1160, 1077, 822, 740, 703 cm
-1
; HRMS 
(ESI/APCI) calcd for C38H56NaO6Si (M+Na): 659.3744, found: 659.3746. 
  Preparation of (E)-7-((S)-2-
((2R,3R)-3-((benzyloxy)methoxy)-2-((4-methoxybenzyl)oxy)butyl)-3,4-dihydro-2H-
pyran-6-yl)-7-methyl-2-((trimethylsilyl) methyl)octa-1,5-dien-4-one (1.114):  To a 
stirring solution of alcohol 1.113 (700 mg, 1.09 mmol, 1.0 equiv) in CH2Cl2 (11 mL) in a 
25 mL rb rlask at -15 C, was added freshly distilled N,N-diisopropylethylamine (1.3 mL, 
7.6 mmol, 7.0 equiv), dropwise via syringe.  After 10 min at -15 C, dimethyl sulfoxide 
(780 µL, 10.9 mmol, 10.0 equiv) was added to the reaction mixture via syringe and the 
solution was allowed to stir for an additional 10 min.  Sulfur trioxide pyridine complex 
(700 mg, 4.3 mmol, 4.0 equiv) was then added in one portion.  The reaction mixture was 
allowed to proceed for 1 h at -15 C, after which time TLC analysis indicated complete 
consumption of starting material.  The reaction mixture was diluted with EtOAc (10 mL), 
quenched by addition of saturated aqueous NaHCO3 solution (20 mL). The layers were 
separated and the aqueous layer was extracted with EtOAc (2x20 mL). The combined 
organic layers were washed with brine (2  20 mL), dried over MgSO4, filtered, and 
concentrated under reduced pressure. Purification was accomplished by flash column 
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chromatography on a 3  13 cm column, eluting with 10% EtOAc/hexanes, collecting 6 
mL fractions.  The product containing fractions (20-55) were combined and concentrated 
under reduced pressure to give the ketone 1.114 (658 mg, 94% yield) as colorless oil: Rf 
= 0.53 (20% EtOAc/hexanes);   20D  +44 (c = 1.0, EtOAc); 500 MHz 
1
H NMR (C6D6) 
δ 7.39-7.09 (m, 7H), 6.83-6.81 (m, 2H), 6.34 (d, J = 15.6 Hz, 1H), 4.81-4.75 (m, 4H), 
4.69 (d, J = 10.7 Hz, 2H), 4.63 (d, J = 2.9 Hz, 1H), 4.59 (d, J = 11.2 Hz, 2H), 4.53 (t, J = 
3.9 Hz, 1H), 4.14-4.00 (m, 3H), 3.30 (s, 3H), 3.11 (s, 2H), 1.98-1.89 (m, 1H), 1.86 (ddd, 
J = 9.2, 6.8, 2.4 Hz, 1H), 1.81-1.75 (m, 1H), 1.61-1.56 (m, 3H), 1.51-1.47 (m, 1H),   
1.41-1.32 (m, 1H), 1.23 (s, 3H), 1.22 (d, J = 4.3 Hz, 3H), 1.19 (s, 3H),  -0.00 (s, 9H); 125 
MHz 
13
C NMR (C6D6) δ 197.0, 160.4, 157.9, 154.1, 142.3, 139.2, 132.0, 129.8, 128.9, 
128.3, 128.0, 126.4, 114.4, 112.4, 94.9, 93.8, 77.9, 73.6, 73.5, 72.7, 69.7, 55.1, 41.8, 36.3, 
28.7, 27.6, 25.6 (x2), 21.0, 15.4, -0.9; 125 MHz DEPT 
13
C NMR (C6D6) CH3 δ 55.1, 25.6 
(x2), 15.4, -0.9; CH2 δ 112.4, 93.8, 73.5, 69.7, 51.5, 36.3, 28.9, 27.2, 21.0; CH1 δ 154.1, 
129.8, 128.9, 128.7, 128.3, 126.4, 114.4, 94.9, 78.0, 73.7, 72.7; CH0 δ 197.0, 160.0, 
157.9, 142.3, 139.2, 132.0, 128.0; IR (neat) 3071, 2956, 2858, 1742, 1682, 1629, 1461, 
1427, 1365, 1246, 1111, 1027, 978, 853, 756, 703, 612 cm
-1
; HRMS (ESI/APCI) calcd 
for C38H58NO6Si (M+NH4): 652.9558, found: 652.4033. 
 Preparation of (R,E)-7-((S)-2-((2R,3R)-3-
((benzyloxy)methoxy)-2-((4-methoxybenzyl)oxy)butyl)-3,4-dihydro-2H-pyran-6-yl)-
7-methyl-2-((trimethylsilyl)methyl) octa-1,5-dien-4-ol (1.68): To a stirring solution of  
138 
 
BH3·DMS (1M in CH2Cl2, 1 mL, 1.03 mmol, 1 equiv) in 10 mL of THF in a flame dried 
50 mL rb flask at 0 ºC was added S-CBS (1 M in toluene, 0.2 mL, 2.07 mmol, 2 equiv) 
dropwise via syringe.  The solution was stirred at 0 ºC for 15 min and was then cooled to 
-42 ºC.  To this solution was added a solution of ketone 1.114 in 1 mL of toluene 
dropwise via syringe down the side of the flask. The reaction was stirred at -42 ºC for 3 h 
after which it was quenched by slow addition of MeOH. The reaction was allowed to 
come to rt and the solvent was evaporated under reduced pressure. Purification was 
accomplished using flash column chromatography with a 3 x 15 cm silica gel column, 
eluting with 10% EtOAc/hexanes, collecting 6 ml fractions.  The fraction 24-37 provided 
the starting material (98 mg) and the product containing fractions (38-135) were 
combined and concentrated under reduced pressure to provide the alcohol 1.68 (485 mg, 
74%) as a clear colorless oil: Rf = 0.47 (30% EtOAc/hexanes);   
20
D +26 (c = 1.0, 
CHCl3); 500 MHz 
1
H NMR (C6D6) δ 7.39-7.10 (m, 7H), 6.82-6.80 (m, 2H), 6.05 (d, J = 
16.4 Hz, 1H), 5.67 (dd, J = 15.6, 6.3 Hz, 1H),  4.82 (d, J = 6.8 Hz, 2H), 4.77 (d, J = 6.8 
Hz, 1H), 4.74 (s, 1H), 4.73 (d, J = 11.2 Hz, 1H), 4.68-4.67 (m, 3H), 4.62 (d, J = 12.2 Hz, 
1H), 4.29 (dd, J = 12.6, 6.5 Hz, 1H), 4.22-4.18 (m, 1H), 4.12 (td, J = 4.9, 1.9 Hz, 1H), 
4.10-4.05 (m, 1H), 3.29 (s, 3H), 2.29-2.21 (m, 2H), 1.99 (ddd, J = 13.6, 10.2, 1.4 Hz, 
1H), 1.94 (ddd, J = 9.7, 6.8, 2.4 Hz, 1H), 1.89-1.83 (m, 1H), 1.77 (s, 1H), 1.60 (ddd, J = 
13.1, 10.7, 2.4 Hz, 1H), 1.56-1.53 (m, 1H), 1.50 (d, J = 2.9 Hz, 3H), 1.47-1.37 (m, 2H),  
1.34 (s, 3H),  1.33 (s, 3H),  1.23 (d, J = 6.3 Hz, 3H), -0.00 (s, 9H); 125 MHz 
13
C NMR 
(C6D6) δ 160.0, 159.6, 144.9, 139.1, 138.8, 132.0, 130.4, 129.9, 128.9, 128.3, 128.0, 
114.4, 110.9, 93.8 (x2), 78.1, 74.0, 73.6, 72.4, 71.0, 69.7, 55.41, 47.7, 41.1, 36.2, 28.8, 
27.3, 26.7, 26.5, 21.0, 15.5, -0.9; 125 MHz DEPT 
13
C NMR (C6D6) CH3 δ 55.1, 26.7, 
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26.5, 15.5, -0.9; CH2 δ 110.9, 93.8, 73.6, 69.7, 47.7, 36.2, 28.8, 27.3, 21.0; CH1 δ 138.8, 
130.4, 129.9, 128.9, 128.3, 128.0, 114.4, 93.8, 78.1, 74.0, 72.4, 71.0; CH0 δ 160.0, 159.6, 
144.9, 139.1, 132.0, 41.1; IR (neat) 2963, 2858, 1725, 1600, 1518, 1427, 1431, 1369, 
1288, 1150, 1076, 735, 701 cm
-1
; HRMS (ESI/APCI) calcd for C38H56NaO6Si (M+Na): 
659.3744, found: 659.3746. 
 Preparation of (S)-(R,E)-7-((S)-2-
((2R,3R)-3-((benzyloxy)methoxy)-2-((4-methoxybenzyl)oxy)butyl)-3,4-dihydro-2H-
pyran-6-yl)-7-methyl-2-((trimethylsilyl) methyl)octa-1,5-dien-4-yl 3,3,3-trifluoro-2-
methoxy-2-phenylpropanoate: To a stirring solution of alcohol 1.68 (9.7 mg, 0.015 
mmol, 1.0 equiv) in CH2Cl2 (150 µL, 0.1 M) in a 5 mL reaction vial at rt was added DCC 
(3.8 mg, 0.018 mmol, 1.2 equiv), DMAP (2 mg, 0.015 mmol, 1.0 equiv), and (S)-3,3,3-
trifluoro-2-methoxy-2-phenylpropanoic acid (4.3 mg, 0.018 mmol, 1.2 equiv).  The 
mixture was stirred at rt for 48 h after which the solvent was evaporated under reduced 
pressure. Purification was accomplished using flash column chromatography (1x10 cm) 
using 5% EtOAc/hexanes collecting 4 mL fractions. Fractions 12-22 provided the desired 
product (9.5 mg, 73%) as a colorless liquid. Rf = 0.58 (30% EtOAc/hexanes);   
20
D
+1.9 (c = 0.35, CHCl3); 500 MHz 
1
H NMR (C6D6) δ 7.78 (d, J = 7.8 Hz, 2H), 7.37 (d, J = 
7.3 Hz, 2H), 7.31 (d, J = 8.7 Hz, 2H), 7.21-7.05 (m, 6H), 6.82-6.80 (m, 2H), 6.18 (d, J = 
15.6 Hz, 1H), 5.89 (ddd, J = 8.3, 8.3, 5.8 Hz, 1H), 5.44 (dd, J = 15.6, 8.8 Hz, 1H), 4.79 
(dd, J = 18.5, 6.8 Hz, 1H), 4.75 (d, J = 0.9 Hz, 1H), 4.69-4.57 (m, 6H), 4.18-4.14 (m, 
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1H), 4.08 (q, J = 6.3 Hz, 1H), 4.02 (ddd, J = 10.2, 4.8, 1.4 Hz, 1H), 3.55 (s, 3H), 3.30 (s, 
3H),  2.41 (dd, J = 14.6, 8.3 Hz, 1H), 2.23 (dd, J = 14.6, 5.3 Hz, 1H), 2.10-1.90 (m, 2H), 
1.87-1.80 (m, 1H), 1.61 (ddd, J = 13.1, 10.7, 2.4 Hz, 1H), 1.56-1.52 (m, 1H), 1.48 (s, 
3H), 1.46-1.36 (m, 1H), 1.27 (s, 3H), 1.24 (s, 3H), 1.23 (s, 3H),  -0.02 (s, 9H); 125 MHz 
13
C NMR (C6D6) δ 166.3, 160.1, 159.0, 144.1, 142.9, 139.2, 133.8, 131.9, 129.9, 129.8, 
128.9, 128.8, 128.6, 128.3, 128.0, 124.5, 114.4, 111.4, 94.3, 93.8, 78.1, 76.5, 73.8, 73.5, 
72.7, 69.7, 56.0, 55.1, 43.7, 41.3, 36.3, 28.8, 27.1, 26.3 (x2), 21.0, 15.4, -1.0; 125 MHz 
DEPT 
13
C NMR (C6D6) CH3 δ 56.0, 55.1, 26.3 (x2), 15.4, -1.0; CH2 δ 111.4, 93.8, 73.5, 
69.7, 43.7, 36.3, 28.8, 27.1, 21.0; CH1 δ 144.1, 129.9, 129.8, 128.9, 128.8, 128.6, 128.0, 
94.3, 93.8, 78.1, 76.5, 73.8, 73.5, 72.7, 69.7; CH0 δ 207.7, 166.3, 160.1, 159.0, 142.9, 
139.2, 133.8, 131.9, 41.3; IR (neat) 3077, 3006, 2934, 2812, 1730, 1621, 1430, 1411, 
1401, 1305, 1232, 1102, 977, 866, 720, 612 cm
-1
; HRMS (ESI/APCI) calcd for 




 Preparation of (R)-(R,E)-7-((S)-2-
((2R,3R)-3-((benzyloxy)methoxy)-2-((4-methoxybenzyl)oxy)butyl)-3,4-dihydro-2H-
pyran-6-yl)-7-methyl-2-((trimethylsilyl) methyl)octa-1,5-dien-4-yl 3,3,3-trifluoro-2-
methoxy-2-phenylpropanoate: This compound was prepared in the similar manner as 
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that  of compound previous compound. Rf = 0.58 (30% EtOAc/hexanes);   
20
D +24 (c 
= 0.25, CHCl3); 500 MHz 
1
H NMR (C6D6) δ 7.76 (d, J = 7.8 Hz, 2H), 7.37 (d, J = 7.3 Hz, 
2H), 7.30 (d, J = 8.7 Hz, 2H), 7.21-7.04 (m, 6H), 6.82-6.79 (m, 2H), 6.22 (d, J = 15.6 Hz, 
1H), 5.92 (ddd, J = 8.3, 8.3, 5.8 Hz, 1H), 5.59 (dd, J = 15.6, 8.8 Hz, 1H), 4.81 (dd, J = 
18.5, 6.8 Hz, 1H), 4.77 (d, J = 0.9 Hz, 1H), 4.69-4.56 (m, 6H), 4.17-4.13 (m, 1H), 4.08 
(q, J = 6.3 Hz, 1H), 4.02 (ddd, J = 10.2, 4.8, 1.4 Hz, 1H), 3.54 (s, 3H), 3.30 (s, 3H),  2.44 
(dd, J = 14.6, 8.3 Hz, 1H), 2.22 (dd, J = 14.6, 5.3 Hz, 1H), 2.01-1.79 (m, 2H), 1.61 (ddd, 
J = 13.1, 10.7, 2.4 Hz, 1H), 1.55-1.49 (m, 1H), 1.46 (s, 3H), 1.44-1.36 (m, 2H), 1.27 (s, 
6H), 1.23 (d, J = 6.3 Hz, 3H), -0.02 (s, 9H); 125 MHz 
13
C NMR (C6D6) δ 166.4, 160.1, 
158.9, 144.7, 142.5, 139.1, 138.1, 133.8, 131.9, 129.9, 129.8, 128.9, 128.8, 128.6, 128.3 
(x2), 128.0, 124.7, 114.4, 111.5, 94.4, 93.8, 78.1, 76.6, 73.7, 73.5, 72.7, 69.7, 55.8, 55.1, 
43.6, 41.4, 36.3, 28.8, 27.2, 26.3 (x2), 21.0, 15.4, -1.0; 125 MHz DEPT 
13
C NMR (C6D6) 
CH3 δ 55.8, 55.1, 26.3 (x2), 15.4, -1.0; CH2 δ 111.5, 93.8, 73.4, 69.7, 43.6, 36.3, 28.8, 
27.2, 21.0; CH1 δ 144.7, 129.9, 129.8, 128.9, 128.8, 128.6, 128.3, 128.0, 124.7,114.4, 
94.4, 78.1, 76.6, 73.7, 72.7,; CH0 δ  166.4, 160.1, 158.9, 142.9, 139.1, 138.1, 133.8, 
131.9, 128.3, 41.3; IR (neat) 3072, 3010, 2911, 2850, 1720, 1614, 1411, 1408, 1401, 
1355, 1310, 1222, 1102, 1007, 972, 864, 713, 619 cm
-1
; HRMS (ESI/APCI) calcd for 









dimethyltetrahydro-2H-pyran-4-yl acetate (1.115):  To a stirring solution of aldehyde 
1.69 (101 mg, 0.154 mmol, 1.0 equiv) and hydroxyallylsilane 1.68 (108 mg, 0.169 mmol, 
1.1 equiv) in Et2O (2.2 mL) in a flame dried 25 mL rb flask at -78 ºC was added a 
solution of TMSOTf  in Et2O (200 μL, 0.926 M, 0.184  mmol, 1.2 equiv). After 1.5 h at -
78 ºC, the reaction was quenched by addition of diisopropylethylamine (0.2 mL), 
followed by addition of saturated aqueous NaHCO3 solution (10 mL). The mixture was 
warmed to rt, the phases were separated, and the aqueous phase was extracted with Et2O 
(2 x 15 mL). The organic phases were combined, dried over Na2SO4 and concentrated 
under reduced pressure. Purification was accomplished by flash column chromatography 
on a 1 x 17 cm silica gel column, eluting with hexanes/EtOAc (9:1), collecting 4 mL 
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fractions. The product containing fractions (20-55) were combined and concentrated 
under reduced pressure to provide the pyran 1.115 (107 mg, 58%) as a white foam. The 
column also furnished a mixture of aldehyde 1.69 and TMS protected silane which were 
separately purified using Hexanes/ EtOAc (95:5) to give 35 mg (35%) of aldehyde 1.69 
and 32 mg (27%) of TMS protected silane. Rf = 0.56 (30% EtOAc/hexanes);    
20
D  
+18.8 (c = 0.65, EtOAc);  500 MHz 
1
H NMR (C6D6) δ 7.83-7.80 (m, 4H), 7.38-7.09 (m, 
13H), 6.82-6.79 (m, 2H), 6.08 (dd, J = 15.6, 0.9 Hz, 1H), 5.71 (dd, J  = 16.1, 5.3 Hz, 1H), 
5.35 (dd, J = 11.7 Hz, 4.8, 1H), 4.88 (s, 1H), 4.82 (d, J = 6.8 Hz, 1H), 4.77 (d, J = 4.3 Hz, 
1H), 4.71-4.66 (m, 3H), 4.64-4.63 (m, 4H), 4.57-4.54 (m, 1H), 4.20-4.16 (m, 1H), 4.08-
4.06 (m, 2H), 3.88-3.85 (m, 1H), 3.65-3.63 (m, 1H), 3.30 (s, 3H), 2.93 (s, 3H), 2.91-2.89 
(m, 2H), 2.33-2.24 (m, 2H), 2.19-2.15 (m, 1H), 2.11 (t, J = 12.4 Hz, 1H), 2.01-1.94 (m, 
2H), 1.91-1.76 (m, 4H), 1.72 (d, J = 3.9 Hz, 1H), 1.69-1.66 (m, 1H), 1.64 (s, 3H), 1.60-
1.52 (m, 4H), 1.43 (s, 9H), 1.34 (s, 3H), 1.33 (s, 3H), 1.23 (d, J = 6.3Hz, 3H), 1.19 (s, 
9H), 1.07(s, 3H), 1.03 (s, 3H); 125 MHz 
13
C NMR (CDCl3) δ 198.1, 169.8, 160.0, 159.6, 
145.5, 139.2, 138.9, 136.7, 136.6, 135.0, 134.2, 132.0, 130.5, 130.4, 129.9, 128.9, 128.6, 
128.4, 128.4, 128.3, 128.0, 114.4, 109.1, 104.7, 94.0, 93.8, 79.1, 78.2, 75.3, 73.9, 73.8, 
73.7, 72.5, 70.3, 69.7, 66.9, 55.1, 54.0, 48.5, 48.3, 44.4, 42.9, 42.6, 41.4, 41.2, 39.9, 36.5, 
35.5, 30.2, 28.9, 27.6, 26.6, 26.4, 21.2, 21.1, 21.0, 20.0, 17.2, 15.6; 125 MHz DEPT 
13
C 
NMR (C6D6) CH3 δ 55.1, 48.5, 30.2, 27.6, 26.6, 26.4, 21.1 (x2), 17.2, 15.6 ; CH2 δ 109.1, 
93.8, 73.6, 69.7, 54.0, 44.4, 42.9, 41.7, 39.9, 36.5, 33.5, 28.9, 21.1; CH δ 138.9, 136.7, 
136.6, 130.5 (x2), 129.9, 128.9, 128.4, 128.4, 128.3, 128.0, 114.4, 94.0, 79.1, 78.2, 75.2, 
73.8, 72.4, 70.3, 66.9; CH0 δ 198.0, 169.8, 160.0, 159.6, 145.5, 139.2, 135.0, 134.2, 
132.0, 130.4, 104.7, 73.9, 48.3, 42.6; IR (neat) 2959, 2361, 1739, 1681, 1513, 1458, 
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1365, 1247, 1039, 822, 740, 703 cm
-1
; HRMS (ESI/APCI) calcd for C71H98NaO12SSi 
(M+Na): 1225.6446, found: 1225.6462. 





acetate (1.117):  To a stirring solution of dihydropyran 1.115 (130 mg, 0.108 mmol, 1.0 
equiv) in CH2Cl2 (1.1 mL) at 0 °C, was added MeOH (0.54 mL).  Powdered NaHCO3 
(13.6 mg, 0.162 mmol, 1.5 equiv) was added in one portion and the solution was stirred 
at 0 °C for 10 min. Magnesium monoperoxyphthalate (80 %, 80 mg, 0.129 mmol, 1.2 
equiv) was added slowly and the mixture was stirred for 30 min at 0°C. The reaction 
mixture was then quenched by the addition of saturated aqueous NaHCO3 solution (10 
mL), then diluted with EtOAc (10 mL) and the layers were separated. The aqueous layer 
was extracted with EtOAc (2 x 20 mL). The combined organic layer was washed with 
brine (30 mL), dried over Na2SO4, filtered, concentrated and taken to the next step 
without further purification. 
To a solution of the previously described crude intermediate alcohol in CH2Cl2 
(2.2 mL), at rt, were added 4 Å molecular sieves (300 mg), TPAP (3.8 mg, 0.01 mmol, 
0.1 equiv), and 4-methylmorpholine-N-oxide (38 mg, 0.324 mmol, 3.0 equiv).  The 
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mixture was stirred at rt for 30 min and then diluted with EtOAc (20 mL). The mixture 
was then filtered through a small plug of Florisil
®
 and washed with copious amounts of 
EtOAc.  The solvent was removed under reduced pressure and purification was 
accomplished with flash column chromatography, using a 25 x 120 mm silica gel 
column, eluting with 15% EtOAc/hexanes, collecting 4 mL fractions.  The product 
containing fractions from 24 to 75 were combined and concentrated under reduced 
pressure to provide pure methoxy ketone 1.117 (78 mg, 58% over 2 steps) as a white 
foam.: Rf = 0.62 (30% EtOAc/hexanes);   
20
D  +22 (c = 1.0, EtOAc); 500 MHz 
1
H 
NMR (C6D6) δ 7.81-7.78 (m, 4H), 7.38-7.09 (m, 13H), 6.79-6.77 (m, 2H), 6.30 (d, J = 
16.1 Hz, 1H), 5.57 (dd, J = 4.8, 16.1 Hz, 1H), 5.32 (dd, J = 4.3, 11.2 Hz, 1H), 4.85 (s, 
1H), 4.78-4.73 (m, 3H), 4.66-4.54 ( m, 7H), 4.44-4.41 (m, 1H), 4.15-4.08 (m, 2H), 4.05-
4.02 (m, 1H), 3.76-3.73 (m, 1H), 3.59-3.58 (m, 1H), 3.30 (s, 3H), 3.25 (s, 3H), 2.93 (s, 
3H), 2.90-2.89 (m, 2H), 2.72-2.08 (m, 5H), 1.99 (ddd, J = 17.1, 12.4, 12.4, Hz, 2H), 1.86-
1.73 (m, 4H), 1.65 (s, 3H), 1.62-1.52 (m, 3H), 1.42 (s, 9H), 1.37 (s, 3H), 1.35 (s, 3H), 
1.21 (d, J = 6.3 Hz, 3H), 1.17 (s, 9H), 1.04 (s, 3H), 1.02 (s, 3H); 125 MHz 
13
C NMR 
(C6D6) δ 205.6, 198.1, 169.8, 160.0, 145.3, 139.0, 137.0, 136.7, 136.5, 135.0, 134.2, 
131.7, 130.5, 130.4, 129.8, 129.7, 128.9, 128.4 (x2), 128.3, 128.1,128.1, 114.4, 109.1, 
104.7, 104.6, 93.8, 78.8, 77.8, 75.1, 73.8, 72.9, 72.5, 70.4, 69.8, 66.9, 55.1, 54.0, 52.8, 
48.5, 48.3, 44.8, 44.3, 42.9, 42.6, 41.6, 39.8, 38.1, 36.7, 33.5, 31.1, 30.2, 27.6, 23.6, 23.0, 
21.2, 21.1, 20.0, 17.3, 15.0; 125 MHz DEPT 
13
C NMR (CDCl3)  CH3 δ 55.1, 52.8, 48.5, 
30.2, 27.6, 23.6, 23.0, 21.2, 21.1, 17.3, 15.0 ; CH2 δ 109.2, 93.8, 72.4, 69.8, 54.0, 44.3, 
42.9, 41.5, 39.9, 38.1, 36.7, 33.5, 31.1; CH δ 137.0, 136.7, 136.6, 130.5, 130.4, 129.8, 
129.7, 129.0, 128.6, 128.4 (x2), 128.3, 128.1, 114.4, 78.9, 77.8, 75.1, 73.8, 72.9, 70.4, 
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66.9; CH0 δ 205.6, 198.1, 169.8, 160.0, 145.3, 139.0, 135.0, 134.2, 131.7, 104.7, 104.6, 
48.3, 44.8, 42.6, 20.0; IR (neat) 3453, 2936, 1734, 1618, 1613, 1588, 1513, 1458, 1428, 
1366, 1301, 1246, 1110, 1042, 895, 822, 742, 703 cm
-1
; HRMS (ESI/APCI) calcd for 
C72H100NaO14SSi (M+Na): 1271.6501, found: 1271.6491.  





4(3H,5H,6H)-ylidene)acetate (1.120): To a stirring solution of (iPr)2NH (0.27 mL, 1.93 
mmol) in 6 mL of THF in a 25 mL rb flask at -78 ºC was added n-BuLi (2.61 M in 
hexanes, 0.67 mL, 1.75 mmol) via syringe.  The solution stirred at -78 ºC for 30 min and 
was then allowed to warm to 0 ºC for 20 min.  This 0.25 M LDA solution was used 
immediately in the following aldol reaction. 
 To a stirring solution of ketone 1.117 (102 mg, 0.0816 mmol, 1.0 equiv) in THF 
(2.7 mL, 0.03 M) in a 10 mL rb flask at -78 ºC was added a 0.25 M solution of LDA in 
THF (0.35 mL, 0.0897 mmol, 1.1 equiv) slowly via syringe down the side of the flask.  
The resulting light-yellow reaction mixture was allowed to stir at -78 ºC for 12 min and a 
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freshly prepared solution of methyl glyoxylate (ca 3.0 M in THF, 0.54 mL, 1.632 mmol, 
20.0 equiv) was added slowly via syringe down the side of the flask upon which the 
yellow color of the solution disappeared. The reaction mixture stirred at -78 ºC for 40 
min and was quenched by addition of 2 mL of saturated aqueous NH4Cl solution. The 
mixture was allowed to warm to rt and was then partitioned between 10 mL of EtOAc 
and 10 mL of brine.  The phases were separated and the aqueous phase was extracted 
with EtOAc (3 x 10 mL).  The combined organic phases were dried over Na2SO4, filtered 
and concentrated under reduced pressure. Purification was accomplished using flash 
column chromatography with a 2 x 8 cm silica gel column, eluting with 20% 
EtOAc/hexanes (100 mL) then 40% EtOAc/hexanes (100 mL), collecting 4 mL fractions.  
Fractions 6-20 gave unreacted starting material which were combined and concentrated 
to provide 48 mg of the starting ketone 1.117 (47%). The product containing fractions 
(22-37) were combined and concentrated under reduced pressure to provide the 
intermediate aldol adduct as a mixture of diastereomers (53.3 mg, 49%).  This material 
was taken into the following elimination reaction. 
 To a stirring solution of the aforementioned aldol adduct (31.2 mg, 0.0233 mmol, 
1.0 equiv) in CH2Cl2 (2.3 mL, 0.01 M) in a 5 mL reaction vial at rt was added 
diisopropylethylamine (23 µL, 0.1631 mmol, 7.0 equiv), DMAP (2.8 mg, 0.0233 mmol, 
1.0 equiv), and carbonyldiimidazole (19 mg, 0.1165 mmol, 5.0 equiv).  The reaction 
mixture was allowed to stir at rt for 24 h and was then quenched by addition of saturated 
aqueous NaHCO3 solution (5 mL).  The mixture was partitioned between EtOAc (10 mL) 
and brine (10 mL).  The phases were separated and the aqueous phase was extracted with 
EtOAc (3 x 10 mL).  The combined organic phases were dried over Na2SO4, filtered, and 
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concentrated under reduced pressure.  Purification was accomplished using flash column 
chromatography with a 1 x 10 cm silica gel column, eluting with 10% EtOAc/hexanes, 
collecting 4 ml fractions.  The product containing fractions (27-54) were combined and 
concentrated under reduced pressure to provide pure enoate 1.120 (25.3 mg, 82% over 2 
steps) as a clear light-yellow oil: Rf = 0.48 (30% EtOAc/hexanes);   
20
D  -8.6 (c = 
0.53, EtOAc); 500 MHz 
1
H NMR (C6D6) δ 7.84-7.81 (m, 4H), 7.40-7.39 (m, 2H), 7.26-
7.11 (m, 11H), 6.79-6.78 (m, 1H), 6.76-6.74 (m, 2H), 6.10 (d, J  = 16.1 Hz, 1H), 5.50 
(dd, J = 16.5, 5.3 Hz, 1H), 5.36 (dd, J = 11.7, 4.8 Hz, 1H), 4.92-4.80 (m, 3H), 4.74 (dd, J 
= 10.7, 6.8 Hz, 2H), 4.67-4.57 (m, 5H), 4.52 (d, J =11.2 Hz, 1H), 4.33 (d, J = 11.2 Hz, 
1H), 4.18-4.02 (m, 4H), 3.76-3.75 (m, 1H), 3.64-3.61 (m, 1H), 3.36 (s, 3H), 3.28 (s, 3H), 
3.24 (s, 3H), 2.95 (s, 3H), 2.93-2.92 (m, 2H), 2.31-2.29 (m, 1H), 2.16-1.79 (m, 5H), 1.89-
1.78 (m, 3H), 1.66 (s, 3H), 1.61-1.57 (m, 2H), 1.45 (s, 9H), 1.33 (s, 3H), 1.28 (s, 3H), 
1.19 (s, 12H), 1.10 (s, 3H), 1.07 (s, 3H); 125 MHz 
13
C NMR (C6D6) δ 198.1, 197.0, 
169.9, 166.4, 160.0, 149.2, 145.4, 139.1, 136.7, 136.6, 135.7, 135.1, 134.2, 131.5, 130.8, 
130.5, 130.4, 129.6, 129.0, 128.6, 128.4 (x2), 122.9, 114.4, 109.2, 105.6, 104.6, 94.0, 
78.8, 77.3, 75.1, 73.9, 72.6, 71.9, 70.7, 70.5, 69.9, 67.0, 55.1, 54.0, 52.7, 51.6, 48.5, 48.4, 
45.4, 44.4, 42.9, 42.7, 40.9, 39.9, 37.1, 36.5, 33.6, 30.2, 27.9, 23.1, 22.2, 21.3, 21.1, 20.0, 
18.9, 17.4, 14.8; 125 MHz DEPT 
13
C NMR (C6D6)  CH3 δ 55.1, 52.7, 51.6, 48.5, 30.3, 
27.6, 23.0, 22.2, 21.2, 21.1, 17.4, 14.8; CH2 δ 109.2, 94.0, 71.9, 69.9, 54.0, 44.4, 42.9, 
40.9, 39.9, 37.1, 36.5, 33.5; CH δ 136.7, 136.6, 135.7, 130.8, 130.5, 130.4, 129.6, 129.0, 
128.6, 128.4, 128.3, 128.1, 122.9, 114.4, 78.8, 77.3, 75.1, 73.9, 72.6, 70.7, 70.4, 67.0; 
CH0 δ 198.1, 197.0, 169.9, 166.4, 160.0, 149.2, 145.4, 139.1, 135.1, 134.2, 131.5, 105.6, 
104.6, 45.4, 42.7, 20.0, 18.9;  IR (neat) 3609, 3583, 3531, 3070, 2956, 2936, 2861, 2362, 
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1727, 1680, 1614, 1514, 1460, 1384, 1365, 1301, 1247, 1208, 1175, 1108, 1079, 1043, 
821, 737, 701, 633 cm
-1
; HRMS (ESI/ APCI) calcd for C75H102NaO16SSi (M+Na): 
1341.6556, found: 1341.6565. 





methoxy-2-oxoethylidene)tetrahydro-2H-pyran-3-yl) octa-2,4-dienoate (1.122):  To a 
stirring solution of ketone 1.120 (10.7 mg, 0.0081 mmol, 1.0 equiv) in MeOH (810 µL, 
0.01 M) in a 5 mL reaction vial at rt was added CeCl3·7H2O (60 mg, 0.162 mmol, 20.0 
equiv). The mixture was stirred until all the CeCl3·7H2O was completely dissolved.  The 
mixture was then cooled to -42 ºC and stirred for 10 min and NaBH4 (3.0 mg, 0.081 
mmol, 10.0 equiv) was then added.  Stirring continued for 2 h at -42 ºC after which 
another 10 equiv of NaBH4 was added. The mixture was warmed slowly to 0 ºC over 2 h, 
and then diluted with 40% EtOAc/hexanes. Saturated aqueous NH4Cl solution (2 mL) 
was then added. The layers were separated and the aqueous layer was extracted with 40% 
EtOAc/hexanes (3 x 5mL).  The organic phase was washed with brine (5 mL), then dried 
150 
 
over Na2SO4, filtered and concentrated under reduced pressure to provide crude 
intermediate alcohol which was carried directly to the next step without purification. 
 To a stirring solution of the aforementioned intermediate alcohol in CH2Cl2 (810 
µL, 0.001 M) in a 5 mL reaction vial at rt was added pyridine (7 µL, 0.081 mmol, 10.0 
equiv), DMAP (2.0 mg, 0.016 mmol, 2.0 equiv), and octadienoic anhydride (11.0 mg, 
0.040 mmol, 5.0 equiv).  The reaction mixture stirred at rt for 12 h and was then 
quenched by the addition of saturated aqueous NaHCO3 solution (2.0 mL).  The mixture 
was stirred vigorously for 30 min and was then partitioned between CH2Cl2 (5 mL) and 
saturated aqueous NaHCO3 solution (5 mL).  The phases were separated and the aqueous 
phase was extracted with CH2Cl2 (3 x 5 mL).  The combined organic phases were dried 
over Na2SO4, filtered, and concentrated under reduced pressure. Purification was 
accomplished using flash column chromatography using 8% EtOAc/hexanes followed by 
a preparative TLC with 30% EtOAc/hexanes to provide the ester 1.122 (10.2 mg, 87%, 2 
steps) as a pale yellow liquid. NMR of the product showed essentially a single 
diastereomer. Rf = 0.43 (30% EtOAc/hexanes);   
20
D  +4.4 (c = 0.35, EtOAc); 500 
MHz 
1
H NMR (C6D6) δ 7.84-7.81(m, 4H), 7.45 (dd, J = 15.1, 10.7 Hz, 1H), 7.40-7.39 
(m, 2H), 7.26-7.11 (m, 11H), 6.78-6.76 (m, 2H), 6.39-6.36 (m, 1H), 6.31 (s, 1H), 6.02 (s, 
1H), 5.94-5.87 (m, 1H), 5.8 (d, J = 15 Hz, 1H), 5.68-5.62 (m, 1H), 5.59 (dd, J = 15.6, 4.3 
Hz, 1H), 5.37 (dd, J = 11.7, 4.8 Hz, 1H), 4.90 (s, 1H), 4.81-4.76 (m, 3H), 4.67 (d, J = 
12.2 Hz, 1H), 4.63 (d, J = 12.2 Hz, 1H), 4.59 (d, J = 11.2 Hz, 1H), 4.48 (d, J = 11.2 Hz, 
1H), 4.34-4.30 (m, 1H), 4.14-4.11 (m, 1H), 4.08-4.05 (m, 1H), 3.83 (s, 2H), 3.66-3.64 
(m, 1H), 3.31(s, 6H), 3.30 (s, 3H), 2.97 (s, 3H), 2.92-2.90 (m, 2H), 2.65 (t, J = 13.1 Hz, 
1H), 2.34-2.25 (m, 2H), 2.20 (dd, J = 16.1, 5.3 Hz, 1H), 2.15-2.08 (m, 2H), 1.94-1.70 (m, 
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8H), 1.66 (s, 3H), 1.63-1.60 (m, 2H), 1.46 (s, 9H), 1.42 (s, 3H), 1.38 (s, 3H), 1.19 (s, 
12H), 1.12 (s, 3H), 1.09 (s, 3H), 0.74 (t, J = 7.3 Hz, 3H); 125 MHz 
13
C NMR (C6D6) δ 
198.0, 169.8, 166.7, 165.7, 160.0, 153.9, 146.8, 145.7, 145.3, 139.2, 137.9, 136.7, 136.6, 
135.0, 134.2, 131.7, 130.5, 130.4, 129.8, 129.1, 128.9, 128.6, 128.4(x2), 128.3, 128.0, 
119.6, 117.8, 117.7, 114.4, 109.1, 104.7, 93.8, 79.0, 77.6, 75.3, 73.9, 72.9, 72.5, 72.3, 
70.3, 69.8, 69.3, 66.9, 55.1, 54.0, 51.7, 51.0, 48.6, 48.3, 46.8, 44.5, 43.1, 42.7, 41.2, 39.9, 
37.1, 35.5, 34.1, 33.6, 30.2, 27.6, 25.2, 24.6, 22.4, 21.3, 21.1, 20.0, 17.3, 15.0, 14.1; 125 
MHz DEPT 
13
C NMR (C6D6)  CH3 δ 55.1, 51.7, 50.9, 48.6, 30.2, 27.6, 25.2, 24.6, 21.3, 
21.1, 17.3, 15.0, 14.1; CH2 δ 109.1, 93.8, 72.3, 69.8, 54.0, 44.5, 43.1, 41.2, 39.9, 37.1, 
35.5, 33.6, 22.4; CH δ 146.8, 145.3, 137.9, 136.7, 136.6, 130.5, 130.4, 129.8, 130.5, 
130.4, 129.8, 128.9, 128.6, 128.4, 128.2, 128.0, 119.6, 114.4, 78.9, 77.5, 75.3, 73.9, 72.9, 
72.4, 70.3, 69.3, 66.9; CH0 δ 198.0, 169.8, 166.7, 165.7, 160.0, 145.7, 135.0, 134.2, 
131.7, 128.4, 117.8, 104.7, 48.3, 46.8, 42.7, 34.1, 20.0;  IR (neat) 3069, 2957, 2933, 
2361, 1720, 1681, 1643, 1614, 1513, 1459, 1431, 1383, 1364, 1302, 1246, 1131, 1107, 
1041, 1003, 891, 859, 821, 737, 702 cm
-1
; HRMS (ESI/ APCI) calcd for 
C83H114NaO17SSi (M+Na): 1465.7444, found: 1465.7462. 







oxoethylidene)tetrahydro-2H-pyran-3-yl) octa-2,4-dienoate (1.124):  To a stirring 
solution of the BPS ether 1.122 (30.2 mg, 0.02 mmol, 1.0 equiv) in a 5:4:1 THF/MeOH/ 
pyridine (1.0 mL, 0.02M) at 0 ºC in a 15 mL plastic centrifuge tube was added HF·Py (20 
%, 0.46 mL).  The reaction mixture was stirred at 0 ºC for 30 min and warmed to rt. 
Stirring continued for 72 h and the reaction mixture was quenched by pipetting into a 
mixture of sat. aqueous NaHCO3 solution and EtOAc (10 mL each). The layers were 
separated and the aqueous layer was extracted with EtOAc (3 x 10 mL). The combined 
organic layer was dried over Na2SO4, filtered and concentrated under reduced pressure.  
Purification was accomplished using flash column chromatography with a 1 x 10 cm 
silica gel column, eluting with 15% EtOAc/hexanes, collecting 4 ml fractions. The 
product containing fractions (18-60) were combined and concentrated under reduced 
pressure to provide alcohol 1.124 (24.3 mg, 96%) as a clear colorless oil: Rf = 0.25 (30% 
EtOAc/hexanes);   20D +10.3 (c = 0.32, EtOAc); 500 MHz 1H NMR (C6D6) δ 7.45 (dd, 
J = 15.1, 10.7 Hz, 1H), 7.41-7.39 (m, 3H), 7.26-7.09 (m, 4H), 6.78-6.76 (m, 2H), 6.35 (d, 
J = 16.1 Hz, 1H), 6.31 (s, 1H), 6.01(s, 1H), 5.93 (dd, J = 14.6, 10.7 Hz, 1H), 5.86-5.83 
(m, 1H), 5.70-5.56 (m, 3H), 4.89 (s, 1H), 4.81-4.77 (m, 3H), 4.68 (d, J = 12.2, Hz, 1H), 
4.63 (d, J = 12.2, Hz, 1H), 4.59 (d, J = 11.2 Hz, 1H), 4.48 (d, J = 11.2 Hz, 1H), 4.34-4.30 
(m, 1H), 4.14-4.11 (m, 1H), 4.08-4.06 (m 1H), 3.90-3.83 (m, 3H), 3.73-3.71 (m, 1H), 
3.31 (s, 3H), 3.31 (s, 3H), 3.29 (s, 3H), 3.13 (s, 3H), 2.64 (t, J = 14.1 Hz, 1H), 2.53 (dd, J 
= 15.1, 8.3 Hz, 1H), 2.45 (dd, J = 15.6, 3.9 Hz, 1H),  2.37 (d, J = 13.1 Hz, 1H), 2.31-2.07 
(m, 5H), 1.94 (t, J = 12.2 Hz, 2H), 1.81-1.71 (m, 5H), 1.70 (s, 3H), 1.52 (d, J = 12.2 Hz, 
153 
 
1H), 1.47 (d, J = 12.2 Hz, 1H), 1.42 (s, 3H), 1.38 (s, 12H), 1.12-1.18 (m, 6H), 1.12 (s, 
3H), 0.74 (t, J = 7.3 Hz, 3H); 125 MHz 
13
C NMR (C6D6) δ 199.8, 170.0, 166.7, 165.7, 
160.0, 153.9, 146.8, 145.8, 145.3, 139.2, 137.8, 131.6, 129.8, 129.2, 128.9, 128.6, 128.3, 
128.0, 127.9, 119.6, 117.8, 114.4, 109.0, 104.6, 93.9, 79.0, 77.5, 75.6, 74.3, 72.9, 72.4, 
72.3, 69.8, 69.2, 65.7, 65.5, 55.1, 52.5, 51.7, 51.0, 48.7, 48.5, 46.8, 42.9(x2), 42.5, 41.1, 
39.9, 37.0, 35.4, 34.0, 33.4, 30.1, 24.9, 24.8, 22.3, 21.2, 21.1, 17.6, 15.0, 14.0; 125 MHz 
DEPT 
13
C NMR (C6D6)  CH3 δ 55.1, 51.7, 50.9, 48.7, 30.1, 24.9, 24.8, 21.2, 21.1, 17.6, 
15.0, 14.0; CH2 δ 109.0, 93.9, 72.3, 69.8, 52.5, 42.9, 42.5, 41.1, 39.9, 37.0, 35.4, 34.1, 
33.3, 22.3; CH δ 146.8, 145.3, 137.8, 129.8, 129.2, 128.9, 128.3, 128.0, 127.9, 119.6, 
117.8, 114.4, 79.0, 77.5, 75.6, 74.2, 72.9, 72.4, 69.2, 65.7, 65.5; CH0 δ 199.8, 170.0, 
166.7, 165.7, 160.0, 153.9, 145.3, 139.2, 131.6, 104.6, 48.5, 46.8, 42.9, 37.0;  IR (neat) 
3421, 2926, 2361, 1719, 1676, 1643, 1614, 1513, 1456, 1365, 1302, 1248, 1133, 1105, 
1041 cm
-1
; LRMS calcd for C67H96O17S (M+Na): 1228.5237, found: 1228.0. 





2H-pyran-2-yl)-3-(triethylsilyloxy)butanoic acid (1.126): To a stirring solution of 
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thiolester 1.124 (6.3 mg, 0.0052 mmol, 1.0 equiv.) in THF (0.4 mL) in a 5 mL vial at 0 
ºC was added pH 8 phosphate buffer (0.1 mL). Aqueous lithium hydroxide solution (0.1 
M, 104 µL, 0.0104 mmol, 2.0 equiv) was added via syringe followed by 2 drops of 30% 
H2O2 via a 10 µL syringe. The resulting solution stirred at 0 °C for 1 h and another 2 
equiv. of LiOH and 2 more drops of H2O2 was added. After 1 more h, the reaction 
mixture was poured into a mixture of pH 6 phosphate buffer solution and EtOAc (10 mL 
each). The layers were separated and the aqueous layer was extracted with EtOAc (3 x 10 
mL). The combined organic layer was dried over Na2SO4, filtered, and concentrated 
under reduced pressure to give the hydroxy acid as sticky pale yellow oil. The product 
was taken to the next step without further purification.  
  To a stirring solution of the after mentioned hydroxy acid in CH2Cl2 (0.4 mL) in a 
5 mL vial at -15 ºC was added DMAP (3 mg, 0.023 mmol, 4.5 equiv), followed by 
TESCl (2 µL, 0.013 mmol, 2.5 equiv) via syringe. The solution was stirred at -15 ºC for 1 
hr and an additional 2.5 equiv of TESCl was added. The mixture was warmed to 0 ºC 
over 1 hr after which it was poured into a mixture of aqueous pH 4 (acetic acid/sodium 
acetate) buffer and EtOAc (10 mL each). The layers were separated and the aqueous 
layer was extracted with EtOAc (3 x 5 mL). The combined organic layer was dried over 
Na2SO4, filtered, and concentrated under reduced pressure. Purification was 
accomplished using flash column chromatography with a 1 x 7 cm silica gel column, 
eluting with 30% EtOAc/hexanes, collecting 2 mL fractions.  The product containing 
fractions (3-9) were combined and concentrated under reduced pressure to provide pure 
carboxylic acid 1.126 (4.4 mg, 76% over 2 steps) as a colorless oil: Rf = 0.38 (50% 
EtOAc/hexanes);   20D  +7 (c = 0.22, EtOAc); 500 MHz 
1
H NMR (C6D6) δ 7.41-7.39 
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(m, 3H), 7.26-7.10 (m, 4H), 6.78-6.76 (m, 2H), 6.39 (d, J = 15.6 Hz, 1H), 6.32 (s, 1H), 
6.02 (s, 1H), 5.95-5.82 (m, 2H), 5.71-5.63 (m, 1H), 5.62-5.58 (m, 2H), 4.86 (s, 1H), 4.83-
4.76 (m, 3H), 4.69 (d, J = 12.2 Hz, 1H), 4.65(d, J = 12.2 Hz, 1H), 4.64-4.59 (m, 2H), 
4.50-4.42 (m, 2H), 4.34-4.30 (m, 1H), 4.16-4.12 (m, 1H), 4.09-4.06 (m 1H), 3.90-3.76 
(m, 3H), 3.32 (s, 3H), 3.31 (s, 3H), 3.30 (s, 3H), 3.20 (s, 3H), 2.73-2.60 (m, 3H), 2.36-
2.21 (m, 3H), 2.14-2.08 (m, 2H), 1.99-1.88 (m, 3H), 1.85-1.1.77 (m, 3H), 1.69 (s, 3H), 
1.53 (d, J = 12.2, Hz, 1H), 1.48 (d, J = 12.2, Hz, 1H), 1.41 (s, 3H), 1.37 (s, 3H), 1.21 (s, 
3H), 1.20 (s, 3H), 1.17 (s, 3H), 1.16 (s, 3H), 1.01 (t, J = 3.4 Hz, 9H), 0.75 (t, J = 7.3 Hz, 
3H), 0.66-0.61 (m, 6H); 125 MHz 
13
C NMR (C6D6) δ 170.1, 166.8, 165.8, 160.0, 153.9, 
146.8, 145.7, 145.4, 139.0, 138.0, 131.6, 129.8, 129.1, 129.0, 128.4, 128.1, 127.9,128.6,  
119.5, 117.8, 114.4, 109.0, 104.9, 93.8, 79.2, 77.5, 75.4, 74.2, 73.1, 72.5, 72.3, 69.8, 69.3, 
68.6, 66.5, 55.1, 51.7, 51.0, 48.8, 46.8, 45.1, 44.0,  42.9, 42.8, 41.3, 40.1, 37.1, 35.5, 34.2, 
25.1, 24.7, 22.4, 21.4, 21.1, 17.7, 15.0, 14.1, 7.5, 5.9; 125 MHz DEPT 
13
C NMR (C6D6)  
CH3 δ 55.1, 51.8, 51.0, 48.8, 25.0, 24.7, 21.4, 21.1, 17.7, 15.0,  14.1, 7.5; CH2 δ 109.0, 
93.8, 72.3, 69.8, 45.1, 44.0, 42.9, 41.3, 40.1, 37.0, 35.5, 34.2, 22.3, 5.9; CH δ 147.0, 
145.5, 138.0, 129.8, 129.1, 128.4, 128.1, 127.9, 119.5, 117.8, 114.4, 103.9, 79.2, 77.5, 
75.4, 74.2, 73.1, 72.4, 69.3, 68.6, 66.5; CH0 δ 170.1, 166.8, 165.8, 160.0, 153.9, 145.7, 
139.0, 131.6, 129.0, 128.6, 104.9, 46.8, 42.8;  IR (neat) 2933, 1733, 1681, 1612, 1513, 
1458, 1365, 1246, 1109, 1041, 821, 736, 701 cm
-1
; LRMS calcd for C69H102NaO18Si 
(M+Na): 1270.6126, found: 1270.0. 
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[21.3.1.13,7.111,15]nonacos-8-en-12-yl octa-2,4-dienoate (1.128): To a solution of the 
PMB ether 1.126 (3.1 mg, 0.0024 mmol, 1 equiv) in CH2Cl2 (100 µL) in a 5 mL vial  at 0 
ºC  was added pH 8 phosphate buffer (100 µL) and t-butanol (50 µL) via syringe. To the 
solution was added DDQ (2.8 mg, 0.0124 mmol, 5 equiv) in one portion and the reaction 
was stirred vigorously for 1 h after which another 5 equiv DDQ was added. After stirring 
1 more h at 0 ºC, the reaction mixture was poured into a mixture of CH2Cl2 and pH 4 
acetate buffer (5 mL each). The layers were separated and the aqueous layer was 
extracted with CH2Cl2 (3 x 5 mL). The combined organic layer was dried over Na2SO4, 
filtered, and concentrated. The crude product was quickly passed through a column of 
silica gel (1 x 7 cm) eluting with 30% EtOAc/hexanes, collecting 4 mL fractions. The 
product containing fractions 4-11 were combined and concentrated under reduced 
pressure to give seco acid (2.1 mg) partially mixed with DDQ byproducts which was 
taken to the next step without further purification.  
 To a stirring solution of the seco acid in THF (60 µL) in a 5 mL vial at 0 °C was 
added a 0.1 M solution of triethylamine in THF (112 µL, 0.011 mmol, 6.0 equiv) and  a 
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0.1M solution of 2,4,6-trichlorobenzoyl chloride in THF (112 µL, 0.0055 mmol, 3.0 
equiv).  After 10 min, the reaction was warmed to rt and stirring continued for an 
additional 3 h.  The reaction mixture was diluted with 3:1 toluene/ THF (1 mL) and taken 
into a 25 mL gas-tight syringe.  This solution was added by syringe pump to a stirring 
solution of DMAP (4.5 mg, 0.037 mmol, 20.0 equiv) in toluene (1.2 mL) at 40 °C over 
12 h.  The residual contents of the syringe were rinsed into the flask with toluene (0.5 
mL) and stirring continued for an additional 2 h. The reaction mixture was cooled to rt 
and diluted with 30% EtOAc/hexanes (10 mL) and washed with saturated aqueous 
NaHCO3 solution (2 x 10 mL) and brine (2 x 5 mL).  The organic phase was dried over 
Na2SO4, filtered, and concentrated under reduced pressure.  Purification was 
accomplished using flash column chromatography with a 1 x 4 cm silica gel column, 
eluting with 10% EtOAc/hexanes, collecting 2 mL fractions. The product containing 
fractions (13-25) were combined and concentrated under reduced pressure to provide 
pure macrolactone 1.128 as a white powder (1.7 mg, 62% over 2 steps): Rf = 0.48 (30% 
EtOAc/hexanes);   20D  +9 (c = 0.085, EtOAc); 500 MHz 
1
H NMR (C6D6) δ 7.46 (dd, 
J = 15.1, 10.7 Hz, 1H), 7.33-7.07 (m, 5H), 6.74 (d, J = 16.1 Hz, 2H), 6.51 (d, J = 1.4 Hz, 
1H), 5.92-5.87 (m, 1H), 5.83-5.78 (m, 3H), 5.71 (dd, J = 11.7, 4.8 Hz, 1H), 5.63-5.55 (m, 
2H), 4.73-4.52 (m, 10H), 4.35-4.31 (m, 2H), 4.05-3.96 (m, 4H), 3.74-3.71 (m, 1H), 3.30 
(s, 3H), 3.27 (s, 3H), 3.14 (s, 3H), 2.70 (dd, J = 17.5, 3.4 Hz, 1H), 2.47-2.42 (m, 1H), 
2.36-2.31 (m, 1H), 2.27-2.18 (m, 2H), 2.12-2.04 (m, 2H), 1.99-1.91 (m, 3H), 1.84-1.80 
(m, 2H), 1.73 (s, 3H), 1.54 (s, 3H), 1.28 (s, 3H), 1.21 (s, 3H), 1.13 (d, J = 7.3 Hz, 1H), 
1.10 (d, J = 7.3 Hz, 1H), 1.09 (s, 3H), 1.03 (d, J = 6.3 Hz, 3H), 1.00 (t, J = 7.8 Hz, 9H), 
0.70 (t, J = 7.3 Hz, 3H), 0.64-0.59 (m, 6H); 125 MHz 
13
C NMR (C6D6) δ 171.2, 170.1, 
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167.0, 165.7, 152.2, 147.1, 145.6 (x2), 140.1, 138.9, 128.9 (x2), 128.7, 128.6, 120.5, 
119.4, 108.9, 104.1, 103.8, 93.8, 80.6, 74.5, 74.4, 74.2, 74.0, 71.5, 69.9, 67.7, 66.5, 65.3, 
53.7, 51.1, 48.6, 45.9, 45.6, 44.0, 42.4 (x2), 42.1, 41.6, 40.7, 36.9, 35.4, 34.7, 31.9, 30.5, 
27.6, 22.3, 21.1 (x2), 18.1, 16.2, 14.0, 7.6, 6.3; 125 MHz DEPT 
13
C NMR (C6D6)  CH3 δ 
53.7, 51.1 (x2), 48.6 (x2), 21.1 (x2), 18.1, 16.1, 14.0, 7.6; CH2 δ 108.8, 93.8, 69.9, 45.9, 
44.0, 42.1, 40.7, 36.9, 35.4, 34.7, 31.9, 30.5, 22.3, 6.3; CH δ 147.1, 145.5, 140.1, 129.0, 
128.9, 128.4, 128.1, 120.5, 119.4, 80.6, 74.5, 74.4, 74.2, 74.0, 71.5, 67.7, 66.5, 65.3; CH0 
δ 171.2, 170.1, 167.0, 165.7, 152.2, 145.6, 128.9, 128.7, 104.1, 45.6, 42.4;  IR (neat)  
3674, 3526, 1996, 1870, 1846, 1650, 1520, 1159, 819, 789 cm
-1
; LRMS calcd for 
C61H92O16Si (M+Na): 1132.4489, found: 1132.1. 
 Preparation of C30-Decarbomethoxy 
Bryostatin 1(Merle 28): To a 2 mL reaction vial containing the analogue precursor 1.128 
(1.6 mg, 0.00144 mmol, 1 equiv) was added a 0.25 M solution of LiBF4 in 25:1 CH3CN/ 
H2O (260 µL, 0.0648 mmol, 45.0 equiv).  The reaction vial was sealed and the mixture 
was allowed to stir at 80 ºC for 24 h.  After cooling to rt, the reaction mixture was diluted 
with EtOAc (5 mL) and was quenched with a saturated aqueous NaHCO3 solution (5 
mL).  The layers were separated and the aqueous phase was extracted with EtOAc (3 x 5 
mL). The combined organic phases were dried over Na2SO4, filtered and concentrated. 
Purification was accomplished using flash column chromatography with a 0.5 x 6 cm 
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silica gel column, eluting with 20% EtOAc/hexanes, collecting 6 x 50 mm test tube 
fractions (1-10) followed by 50% EtOAc/hexanes.  The product containing fractions (20-
32) were combined and concentrated under reduced pressure to provide Merle 28 (1.0 
mg, 83%) as white solid: Rf = 0.25 (50% EtOAc/hexanes;   
20
D  +4 (c = 0.1, EtOAc); 
500 MHz 
1
H NMR (CDCl3) δ 6.18-6.16 (m, 1H), 6.01 (d, J = 1.9 Hz, 1H), 5.81 (d, J = 
11.7 Hz, 1H), 5.78 (d, J =  12.2 Hz, 1H), 5.30 (dd, J = 15.6, 8.3 Hz, 1H), 5.25 (s, 1H), 
5.20 (s, 1H), 5.16 (dd, J = 11.7, 4.3 Hz, 1H), 4.75 (d, J = 7.8 Hz, 2H), 4.29-4.16 (m, 3H), 
4.06-4.01 (m, 1H), 3.85-3.82 (m, 1H), 3.71-3.62 (m 3H), 3.67 (s, 3H), 2.51-2.43 (m, 2H), 
2.39 (s, 1H), 2.18-2.13 (m, 2H), 2.10-2.07 (m, 2H), 2.05 (s, 3H), 2.00-1.94 (m, 3H), 1.86-
1.81 (m, 1H), 1.79-1.76 (m, 1H), 1.79-1.76 (m, 1H), 1.69-1.62 (m, 2H), 1.57 (s, 3H), 
1.51-1.44 (m, 3H), 1.26-1.23 (m, 6H), 1.51 (s, 3H), 1.00 (s, 6H), 0.96 (s, 3H), 0.92 (t, J = 
7.3 Hz, 3H); 125 MHz 
13
C NMR (C6D6) δ 172.7, 170.3, 167.1, 165.9, 146.9, 145.3, 
144.5, 139.8, 130.7, 128.9, 128.7, 128.6, 120.8, 119.7, 109.2, 102.2, 100.2, 80.6, 75.3, 
74.4, 73.2, 72.3, 70.6, 69.1, 66.0, 65.7, 50.9, 45.8, 43.2, 42.8, 42.7, 42.0, 40.2, 36.6, 35.4, 
33.9, 32.4, 25.7, 22.3, 21.5, 21.0, 20.4, 20.2, 17.2, 14.0; 125 MHz DEPT 
13
C NMR 
(C6D6) CH3 δ 50.9, 25.7, 21.5, 21.0, 20.4, 20.2, 17.2, 14.0; CH2 δ 109.2, 43.2, 42.8, 42.7, 
42.0, 40.2, 36.6, 35.4, 33.9, 32.4, 22.3; CH δ 146.9, 145.3, 139.8, 130.7, 129.1, 120.8, 
119.7, 80.6, 75.3, 74.4, 73.2, 72.3, 70.6, 69.2, 66.0, 65.7; CH0 δ 172.7, 170.3, 167.1, 
165.9, 144.5, 128.7, 128.6, 102.2, 100.2, 45.8; IR (neat) 3608, 3583, 2932, 2360, 2339, 
1736, 1680, 1515, 1459, 1386, 1246, 1109, 820, 663 cm
-1
; LRMS calcd for C45H66O15 










. The inhibitory dissociation constant (Ki) of Merle 28 
was determined by the ability of the ligand to displace bound [20-
3
H]phorbol 12,13-
dibutyrate (PDBu) from mouse recombinant isozyme PKC á in the presence of calcium 
and phosphatidylserine, using a polyethylene glycol precipitation assay previously 
described by Blumberg and Lewin. Briefly, the assay mixture (250 µL) contained 50 mM 
Tris-HCl (pH 7.4 at room temperature), 100 µg/mL  phosphatidylserine,  0.1 mM Ca
2+
, 4 
mg/mL bovine immunoglobulin G and .003% Tx-100, 2 nM [
3
H]PDBu and various 
concentrations of the competing ligand.  The assay tubes were incubated at 37°C for 5 
min, then chilled for 10 min on ice, after which 200 µL of 35% polyethylene glycol 6000 
in 50 mM Tris-HCl (pH 7.4) was added. The tubes were vortexed and chilled an 
additional 10 min and then centrifuged in a Beckman Allegra 21R centrifuge at 4°C 
(12,200 rpm, 15 min). A 100 µL aliquot of each supernatant was removed and placed in a 
scintillation vial for the determination of the free concentration of [
3
H]PDBu.  Each 
assay pellet, located in the tip of the assay tube, was carefully dried, cut off, and placed in 
a scintillation vial for the determination of the total bound [
3
H]PDBu.   The radioactivity 
was determined by scintillation counting, using Cytoscint (ICN, Costa Mesa, CA). 
Specific binding was calculated as the difference between total and nonspecific PDBu 
binding. The inhibitory dissociation constant (Ki) was calculated using the method 
previously described by Blumberg and Lewin.  The Ki for Merle 28 was found to be 0.52 
± 0.06 nM (average of three determinations). 
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Attachment and proliferation of U937 cells
76 
U937 cells (Figure 1.67), purchased 
from ATCC (Manassas, VA) and cultured in RPMI-1640 medium supplemented with 10 
% FBS (ATCC, Manassas, VA), were plated in 35 mm dishes at a density of 1 X 10
5
 
living cells/ml and treated with different concentrations of the drugs or DMSO. After 72 
h, the number of cells in the supernatant (nonattached cells) and the number of attached 
cells (after trypsinization) were counted using a particle counter. The number of attached 




Figure 1.67. Attachment Assay for Merle 28  
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U937 cells (Figure 1.68) were treated with PMA (0.01-100 nM), bryostatin1 (0.1- 
1000 nM), analogue 12 (0.1-1000 nM), 10 nM PMA   with different concentrations of 
bryostatin 1 (0.1-1000 nM) or 10 nM PMA with different concentrations of analogue 12 
(0.1-1000 nM).  The numbers of attached and nonattached cells were counted and the 
number of total cells was expressed as % of control. The bars and error bars represent the 
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butylthio)-4-oxobutyl)-3,3-dimethyltetrahydro-2H-pyran-4-yl acetate (1.131):  To a 
stirring solution of bismethylketal 1.117 (97 mg, 0.077 mmol, 1.0 equiv) in CH2Cl2 (1.6 
mL) in a 10 mL rb flask at -78 ºC was added triethylsilane (248 μL, 1.55 mmol, 20 equiv) 
followed by a solution of TMSOTf in Et2O (251 μL, 0.92 M, 0.23 mmol, 3 equiv). After 
1 h at -78 ºC, the reaction was quenched by addition of saturated aqueous NH4Cl 
solution. The mixture was warmed to rt and diluted with CH2Cl2 (10 mL). The phases 
were separated, and the aqueous phase was extracted with CH2Cl2 (2 x 10 mL). The 
organic phases were combined, dried over Na2SO4 and concentrated under reduced 
pressure. Purification was accomplished by flash column chromatography on a 1 x 11 cm 
silica gel column, eluting with hexanes/EtOAc (9:1), collecting 4 mL fractions. The 
product containing fractions (30-48) were combined and concentrated under reduced 
pressure to provide the pyran 1.131 as a single diastereomer as a white foam (77 mg, 
82%).  Rf = 0.40 (30% EtOAc/hexanes);   
20
D  +22 (c = 1.0, CHCl3); 500 MHz 
1
H 
NMR (CDCl3) δ 7.70-7.67 (m, 4H), 7.45-7.20 (m, 13H), 6.85-6.83 (m, 2H), 6.02 (d, J = 
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15.6 Hz, 1H), 5.46 (dd, J  = 15.6, 5.8 Hz, 1H), 4.86 (d, J = 6.8 Hz, 1H), 4.84 (d, J = 6.8 
Hz, 1H), 4.71-4.70 (m, 2H), 4.65 (s, 2H), 4.64-4.61 (m, 1H), 4.47-4.43 (m, 2H), 4.62 
(ddd, J = 7.0, 5.3, 5.3 Hz, 1H), 4.17-4.12 (m, 1H), 4.11-4.06 (m, 1H), 3.87 (ddd, J = 10.2, 
4.8, 1.9 Hz, 1H), 3.80-3.76 (m, 1H), 3.79 (s, 3H), 3.45-3.41 (m, 1H), 3.23 (s, 3H), 3.06-
3.01 (m, 1H), 2.87-2.85 (m, 1H), 2.66 (dd, J = 14.6, 6.8 Hz, 1H), 2.62 (dd, J = 14.1, 5.3 
Hz, 1H), 2.50-2.38 (m, 2H), 2.20-2.18 (m, 2H), 2.09 (s, 3H), 1.95-1.85 (m, 4H), 1.80-
1.63 (m, 5H), 1.43 (s, 3H), 1.33 (dd, J = 4.7, 2.3 Hz, 1H), 1.30 (dd, J = 4.8, 2.4 Hz, 1H), 
1.21 (d, J = 6.3 Hz, 3H), 1.13 (s, 3H), 1.09 (s, 3H), 1.02 (s, 9H), 0.79 (s, 3H), 0.72 (s, 
3H); 125 MHz 
13
C NMR (CDCl3) δ 207.2, 197.7, 170.6, 159.3, 163.5, 137.9, 137.0, 
136.0, 135.9, 134.4, 133.7, 130.6, 129.8, 129.7, 129.3, 129.1, 128.5, 127.9, 127.8, 
127.7(x2), 113.9, 109.5, 104.0, 93.5, 79.6, 79.0, 77.2, 77.0, 75.5, 72.9, 72.6, 72.1, 69.7, 
69.5, 69.4, 55.3, 52.6, 52.3, 47.9, 44.2, 43.6, 41.1, 39.5, 37.6, 37.4, 36.3, 35.8, 33.8, 30.2, 
29.9, 27.1, 22.9, 22.3, 21.8, 21.2, 19.5, 14.8, 13.5; 125 MHz DEPT 
13
C NMR (CDCl3) 
CH3 δ 55.3, 52.3, 29.9, 27.1, 22.9, 22.3, 21.8, 21.2, 14.8, 13.5; CH2 δ 109.5, 93.4, 72.1, 
69.5, 52.6, 43.6, 41.1, 39.5, 37.6, 36.3, 35.7, 33.8, 30.2; CH1 δ 137.0, 135.9 (x2), 129.8, 
129.7, 129.3, 129.1, 128.5, 127.8, 127.7, 127.6, 113.9, 79.6, 79.0, 77.2, 77.0, 75.5, 72.9, 
72.5, 69.7, 69.4 CH0 δ 207.2, 197.7, 170.6, 159.3, 143.5, 137.9, 134.4, 133.7, 130.6, 
104.0, 47.9, 44.2, 37.4, 19.5; IR (neat) 3070, 2959, 2858, 1741, 1722, 1680, 1473, 1427, 
1388, 1241, 1111, 1073, 1029, 979, 822, 739, 704, 682, 611 cm
-1
; HRMS (ESI/APCI) 
calcd for C71H98NaO13SSi (M+Na): 1241.6395, found: 1241.6405. 
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oxobutyl)-3,3-dimethyltetrahydro-2H-pyran-4-yl acetate (1.136):  In a 100 ml flask, 
30 mL of CH2Cl2 was cooled to -78 °C, and a stream of O3 was passed in until the color 
changed to light blue (5 min). The flask was sealed and kept at -78 °C for immediate use. 
The O3 solution prepared above was added 50 μL at a time via a plastic syringe to a 
stirring solution of olefin 1.117(35 mg, 0.028 mmol, 1.0 equiv) at -78 °C. The reaction 
was monitored by TLC and the addition of the O3 solution was continued every 10 min 
until the starting material was fully consumed. Dimethyl sulfide (1 mL) was then added 
and the mixture was allowed to warm to rt.  
The solution was stirred at rt for 12 h after which the solvent was removed under 
reduced pressure. Purification was accomplished via flash column chromatography, using 
a 1 x 7 cm silica gel column, eluting with 20% EtOAc/hexanes, collecting 4 mL fractions.  
The product containing fractions (17 to 30) were combined and concentrated under 
reduced pressure to provide ketone 1.136 (31 mg, 89%) as a white foam. Rf = 0.46 (30% 
EtOAc/hexanes);   20D  +4 (c = 1.0, CHCl3); 500 MHz 
1
H NMR (CHCl3); 500 MHz 
1
H NMR (CDCl3) δ 7.70-7.67 (m, 4H), 7.45-7.27 (m, 11H), 7.22-7.21 (m, 2H), 6.84-6.83 
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(m, 2H), 6.05 (d, J = 16.1 Hz, 1H), 5.46 (dd, J  = 16.1, 6.3 Hz, 1H), 4.85 (dd, J = 11.7, 
7.3 Hz, 2H), 4.65 (s, 2H), 4.62 (d, J = 11.2 Hz, 1H),  4.45-4.43 (m, 1H), 4.40 (dd, J =  
11.7, 4.3 Hz, 1H), 4.25 (q, J = 4.8 Hz, 1H), 4.18-4.14 (m, 1H), 4.10-4.08 (m, 1H), 3.86 
(ddd, J = 10.1, 4.3, 1.8 Hz, 1H), 3.78 (s, 3H), 3.75-3.71 (m, 1H), 3.22 (s, 3H), 2.94-2.91 
(m, 1H), 2.76-2.60 (m, 3H), 2.50-2.26 (m, 4H), 2.07 (dd, J = 14.1, 11.7 Hz, 1H), 2.02 (s, 
3H), 1.92-1.84 (m, 4H), 1.70-1.63 (m, 3H), 1.56 (dd, J = 12.6, 9.7 Hz, 2H), 1.43 (s, 9H), 
1.32-1.31 (m, 2H), 1.21 (d, J = 6.3 Hz, 3H), 1.13 (s, 3H), 1.11 (s, 3H), 1.02 (s, 9H), 0.78 
(s, 3H), 0.71 (s, 3H); 125 MHz 
13
C NMR (CDCl3) δ 207.0, 206.1, 197.8, 170.6, 159.3, 
138.3, 138.0, 136.1, 136.0, 134.4, 133.7, 130.6, 129.9, 129.8, 129.4, 128.6, 127.9 (x2), 
127.8, 127.7, 114.0, 103.9, 93.6, 79.2, 77.4, 77.3, 76.8, 74.1, 73.1, 72.6, 72.2, 69.7, 69.6, 
69.1, 55.4, 53.0, 52.5, 48.1, 47.8, 46.6, 44.4, 43.6, 37.7, 37.5, 36.3, 36.0, 33.5, 30.4, 30.0, 
29.8, 27.1, 23.0, 22.3, 21.8, 21.2, 19.6, 14.9, 13.5; 125 MHz DEPT 
13
C NMR (CDCl3) 
CH3 δ 55.4, 52.5, 29.9, 27.1, 23.0, 22.3, 21.8, 21.3, 14.9, 13.5; CH2 δ 93.6, 72.2, 69.6, 
53.0, 47.8, 46.6, 43.6, 37.7, 36.3, 36.0, 33.5, 30.4, 29.8; CH1 δ 138.3, 136.1, 136.0, 129.9, 
129.8, 129.4, 128.6,  127.9 (x2), 127.8, 127.7, 114.0, 79.2, 77.4, 77.3, 76.8, 74.1, 73.1, 
72.6, 69.7, 69.1; CH0 δ 207.0, 206.1, 197.8, 170.6, 159.3, 138.0, 134.4, 133.7, 130.6, 
103.9, 48.1, 44.4, 37.5, 19.6; IR (neat) 2959, 2932, 2360, 2339 1723, 1683, 1514, 1456, 
1363, 1247, 1111, 1041, 822, 741, 703 cm
-1
; HRMS (ESI/APCI) calcd for 
C71H96NaO14SSi (M+Na): 1243.6188, found: 1243.6194.  
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dimethyltetrahydro-2H-pyran-4-yl acetate (1.140): To a stirring solution of the PMB 
ether 1.117 (51 mg, 0.041 mmol, 1 equiv) in CH2Cl2 (3.2 mL) in a 15 mL flask at 0 ºC  
was added pH 7 phosphate buffer (800 µL). To the solution was added DDQ (47 mg, 
0.20 mmol, 5 equiv) in one portion and the mixture was stirred vigorously for 1 h after 
which another 5 equiv DDQ was added. After stirring 1 more h at 0 ºC, the reaction was 
quenched by adding saturated aq. NaHCO3 solution (1 mL) and stirring for 15 min. The 
layers were separated and the aqueous layer was extracted with CH2Cl2 (2 x 5 mL). The 
combined organic layer was dried over Na2SO4, filtered, and concentrated. Purification 
was accomplished with flash column chromatography, using a 1 x 7 cm silica gel column, 
eluting with 30% EtOAc/hexanes, collecting 4 mL fractions.  The product containing 
fractions (25 to 50) were combined and concentrated under reduced pressure to provide 
alcohol 1.140 (42 mg, 91%) as a white foam. Rf = 0.3 (50% EtOAc/hexanes);   
20
D  -
9.6 (c = 0.7, CHCl3); 500 MHz 
1
H NMR (CDCl3) δ 7.70-7.66 (m, 4H), 7.45-7.29 (m, 
11H), 6.02 (d, J = 16.1 Hz, 1H), 5.46 (dd, J  = 16.1, 6.3 Hz, 1H), 4.89 (d, J = 6.8 Hz, 1H), 
4.85 (d, J = 7.3 Hz, 1H), 4.68 (d, J = 11.7 Hz, 1H), 4.64 (d, J = 11.7 Hz, 1H),  4.40 (dd, J  
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= 11.7, 4.8 Hz, 1H),  4.28-4.24 (m, 2H), 4.11-4.07 (m, 1H), 3.83 (ddd, J = 12.6, 6.3, 3.9 
Hz, 1H), 3.77-3.71 (m, 1H), 3.61 (q, J = 6.3 Hz, 1H), 3.33 (s, 3H), 2.93 (dddd, J = 10.9, 
7.5, 4.1, 2.3 Hz, 1H), 2.81-2.80 (m, 1H), 2.75 (dd, J = 10.2, 1.4 Hz, 1H), 2.68 (dd, J = 
14.6, 16.8 Hz, 1H), 2.62 (dd, J = 14.1, 4.8 Hz, 1H), 2.57-2.50 (m, 1H), 2.41-2.26 (m, 
4H), 2.08 (dd, J = 14.1, 11.7 Hz, 1H), 2.02 (s, 3H), 1.92-1.83 (m, 3H), 1.70-1.55 (m, 5H), 
1.43 (s, 9H), 1.31 (ddd, J = 12.6, 4.3, 1.9 Hz, 2H), 1.25 (d, J = 6.3 Hz, 3H), 1.15 (s, 3H), 
1.10 (s, 3H), 1.02 (s, 9H), 0.78 (s, 3H), 0.71 (s, 3H); 125 MHz 
13
C NMR (CDCl3) δ 
206.8, 206.2, 197.8, 170.6, 138.4, 137.6, 136.1, 136.0, 134.4, 133.7, 130.0, 129.8, 128.7, 
128.1,  128.0, 127.9, 127.8, 127.6, 103.8, 94.0, 79.3, 78.4, 77.4, 76.8, 74.2, 73.1, 71.3, 
70.1, 69.6, 69.2, 53.0, 52.0, 48.2, 47.9, 46.7, 44.2, 43.6, 39.5, 37.5, 37.4, 36.0, 33.6, 30.3, 
30.0, 27.1, 22.9, 22.4, 22.2, 21.3, 19.6, 17.0, 13.5; 125 MHz DEPT 
13
C NMR (CDCl3) 
CH3 δ 52.0, 30.0, 27.1, 22.9, 22.4, 22.2, 21.3, 17.0, 13.5; CH2 δ 94.0, 70.1, 53.0, 47.9, 
46.7, 43.6, 39.5, 37.4, 36.0, 33.5, 30.3; CH1 δ 138.4, 136.1, 136.0, 129.9, 129.8, 128.6, 
128.0, 127.9, 127.7, 127.5, 79.2, 78.4, 77.4(x2), 76.8, 74.2, 73.1, 71.3, 69.6, 69.1; CH0 δ 
206.8, 206.2, 179.8, 170.6, 137.6, 134.4, 133.7, 128.1, 103.8, 48.2, 44.2, 37.5, 19.6; IR 
(neat) 3046, 2960, 2931, 2858, 2360, 2337, 1718, 1678, 1540, 1472, 1456, 1419, 1363, 
1244, 1111, 1043, 822, 741, 702, 667 cm
-1
; HRMS (ESI/APCI) calcd for 
C62H88NaO13SSi (M+Na): 1123.5613, found: 1123.5614. 
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(tert-butyldiphenylsilyloxy) butanoic acid (1.141):  To a stirring solution of thiolester 
1.140 (71 mg, 0.064 mmol, 1.0 equiv) in a 4:1 mixture of THF/H2O (3.2 mL, 0.02 M) at 
0 ºC was added mCPBA (44 mg, 0.257 mmol, 4.0 equiv). The mixture was stirred at 0 ºC 
for 1 hr and at rt for 8 h after which TLC showed the completion of reaction.  The 
reaction was diluted with EtOAc (15 ml) and washed with saturated aq. NaHSO3 solution 
(5 mL) and brine (5 mL). The organic phase was dried over Na2SO4, filtered and 
concentrated under reduced pressure to provide the crude seco acid. Purification was 
accomplished using flash column chromatography using 1 x 10 cm silica gel column 
using 30% EtOAc/hexanes (50 mL) which removed mCPBA. Elution of the column with 
a mixture of 50% hexanes, 30% EtOAc, and 20% MeOH, collecting 4 mL fractions, 
provided the desired seco acid 1.141 (fractions 21 to 50) (55 mg, 83%) as a white foam.  
Rf = 0.7 (2:2:1 EtOAc/hexanes/MeOH);   
20
D  -2.1 (c = 1.2, EtOAc); 500 MHz 
1
H 
NMR (CDCl3) δ 7.68-7.65 (m, 4H), 7.46-7.29 (m, 9H), 6.09 (d, J = 16.1 Hz, 1H), 5.45 
(dd, J  = 15.6, 6.3 Hz, 1H), 4.83 (dd, J = 13.6, 6.8 Hz, 2H), 4.63 (s, 2H),  4.40 (dd, J  = 
11.2, 4.3 Hz, 1H),  4.27 (ddd, J = 12.6, 9.4, 3.9 Hz, 1H), 4.21 (ddd, J = 11.2, 8.3, 4.8 Hz, 
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1H), 4.05 (dd, J  = 14.6, 6.3 Hz, 1H),  3.89-3.85 (m, 1H), 3.66 (q, J = 5.8 Hz, 2H), 3.33 
(s, 3H), 2.95-2.91 (m, 1H), 2.71-2.67 (m, 2H), 2.62-2.51 (m, 3H), 2.41-2.31 (m, 4H), 
2.10 (dd, J = 14.1, 11.7 Hz, 1H), 2.02 (s, 3H), 1.94-1.83 (m, 4H), 1.74-1.64 (m, 4H), 1.57 
(dd, J = 12.2, 9.2 Hz, 1H), 1.53 (t, J = 3.4 Hz, 1H), 1.50 (t, J = 3.4 Hz, 1H), 1.40-1.33 (m, 
2H), 1.24 (d, J = 6.3 Hz, 3H), 1.20 (s, 3H), 1.07 (s, 3H), 1.03 (s, 9H), 0.81 (s, 3H), 0.71 
(s, 3H); 125 MHz 
13
C NMR (CDCl3) δ 206.7, 206.5, 173.4, 170.6, 139.2, 137.5, 
136.0(x2), 133.9, 133.4, 130.1, 130.0, 128.7, 128.0(x2), 127.9(x2), 127.0, 94.0, 79.8, 
78.2(x2), 76.8, 74.7, 73.3, 71.2, 70.1, 69.7, 69.2, 51.9, 48.2, 47.2, 44.0, 43.6, 43.2, 39.1, 
37.4, 37.3, 36.4, 33.8, 30.4, 27.0, 23.2, 22.3(x2), 21.3, 19.4, 17.0, 13.6; 125 MHz DEPT 
13
C NMR (CDCl3) CH3 δ 51.9, 27.0, 23.2, 22.3(x2), 21.3, 17.0, 13.6; CH2 δ 94.0, 70.0, 
48.1, 47.2, 43.6, 43.2, 39.1, 37.3, 36.4, 33.8, 30.4; CH1 δ 139.2, 136.0, 130.1, 130.0, 
128.6, 128.0(x2), 127.9(x2), 127.0, 79.8, 78.2, 78.1, 76.8, 74.7, 73.3, 71.2, 69.7, 69.2; 
CH0 δ 206.8, 206.5, 173.4, 170.6, 137.5, 126.0, 133.9, 133.4, 44.0, 37.4, 19.4; IR (neat) 
2970, 2935, 1732, 1607, 1513, 1455, 1377, 1247, 1170, 1103, 1036, 823, 741, 700 cm
-1
; 
HRMS (ESI/APCI) calcd for C58H80NaO14Si (M+Na): 1051.5215, found: 1051.5232. 
 Preparation of (1S,3R,7R,11S 
,15S,17R,21R,23S,25S,E)-17-((R)-1-((benzyloxy)methoxy)ethyl)-21-((tert-butyl 
diphenylsilyl)oxy)-11-methoxy-10,10,26,26-tetramethyl-5,12,19-trioxo-18,27,28,29-
tetraoxatetracyclo [21.3.1.13, 7.111,15] nonacos-8-en-25-yl acetate (1.137):  To a 
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stirring solution of the seco acid 1.141 (29 mg, 0.028 mmol, 1.0 equiv) in THF (1 mL) in 
a 5 mL vial at 0 °C was added triethylamine (23 µL, 0.17 mmol, 6.0 equiv) and  2,4,6-
trichlorobenzoyl chloride (13 µL, 0.086 mmol, 3.0 equiv).  After 1 h, the reaction was 
warmed to rt and stirring continued for an additional 5 h.  The reaction mixture was 
diluted with 3:1 toluene/ THF (10 mL) and taken up in a 25 mL gas-tight syringe.  This 
solution was added by syringe pump to a stirring solution of DMAP (70 mg, 0.57 mmol, 
20.0 equiv) in toluene (20 mL) at 45 °C over 12 h.  The residual contents of the syringe 
were rinsed into the flask with toluene (0.5 mL) and stirring continued for an additional 2 
h. The reaction mixture was cooled to rt and washed with saturated aqueous NaHCO3 
solution (2 x 10 mL) and brine (2 x 10 mL).  The organic phase was dried over Na2SO4, 
filtered, and concentrated under reduced pressure.  Purification was accomplished using 
flash column chromatography with a 1 x 10 cm silica gel column, eluting with 20% 
EtOAc/hexanes, collecting 4 mL fractions. The product containing fractions (15-30) were 
combined and concentrated under reduced pressure to provide pure macrolactone 1.137 
as a white foam (23 mg, 79%): Rf = 0.5 (40% EtOAc/hexanes);   
20
D +3.7 (c = 1.5, 
CHCl3); 500 MHz 
1
H NMR (CDCl3) δ 7.71-7.69 (m, 5H), 7.47-7.30 (m, 10H), 6.31 (d, J 
= 15.6 Hz, 1H), 5.50 (ddd, J  = 11.2, 3.9, 2.4 Hz, 1H), 5.38 (dd, J  = 16.1, 8.3 Hz, 1H), 
4.87 (d, J = 6.8 Hz, 1H), 4.81 (d, J = 6.8 Hz, 1H), 4.65 (s, 2H),  4.43 (ddd, J  = 10.3, 7.4, 
4.5 Hz, 2H), 4.23-4.18 (m, 2H), 4.16-4.12 (m, 1H), 4.04 (ddd, J  = 10.7, 7.8, 4.3 Hz, 1H),  
3.54-3.50 (m, 1H), 3.24 (s, 3H), 2.68 (ddd, J  = 14.6, 9.7, 5.3 Hz, 1H), 2.58 (dd, J = 15.1, 
9.2 Hz, 1H), 2.47-2.29 (m, 8H), 2.18-2.13 (m, 1H), 2.12-2.03 (m, 1H),  1.99 (s, 3H), 
1.97-1.85 (m, 3H), 1.58-1.35 (m, 4H), 1.33 (s, 3H), 1.17 (d, J = 6.3 Hz, 3H), 1.12 (ddd, J  




C NMR (CDCl3) δ 206.8, 205.4, 171.7, 170.6, 142.2, 137.9, 136.2, 135.9, 134.5, 133.3, 
130.3, 129.9, 128.6, 128.1, 128.0, 127.8 (x2), 126.0, 93.7, 80.5, 79.0, 76.9, 74.4, 74.1, 
72.2, 70.8, 70.7, 69.7, 65.2, 53.5, 48.4, 47.8, 44.9, 43.6, 43.5, 37.9, 37.2, 35.9, 33.4, 33.3, 
31.1 29.9, 27.0, 24.7, 22.2, 21.2, 19.7, 19.5, 14.9, 13.5; 125 MHz DEPT 
13
C NMR 
(CDCl3) CH3 δ 52.5, 27.0, 24.7, 22.2, 21.2, 19.7, 14.9, 13.5; CH2 δ 93.7, 69.7, 48.4, 47.8, 
44.9, 43.9, 37.9, 35.9, 33.4, 33.3, 31.1; CH1 δ 142.2, 136.1, 135.9, 130.3, 129.9, 128.6, 
128.0 (x2), 127.8, 126.0, 80.5, 79.0, 77.4, 76.8, 74.3, 74.1, 72.2, 70.7, 65.2; CH0 δ 206.8, 
205.4, 171.7, 170.6, 137.9, 134.5, 133.3, 127.8, 70.8, 43.5, 37.2, 29.9, 19.5; IR (neat) 
2933, 2857, 2337, 1733, 1652, 1540, 1456, 1363, 1150, 1109, 1038, 747, 703 cm
-1
; 
HRMS (ESI/APCI) calcd for C58H78NaO13Si (M+Na): 1033.5109, found: 1033.5096. 
 Preparation of (Z)-methyl 2-
((1S,3S,7R, 11S,15S, 17R,21R,23S,25S,E) -25-acetoxy-17-((R)-1-((benzyloxy) 
methoxy)ethyl)-21-((tert-butyldiphenylsilyl)oxy)-11-methoxy-10,10,26,26-tetra 
methyl -12,19-dioxo-18,27,28,29-tetraoxatetracyclo [21.3.1.13,7.111,15]nonacos-8-en-
5-ylidene)acetate (1.139): To a stirring solution of the R-BINOL phosphonate 1.138 (58 
mg, 0.144 mmol, 8 equiv) in THF (1.5 mL) in a 5 mL vial at -78 °C was added a 1M 
solution of NaHMDS in THF (135 µL, 0.135 mmol, 7.5 equiv) down the wall of the vial 
via syringe. The resulting solution was stirred at -78 °C for 30 min. During this time, the 
diketone 1.137 (18.3 mg, 0.018 mmol, 1equiv) was dissolved in 0.1 mL of THF and 
added dropwise along the side of the vial via syringe and then rinsed in with THF (2 x 0.1 
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mL). The solution was stirred at -78 °C for 1 h then warmed to 0 °C and stirring was 
continued for 12 h. The reaction was quenched by dropwise addition of saturated aq. 
NH4Cl solution (3 mL) and was diluted with EtOAc (3 mL). The layers were separated 
and the aqueous layer was extracted with EtOAc (3 x 5 mL). The combined organic layer 
was dried over Na2SO4, filtered and concentrated in vacuo. Purification was accomplished 
using flash column chromatography with a 2 x 7 cm silica gel column, eluting with 15% 
EtOAc/hexanes, collecting 4 mL fractions. The product containing fractions (34-45) were 
combined and concentrated under reduced pressure to provide the desired unsaturated 
ester as a 4:1, Z:E mixture of diastereomers. The E and Z diastereomers were further 
separated using preparative thin layer chromatography eluting with 10% EtOAc/benzene 
providing 13 mg of the desired Z isomer as 12:1 mixture and 3.3 mg of the E isomer 
(combined yield 85%): The stereochemistry of Z isomer was confirmed by a NOE 
interaction between the C31 olefin proton and the C12 equatorial proton. Rf = 0.55 (30% 
EtOAc/hexanes); Analytical data for Z isomer:   20D +12.8 (c = 1.0, CHCl3); 500 
MHz 
1
H NMR (CDCl3) δ 7.70-7.68 (m, 4H), 7.45-7.28 (m, 11H), 6.26 (d, J = 15.6 Hz, 
1H), 5.78 (s, 1H), 5.44-5.39 (m, 2H), 4.91(d, J  = 6.8 Hz, 1H), 4.83 (d, J  = 6.8 Hz, 1H), 
4.68 (d, J = 12.2 Hz, 1H), 4.62 (d, J = 12.2 Hz, 1H), 4.44 (ddd, J  = 12.8, 4.0, 4.0 Hz, 
1H), 4.27 (dd, J  = 11.3, 2.8 Hz, 1H), 4.18-4.14 (m, 1H), 4.02 (ddd, J  = 15.1, 7.5, 3.9 Hz, 
1H), 3.94-3.90 (m, 1H), 3.84-3.76 (m, 1H), 3.73 (s, 3H), 3.38-3.34 (m, 1H), 3.23 (s, 3H), 
2.64 (ddd, J  = 14.1, 9.2, 5.3 Hz, 1H),  2.57-2.44 (m, 3H), 2.40-2.34 (m, 1H), 2.23-2.18 
(m, 1H), 2.15-2.2.08 (m, 1H),    2.04-1.99 (m, 3H), 2.0 (s, 3H), 1.91-1.80 (m, 2H), 1.51-
1.44 (m, 2H), 1.41-1.37 (m, 2H),  1.32 (s, 3H), 1.26 (d, J = 2.4 Hz, 1H), 1.18 (d, J = 6.3 
Hz, 3H),  1.12-1.09 (m, 1H), 1.04-1.02 (m, 1H), 1.00 (s, 3H), 0.98 (s, 9H), 0.73 (s, 3H), 
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0.68 (s, 3H); 125 MHz 
13
C NMR (CDCl3) δ 205.7, 171.4, 170.6, 167.0, 157.2, 141.5, 
136.1, 136.0, 135.9, 134.6, 133.5, 130.0, 129.8, 128.5, 128.0, 127.9, 127.8, 127.7, 120.0, 
114.9, 93.8, 81.0, 79.6, 76.8, 75.5, 74.0, 72.3, 70.9, 70.8, 69.6, 65.8, 52.5, 51.2, 44.8, 
43.6, 43.5, 43.1, 43.0, 37.9, 37.3, 36.0, 35.8, 33.4(x2), 30.8, 27.0, 24.6, 22.3, 21.2, 19.8, 
19.4, 15.0, 13.5; 125 MHz DEPT 
13
C NMR (CDCl3) CH3 δ 52.5, 51.2, 27.0, 24.6, 22.3, 
21.3, 19.8, 15.1, 13.5; CH2 δ 93.8, 69.6, 44.0, 43.6, 43.0, 37.9, 36.0, 35.8, 33.4(x2), 30.8; 
CH1 δ 141.6, 136.1, 135.9, 130.0, 129.9, 128.5, 128.0, 127.9, 127.8, 127.7, 127.0, 114.9, 
81.0, 79.6, 76.8, 75.5, 74.0, 72.3, 70.9, 70.8; CH0 δ 205.7, 171.4, 170.6, 167.0, 157.2, 
136.0, 134.6, 65.8, 43.1, 37.3, 30.8, 19.4; IR (neat) 2934, 2361, 2337, 1734, 1652, 1456, 
1374, 1243, 1149, 1107, 1028 cm
-1
; HRMS (ESI/APCI) calcd for C61H82NaO14Si 
(M+Na): 1089.5372, found: 1089.5371. Spectroscopic data for E isomer: 500 MHz 
1
H 
NMR (CDCl3) δ 7.70-7.67 (m, 4H), 7.45-7.30 (m, 11H), 6.27 (d, J = 15.6 Hz, 1H), 5.77 
(s, 1H), 5.49 (ddd, J = 11.8, 3.9 1.8 Hz, 1H), 5.38 (dd, J  = 15.6, 8.3 Hz, 1H), 4.89 (d, J  = 
6.8 Hz, 1H), 4.81 (d, J  = 6.6 Hz, 1H), 4.66 (s, 2H), 4.45 (ddd, J  = 11.6, 6.0, 2.0 Hz, 1H), 
4.23 (dd, J  = 11.2, 6.3 Hz, 1H), 4.19 (dd, J  = 10.7, 3.9 Hz, 1H), 4.04-3.98 (m, 2H), 3.93 
(d, J  = 13.6, 1H), 3.78 (s, 3H), 3.29 (t, J  = 10.7, 1H), 3.24 (s, 3H), 2.68 (ddd, J  = 19.5, 
9.2, 5.3 Hz, 1H),  2.58-2.45 (m, 3H), 2.37 (ddd, J  = 20.6, 8.0, 5.8 Hz, 1H), 2.27-2.23 (m, 
1H), 2.21-2.13 (m, 3H), 1.99 (s, 3H), 1.93-1.83 (m, 3H), 1.77-1.72 (m, 3H),  1.52 (dd, J = 
13.6, 7.8 Hz, 2H), 1.47-1.39 (m, 2H), 1.32 (s, 3H), 1.18 (d, J = 6.3 Hz, 3H),   1.06-1.04 
(m, 1H), 1.01 (s, 3H), 0.98 (s, 9H), 0.71 (s, 3H), 0.69 (s, 3H); 125 MHz 
13
C NMR 
(CDCl3) δ 205.6, 171.6, 170.5, 167.1, 157.7, 141.7, 137.9, 136.1, 135.9, 134.6, 133.5, 
130.2, 129.9, 128.6, 128.0, 127.8, 126.9, 114.7, 93.6, 81.1, 80.2, 77.4, 76.9,  75.4, 73.9,  
72.1, 70.9, 70.7, 69.7, 65.4, 52.6, 51.2, 44.9, 43.6, 42.6, 37.9, 37.3, 37.3, 36.3, 36.0, 33.4, 
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33.2, 31.2,  29.9, 27.0, 24.8, 22.3, 21.3, 19.8, 19.5, 14.8, 13.6; 125 MHz DEPT 
13
C NMR 
(CDCl3) CH3 δ 52.6, 51.2, 27.0, 24.8, 22.3, 21.3, 19.8, 14.8, 13.6; CH2 δ 93.6, 69.7, 44.9, 
43.6, 42.6, 37.9, 36.3, 36.0,  33.4, 33.2, 31.2, 29.9; CH1 δ 141.7, 136.1, 135.9, 130.3, 
129.9, 128.6, 128.1, 128.0, 127.8, 126.9, 114.7, 81.1, 80.2, 77.4, 76.9, 75.4, 73.9, 72.1, 
70.9, 70.7, 65.4; CH0 δ 205.6, 171.6, 170.5, 167.1, 157.7, 137.9, 134.6, 133.5, 37.3, 19.5.  




8-ene-5,13-diylidene)diacetate (1.146): To a stirring solution of ketone 1.139-Z (5.0 mg, 
0.00468 mmol, 1.0 equiv) in 234 µL of MeOH in a 4 mL vial at room temperature was 
added K2CO3 (3.2 mg, 0.0234 mmol, 5 equiv) and the methyl acetal of methyl glyoxylate 
(11 mg, 0.0936 mmol, 20 equiv).  The mixture was stirred overnight, during which time 
the color of the solution changed to yellow. The reaction was quenched by addition of 3 
mL of saturated aqueous NH4Cl solution and was then diluted with 5 mL of EtOAc.  The 
phases were separated and the aqueous phase was extracted with EtOAc (3 x 5 mL).  The 
combined organic phases were dried over Na2SO4, filtered and concentrated under 
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reduced pressure. This crude material was taken into the following reaction without 
further purification. 
 To a stirring solution of the aforementioned product in pyridine (500 µL, 0.01 M) 
in a 4 mL reaction vial at rt was added DMAP (6 mg, 0.0468 mmol, 10 equiv), and acetic 
anhydride (22 µL, 0.234 mmol, 50 equiv).  The reaction mixture was allowed to stir at rt 
for 24 h and was then quenched by addition of saturated aqueous NaHCO3 solution (4 
mL).  The mixture was diluted with 5 mL CH2Cl2, the phases were separated, and the 
aqueous phase was extracted with CH2Cl2 (3 x 5 mL).  The combined organic phases 
were dried over Na2SO4, filtered, and concentrated under reduced pressure.  Purification 
was accomplished using flash column chromatography with a 1 x 5 cm silica gel column, 
eluting with 10% EtOAc/hexanes, collecting 4 ml fractions.  The product containing 
fractions (9-21) were combined and concentrated under reduced pressure to provide pure 
enoate 1.146 (2.3 mg, 60% over 2 steps): Rf = 0.44 (40% EtOAc/hexanes);   
20
D +8 (c 
= 0.4, CHCl3); 500 MHz 
1
H NMR (CDCl3) δ 7.73-7.70 (m, 4H), 7.45-7.27 (m, 11H), 
6.56 (dd, J = 2.4, 1.9 Hz, 1H), 5.97 (d, J = 15.6 Hz, 1H), 5.72 (s, 1H), 5.42 (dd, J = 15.6, 
6.8 Hz, 1H), 5.22-5.20 (m, 1H), 4.84 (dd, J  = 16.1, 6.8 Hz, 2H), 4.65 (s, 2H), 4.38 (dd, J 
= 11.2, 4.3 Hz, 1H), 4.34-4.33 (m, 1H), 4.09-4.05 (m, 2H), 3.72 (s, 3H), 3.70 (s, 3H), 
3.46-3.41 (m, 2H), 3.24 (s, 3H), 2.96 (dd, J  = 10.7, 2.9 Hz, 1H),  2.92 (dd, J  = 10.7, 3.4 
Hz, 1H), 2.68 (dd, J  = 15.1, 6.8 Hz, 2H),  2.62-2.56 (m, 2H), 2.22 (ddd, J  = 14.9, 6.61, 
2.7 Hz, 1H),  2.15-2.03 (m, 2H), 2.00 (s, 3H), 1.89 (t, J = 13.4 Hz, 1H), 1.75-1.69 (m, 
1H), 1.58-1.49 (m, 2H), 1.47 (t, J = 4.8 Hz, 1H), 1.44 (t, J = 4.3 Hz, 1H), 1.26 (s, 3H), 
1.25(s, 3H), 1.23 (d, J = 2.9 Hz, 3H),  0.99 (s, 9H), 0.96 (s, 3H), 0.76 (s, 3H), 0.67 (s, 
3H); 125 MHz 
13
C NMR (CDCl3) δ 220.5, 171.0. 170.5, 166.9, 166.1, 157.2, 147.9, 
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137.9, 136.1, 136.0, 134.5, 133.7, 129.9, 129.8, 129.2, 128.5, 127.9, 127.8 (x2), 123.1, 
114.8, 103.5, 93.8, 80.9, 78.6, 77.4, 77.0, 76.2, 73.2, 73.0, 71.9, 69.7, 63.3, 52.4, 52.0, 
51.2, 44.4, 43.2, 43.1, 37.8, 37.9, 36.8, 36.3, 34.5, 34.3, 33.3, 29.9, 27.0, 24.8, 23.6, 22.4, 
21.3, 21.1, 19.4, 15.4, 13.6; 125 MHz DEPT 
13
C NMR (CDCl3) CH3 δ 52.4, 52.0, 51.2, 
27.0, 22.4, 22.3, 21.3, 21.1, 15.4, 13.6; CH2 δ 103.5, 93.8, 69.7, 43.1, 37.8, 36.8, 36.2, 
34.5, 34.3, 33.3, 24.8; CH1 δ 136.1, 136.0, 129.9, 129.8, 129.2, 128.5, 127.9, 127.8(x), 
123.1, 114.7, 80.9, 78.6, 77.4, 77.0, 76.2, 73.2, 73.0, 71.9, 69.2; CH0 δ 220.5, 171.0, 
170.5, 166.9, 166.1, 157.2, 147.9, 137.9, 134.5, 133.7, 63.3, 37.9, 23.6, 19.4; IR (neat) 
2952, 2359, 2341, 1662, 1616, 1586, 1513, 1454, 1381, 1300, 1248, 1172, 1092, 1038, 
848, 736, 698 cm
-1
; HRMS (ESI/APCI) calcd for C64H84NaO16Si (M+Na): 1159.5426, 
found: 1159.5419. 





To a stirring solution of ketone 1.146 (4.1 mg, 0.0036 mmol, 1.0 equiv) in MeOH (360 
µL, 0.01 M) in a 5 mL reaction vial at rt was added CeCl3·7H2O (27 mg, 0.072 mmol, 
20.0 equiv). The mixture was stirred until all the CeCl3·7H2O was completely dissolved.  
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The mixture was then cooled to -42 ºC and stirred for 10 min and then NaBH4 (1.3 mg, 
0.036 mmol, 10.0 equiv) was added.  Stirring continued for 1 h at -42 ºC after which the 
reaction was quenched by slow addition of saturated aqueous NH4Cl solution (2 mL) and 
diluted with 40% EtOAc/hexanes (5 mL). The layers were separated and the aqueous 
layer was extracted with 40% EtOAc/hexanes (3 x 5 mL).  The organic phase was 
washed with brine (5 mL), then dried over Na2SO4, filtered and concentrated under 
reduced pressure to provide the crude intermediate alcohol which was carried directly to 
the next step without purification. 
 To a stirring solution of this alcohol in CH2Cl2 (360 µL, 0.001 M) in a 5 mL 
reaction vial at rt was added pyridine (15 µL, 0.18 mmol, 50 equiv), DMAP (4.0 mg, 
0.036 mmol, 10 equiv), and octadienoic anhydride (29 mg, 0.108 mmol, 30 equiv).  The 
reaction mixture stirred at rt for 12 h and was then quenched by the addition of saturated 
aqueous NaHCO3 solution (2.0 mL).  The mixture was stirred vigorously for 30 min and 
was then diluted with 40% EtOAc/hexanes (5mL). The phases were separated and the 
aqueous phase was extracted with 40% EtOAc/hexanes (3 x 5 mL).  The combined 
organic phases were dried over Na2SO4, filtered, and concentrated under reduced 
pressure. Purification was accomplished using flash column chromatography using 10% 
EtOAc/hexanes (50 mL) followed by 20% EtOAc/hexanes collecting 4 mL fractions. 
Fractions 16-23 provided the desired product as 4.2:1 mixture of diastereomers which 
were further separated by a preparative TLC with 4% acetone/benzene to provide the 
ester 1.147 (3 mg, 66%, 2 steps) as a pale yellow liquid. Rf = 0.53 (30% EtOAc/hexanes); 
  20D +12 (c = 0.11, CHCl3); 500 MHz 1H NMR (CDCl3) δ 7.71-7.69 (m, 4H), 7.45-
7.24 (m, 11H), 6.20-6.15(m, 2H), 5.99 (d, J = 1.6 Hz, 1H), 5.79-5.76 (m, 2H), 5.60 (ddd, 
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J = 7.2, 5.6, 3.9 Hz, 1H), 5.31(dd, J  = 15.6, 8.7 Hz, 1H),  5.22 (s, 1H), 4.94 (d, J  = 6.8 
Hz, 1H), 4.84 (d, J  = 6.8 Hz, 1H), 4.71 (d, J  = 12.2 Hz, 1H), 4.67 (d, J  = 12.2 Hz, 1H), 
4.44 (ddd, J = 13.2, 6.3, 3.5 Hz, 1H), 4.24 (dd, J = 11.2, 4.8 Hz, 1H), 4.18-4.13 (m, 1H),  
3.90-3.81 (m, 2H), 3.75 (s, 3H), 3.69 (s, 3H), 3.28 (t, J  = 10.7, 1H), 3.05 (s, 3H), 2.51 
(dd, J  = 15.1, 9.7 Hz, 1H),  2.35-2.34 (m, 3H), 2.22-2.13 (m, 4H), 1.98 (s, 3H), 1.49-1.44 
(m, 4H), 1.40-1.26 (m, 7H), 1.18 (d, J  = 6.3, 1H), 1.10 (s, 3H), 1.06 (s, 3H), 1.05-1.00 
(m, 2H), 0.97 (s, 12H), 0.92(t, J  = 7.3, 3H), 0.69 (s, 3H), 0.66 (s, 3H); 125 MHz 
13
C 
NMR (CDCl3) δ 171.7, 170.6, 167.0, 165.6, 157.2, 151.7, 146.7, 145.9, 142.9, 138.0, 
136.2, 135.9, 134.7, 133.5, 130.0, 129.8, 128.1, 127.9, 127.8, 125.1, 121.0, 119.4, 118.6, 
115.0, 103.4, 93.8, 81.0, 80.3, 76.8, 75.8, 74.1, 73.3, 72.5, 70.8, 70.1, 69.6, 67.2, 52.9, 
51.3, 51.2, 45.4, 45.2, 43.8, 43.0, 38.0, 37.2, 36.8, 35.8, 35.3, 34.5, 33.7, 33.6, 31.1, 27.0, 
25.8, 22.3, 22.0, 21.3, 20.1, 19.4, 15.0, 13.9, 13.4; 125 MHz DEPT 
13
C NMR (CDCl3) 
CH3 δ 52.9, 51.3, 51.2, 27.0, 25.8, 22.3, 21.3, 20.1, 15.0, 13.9, 13.4; CH2 δ 93.8, 69.7, 
45.2, 43.8, 430, 38.0, 36.8, 35.8, 35.2, 33.6, 31.1, 22.0; CH1 δ 146.7, 145.9, 142.9, 136.2, 
135.9, 130.0, 129.8, 128.5, 128.1, 127.9, 127.8, 125.1, 119.4, 118.6, 115.4, 81.0, 80.3, 
77.4, 76.8, 75.8, 74.1, 73.7, 72.5, 70.8, 70.1, 67.2; CH0 δ 171.7, 170.6, 167.0, 165.6, 
157.2, 151.7, 138.0, 134.7, 121.0, 103.4, 45.4, 37.2, 34.5, 19.4; IR (neat) 2993, 1738, 
1680, 1513, 1462, 1383, 1364, 1247, 1110, 1079, 1040, 821, 736, 701, 665 cm
-1
; HRMS 
(ESI/APCI) calcd for C72H96NaO17Si (M+Na): 1283.6315, found: 1283.6298. 
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 Preparation of C9-Deoxy Bryostatin 1 (Merle 
30): To a stirring solution of the BPS ether 1 (2.3 mg, 0.0018 mmol, 1.0 equiv) in a 5:4:1 
THF/MeOH/ pyridine solution (0.9 mL, 0.002M) at 0 ºC in a 2 mL plastic centrifuge tube 
was added HF·Py (20 %, 0.40 mL).  The reaction mixture was stirred at 0 ºC for 30 min 
and then warmed to rt. Stirring was continued for 72 h and the reaction mixture was then 
quenched by pipetting into a mixture of saturated aqueous NaHCO3 solution and EtOAc 
(5 mL each). The layers were separated and the aqueous layer was extracted with EtOAc 
(3 x 5 mL). The combined organic layer was dried over Na2SO4, filtered and concentrated 
under reduced pressure. The crude product was taken to the next step without further 
purification. 
 To a 4 mL reaction vial containing the analogue precursor from the previous 
reaction  was added a 0.25 M solution of LiBF4 in 25:1 CH3CN/ H2O (328 µL, 0.082 
mmol, 45.0 equiv).  The reaction vial was sealed and the mixture was allowed to stir at 80 
ºC for 14 h.  After cooling to rt, the reaction mixture was diluted with EtOAc (6 mL) and 
was quenched with saturated aqueous NaHCO3 solution (5 mL).  The layers were 
separated and the aqueous phase was extracted with EtOAc (3 x 5 mL).  The combined 
organic phases were dried over Na2SO4, filtered and concentrated. Purification was 
accomplished using flash column chromatography with a 0.5 x 6 cm silica gel column, 
eluting with 20% EtOAc/hexanes, collecting 6 x 50 mm test tube fractions (1-10) 
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followed by 50% EtOAc/hexanes.  The product containing fractions (11-45) were 
combined and concentrated under reduced pressure to provide C9-deoxy bryostatin 1 (1.1 
mg, 68% over 2 steps) as white solid: Rf = 0.3 (50% EtOAc/hexanes;   
20
D  +5 (c = 
0.11, EtOAc); 500 MHz 
1
H NMR (CDCl3) δ 6.18-6.17 (m, 1H), 6.01 (d, J = 1.5 Hz, 1H), 
5.8 (dd, J = 15.1, 6.8 Hz, 2H), 5.68 (s, 1H), 5.33 (dd, J = 15.6, 8.3 Hz, 1H), 5.24-5.18 (m, 
3H), 4.58 (dd, J = 11.2, 4.3 Hz, 1H), 4.37 (d, J = 12.2 Hz, 1H), 4.25-4.21 (m, 1H), 4.09-
4.01 (m, 2H), 3.81 (dd, J = 12.2, 6.3 Hz, 1H), 3.72 (s, 3H), 3.67 (s, 3H), 3.59-3.56 (m, 
2H), 3.17 (dd, J = 11.7, 1.99 Hz, 1H), 2.48 (dd, J = 12.9, 2.7 Hz, 1H), 2.40 (t, J = 11.7 
Hz, 1H), 2.21-2.07 (m 6H), 2.06 (s, 3H), 2.00-1.78 (m, 6H), 1.73 (ddd, J = 12.5, 4.4, 1.8 
Hz, 2H), 1.53-1.45 (m, 7H), 1.25 (d, J = 6.3 Hz, 3H), 1.16 (s, 3H), 1.01 (s, 3H), 0.93 (t, J 
= 7.3 Hz, 3H), 0.91 (s, 3H), 0.83 (s, 3H). ; 125 MHz 
13
C NMR (CDCl3) δ 172.0, 170.9, 
167.2, 166.9, 165.7, 165.2, 156.7, 152.1, 151.0, 146.5, 145.6, 139.1, 129.8, 128.5, 121.2, 
119.7, 118.8, 114.5, 99.2, 85.0, 79.0, 76.7, 74.2, 73.7, 70.4, 68.8, 64.8, 51.2(x2), 45.1, 
44.2, 42.9, 40.1, 37.7, 36.6, 36.2, 36.0, 35.2, 33.9, 31.5, 24.8, 22.7, 22.1, 21.3, 20.1, 20.0, 
13.9; 125 MHz DEPT 
13
C NMR (CDCl3) CH3 δ 51.2 (x2), 24.8, 22.7, 21.3, 20.0 (x2), 
13.9; CH2 δ 44.2, 43.0, 40.1, 36.6, 36.3, 36.1, 35.2, 34.0, 31.5, 22.1; CH δ 146.5, 145.6, 
139.2, 129.8, 128.6, 119.8, 118.9, 114.6, 85.1, 79.0, 76.7, 74.3, 73.8, 70.4, 68.8, 64.9; 
CH0 δ 172.4, 170.9, 167.2, 166.9, 165.7, 156.7, 152.1, 121.2, 45.1, 37.7; IR (neat) 2360, 
2341, 1732, 1470, 1428, 1263, 1245, 1166, 1110, 1037 cm
-1
; LRMS calcd for C47H68O16 






Biological Experiments and Data for Merle 30  
[
3
H]PDBu binding assay: The binding assay for Merle 30 was performed similar 
to that of Merle 28. The Ki for Merle 30 was found to be 0.38 ± 0.07 nM (average of 
three determinations). 
Attachment and cell proliferation of U937 cells: The attachment and proliferation 
assay for Merle 30 was done similar to  that of Merle 28 and the results are shown in 









Figure 1.70. Inhibition of Proliferation Assay for Merle 28 and Merle 30 
 
 
Proliferation of LNCaP cells (Figure 1.71): LNCaP human prostate cancer cells 
(from ATCC, Manassas, VA) were plated at a concentration of 80,000 cells/ml (1 ml 
total volume) into the wells of 24 well plates and cultured for 2 days in RPMI-1640 
medium containing 10 %  fetal bovine serum (ATCC, Manassas, VA). The cells were 
then treated with the indicated concentrations of the experimental compounds diluted in 
DMSO (final DMSO concentration 0.1 %). The LNCaP cells were imaged by phase 




Figure 1.71. Proliferation of LNCaP Cells by Merle 30 
 
 
Instruments, Ann Arbor, MI) starting 24 h before compound treatment and continuing for 
72 h after treatment. The proliferation of the LNCaP cells was expressed as the difference 
in cell confluency before and after treatment as determined by the instrument. Three 
independent experiments were performed and values represent the mean ± SEM of the 
three experiments. 
Secretion of TNF-alpha from LNCaP cells (Figure 1.72): 200,000 LNCaP cells in 
1 ml medium were plated into the wells of 24 well plates and cultured for 2 days in 
RPMI-1640 medium containing 10 %  fetal bovine serum (ATCC, Manassas, VA).  The  
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Figure 1.72. The Effect of Merle 30 Compared to That of PMA and Bryostatin 1 on the 
Secretion of Tumor Necrosis Factor  by LNCaP Cells 
 
 
cells were then treated with the indicated concentrations of the experimental compounds 
diluted in DMSO (final DMSO concentration 0.1 %). The medium was collected 24 h 
after treatment and centrifuged at 1500 x g to remove floating cells. The amount of TNF-
alpha secreted into the medium was then measured by ELISA (Invitrogen, Carlsbad, CA) 
following the manufacturer‟s instructions. Four independent experiments were performed 
and values represent the mean ± SEM of the four experiments.  








PMA (0.1, 1, 10, 100, 1000 nM)
Bryostatin 1 (0.1, 1, 10, 100, 1000 nM)
10 nM PMA + 1000 nM Bryostatin 1
Merle 30 (0.1, 1, 10, 100, 1000 nM)
10 nM PMA + 1000 nM Merle 30















Description of Modeling and Docking Approach for Merle 30 
Before beginning the docking we first performed a conformational search of 
bryostatin 1 in implicit water and octanol solvents. The global energy minimum 
conformation found in both solvents was essentially identical to the crystal and NMR
 
conformations, and characterized by a bifurcated H-bond between the proton of the C3-
OH and the pyran oxygens of the A- and B-rings, and a second H bond between the 
proton of the C19-OH and the oxygen of the C3-OH.  The four lowest-energy 
conformations from the search were saved, and corresponding structures of C9-deoxy 
bryostatin 1 for each of these conformations were built by simply replacing the C9 
hydroxyl with a hydrogen atom. 
These conformations of bryostatin 1 and C9-deoxy bryostatin were then docked into 
the crystal structure of the C1b domain of PKC-δ.77  We included a similarity constraint 
to the crystallized phorbol-13-acetate ligand to bias the optimization toward solutions 
where the acceptor atoms in bryostatin 1 and phorbol are close in space.  The highest-
scoring pose for both compounds was the global minimum conformation in solution, 
suggesting that bryostatin 1 does not undergo a conformational change upon binding to 
the C1 domain.  
Modeling methods: First, a conformational search of the bryostatin 1 was performed. 
The initial structure for bryostatin 1 was downloaded from the Cambridge Structural 
Database (reference code BOKKIV).  Hydrogen atoms were added as needed to fill 
valences.  Two conformational searches were performed, using the Monte Carlo multiple 
minimum (MCMM) method in the MacroModel program from Schrödinger.
78
   Both 
searches used the OPLS_2005 forcefield, one with water implicit solvent, and the other 
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with octanol, to see whether the polarity of the environment had any effect on 
bryostatin‟s conformational preferences.  During the conformational searches all torsions 
were varied for 5,000 MCMM steps, but all of the chiral centers and double bonds were 
restricted to the crystal conformation. After each step the resulting structure was energy 
minimized to a gradient convergence of 0.05. If the minimized structure was within an 
energy cutoff of 41 kJ/mol of the global minimum, it was then compared to previously 
stored structures and either kept as a unique conformer or rejected as a duplicate, using a 
1.00 Å RMSD cutoff to the heavy atoms in the central macrolide ring structure.  Four 
low-energy conformers within 20 kJ/mol of the global minimum were found, and these 
were identical in water and octanol, though the ranking of conformers 3 and 4 was 
reversed.  These four conformers were passed on to the docking program, in order to seed 
the calculation with a set of precomputed conformations to ensure that the conformational 
space available was thoroughly explored. 
 Next, the docking of the bryostatin 1 and C9-Deoxy bryostatin 1 with the C1 
domain of the PKC- was performed. The crystal structure of the C1b domain of PKC- 
was prepared for docking by adding hydrogen atoms and deleting the phorbol-13-acetate 
ligand. This was saved to a separate file to be used as a template for the similarity 
constraint (see below).  Docking was done using the program GOLD 4.0 which uses a 
genetic algorithm to optimize the set of interactions between the ligand and the protein.  
Default settings were used for the genetic algorithm.  The binding site was defined as a 
sphere with a 10.0 Ǻ radius, centered on the N atom of residue Gln 257.  For each ligand 
conformer, we performed 20 docking runs, with no early termination.  We used the 
GoldScore scoring function with default parameters.  All solutions with fitness score > 
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0.0 were kept. Free corners of ligand rings were allowed to flip above or below the plane 
of their neighboring atoms during docking, and intramolecular hydrogen bonds in the 
ligand were allowed to form. Torsion angle distributions were from the CSD.  
Additionally, we added a template similarity constraint with a weight of 30 to bias the 
conformation of docked ligands toward solutions where the acceptor atoms in the ligand 
were close in space to the acceptor atoms in phorbol. Finally the energy was minimized 
(Figure 1.74 and Figure 1.75)). The highest-scoring pose for each ligand was then further  







































Figure 1.75. Structures of C9-Deoxy Bryostatin Docked into the C1 Domain of PKC


refined by energy minimization in MacroModel,
[4]
 using the OPLS_2005 forcefield and 
octanol implicit solvent.  All atoms in the C1 domain were held fixed, while ligand atoms 
were free to move, and the complex was minimized using the Polak-Ribiere conjugate 
gradient scheme to a gradient convergence of 0.05.  Hydrogen bonds in the docked poses 
were preserved using distance constraints.The result of these docking studies revealed the 
similar conformation of both of the ligands. 
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Experimental Procedures and Analytical Data for Merle 32 




oxobutyl)-3,3-dimethyltetrahydro-2H-pyran-4-yl acetate (1.153):  To a stirring 
solution of the PMB ether 1.131 (105 mg, 0.086 mmol, 1 equiv) in CH2Cl2 (7 mL) in a 25 
mL flask at 0 ºC  was added pH 7 phosphate buffer (1.6 mL). To the solution was added 
DDQ (98 mg, 0.43 mmol, 5 equiv) in one portion and the mixture was stirred vigorously. 
After stirring for 2 h at 0 ºC, the reaction was quenched by adding saturated aq. NaHCO3 
solution (5 mL) and stirring for 15 min. The layers were separated and the aqueous layer 
was extracted with CH2Cl2 (2 x 5 mL). The combined organic layer was dried over 
Na2SO4, filtered, and concentrated. Purification was accomplished with flash column 
chromatography, using a 1 x 10 cm silica gel column, eluting with 20% EtOAc/hexanes, 
collecting 4 mL fractions.  The product containing fractions (18 to 60) were combined 
and concentrated under reduced pressure to provide alcohol 1.153 (86 mg, 91%) as a 
white foam. Rf = 0.44 (50% EtOAc/hexanes);   
20
D  -22 (c = 1.5, CHCl3); 500 MHz 
1
H 
NMR (CDCl3) δ 7.70-7.66 (m, 4H), 7.45-7.30 (m, 11H), 5.99 (d, J = 16.0 Hz, 1H), 5.46 
(dd, J  = 16.1, 6.3 Hz, 1H), 4.90 (d, J = 7.3 Hz, 1H), 4.85 (d, J = 6.8 Hz, 1H), 4.71 (dd, J 
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= 10.0, 1.7 Hz, 1H), 4.68 (d, J = 11.7 Hz, 1H), 4.63 (d, J = 11.7 Hz, 1H),  4.45 (dd, J  = 
11.7, 4.8 Hz, 1H),  4.28-4.23 (m, 2H), 3.85 (ddd, J = 12.9, 6.3, 3.5 Hz, 1H), 3.80-3.76 (m, 
1H), 3.62 (quin, J = 6.3 Hz, 1H), 3.45-3.41 (m, 1H), 3.33 (s, 3H), 3.04-3.02 (m, 1H), 2.86 
(dd, J = 11.0, 1.7 Hz, 1H), 2.80 (d, J = 3.9 Hz, 1H), 2.64 (ddd, J = 14.6, 14.6, 6.8, Hz, 
2H), 2.53 (quin, J = 9.2 Hz, 1H), 2.43 (dd, J = 6.8, 3.9 Hz, 1H), 2.39 (dd, J = 6.8, 3.4 Hz, 
1H), 2.21 (s, 1H), 2.18 (s, 1H), 2.02 (s, 3H), 1.93-1.89 (m, 2H), 1.79-1.68 (m, 6H), 1.62 
(ddd, J = 13.1, 10.7, 2.9 Hz, 1H), 1.57 (s, 2H), 1.43 (s, 9H), 1.31 (ddd, J = 12.9, 5.1, 3.1 
Hz, 1H), 1.26 (d, J = 6.3 Hz, 3H), 1.25 (s, 3H), 1.09 (s, 3H), 1.02 (s, 9H), 0.79 (s, 3H), 
0.72 (s, 3H); 125 MHz 
13
C NMR (CDCl3) δ 207.2, 197.8, 170.7, 143.5, 137.5, 137.1, 
136.0 (x2), 134.4, 133.8, 129.8, 129.7, 129.1, 128.6, 128.0 (x2), 127.8, 127.7, 109.5, 
104.0, 94.0, 79.7, 79.1, 78.4, 77.0, 51.9, 48.0, 44.1, 43.6, 41.2, 39.6, 39.5, 37.5 (x2), 35.8, 
33.8, 30.1, 30.0, 27.1, 22.9, 22.4, 22.2, 21.3, 19.6, 16.9, 13.6; 125 MHz DEPT 
13
C NMR 
(CDCl3) CH3 δ 51.9, 30.0, 22.9, 22.4, 22.1, 21.3, 16.9, 13.6; CH2 δ 109.5, 94.0, 70.0, 
52.7, 43.6, 41.2, 39.6, 39.5, 37.5, 35.8, 33.8, 30.1; CH1 δ 137.1, 136.0 (x2), 129.8 (x2), 
129.1, 128.6, 128.0 (x2), 127.8 (x2), 79.6, 79.1, 78.4, 77.0, 75.6, 73.0, 71.3, 70.0, 69.7, 
69.4; CH0 δ 207.2, 197.8, 170.7, 143.5, 137.5, 134.4, 133.8, 104.0, 48.0, 44.1, 39.5, 19.6; 
IR (neat)  2958, 2934, 2858, 2360, 2337, 1735, 1683, 1652, 1456, 1363, 1244, 1111, 
1043, 740, 702 cm
-1
; HRMS (ESI/APCI) calcd for C62H90NaO12SNaSi (M+Na): 
1121.5820, found: 1121.5817. 
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yl)-3-(tert-butyldiphenylsilyloxy)butanoic acid (1.154):  To a stirring solution of 
thiolester 1.153  (86 mg, 0.078 mmol, 1.0 equiv) in a 4:1 mixture of THF/H2O (4 mL, 
0.02 M) at 0 ºC was added mCPBA (54 mg, 0.312 mmol, 4.0 equiv). The mixture was 
stirred at 0 ºC for 1 h and at rt for 2.5 h.  The reaction was diluted with EtOAc (5 ml) and 
washed with saturated aq. NaHSO3 solution (5 mL). The aqueous layer was extracted 
with EtOAc (3x5 mL). The combined organic layers were washed with brine (5 mL). The 
organic phase was dried over Na2SO4, filtered and concentrated under reduced pressure 
to provide the crude seco acid. Purification was accomplished using flash column 
chromatography using 1 x 10 cm silica gel column using 30% EtOAc/hexanes collecting 
4 mL fractions. The fractions from 6 to 16 provided starting material (22.6 mg, 26%) 
whereas those from 17 to 84 provided the desired seco acid 1.154 (51.6 mg, 64%) as a 
white foam.  Rf = 0.44 (2:2:1 EtOAc/hexanes/MeOH);   
20
D  -5.8 (c = 1.0, CHCl3); 
500 MHz 
1
H NMR (CDCl3) δ 7.69-7.66 (m, 4H), 7.46-7.30 (m, 11H), 6.04 (d, J = 16.1 
Hz, 1H), 5.44 (dd, J = 16.1, 6.3 Hz, 1H), 4.83 (dd, J = 15.1, 7.2 Hz, 2H), 4.70-4.66 (m, 
2H),  4.63 (s, 2H),  4.45 (dd, J  = 11.7, 4.8 Hz, 1H),  4.28-4.19 (m, 2H), 3.88 (ddd, J = 
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9.7, 6.8, 2.4 Hz, 1H), 3.77-3.72 (m, 1H), 3.66 (q, J = 5.8 Hz, 1H), 3.39-3.28 (m, 1H),  
3.33 (s, 3H), 3.02-2.97 (m, 1H), 2.81 (dd, J = 11.5, 1.5 Hz, 1H), 2.70 (dd, J = 15.1, 4.8 
Hz, 1H), 2.63-2.51 (m, 2H), 2.40 (ddd, J = 17.5, 5.8, 5.8 Hz, 1H), 2.17-2.14 (m, 2H), 
2.03 (s, 3H), 2.02-1.99 (m, 1H), 1.94-1.89 (m, 2H), 1.81-1.62 (m, 7H), 1.54-1.50 (m, 
2H), 1.40-1.36 (m, 2H), 1.25 (d, J = 5.8 Hz, 3H), 1.19 (s, 3H), 1.06 (s, 3H), 1.03 (s, 9H), 
0.81 (s, 3H), 0.73 (s, 3H); 125 MHz 
13
C NMR (CDCl3) δ 206.9, 174.2, 170.8, 143.8, 
137.9, 137.5, 136.0 (x20, 133.9, 133.5, 130.0 (x2), 128.7, 128.6, 128.0 (x2), 127.9 (x2), 
109.2, 103.6, 94.0, 80.2, 79.1, 78.4, 77.0, 76.1, 73.2, 71.2, 70.0, 69.7, 51.8, 43.9, 43.6, 
41.2, 39.9, 39.2, 37.5, 37.3, 36.8, 33.9, 30.3, 27.1, 23.0, 22.3, 21.3, 19.4, 16.9, 13.5; 125 
MHz DEPT 
13
C NMR (CDCl3) CH3 δ 51.9, 27.0, 23.0, 22.3, 21.3, 17.0, 13.5; CH2 δ 
109.2, 94.0, 70.0, 43.6, 43.0, 41.2, 39.9, 39.2, 37.3, 36.1, 33.9, 30.3; CH1 δ 137.9, 136.0 
(x2), 130 (x2), 128.7, 128.6, 128.0 (x2), 127.9 (x2), 80.2, 79.7, 77.0, 76.1, 73.2, 71.1, 
69.7, 69.1; CH0 δ 206.9, 174.2, 170.8, 143.8, 137.9, 103.6, 79.1, 43.9, 36.8, 19.4; IR 
(neat) 2934, 2892, 2858, 2337, 1733, 1718, 1427, 1384, 1244, 1111, 1027, 753, 703 cm
-1
; 
HRMS (ESI/APCI) calcd for C59H82O13NaSi (M+Na): 1049.5422, found: 1049.5415. 
 Preparation of (1S,3S,7R,11S,15S,17R, 
21R,23S,25S,E)-17-((R)-1-((benzyloxy)methoxy)ethyl)-21-((tert-butyldiphenylsilyl) 
oxy)-11-methoxy-10,10,26,26-tetramethyl-5-methylene-12,19-dioxo-18,27,28,29-
tetraoxatetracyclo [21.3.1.13,7.111,15] nonacos-8-en-25-yl acetate (1.155): To a 
stirring solution of the seco acid 1.154 (63.6 mg, 0.061 mmol, 1.0 equiv) in THF (2 mL) 
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in a 5 mL vial at 0 °C was added triethylamine (48 µL, 0.37 mmol, 6.0 equiv) and  2,4,6-
trichlorobenzoyl chloride (29 µL, 0.185 mmol, 3.0 equiv).  After 1 h, the reaction was 
warmed to rt and stirring continued for additional 5 h.  The reaction mixture was diluted 
with 3:1 toluene/ THF (20 mL) and taken up in a 25 mL gas-tight syringe.  This solution 
was added by syringe pump to a stirring solution of DMAP (151mg, 1.23 mmol, 20.0 
equiv) in toluene (41 mL) at 45 °C over 12 h.  The residual contents of the syringe were 
rinsed into the flask with toluene (2 mL) and stirring continued for an additional 2 h. The 
reaction mixture was cooled to rt and washed with saturated aqueous NaHCO3 solution (2 
x 10 mL) and brine (2 x 10 mL).  The organic phase was dried over Na2SO4, filtered, and 
concentrated under reduced pressure.  Purification was accomplished using flash column 
chromatography with a 1 x 11 cm silica gel column, eluting with 15% EtOAc/hexanes, 
collecting 4 mL fractions. The product containing fractions (25-41) were combined and 
concentrated under reduced pressure to provide pure macrolactone 1.155 as a white foam 
(50 mg, 81%): Rf = 0.37 (30% EtOAc/hexanes);   
20
D -1.3 (c = 1.1, CHCl3); 500 MHz 
1
H NMR (CDCl3) δ 7.71-7.69 (m, 4H), 7.46-7.28 (m, 11H), 6.24 (d, J = 15.6 Hz, 1H), 
5.46 (ddd, J  = 11.8, 3.4, 2.6 Hz, 1H), 5.39 (dd, J  = 16.1, 8.3 Hz, 1H), 4.89 (d, J = 6.8 
Hz, 1H), 4.85-4.84 (m, 2H), 4.81 (d, J = 6.8 Hz, 1H), 4.66 (s, 2H),  4.65 (ddd, J  = 11.5, 
7.3, 6.5 Hz, 1H), 4.25 (dd, J  = 11.2, 4.8 Hz, 1H), 4.21 (dd, J  = 6.3, 3.9 Hz, 1H), 4.03 
(ddd, J  = 14.6, 7.8, 3.9 Hz, 1H), 3.92-3.87 (m, 1H),  3.29-3.27 (m, 1H), 3.24 (s, 3H), 
2.66 (ddd, J  = 14.6, 9.7, 5.3 Hz, 1H),  2.55 (dd, J = 14.6, 8.3 Hz, 1H), 2.50 (dd, J = 15.1, 
3.9 Hz, 1H), 2.43 (d, J = 9.2 Hz, 1H),  2.39-2.33 (m, 2H), 2.24 (t, J = 14.6 Hz, 2H), 2.13-
2.03 (m, 3H), 1.99 (s, 3H), 1.91-1.82 (m, 3H), 1.50-1.37 (m, 4H), 1.32 (s, 3H), 1.18 (d, J 
= 6.3 Hz, 3H), 1.09 (ddd, J  = 11.7, 4.3, 1.9 Hz, 1H), 1.00 (s, 3H), 0.99 (s, 9H), 0.72 (s, 
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3H), 0.68 (s, 3H); 125 MHz 
13
C NMR (CDCl3) δ 205.7, 171.4, 170.6, 137.9, 136.1, 
135.8, 135.2, 134.6, 133.4, 130.0, 129.8, 128.5, 128.3, 128.0, 127.9, 127.8, 127.4, 109.2, 
102.2, 93.6, 81.1, 80.6, 77.0, 76.0, 73.9, 71.9, 70.8, 69.7, 65.7, 52.6, 44.8, 43.5 (x2), 42.8, 
41.3, 40.6, 37.9, 36.0, 33.4, 31.0, 26.9, 24.6, 22.3, 21.2, 19.8, 19.4, 14.7, 13.9, 12.5; 125 
MHz DEPT 
13
C NMR (CDCl3) CH3 δ 52.6, 26.9, 24.6, 22.2, 21.2, 19.8, 14.7, 13.9, 12.5; 
CH2 δ 109.2, 93.6, 69.6, 44.8, 43.5, 40.6, 37.8, 36.0, 33.4, 33.2, 31.0; CH1 δ 141.1, 136.1, 
135.8, 130.0, 129.8, 128.9, 128.5, 128.3, 128.0, 127.7, 127.4, 81.1, 80.6, 76.9, 76.0, 73.9, 
71.9, 70.8, 69.7; CH0 δ 205.7, 171.4, 170.6, 137.9, 135.2, 134.6, 102.2, 65.7, 42.8, 37.3, 
19.4; IR (neat) 3070, 2970, 2734, 2888, 2360, 2337, 1734, 1651, 1576, 1419, 1363, 1244, 
1109, 1039, 879, 819, 738, 702, 667 cm
-1
; HRMS (ESI/APCI) calcd for C59H80NaO12Si 
(M+Na): 1031.5317, found: 1031.5313. 
 Preparation of (1S,3S,7R,11S,15S 
,17R,21R,23S,25S,E)-17-((R)-1-((benzyloxy)methoxy)ethyl)-21-((tert-butyldiphenyl 
silyl)oxy)-25-hydroxy-11-methoxy-10,10,26,26-tetramethyl-5-methylene-18,27,28,29-
tetraoxatetracyclo[21.3.1.13,7.111,15] nonacos-8-ene-12,19-dione (1.156):  To a 
stirring solution of acetate 1.155 (20 mg, 0.019 mmol, 1.0 equiv) in 1 mL of MeOH in a 4 
mL vial at room temperature was added K2CO3 (13.6 mg, 0.099 mmol, 5 equiv) and the 
mixture was stirred for 6 h.  The reaction was quenched by addition of 5 mL of saturated 
aqueous NH4Cl solution and was then diluted with 5 mL of 40% EtOAc/hexanes.  The 
phases were separated and the aqueous phase was extracted with 40% EtOAc/hexanes (2 
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x 5 mL).  The combined organic phases were dried over Na2SO4, filtered and 
concentrated under reduced pressure. Purification was accomplished using flash column 
chromatography with a 1 x 9 cm silica gel column, eluting with 15% EtOAc/hexanes, 
collecting 4 mL fractions. The product containing fractions (11-42) were combined and 
concentrated under reduced pressure to provide alcohol 1.156 (18 mg, 94%) as white 
foam.  Rf = 0.4 (30% EtOAc/hexanes);   
20
D  -2 (c = 1.0, CHCl3); 500 MHz 
1
H NMR 
(CDCl3) δ 7.72-7.70 (m, 4H), 7.45-7.27 (m, 11H), 6.23 (d, J = 15.6 Hz, 1H), 5.46 (ddd, J  
= 11.2, 3.9, 1.9 Hz, 1H), 5.40 (dd, J  = 15.6, 8.3 Hz, 1H), 4.89 (d, J = 6.8 Hz, 1H), 4.84 
(dd, J  = 7.8, 1.4 Hz, 2H), 4.82 (d, J = 6.8 Hz, 1H), 4.66 (s, 2H),  4.50 (ddd, J  = 9.6, 9.6, 
3.9 Hz, 1H), 4.24-4.19 (m, 1H), 4.04 (ddd, J  = 15.1, 8.3, 4.3 Hz, 1H), 3.89 (ddd, J  = 
14.4, 7.0, 1.9 Hz, 1H), 3.28-3.26 (m, 1H), 3.25 (s, 3H), 2.97 (ddd, J  = 10.7, 5.3, 5.3 Hz, 
1H),  2.66 (ddd, J = 14.6, 9.2, 5.3 Hz, 1H), 2.59-2.50 (m, 2H), 2.39-2.32 (m, 3H), 2.28-
2.21 (m, 2H), 2.14-1.98 (m, 3H), 1.92-1.83 (m, 3H), 1.51-1.37 (m, 4H), 1.32 (s, 3H), 1.18 
(d, J = 6.3 Hz, 3H), 1.17-1.15 (m, 1H), 1.01 (s, 3H), 0.99 (s, 9H), 0.78 (s, 3H), 0.63 (s, 
3H); 125 MHz 
13
C NMR (CDCl3) δ 205.8, 171.5, 144.3, 141.0, 138.0, 136.2, 135.9, 
134.8, 133.7, 129.9, 129.7, 128.5, 128.1, 127.9, 127.7, 127.5, 109.1, 93.6, 81.1, 80.6, 
76.2, 75.6, 74.1, 72.0, 70.9, 70.8, 69.7, 65.8, 52.6, 44.9, 43.7, 43.5, 41.1, 40.7, 38.5, 38.0, 
36.9, 36.1, 33.2, 31.0, 27.0, 24.6, 22.3, 19.9, 19.5, 14.8, 12.3; 125 MHz DEPT 
13
C NMR 
(CDCl3) CH3 δ 52.6, 27.0, 24.6, 22.3, 19.9, 14.8, 12.4; CH2 δ 109.1, 93.6, 69.7, 44.9, 
43.7, 41.4, 40.7, 38.0, 36.9, 36.1, 33.2, 31.0; CH1 δ 141.0, 136.1, 135.9, 129.8, 129.7, 
128.5, 128.1, 127.9, 127.8, 127.7, 127.5, 81.1, 80.6, 76.2, 75.6, 74.1, 72.0, 70.9, 70.8; 
CH0 δ 205.8, 171.5, 144.3, 138.0, 134.8, 133.7, 65.8, 43.5, 38.5, 19.5; IR (neat) 3069, 





; HRMS (ESI/APCI) calcd for C59H80NaO12Si (M+Na): 1031.5317, found: 
1031.5313. 
 Preparation of (1S,3S,7R,11S,15S, 
17R,21R,23R,25S,E)-17-((R)-1-((benzyloxy)methoxy)ethyl)-21-((tert-butyldiphenyl 
silyl)oxy)-11-methoxy-10,10,26,26-tetramethyl-5-methylene-25-((triethylsilyl)oxy)-
18,27,28,29-tetraoxatetracyclo [21.3.1.13,7.111,15] nonacos-8-ene-12,19-dione 
(1.157):  To a stirring solution of alcohol 1.156 (13 mg, 0.013 mmol, 1.0 equiv) in 670 
µL of CH2Cl2 in a 4 mL vial at 0 °C was added Et3N (10 µL , 0.08 mmol, 6 equiv) 
followed by a small crystal of DMAP. To the reaction mixture was then added TESCl (6 
µL, 0.04 mmol, 3 equiv) and stirred at 0 °C for 1 h. The reaction was warmed to rt and 
stirred overnight.  The reaction was quenched by addition of 5 mL of water and was then 
diluted with 5 mL of CH2Cl2.  The phases were separated and the aqueous phase was 
extracted with CH2Cl2 (3 x 5 mL).  The combined organic phases were dried over 
Na2SO4, filtered and concentrated under reduced pressure. Purification was accomplished 
using flash column chromatography with a 1 x 7 cm silica gel column, eluting with 10% 
EtOAc/hexanes, collecting 4 mL fractions. The product containing fractions (2-8) were 
combined and concentrated under reduced pressure to provide TES ether 1.157 (13.5 mg, 
93%) as colorless oil.  Rf = 0.63 (30% EtOAc/hexanes);   
20
D  -4.7 (c = 1.0, CHCl3); 
500 MHz 
1
H NMR (CDCl3) δ 7.72-7.69 (m, 4H), 7.45-7.29 (m, 11H), 6.22 (d, J = 15.6 
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Hz, 1H), 5.47 (ddd, J  = 10.4, 4.0, 2.1 Hz, 1H), 5.39 (dd, J  = 16.1, 8.3 Hz, 1H), 4.90 (d, J 
= 6.8 Hz, 1H), 4.82 (d, J  = 6.3 Hz, 2H), 4.84-4.82 (m, 2H), 4.66 (s, 2H),  4.54-4.49 (m, 
1H), 4.25-4.21 (m, 1H), 4.05 (ddd, J  = 14.6, 7.8, 4.3 Hz, 1H), 3.88 (ddd, J  = 11.2, 8.4, 
2.0 Hz, 1H), 3.25 (s, 3H), 2.95 (ddd, J  = 11.2, 4.3 Hz, 1H), 2.66 (ddd, J = 14.6, 9.2, 5.3 
Hz, 1H), 2.56-2.54 (m, 2H), 2.39-2.18 (m, 5H), 2.12 (dd, J = 13.6, 7.8 Hz, 1H),, 2.08-
1.98 (m, 2H), 1.92-1.81 (m, 3H), 1.49-1.34 (m, 3H), 1.31 (s, 3H), 1.27-1.22 (m, 2H), 1.18 
(d, J = 6.3 Hz, 3H), 1.01 (s, 3H), 1.00 (s, 9H), 0.91 (t, J = 7.8 Hz, 9H), 0.82 0.78 (m, 1H), 
0.70 (s, 3H), 0.61 (s, 3H), 0.50 (q, J = 7.8 Hz, 6H) ; 125 MHz 
13
C NMR (CDCl3) δ 205.8, 
171.6, 144.4, 141.0, 138.0, 135.9, 135.0, 133.9, 129.8, 128.5, 128.1, 127.8, 127.7, 127.5, 
109.0, 102.5, 93.6, 81.2, 80.6, 76.0, 74.0, 71.9, 71.2, 70.7, 69.7, 65.7, 52.6, 45.0, 43.8, 
43.5, 41.4, 40.7, 38.8, 38.2, 37.5, 36.0, 33.1, 31.1, 27.0, 24.6, 22.7, 19.8, 19.5, 14.7, 12.6, 
7.1, 5.2; 125 MHz DEPT 
13
C NMR (CDCl3) CH3 δ 52.6, 27.0, 24.6, 22.7, 19.8, 14.7, 
12.6, 7.1; CH2 δ 109.0, 93.6, 69.7, 45.0, 43.8, 41.4, 40.7, 38.2, 37.5, 36.5, 36.0, 33.1, 
31.0, 5.2; CH1 δ 141.0, 136.1, 135.9, 129.8, 129.7, 128.5, 128.1, 127.8, 127.7, 127.5, 
81.2, 80.6, 76.2, 76.0, 74.0, 71.9, 71.2, 70.7; CH0 δ 205.8, 171.6, 144.4, 138.0, 135.0, 
133.9, 102.5, 65.7, 38.8, 19.5; IR (neat) 2955, 2876, 1735, 1460, 1427, 1362, 1311, 1236, 
1165, 1105, 1036, 839, 737, 702 cm
-1
; HRMS (ESI/APCI) calcd for C63H92NaO11Si2 
(M+Na): 1103.6076, found: 1103.6093. 
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13-ylidene)acetate (1.159): To a stirring solution of (iPr)2NH (0.27 mL, 1.93 mmol) in 6 
mL of THF in a 25 mL rb flask at -78 ºC was added n-BuLi (2.61 M in hexanes, 0.67 mL, 
1.75 mmol) via syringe.  The solution stirred at -78 ºC for 30 min and was then allowed 
to warm to 0 ºC for 20 min.  This 0.25 M LDA solution was used immediately in the 
following aldol reaction. 
 To a stirring solution of ketone 1.157 (9 mg, 0.083 mmol, 1.0 equiv) in THF (277 
µL, 0.03 M) in a 4 mL vial at -78 ºC was added a 0.25 M solution of LDA in THF (66 
µL, 0.016 mmol, 2 equiv) slowly via syringe down the side of the vial.  The resulting 
light-yellow reaction mixture was allowed to stir at -78 ºC for 10 min and a freshly 
prepared solution of methyl glyoxylate (ca 3.0 M in THF, 55 µL, 1.66 mmol, 20.0 equiv) 
was added slowly via syringe down the side of the flask upon which the yellow color of 
the solution disappeared. The reaction mixture stirred at -78 ºC for 40 min and was 
quenched by addition of 2 mL of saturated aqueous NH4Cl solution. The mixture was 
allowed to warm to rt and was then partitioned between 5 mL of EtOAc and 5 mL of 
brine.  The phases were separated and the aqueous phase was extracted with EtOAc (3 x 
200 
 
5 mL).  The combined organic phases were dried over Na2SO4, filtered and concentrated 
under reduced pressure. Purification was accomplished using flash column 
chromatography with a 1 x 5 cm silica gel column, eluting with 10% EtOAc/hexanes (50 
mL) then 30% EtOAc/hexanes (50 mL), collecting 4 mL fractions.  Fractions 4-12 gave 
unreacted starting material which were combined and concentrated to provide 1.5 mg of 
the starting ketone 1.157. The product containing fractions (13-24) were combined and 
concentrated under reduced pressure to provide the intermediate aldol adduct as a mixture 
of diastereomers (7.6 mg, 78%).  This material was taken into the following elimination 
reaction. 
 To a stirring solution of the aforementioned aldol adduct (5 mg, 0.0042 mmol, 1.0 
equiv) in pyridine (400 µL) in a 5 mL reaction vial at rt was added a 0.1 M solution of 
DMAP in CH2Cl2 (42 µL, 0.0047 mmol, 1.0 equiv), and  0.5 M solution of Ac2O in 
CH2Cl2 (170 µL, 0.085 mmol, 1.0 equiv),.  The reaction mixture was allowed to stir at rt 
for 24 h and was then quenched by addition of saturated aqueous NaHCO3 solution (2 
mL).  The mixture was diluted with 5 mL CH2Cl2 and the phases were separated.  The 
aqueous phase was extracted with CH2Cl2 (2 x 5 mL).  The combined organic phases 
were dried over Na2SO4, filtered, and concentrated under reduced pressure.  Purification 
was accomplished using flash column chromatography with a 1 x 5 cm silica gel column, 
eluting with 10% EtOAc/hexanes, collecting 4 ml fractions.  The product containing 
fractions (6-12) were combined and concentrated under reduced pressure to provide pure 
enoate 1.159 (4.6 mg, 93%) as a clear light-yellow oil: Rf = 0.62 (40% EtOAc/hexanes); 
  20D -17 (c = 0.4, CHCl3); 500 MHz 1H NMR (CDCl3) δ 7.78-7.68 (m, 4H), 7.44-7.25 
(m, 11H), 6.54 (s, 1H), 5.97 (d, J = 16.1 Hz, 1H), 5.36 (dd, J = 15.6, 6.8 Hz, 1H), 5.30 
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(ddd, J = 9.3, 3.4, 3.4 Hz, 1H), 4.85 (d, J  = 7.3 Hz, 1H), 4.82 (d, J  = 6.8 Hz, 1H), 4.81-
4.77 (m, 2H), 4.65 (s, 2H), 4.49-4.47 (m, 1H), 4.12-4.09 (m, 2H), 4.03 (dd, J = 6.3, 3.9 
Hz, 1H),  3.72 (s, 3H), 3.68-3.67 (m, 1H), 3.46-3.3.42 (m, 1H), 3.26 (s, 3H), 3.03 (dd, J  
= 10.7, 2.9 Hz, 1H),  2.99 (dd, J  = 10.7, 2.9 Hz, 1H), 2.78 (dd, J  = 11.2, 4.8 Hz, 1H), 
2.73 (dd, J  = 11.2, 4.8 Hz, 1H), 2.69-2.67 (m, 1H), 2.62 (dd, J  = 15.6, 3.9 Hz, 1H),  
2.29-2.25 (m, 1H), 2.21-2.08 (m, 2H), 2.03 (ddd, J = 14.6, 9.7, 4.8 Hz, 1H), 1.98-1.83 
(m, 2H), 1.58-1.34 (m, 7H), 1.24 (d, J = 7.3 Hz, 3H), 1.23 (s, 3H), 0.97 (s, 12H), 0.90 (t, 
J = 8.3, 3H), 0.67 (s, 3H), 0.63 (s, 3H), 0.47 (q, J  = 8.2 Hz, 6H); 125 MHz 
13
C NMR 
(CDCl3) δ 195.9, 171.3, 166.1, 148.2, 144.5, 137.9, 137.7, 1366.2, 136.0, 134.8, 133.8, 
129.8, 129.7, 129.3, 128.5, 128.0, 127.9, 127.8, 127.7, 123.0, 108.9, 103.9, 93.6, 81.3, 
79.5, 76.4, 76.1, 73.2, 73.0, 71.2, 69.8, 69.7, 69.0, 52.5, 51.9, 44.4, 43.9, 43.7, 41.5, 40.9, 
39.0, 37.7, 37.4, 34.2, 33.9, 27.0, 23.4, 22.8, 21.1, 19.6, 15.3, 12.7, 7.1, 5.2; 125 MHz 
DEPT 
13
C NMR (CDCl3) CH3 δ;52.5, 51.9, 27.0, 23.4, 22.8, 21.2, 15.3, 12.7, 7.; CH2 δ 
108.9, 93.7, 69.7, 44.0, 43.7, 41.5, 40.9, 37.7, 37.4, 34.2, 33.9, 5.3; CH1 δ 137.7, 136.2, 
136.0, 129.8, 129.7, 129.4, 128.6, 128.0, 127.9, 127.8, 127.7, 123.1, 81.3, 79.5, 76.5, 
76.1, 73.2, 73.0, 71.2, 69.8, ; CH0 δ 195.9, 171.3, 166.1, 148.2, 144.5, 137.9, 134.8, 
129.7, 103.9, 69.0, 43.9, 19.6; IR (neat) 2970, 2936, 1734, 1513, 1455, 1378, 1248, 1170, 
1103, 1036, 824, 741, 700 cm
-1
; HRMS (ESI/APCI) calcd for C66H94NaO13Si2 (M+Na): 
1173.6131, found: 1173.6129. 
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oxatetracyclo [21.3.1.13,7.111,15]nonacos-8-en-12-yl octa-2,4-dienoate (1.160): To a 
stirring solution of ketone 1.159 (9.5 mg, 0.008 mmol, 1.0 equiv) in MeOH (800 µL, 0.01 
M) in a 5 mL reaction vial at rt was added CeCl3·7H2O (61 mg, 0.16 mmol, 20.0 equiv). 
The mixture was stirred until all the CeCl3·7H2O was completely dissolved.  The mixture 
was then cooled to -42 ºC and stirred for 10 min and then NaBH4 (3 mg, 0.08 mmol, 10.0 
equiv) was added.  Stirring continued for 1 h at -42 ºC after which the reaction was 
quenched by slow addition of saturated aqueous NH4Cl solution (2 mL) and diluted with 
40% EtOAc/hexanes (5 mL). The layers were separated and the aqueous layer was 
extracted with 40% EtOAc/hexanes (3 x 5 mL).  The organic phase was washed with 
brine (5 mL), then dried over Na2SO4, filtered and concentrated under reduced pressure 
to provide the crude intermediate alcohol which was carried directly to the next step 
without purification. 
 To a stirring solution of this alcohol in CH2Cl2 (800 µL, 0.001 M) in a 5 mL 
reaction vial at rt was added pyridine (33 µL, 0.41 mmol, 50 equiv), DMAP (10 mg, 0.08 
mmol, 10 equiv), and octadienoic anhydride (66 mg, 0.24 mmol, 30 equiv).  The reaction 
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mixture stirred at rt for 12 h and was then quenched by the addition of saturated aqueous 
NaHCO3 solution (2.0 mL).  The mixture was stirred vigorously for 30 min and was then 
diluted with 40% EtOAc/hexanes (5mL). The phases were separated and the aqueous 
phase was extracted with 40% EtOAc/hexanes (3 x 5 mL).  The combined organic phases 
were dried over Na2SO4, filtered, and concentrated under reduced pressure. Purification 
was accomplished using flash column chromatography using 10% EtOAc/hexanes (50 
mL) followed by 20% EtOAc/hexanes collecting 4 mL fractions. Fractions 16-23 
provided the desired product as 4.2:1 mixture of diastereomers which were further 
separated by a preparative TLC with 4% acetone/benzene to provide the ester 1.160 (8.6 
mg, 82%, 2 steps) as a pale yellow liquid. Rf = 0.46 (30% EtOAc/hexanes);   
20
D +2.5 
(c = 0.5, CHCl3); 500 MHz 
1
H NMR (CDCl3) δ 7.72-7.70 (m, 4H), 7.45-7.24 (m, 11H), 
6.19-6.14(m, 2H), 5.98 (d, J = 1.4 Hz, 1H), 5.77 (d, J = 15.1 Hz, 1H), 5.64-5.61 (m, 1H), 
5.29 (dd, J = 15.1, 8.7 Hz, 1H), 5.23 (s, 1H), 4.94 (d, J  = 6.8 Hz, 1H), 4.86-4.84 (m, 2H), 
4.73 (d, J  = 11.7 Hz, 1H), 4.69 (d, J  = 11.7 Hz, 1H), 4.52-4.51 (m, 1H), 4.26-4.19 (m, 
1H), 3.85 (t, J = 10.7 Hz, 1H), 3.75-3.72 (m, 1H), 3.69 (s, 3H), 3.19 (t, J  = 8.7, 1H), 3.08 
(s, 3H), 2.92 (dd, J  = 11.2, 4.3 Hz, 1H), 2.51 (dd, J  =  15.1, 9.7 Hz, 1H), 2.42 (dd, J  =  
15.1, 1.9 Hz, 1H), 2.29-2.13 (m, 7H), 2.05 (t, J = 13.1 Hz, 1H), 2.00 (t, J = 6.8 Hz, 1H), 
1.82 (t, J = 12.2 Hz, 1H),  1.49-1.26 (m, 5H), 1.19 (d, J  = 6.3, 1H), 1.10 (s, 3H), 1.06 (s, 
3H), 1.00 (s, 9H), 0.95-0.93 (m, 3H), 0.91 (t, J  = 7.8, 9H), 0.76-0.73 (m, 1H), 0.69 (s, 
3H), 0.58 (s, 3H), 0.49 (q, J  = 8.3 Hz, 6H); 125 MHz 
13
C NMR (CDCl3) δ 171.8, 167.0, 
165.5, 151.7, 146.6, 145.8, 144.5, 142.4, 138.0, 136.2, 135.9, 135.1, 134.0, 131.0, 129.8, 
129.6, 128.9, 128.1, 127.8, 127.7, 125.4, 119.4, 118.6, 109.0, 103.4, 93.6, 81.3, 81.2, 
76.5, 75.9, 74.0, 73.3, 72.1, 70.0, 69.7, 67.2, 53.0, 52.3, 45.3 (x2), 44.0, 41.4, 40.6, 38.8, 
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38.2, 37.6, 35.2, 33.4, 31.1, 29.9, 27.0, 25.8, 22.7, 22.0, 19.5, 14.7, 13.9, 12.5, 7.1, 5.3; 
125 MHz DEPT 
13
C NMR (CDCl3) CH3 δ 53.0, 51.3, 27.0, 25.8, 22.7, 14.7, 13.9, 12.5, 
7.1; CH2 δ 109.0, 93.6, 69.7, 45.3, 44.0, 41.4, 40.6, 38.2, 37.6, 35.2, 33.4, 31.1, 22.0, 5.3; 
CH1 δ 146.6, 145.8, 142.4, 136.2, 135.9, 129.8, 129.6, 128.5, 128.1, 127.8, 127.7, 125.5, 
119.4, 118.7, 81.2, 76.5, 75.9, 74.0, 73.7, 72.1, 71.2, 70.0, 67.2; CH0 δ; 171.8, 167.0, 
165.5, 151.7, 144.5, 138.0, 131.0, 128.9, 103.4, 38.8, 29.9, 19.5; IR (neat) 2933, 1760, 
1470, 1427, 1378, 1246, 1111, 1038, 843, 740, 702, 677 cm
-1
; HRMS (ESI/APCI) calcd 
for C74H106NaO14Si2(M+Na): 1297.7019, found: 1297.7025. 




[21.3.1.13,7.111,15]nonacos-8-en-12-yl octa-2,4-dienoate (1.161): To a stirring solution 
of ketone TES ether  1.160 (6.3 mg, 0.0049 mmol, 1.0 equiv) in MeOH (250 µL, 0.02 M) 
in a 5 mL reaction vial at rt was added 0.1 M solution of PPTS in MeOH (25 µL, 0.0024 
mmol, 0.5 equiv). The mixture was stirred at rt for 48 h after which the reaction was 
quenched by addition of saturated aqueous NaHCO3 solution (2 mL) and diluted with 
EtOAc (5mL). The layers were separated and the aqueous layer was extracted with 
EtOAc (3 x 5mL).  The organic phase was washed with brine (5 mL), then dried over 
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Na2SO4, filtered and concentrated under reduced pressure to provide crude intermediate 
alcohol which was carried directly to the next step without purification. 
 To a stirring solution of the aftermentioned intermediate alcohol in CH2Cl2 (200 
µL, 0.01 M) in a 5 mL reaction vial at 0 ºC was added pyridine (3 µL, 0.014 mmol, 20 
equiv) followed by Dess-Martin reagent (1.7 mg, 0.0041 mmol, 2 equiv). The reaction 
mixture was stirred at 0 ºC for 45 min and at rt for 15 min. The reaction was then 
quenched by the addition of saturated aqueous NaHCO3 solution (5.0 mL) and diluted 
with 40% EtOAc/hexanes (5mL). The phases were separated and the aqueous phase was 
extracted with 40% EtOAc/hexanes (3 x 5 mL).  The combined organic phases were 
dried over Na2SO4, filtered, and concentrated under reduced pressure. Purification was 
accomplished using flash column chromatography using 15% EtOAc/hexanes collecting 
2 mL fractions. The fractions from 17-24 provided the desired product. One more batch 
of the same was reaction was repeated with same amount of starting material to provide 
ketone 1.161 (4.8 mg, 84%, 2 steps) as a pale yellow liquid. Rf = 0.58 (30% 
EtOAc/hexanes); Analytial data:   20D +13.6 (c = 0.2, CHCl3); 500 MHz 1H NMR 
(CDCl3) δ 7.70-7.69 (m, 4H), 7.44-7.28 (m, 11H), 6.21-6.16 (m, 2H), 5.99 (s, 1H), 5.78 
(d, J = 16.5 Hz, 1H), 5.64-5.63 (m, 1H), 5.30 (dd, J = 15.6, 8.2 Hz, 1H), 5.24 (s, 1H), 
4.92 (d, J  = 6.8 Hz, 1H), 4.87 (s, 2H), 4.84 (d, J  = 6.8 Hz, 1H), 4.72 (d, J  = 11.7 Hz, 
1H), 4.68 (d, J  = 12.1 Hz, 1H),  4.55-4.50 (m, 1H), 4.19-4.17 (m, 1H), 4.07 (d, J  = 4.3 
Hz, 1H), 3.88 (t, J = 10.2 Hz, 1H), 3.75-3.73 (m, 1H), 3.69 (s, 3H), 3.23 (t, J  = 7.8, 1H), 
3.11 (s, 3H), 2.61-2.54 (m, 2H), 2.41 (dd, J  = 14.4, 1.2 Hz, 1H), 2.24 (t, J  =  11.7 Hz, 
1H), 2.20-2.15 (m, 2H), 2.08-1.99 (m, 2H), 1.85 (t, J = 11.7 Hz, 1H), 1.59-1.40 (m, 4H), 
1.32-1.31 (m, 4H), 1.26 (s, 3H),  1.19 (d, J  = 6.4, 1H), 1.12 (s, 3H), 1.08 (s, 3H), 0.98 (s, 
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9H), 0.92 (t, J  = 7.3, 3H), 0.90 (s, 3H), 0.58 (s, 3H), 0.84 (s, 3H); 125 MHz 
13
C NMR 
(CDCl3) δ 211.0, 171.4, 167.0, 165.6, 151.7, 146.7, 145.9, 144.2, 142.4, 138.1, 136.2, 
135.9, 134.6, 133.5, 130.0, 129.9, 128.6, 128.1, 128.0, 127.9, 127.8, 125.5, 119.5, 118.7, 
109.3, 103.4, 93.7, 81.7, 81.3, 76.1, 75.4, 73.7, 73.6, 72.3, 70.2, 69.7, 67.3, 52.9, 
51.3(x2), 48.9, 45.3, 45.1,  44.3, 41.4, 40.6, 38.3, 35.2, 33.7, 31.1, 29.9, 27.0, 25.8, 22.0, 
20.3, 19.5, 19.1, 18.7, 14.8, 13.8; 125 MHz DEPT 
13
C NMR (CDCl3) CH3 δ 52.9, 51.3, 
27.0, 25.8, 20.2, 19.1, 18.6, 14.8, 13.8; CH2 δ 109.3, 93.7, 69.7, 45.1, 44.3, 41.4, 40.6, 
38.3, 35.2, 33.7, 31.1, 29.9, 22.0; CH1 δ 146.7, 145.9, 142.3, 136.2, 135.9, 130.0, 129.9, 
128.6, 128.5, 128.1, 128.0, 127.9, 127.8, 125.5, 119.4, 118.7, 81.7, 81.3, 76.1, 75.4, 73.7, 
72.2, 70.2, 63.7; CH0 δ; 211.0, 171.4, 167.0, 165.6, 151.7, 144.2, 138.1, 134.6, 103.4, 
73.6, 48.9, 45.3, 19.5; IR (neat) 2950, 1715, 1609, 1513, 1454, 1382, 1249, 1171, 1102, 
1038, 846, 739, 698 cm
-1
; HRMS (ESI/APCI) calcd for C68H90NaO14Si(M+Na): 
1181.5998, found: 1181.6001. 




[21.3.1.13,7.111,15]nonacos-8-en-12-yl octa-2,4-dienoate (1.162): To a stirring solution 
of methyltriphenylphosphonium bromide (recrystallized from hexanes/CH2Cl2 and dried 
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under high vacuum at 100 ºC overnight; 180 mg, 0.5 mmol, 1.0 equiv) in 5 mL THF at rt 
was added a 2.5 M solution of n-BuLi in THF (181 mL, 0.45 mmol, 0.9 equiv) dropwise 
via a syringe during which the white salt was barely left in the solution and  the color of 
solution changed to yellow. The reaction mixture was stirred at rt for 10 min and allowed 
to settle. The clear yellow supernatant liquid was drawn by a syringe and was used in the 
following reaction.   
The aftermentioned clear yellow solution of Wittig reagent (114 µL, 0.011 mmol, 
7 equiv) was taken in a 5 mL vial and cooled to 0 ºC. To this solution was added a 
solution of the ketone 1.161 in 100 µL THF (1.9 mg, 0.0016 mmol, 1 equiv) dropwise via 
syringe and rinsed with THF (50 µL). The initial clear yellow solution in the vial turned 
into a white ppt. After stirring for 10 min at 0 ºC, the reaction was quenched by addition 
of pH 7 buffer (2 mL) and diluted with 20% EtOAc/hexanes (5 mL). The phases were 
separated and the aqueous phase was extracted with 20% EtOAc/hexanes (3 x 5 mL).  
The combined organic phases were dried over Na2SO4, filtered, and concentrated under 
reduced pressure. Purification was accomplished using flash column chromatography in a 
pipette column (0.5 x 6 cm) using 10% EtOAc/hexanes collecting 6 x 50 mm fractions. 
The fractions from 6-12 provided the desired product 1.162 (1.9 mg, 70%,) as a colorless 
liquid. Rf = 0.42 (20% EtOAc/hexanes); Analytial data:   
20
D +7 (c = 0.1, CHCl3); 500 
MHz 
1
H NMR (CDCl3) δ 7.72-7.70 (m, 4H), 7.45-7.24 (m, 11H), 6.19-6.15 (m, 2H), 5.99 
(d, J = 1.4 Hz,, 1H), 5.77 (d, J = 15.1 Hz, 1H), 5.64-5.60 (m, 1H), 5.30 (dd, J = 15.6, 8.3 
Hz, 1H), 5.23 (s, 1H), 4.93 (d, J  = 6.8 Hz, 1H), 4.85 (d, J  = 6.8 Hz, 1H), 4.83 (s, 2H), 
4.72 (d, J  = 11.7 Hz, 1H), 4.68 (d, J  = 11.7 Hz, 1H),  4.55 (s, 1H), 4.53-4.4.50 (m, 1H), 
4.41 (s, 1H), 4.22-4.20 (m, 1H), 3.85 (ddd, J  = 11.5, 8.9, 2.2 Hz, 1H), 3.75-3.70 (m, 1H), 
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3.69 (s, 3H), 3.20 (t, J  = 8.7, 1H), 3.09 (s, 3H), 2.52 (dd, J  = 15.1, 9.7 Hz, 1H), 2.42 (dd, 
J  = 15.1, 2.4 Hz, 1H), 2.38-1.98 (m, 9H), 1.82 (t, J = 13.1 Hz, 1H), 1.78 (t, J = 11.2 Hz, 
1H), 1.56-1.29 (m, 8H), 1.25 (s, 3H),  1.18 (d, J  = 6.3, 1H), 1.10 (s, 3H), 1.06 (s, 3H), 
0.98 (s, 9H), 0.92 (t, J  = 7.3, 3H), 0.86 (s, 3H), 0.79 (s, 3H); 125 MHz 
13
C NMR 
(CDCl3) δ 171.1, 167.0, 165.6, 153.2, 151.8, 146.7, 145.9, 144.5, 142.6, 138.1, 136.2 
(x2), 136.0, 135.1, 133.6, 129.8, 129.7, 128.6, 128.5, 128.2, 127.9, 127.7, 125.5, 119.4, 
118.7, 110.0, 109.1, 106.3, 103.4, 93.7, 82.4, 81.3, 76.5, 73.7, 72.2, 70.9 (x2), 70.1, 69.7, 
67.2, 53.0, 51.3, 48.9, 45.3, 44.1, 41.4, 40.6, 39.2, 38.7, 35.2, 33.5, 31.1, 29.9, 27.0, 25.8, 
22.3, 22.0, 20.1 (x2), 19.5, 14.8, 13.9; 125 MHz DEPT 
13
C NMR (CDCl3) CH3 δ 53.0, 
51.3, 27.0, 25.8, 22.3, 20.1 (x2), 14.8, 13.9; CH2 δ 109.1, 106.3, 93.7, 69.7, 45.3, 44.1, 
41.4, 40.7, 39.2, 38.7, 35.2, 33.6, 31.1, 22.0; CH1 δ 146.7, 145.8, 142.4, 136.2 (x2), 
136.0, 129.8, 129.7, 128.6 (x2), 128.2, 127.9, 127.7, 125.6, 119.4, 118.7, 82.4, 81.3, 77.2, 
76.5, 73.7, 72.2, 70.9, 70.1, 67.2; CH0 δ; 171.7, 167.0, 165.6, 153.2, 151.8, 144.5, 138.1, 
135.1, 133.6, 110.0, 103.4, 29.9, 19.5; IR (neat) 2954, 2857, 1652, 1461, 1348, 1253, 
1178, 1083, 933, 836, 776 cm
-1
; HRMS (ESI/APCI) calcd for C69H92NaO13Si(M+Na): 
1179.6205, found: 1179.6216. 
Preparation of Merle 32: To a stirring 
solution of the BPS ether 1.162 (1.9 mg, 0.0016 mmol, 1.0 equiv) in a 5:4:1 THF/MeOH/ 
pyridine solution (800 µL, 0.002M) at 0 ºC in a 2 mL plastic centrifuge tube was added 
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HF·Py (20 %, 400 µL).  The reaction mixture was stirred at 0 ºC for 30 min and then 
warmed to rt. Stirring was continued for 48 h and the reaction mixture was then quenched 
by pipetting into a mixture of saturated aqueous NaHCO3 solution and EtOAc (5 mL 
each). The layers were separated and the aqueous layer was extracted with EtOAc (3 x 5 
mL). The combined organic layer was dried over Na2SO4, filtered and concentrated under 
reduced pressure. The crude product was taken to the next step without further 
purification. 
 To a 4 mL reaction vial containing the analogue precursor from the previous 
reaction  was added a 0.25 M solution of LiBF4 in 25:1 CH3CN/ H2O (300 µL, 0.073 
mmol, 45.0 equiv).  The reaction vial was sealed and the mixture was allowed to stir at 80 
ºC for 16 h.  After cooling to rt, the reaction mixture was diluted with EtOAc (5 mL) and 
was quenched with saturated aqueous NaHCO3 solution (5 mL).  The layers were 
separated and the aqueous phase was extracted with EtOAc (3 x 5 mL).  The combined 
organic phases were dried over Na2SO4, filtered and concentrated. Purification was 
accomplished using flash column chromatography with a 0.5 x 6 cm silica gel column, 
eluting with 20% EtOAc/hexanes (10 mL), collecting 6 x 50 fractions followed by 50% 
EtOAc/hexanes. The product containing fractions (15-29) were combined and 
concentrated under reduced pressure to provide Merle 32 (0.8 mg, 61% over 2 steps) as 
white powder: Rf = 0.57 (50% EtOAc/hexanes;   
20
D  -3 (c = 0.08, CHCl3); 500 MHz 
1
H NMR (CDCl3) δ 6.18-6.16 (m, 2H), 6.02 (d, J = 1.9 Hz, 1H), 5.81 (d, J = 15.1Hz, 
2H), 5.77 (d, J = 16.1 Hz, 1H),  5.33 (dd, J = 15.6, 8.3 Hz, 1H), 5.26 (s, 1H), 5.21 (s, 1H), 
4.73 (dd, J = 6.4, 1.5 Hz, 1H), 4.71 (s, 1H), 4.66 (s, 1H), 4.48 (d, J = 11.7 Hz, 1H), 4.26-
4.22 (m, 1H), 4.09-4.00 (m, 2H), 3.82 (dd, J = 12.2, 5.8 Hz, 1H), 3.71 (dd, J = 8.7, 2.4 
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Hz, 1H), 3.68 (s, 3H),  3.51 (t, J = 11.7Hz, 1H), 3.44 (ddd, J = 11.0, 5.9, 1.7 Hz, 1H), 
3.12 (dd, J = 11.4, 1.7 Hz, 1H), 2.49 (dd, J = 12.0, 1.8 Hz, 1H), 2.45-2.41 (m, 1H), 2.28 
(t, J = 13.1 Hz, 1H), 2.18-1.90 (m 12H), 1.83 (ddd, J = 14.0, 11.6, 2.7 Hz, 2H), 2.06 (s, 
3H), 1.80-1.74 (m, 2H), 1.50-1.43 (m, 3H), 1.24 (d, J = 6.8 Hz, 3H), 1.15 (s, 3H), 1.01 (s, 
6H), 0.99 (s, 3H), 0.92 (t, J = 7.3 Hz, 3H); 125 MHz 
13
C NMR (CDCl3) δ 172.3, 167.2, 
165.7, 152.6, 152.2, 146.4, 145.6, 144.1, 138.5, 130.3, 128.6, 119.7, 118.9, 108.6, 106.7, 
99.2, 86.3, 80.0, 78.0, 74.3 (x2), 73.8, 73.3, 70.5, 70.4, 68.9, 64.8 (x2), 45.0, 43.0, 42.7, 
41.5, 40.5, 39.7, 37.1, 36.0, 35.2, 31.5, 24.8, 22.8, 22.0, 20.7, 20.0, 13.9 ; IR (neat) 2928, 
1778, 1721, 1659, 1454, 1368, 1214, 1073, 837, 757, 701 cm
-1
; HRMS calcd for 
C44H64O12Na (M+Na): 807.4295, found: 807.4300. 
 
Biological Experiments and Data for Merle 32 
[
3
H]PDBu binding assay. The binding assay of Mele 32 was done similar to that 
of Merle 30. The Ki for Merle 30 was found to be 1.08 nM. nM (average of three 
determinations). 
Attachment and cell proliferation of U937 and LNCaP cells. The attachment and 
proliferation of U937 and LNCaP cells were performed similar to that of Merle 30 and 


















Cell proliferation of U937 cells 
01.23.2010 
Treatment for 48 hours 
Attachment of U937 cells 
01.23.2010 
Treatment for 48 hours 
[II DMSO 
• PMA (O.1.1.10.10D.1000nM) 
• Bryostatin 1 (0.1. 1, 10, 100, 1000 nM) 
• Merle 32 (0.1. 1.1 0. 100.1000 nM) 
E23 100 nM PMA + Bryostatin 1 (1. 1 D, 100, 1000 nM) 
























Proliferation of LNCaP cells (01.27.2010) 
Treatment for 60 hours 
Attachment of LNCaP cells (01.27.2010) 
Treatment for 60 hours 
iii DMSO 
• PMA(O.1.1.1 0.1 0D.1 000 nM) 
• Bryostatin 1 (0 .1. 1. 10. 100. 1000 nM) 
• Merle 32 (0 .1. 0 .3, 1. 3, 1 D, 30. 100, 300. 1000, 5000 nM) 
E 100 nM PMA + Bryostatin 1 (1. 1 D, 100, 1000 nM) 
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THE TOTAL SYNTHESIS OF BRYOSTATIN 1  
 
Introduction 
Bryostatin 1 is the flagship member of a family of 20 macrolides that were 
isolated by Pettit and co-workers from the marine bryozoan Bugula neritina, after finding 
the antineoplastic activity of its extracts against murine P388 lymphocytic leukemia.
1
 The 
gross structure of bryostatin 1 (Figure 2.1) was determined in 1982 using NMR, IR, and 
mass spectrometry, whereas the absolute stereochemistry was determined using single 
crystal X-ray crystallography of bryostatin 1
2










Since the first isolation of bryostatin 1, nineteen other members of the 
family have been isolated and characterized.
4
 
Bryostatin 1 is a highly oxygenated natural product that has a number of 
architecturally interesting features. The 20-membered macrolactone houses three 
embedded functionalized pyran rings often referred to as A-, B- and C-rings. The A- and 
the C-rings of the bryostatin 1 are more functionalized and are present in sensitive lactol 
forms. The B- and C-ring each have an unique exocyclic ,-unsaturated methyl ester at 
4 position. In addition, bryostatin 1 has a pair of gem-dimethyl group at the C8 and C18 
positions. The molecule has three olefins, a trans olefin in the macrocycle and a pair of E 
olefins on the octadieoante side chain on the C-ring. The three-dimensional structure of 
bryostatin 1 is held together by a network of three hydrogen bonds. The C3 hydroxyl 
group serves as a hydrogen bold acceptor for C19 hydroxyl group as well as acts as a 
donor for a bifurcated hydrogen bond to the A- and B-ring pyran oxygens. Most of the 
bryostatins differ from each other at C7 and C20 positions in which they have different 
ester substituents. One of the simplest members of the family is bryostatin 16 which has 
t-butyl acetate at the C7 position and the C19-C20 groups are replaced by an olefin. On the 
other hand, bryostatin 3, 19 and 20 have an additional five membered lactone fused with 
the C-ring.  
Due to its promising anticancer activity, bryostatin 1 is in some 80 clinical trials 
for cancer chemotherapy.
5
 Additionally, it has shown other impressive biological 
activities such as reversal of multidrug resistance,
6
 synergetic effect with other anticancer 
agents,
7
 stimulation of the immune system,
8
 enhancement of memory,
9
 activity against 
Alzheimer‟s disease,10 and neutoprotective activity after stroke.11 More recently, 
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bryostatin has been shown to have anti-HIV activity.
12
 Although the mechanism of action 
of bryostatin 1 with respect to these biological activities is still under investigation, it is 




Because of these remarkable biological activities, bryostatin 1 has potential as a 
therapeutic agent against numerous diseases. However, further clinical development of 
the natural product has been hampered by extremely low natural abundance. The largest 
isolation of the bryostatins from 28000 lbs of Bugula neritina provided only 18 grams of 
bryostatin 1 with a yield of 0.0014%.
14
 As the isolation of the bryostatins from such non-
renewable source has a harmful ecological impact, other sources of bryostatins have been 
explored. One of them is the aquaculture of the Bubula neritina by CalBiomarine 
Technologies.
15 
However, the process has not been cost effective due to low production 
of bryostatins and has been abandoned. A study towards the biosynthesis of the 





Previous Total Syntheses of Bryostatins 
The challenging architecture, impressive biological profile and scarce natural 
abundance of bryostatins have prompted a number of research groups towards the total 
synthesis of these natural products. Despite the enormous effort in this area, only four 
completed total syntheses of bryostatins have been reported (Figure 2.2). The first 
bryostatin to be synthesized was bryostatin 7 by Masamune
17
 group in 1990
 
which was 




Figure 2.2. Structure of Synthesized Bryostatins 
 
 
the synthesis of the most complex member of the family, bryostatin 3.
19
 More recently, 
the Trost group finished the total synthesis of bryostatin 16 in 2002.
20
 Moreover, Hale has 
reported the formal synthesis of bryostatin 7.
21
 In addition, numerous fragments, partial 
syntheses and studies towards the syntheses have been disclosed.
22
 This chapter will 
focus on the discussion of only the completed total syntheses of bryostatins and interested 






Masamune‟s Total Synthesis of Bryostatin 717 
 Bryostatin 7 was the first member of its family to be synthesized by Masamune in 
1990. This synthesis is based on the extensive use of chiral boron enolate aldol chemistry 
developed earlier by Masamune. The synthetic plan involved a key C16-C17 bond 
disconnection leading to a convergent union of A-B and C-ring fragments by Julia 
olefination which would be shared by most of the succeeding syntheses (Figure 2.3). An 
intramolecular esterification would construct the macrocyclic lactone. This retrosynthesis 
thus divides the molecule horizontally into northern A-B-ring fragment and southern C-
ring fragment. Both A and C pyran rings would be constructed from the ketalization of 
the corresponding keto alcohols where as B-ring would be formed by oxymercuration 
process. The linear A-B fragment would be formed by an asymmetric aldol reaction 
between the boron enolate of ketone 2.6 and aldehyde 2.5 whereas the all carbon skeleton 
of the C-ring 2.2 would be formed by an organometallic addition of iodide 2.8 to the 
aldehyde 2.7.  
The synthesis of the A-B-ring fragment commenced from aldehyde 2.10 which 
was prepared in three steps from commercially available 2,2-dimethylpropane-1,3-diol 
(Figure 2.4). A two carbon homologation using Horner-Wadsworth-Emmons (HWE) 
reaction followed by DIBAL-H reduction of the ester provided an allylic alcohol 2.11 for 
the Sharpless asymmetric epoxidation (SAE) in the next step. The alcohol was oxidized 
and another two carbon homologation using Wittig reaction provided the ,-unsaturated 
aldehyde 2.13. Reduction of the aldehyde provided the allylic alcohol which was 
subjected to another SAE reaction providing the bisepoxide 2.14. Both of the epoxides 












Figure 2.4. Preparation of C3-C10 Subunit 
 
 
stereocenters and the primary alcohol was selectively protected as BPS ether. The 1,3 
diol was protected as acetonide which also verified their antistereochemical relationship. 
Deprotection of the benzyl group liberated the alcohol which was oxidized to aldehyde. 
Addition of the methyl lithium followed by the oxidation of resulting alcohol completed 
the synthesis of C3-C10 fragment needed for the construction of A-B-ring. The aldehyde 





propargyl alcohol 2.17. Homologation using formaldehyde gave the primary alcohol 
which directed the Red-Al reduction of the alkyne and trapping it using iodine 
providedthe desired Z vinyl iodide. Coupling of the vinyl iodide with allylmagnesium 
bromide followed by the deprotection of the THP group and subsequent oxidation 
provided the aldehyde coupling partner 2.19.  
With both coupling partners in hand, enolization of the ketone 2.6 using chiral 
boron reagent followed by its addition to aldehyde 2.19 set the C11 sereocenter. Removal 
of the acetonide and insitu ketalization was carried out using PPTS/MeOH providing the 
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A-ring. In order to prepare B-ring, the precursor 2.21 was subjected to oxymercuration 
reaction giving an epimeric mixture at C15. Demercuration of the intermediate 2.22 
followed by Swern oxidation provided the epimeric aldehyde which was equilibrated to 
the desired cis pyran using wet alumina. This completed the synthesis of the A-B-ring 
unit in 24 longest linear steps starting from diol 2.9.  
The preparation of the C-ring subunit 2.7 began with carbamate formation 
followed by opening of the epoxide 2.23 (Figure 2.6). The carbamate protecting group 
was swapped with the primary acetonide and the free secondary alcohol was protected as 
a DMP ether. Removal of the benzyl group followed by mesylation and displacement 
provided the pheyl sulfide 2.26. An acidic removal of the acetonide followed by 






The C26 and C27 stereocenters of the C-ring were bought from the commercially 
available L-threonine (Figure 2.7). Conversion of the amine into an alcohol group was 
carried out by diazotization followed by its displacement with water. Fischer 
esterification of the carboxylic acid followed by acetonide formation provided the methyl 
ester 2.28 with an yield of 64% over three steps. Half reduction of the ester using 
DIBAL-H led to the formation of an aldehyde which was then one carbon homologated 
using Wittig reaction. The olefin was subjected to hydroboration-oxidation followed by 
the PCC oxidation providing the aldehyde 2.30. The C24 stereocenter was installed using 
a substrate controlled addition of allenyl zinc to the aldehyde 2.7 giving a 8:1 mixture of 
diastereomers in favor of desired isomer. The newly formed alcohol was protected as a 
MPM ether and the methyl ester was installed using chloroformate. A conjugate addition 
of the stannane followed by the full reduction of the methyl ester gave alcohol. The free 
alcohol was protected as a BPS ether and the stannane was converted into an iodide by 
treating it with iodine. A substrate controlled addition of the lithiate of vinyl iodide 2.8 to 
the aldehyde 2.7 installed the C20 stereocenter providing 6:1 mixture of alcohols. 
Protection of the newly formed alcohol as TES group, deprotection of the DMPM group 
and oxidation of the resulting alcohol provided the ketone 3.24. At this point, the phenyl 
sulfide was oxidized to a sulfone and the MPM group was removed using DDQ.The C- 
ring of the bryostatin was prepared as methyl ketal using TESOTf/TMSOMe. Thus the 
synthesis of C-ring was completed in 21 longest linear steps starting from L-threonine. 
The synthesis utilized commercially available amino acid in order to install two 
stereocenters. Remaining stereocenters were installed using chelation controlled addition 
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Figure 2.7. Completion of the C-ring 
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With two major fragments aldehyde 2.1 and sulfone 2.2 in hand, a Julia 
olefination using phenyllithium as a base provided the desired E-olefin in 60% yield after 
reductive elimination (Figure 2.8). The choice of base for Julia olefination was crucial for 
the success of coupling reaction. Use of stronger base such as n-BuLi or t-BuLi led to the 
formation of byproducts whereas weaker bases like LDA or LEA resulted into 
incomplete deprotonation. In order to reveal the C20 alcohol, all the silicon protecting 
groups were removed using TBAF and selective protection of all alcohols as TBS ether 
except the C20 alcohol provided the desired product. Esterification of C20 alcohol as 
acetate followed by one more global silyl deprotection provided the triol 2.36. Selective 
conversion of bis allylic alcohol to bismethyl ester installed the desired methyl esters on 
the B and the C-rings. The remaining C3 alcohol was converted into the corresponding 
aldehyde. The C3 stereocenter was then installed by using an asymmetric boron aldol 
reaction providing a 3:1 mixture of diastereomers in favour of the desired isomer. 
Removal of the acetonide led to the formation of a triol. A three step sequence involving 
TES protection of the triol, hydrolysis of the thioester and global silyl deprotection 
provided the trihydroxy carboxylic acid 2.40. Although the macrolactonization of the 
thioester using thiophilic metal failed, use of Keck macrolactonization condition provided 
the desired C25 macrolactone in moderate yield. It is interesting to note that the acidic 
hydrolysis of the C19 methylketal could not be carried out in the presence of C20 acetate. 
It was thus necessary to remove C20 acetate for the acidic hydrolysis of C19 methyl ketal. 
The C26 alcohol of the triol was selectively protected as TBS ether and the remaining two 
alcohols were esterified as acetates. Removal of the TBS group completed the synthesis 
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Figure 2.8. Masamune's Completion of Bryostatin 7 
232 
 
Thus the first total synthesis of bryostatin 7 by Masamune was accomplished in 
42 longest linear steps and required more than 84 chemical steps. The synthesis provided 
half a milligram of synthetic bryostatin 7. Although Masamune targeted bryostatin 1 
initially, setbacks in the route led to the synthesis of bryostatin 7. The major problem in 
the first generation route was removal of the C3 MEM group. In order to remove such a 
problem in the future synthesis, the entire route had to be altered. The highlights of the 
synthesis involve the extensive use of Sharpless epoxidation, Masamune‟s chiral boron 
enolate as well as chelation controlled addition reactions to install the key stereocenters.  
 
Evans‟ Total Synthesis of Bryostatin 218 
In 1999, Evans and coworkers disclosed the total synthesis of another member, 
bryostatin 2. The major disconnection used by Evans is similar to that of Masamune in 
that the B and C-rings would coupled by Julia olefination whereas the macrocycle would 
be formed by a Yamaguchi reaction (Figure 2.9). The A and B-rings were joined by an 
alkylation of B-ring triflate with A-ring sulfone. This synthetic plan would divide the 
molecule to separate A, B and C-rings. It was initially envisioned to couple the fully 
functionalized three rings but due to the complication raised by functionalities mainly on 
the B and C-ring, it was decided to couple simpler fragments. Thus coupling was done 
using simplified B and the C-rings and were functionalized in late stage. The best order 
for the coupling of these rings was realized as B+C=BC+A=ABC although other 
sequences such as A+B=AB+C=ABC were attempted. The synthesis is heavily based on 
the methodologies developed in their labs such as Evans chiral auxiliary mediated aldol 
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The synthesis of A-ring was started from aldehyde 2.47, which was prepared in 5 
steps from commercially available 2,2-dimethylpropane-1,3-diol (Figure 2.10). A 
diastereoselective aldol reaction of aldehyde 2.47 using chiral chloroacetate 
oxazolidinone provided the chloroalcohol 2.48 in excellent diastereoseleectivity. A 
reductive removal of chlorine followed by removal of the chiral auxillary provided the 
diol which were differentiated by first converting it into a PMP acetal followed DIBAL-
H reduction. The aldehyde was subjected substrate mediated 1,3-chelation controlled 






diastereoselectivity. One more substrate controlled antireduction of the beta keto alcohol 
provided the diol with high diastereoselectivity. The diols were differentiated by forming 
a six membered lactone with one of them and the remaining was protected as a TBS 
ether. Opening of the lactone to anilide followed by ozonolysis and subsequent 
cyclization provided the lactol as mixture of diastereomers which was carried on withoyt 
separation. Selective acetylation of the lactol and its displacement with phenyl sulfide 
provided the diastereometically pure sulfide which was oxidized using m-CPBA 
providing the A-ring sulfone in 20 steps from commercially available material.  
Preparation of B the ring component also relied on the asymmetric aldol reaction 
and 1,3 anti reduction (Figure 2.11). The B-ring was completed in 9 steps from aldehyde 
2.54 which was in turn prepared in 2 steps from commercial (Z)-but-2-ene-1,4-diol via 
dibenzyl protection and ozonolysis. An asymmetric aldol reaction of the bis TMS enol 
ether using Evans‟ chiral py-box catalyst was used to install the C15 stereocenter. One 
more a 1,3 chelation controlled Saksena-Evans‟ reduction of the beta keto alcohol 
provided the diol in excellent diastereoselectivity. The diols were differentiated through 
lactone formation and TBS protection. Treatment of the lactone with benzyloxymethyl 
lithiate provided the lactol as single diastereomer which was reduced to pyran in high 
diasereoselectivity. The reduction also removed the PMB and TES protecting groups. Bis 
TBS protection followed by debenzylation and oxidation completed the synthesis of the 
B-ring of bryostatin. 
The synthesis of the C-ring required the preparation of ketone 2.62 (Figure 2.12). 
Subjection of the racemic alcohol 2.60 to Sharpless asymmetric kinetic resolution 
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Figure 2.11. Synthesis of B-ring of Bryoststin 2 
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Figure 2.12. Synthesis of C24-C27 Fragment 
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Ozonolysis of the olefin provided the ketone 2.62 in 30% yield over 3 steps. 
Preparation of the aldehyde coupling partner for the aldol reaction is shown in 
Figure 2.13. The precursor aldehyde 2.64 was prepared in 4 steps from the diol 2.63 via 
monotosylation, phenyl sulfide displacement, sulfide oxidation and alcohol oxidation. A 
Grignard addition to the aldehyde and oxidation of the resulting alcohol followed by 
oxidative cleavage of the terminal olefin provide the aldehyde 2.65. Paterson borane aldol 
transformation provided the adduct 2.66 in high yield and diasteroselectivity. A directed 
Evans-Tishchenko reduction of the ketone not only installed the C23 stereocenter but also 
differentiated the diol after reduction. Protection of the newly formed alcohol as TBS 






was converted to glycal 2.46 under dehydrative cyclization. 
With the completion of the synthesis of all three rings, coupling of these 
fragments was undertaken (Figure 2.14). The three rings could be coupled in different 
ways, either A+B=AB+C=ABC or B+C=BC+A=ABC. A more convergent coupling of 
the fully functionalized C-ring sulfone with B-ring aldehyde could not be carried out. It 
was eventually discovered that the later coupling sequence provided the better overall 
yield of the tricycle. Addition of the anion of the C-ring sulfone to the B-ring aldehyde 
2.45 formed the hydroxyl sulfone which was in situ acetylated and finally eliminated 
providing the BC fragment. In order to combine it with the A-ring, the C10 alcohol was 
revealed by selective deprotection of the primary TBS group and converted into a 
unstable triflate which was immediately displaced with the dianion derived from the A-
ring sulfone 2.44. This reaction sequence provided the ABC tricycle in a 19 step longest 
linear sequence from commercially available starting materials. Attempts to carry this 
tricycle were frustrated due to the acid/base instability of the A-ring. Functionalization of 
tricycle core required the opening of the unstable A-ring lactol to the more robust TES 
protected ketone. The N-phenyl amide at C1 was switched for a benzyl ester. The acid 
sensitive C-ring glycal was converted into more stable methoxy ketone via epoxide 
formation, opening of the epoxide, equilibrium of the mehtylketal and oxidation of the 
alcohol. A global silyl deprotection using acidic methanol resulted in a triol with 
simultaneous formation of the A-ring methylketal. Selective protection of the C3 and C13 
alcohols followed by benzoyl deprotection provided the seco acid. Yamaguchi 
esterification to close the macrolactone was followed by the selective deprotection of the 
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Figure 2.14. Coupling of the A-, B- and C-rings 





With the macrocrolactone in hand, the functionalization of the B-ring was 
addressed first. The C13 alcohol was oxidized to a ketone using Dess-Martin oxidation 
(Figure 2.15). An asymmetric HWE reaction of the bisketone with chiral R-BINOL 
phosphate proved to be regioselective and provided the desired Z olefin as a separable 6:1 
mixture of isomers favouring the desired isomer. Functionalization of the C-ring involved 
an aldol reaction with methyl glyoxylate which the led to the formation of the aldol 
adduct. Dehydration of the adduct using Buress reagent provided the keto enoate in good 
yield as a 6:1 mixture of E:Z isomers. Initial attempts to reduce the ketone using Luche 
condition were unsuccessful due to low yield and poor selectivity. But use of CBS regent 
provided the desired alcohol in good yield and selectivity and was temporarily protected 
as methoxyacetate. Hydrolysis of the C9 methylketal and TES deprotection was followed 
by saponification of the methoxyacetate. Further acidic hydrolysis removed the C19 
methylketal and also equilibrated the C9 hemiketal providing the tetraol 2.74. A selective 
esterification of the C20 alcohol with octadienoic acid followed by global PMB 
deprotection completed the total synthesis of bryostatin 2. 
Evans and coworkers thus completed the total synthesis of bryostatin 2 in 75 total 
steps and 42 longest linear steps. The synthesis provided 0.8 mg of the synthetic 
bryostatin 2. Evan‟s synthesis is based on an impressive use of methodology developed 
by Evans and coworkers earlier in their laboratory. Among all, the noteable 
methodologies are Lewis acid mediated substrate controlled 1,3-chelation controlled 
additions, chiral auxiliary mediated aldol reactions and a 1,3 directed reduction of the 
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Yamamura‟s Total Synthesis of Bryostatin 319 
Bryostatin 3, the most complex member of the family, was the third bryostatin to 
be synthesized by Yamamura and coworkers in 2000. Bryostatin 3 is more complex than 
other members of the family due to the presence of an unsaturated -ring ring on the C-
ring. Similar to the previous two syntheses, this synthesis would be based on a 
convergent coupling of the C-ring system with the A-B-ring system via Julia olefination 
and macrolactonization (Figure 2.16). The A and B-rings fragment were in turn were 
joined using dithane coupling of the acyclic A-ring anion with B-ring iodide. The A and 
C-rings would be prepared by acid catalyzed ketalization of the corresponding acyclic 
keto alcohols whereas B-ring was formed using an asymmetric hetero Diels-Alder 
reaction. This would require the preparation of the four fragments. 
Starting from D-mannitol, the preparation of B-ring required 11 steps (Figure 
2.17). Bisacetonide formation of the terminal alcohols followed by oxidative cleavage of 
the middle diol provided the chiral aldehyde 2.84. The aldehyde was subjected to a herero 
Diels-Alder reaction using Danishefsky diene 2.85. This substrate controlled reaction 
provided the dihydropyranone 2.86 as a single isomer. A vinyl cuprate conjugate addition 
on the resulting dihydropyranone provided the trans-pyran. The ketone group was 
protected as methyl acetal which was followed by ozonolysis of the terminal olefin 
providong a aldehyde. The trans pyran was then converted into cis by epimerization of 
the C15 stereocenter with potassium carbonate. Reduction of the aldehyde and benzyl 
protection was followed by removal of the acetonide and cleavage of the diol to an 
aldehyde. Two more steps involving an aldehyde reduction and iodination completed the 
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The synthesis of the A-ring commenced from the commercially available diol 
2.89 which after five steps provided the epoxy alcohol 2.91 (Figure 2.18). Regioselective 
opening of the epoxide, bis-TBS protection and benzyl deprotection provided the alcohol 
which was oxidized and converted into dithaine 2.93. Displacement of the B-ring iodide 
with the anion derived from the dithaine led the coupling of A and B-ring fragment. 
Selective removal of the primary TBS group followed by oxidation provided the 
aldehyde 2.94 for an asymmetric aldol reaction.  Deprotonation of the menthone enol 
ether 2.95 followed by addition to aldehyde 2.94 provided the desired alcohol in excellent 
selectivity. Removal of the chiral auxillary followed by the 1,3 chelation controlled 
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dedithianolization followed by acid catalyzed methyl ketalization secured the A-ring. 
Debenzylation, basic hydrolysis of the ester, alkylation of the acid followed by the 
oxidation of the alcohol completed the synthesis of the A-B-ring system of bryostatin 3.  
The aldehdye precursor 2.82 for the synthesis of C-ring was prepared from D-
glucose (Figure 2.19). Bisacetonide formation, tosylation of the remaining alcohol, 
elimination and hydrogenation provided the tetrahydrofuran 2.100 with correct 
stereochemistry. The more labile acetonide was selectively removed and the terminal 
alcohol was tosylated. Reduction of the tosyl group installed the C27 methyl group. 
Removal of the remaining acetonide was accompained by opening of the lactol and its 
subsequent conversion into a dithaine. The triol was once again subjected to 
regioselective terminal acetonide formation and BOM protection. Removal of the 






Similar to the A-ring synthesis, the synthesis of C-ring also commenced from diol 
2.89 (Figure 2.20). A six step protocol furnished the olefin 2.104 which was subjected to 
SAD followed by acetonide protection. Half reduction of the ester provided the 
aldehyhde which was then converted into a dibromoalkene with one carbon 
homologation. Conversion of the dibromo species to a propargylic alcohol was followed 






and regioselective opening of which provided the alcohol 2.81. With both iodide 2.81 and 
aldehyde 2.82 in hand, the coupling of these fragments was attempted using Nozaki-
Himaya-Kishi reaction which proved to be unsuccessful. A sequential treatment of the 
iodide 2.81 with MeLi and t-BuLi followed by addition of the aldehyde provided the 
desired product as 3:1 mixture of diastereomers. It is interesting to note that Masamune 
also performed similar coupling with switched iodide and aldehyde pieces and was able 
to get higher yield and selectivity (vide supra). Protection of the alcohol, oxidation of the 
sulfone and removal of PMB group provided the alcohol which was oxidized to a ketone. 
The BOM group was removed and keto alcohol was cyclized to hemiketal which was 
finally converted into methylketal. A global exchange of the silyl groups with TES group 
completed the synthesis of C-ring. 
The key Julia coupling of the A-B-ring aldehyde with the C-ring sulfone was 
accomplished providing the tricycle in moderate yield (Figure 2.21). Selective 
deprotection of the C21 and C22 alcohols followed by Lay oxidation afforded the ,-
unsaturated -lactone. One more site selective silyl deprotection provided the C20 alcohol 
which was esterified with the bryostatin side chain using Yamaguchi reaction. Selective 
removal of the acetonide and the C3 TBS ether provided a triol in which C3 and C27 
alcohols were selectively protected as TES ethers leaving the C26 alcohol free. The seco 
acid was prepared after the removal of the allyl ester and was subjected to Yamaguchi  
macrolactonization.  
With the macrolactone in hand, the functionalization of the B-ring commenced 
with removal of the methylacetal on the B-ring. An asymmetric HWE reaction of the 
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good selectivity. It is interesting to note that the HWE reaction was less selective in 
Evan‟s synthesis of bryostatin 2. Hydrolysis of the C19 methylketal was found to be 
problematic initially but was finally accomplished using TFA/H2O. A temporary 
protection of C26 alcohol followed by acetylation of C7 alcohol and final deprotection 
completed the synthesis of bryostain 3. 
In summary, Yamamura completed the synthesis of most complex member of 
bryostatin in 43 steps (longest linear sequence) and 87 steps total. This synthesis utilized 
carbohydrates as a major source of chiral pool. Although Yamamura and coworkers said 
that they made 25 mg of bryostatin 3, the biological evaluation on this material is yet to 
be reported.  
 
Trost‟s Total Synthesis of Bryostatin 1619 
Trost and coworkers have recently published the total synthesis of bryostatin 16. 
Structurally, bryostatin 16 is one of the less complex bryostatins due the absence of 
oxidatin at C19-C20 position on the C-ring. In addition, bryostatin 16 has significantly 
lower binding affinity (Ki = 116 nM) compared to other bryostatins (bryostatin 1, for 
example, has binding affinity of 1.4 nM). However, with an aim to elaborate to other 
bryostatins, Trost and coworkers targeted the synthesis of bryostatin 16. The synthetic 
plan is different from the previous three syntheses in that the C-ring is formed by an 
alkyne-alkyne coupling with concurrent formation of the macrocycle (Figure 2.22). The 
B-ring was formed by a palladium catalyzed alkene-alkyne coupling followed by 
cyclization. The A-ring was formed by the acid catalyzed methyl-ketalization of the 
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Figure 2.22. Trost's Retrosynthesis of Bryostatin 16 
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The synthesis began with the preparation of the alkene fragment 2.117 (Figure 
2.23). Starting from aldehyde 2.118 (prepared in two steps from commercially available 
diol), a brown allylation followed by PMB protection installed the C7 stereocenter. 
Oxidative cleavage of the diol derived from the olefin provided the aldehyde which was 
subjected to a 1,3 chelation controlled Mukiyama aldol addition using TMS enol ether as 
the nucleophile. One more hydroxy directed substrate controlled reduction installed the 
C3 stereocenter. The diols were differentiated by a selective formation of six membered 
lactone using Otera‟s catalyst. Removal of the TBS ether, oxidation to aldehyde followed 







The alkyne partner 2.116 for the alkene-alkyne coupling was also prepared from 
the aldehyde 2.118 (Figure 2.24). A two carbon homologation followed by indium 
mediated propargylation provided the racemic alcohol which was oxidized and reduced 
bromide followed by oxidation provided the aldehyde 2.125. The aldehyde was 
homologated to an alkyne using Ohira-Bestmann reaction. Removal of the BPS ether 
with CBS reagent. With both partners in hand, a ruthenium catalyzed cascade alkene-
alkyne coupling /conjugate addition generated the B-ring in moderate yield. Bromination 






in MeOH which also deprotected the TBS group. A palladium mediated carbonylation of 
the B-ring followed by hydroxyl directed saponification and reprotection of the alcohol 
completed the synthesis of the northern hemisphere. 
The alkyne fragment 2.115 was prepared from D-glactonic acid 1,4 lactone 2.126 
(Figure 2.25). All three stereocenters in this piece were bought from the starting material. 
Conversion of the primary alcohol to a bromide followed by acetylation provided the 
triacetate. The bromide was reduced to a methyl group and hydride reduction provided 
the tetraol which was protected as bisacetonide. Selective removal of the more labile 
primary acetonide followed tosylate formation which under basic conditions yielded the 
epoxide 2.128. Opening of the epoxide and protecting group manipulation furnished the 
alcohol 2.115 in ten steps from commercially available material. 
The coupling of the alcohol 2.115 and acid 2.114 under Yamaguchi condition 
provided the entire carbon framework of bryostatin 16. A bis-PMB deprotection led to 
the formation of diol ready for the critical alkyne-alkyne coupling. The optimized 
condition using 12 mole% Pd(OAc)2 and 15 mol% tris(2,6-dimethoxyphenyl) phosphate 
ligand provided the macrocycle in moderate yield. Formation of the C-ring using a gold 
catalyzed 6-endo-dig cyclization closed the C-ring.  Conversion of the C7 alcohol into its 
pivalate followed by global deprotection of the silyl groups completed the synthesis of 
bryostatin 16. 
Trost‟s synthesis of bryostatin 16 took 28 longest linear steps (41 chemical steps) 
from commercially available 2,2-dimethylpropane-1,3-diol. Their synthesis provided 0.4 
mg of bryostatin 16. The synthesis utilizes their atom economical alkene-alkyne and 
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With the completion of bryostatin 16, Trost and coworkers attempted to elaborate 
the intermediate 2.131, which was prepared en route to bryostatin 16, to other bryostatins 
(Figure 2.26).
24
 Unfortunately, the dihydroxylation of the C19-C20 glycal using Sharpless 
asymmetric AD-mix catalyst was unsuccessful. As an alternative, oxidation of the C19-
C20 olefin using rhenium oxide provided the undesired epoxide 2.132. Opening of the 
epoxide followed by acetylation of the resulting alcohol and global deprotection provided 
20-epi-bryostatin 7. Thus the conversion of bryostatin 16 like intermediates to other 






Results and Discussion 
The extremely low availability of the bryostatin 1 from natural as well as other 
sources has affected the further clinical development of this promising therapeutic lead. 
Moreover, synthesis of bryostatin 1, the most clinically used member of the family, has 
either not been attempted or not been successful so far. This led our group to direct 
studies towards the total synthesis of bryostatin 1. 
Towards this end, our group has developed a powerful methodology for the 
construction of the 2,6-disubstituted-4-methylene tetrahydropyran, a structural motif 
present in the B-ring of all the bryostatins.
25 Also referred as “pyran annulations,” the 
process involves the coupling of a -hydroxyallyl trimethylsilane 2.137 to an aldehyde  
2.138 in the presence of TMSOTf at -78°C providing the cis-pyran 2.140 as a single 
diastereomer in high yield (Figure 2.27). The reaction involve the formation of one 







membered ring and an exomethylene handle. The starting material -hydroxyallyl 
trimetylsilane 2.137 can be prepared in high yield and enantiomeric excess by a catalytic 
asymmetric allylation (CAA) of corresponding aldehyde 2.135. 
 The pyran annulation methodology allows for the synthesis of the pyran building 
blocks like 2.140 in just three steps from commercially available starting material. Using 
this methodology, our group has prepared a number of bryostatin analogues in which the 
B-ring or both A and B-rings of the bryostatins have been replaced by simple pyrans 
(Figure 2.28). In Merle 23, both A and B-rings of bryostatin 1 have been replaced by 
exomethylene pyrans.
26
 On the other hand, in the Merle 27, the exomethylene in the A-
ring pyran has been cleaved to a  ketone, reduced and acetylated.
27
 Merle 28 and Merle 
30 are our most bryostatin 1 like analogues with difference being just at one point. In 
Merle 28,
28
 the B-ring is replaced by a simple pyran whereas in Merle 30,
29
 the - 
unsaturated methyl ester has been prepared by a Horner-Wadsworth–Emmons olefination 
of the ketone derived from the cleavage of the exocyclic olefin. In addition to our group, 
Wender‟s group has also used an intramolecular version of the pyran annulation in the 




Retrosynthetic Analysis of Bryostatin 1 
   As mentioned earlier, three of the four previous total syntheses use the same 
major disconnection. Masanune, Evans and Yamamura construct the C16-C17 olefin by 
using Julia coupling whereas a macrolactone ester is formed by a intramolecular 
lactonization fragment and a southern C- ring fragment. Trost‟s strategy is different from 
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Figure 2.28, Representative Analogues Prepared Using Pyran Annulation 
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alkyne coupling followed by conjugate addition. Instead of conventional disconnections 
that divide the molecules into northern and southern parts, we sought a novel approach 
for bryostatin 1 synthesis. The discovery of the novel pyran annulation reaction and its 
successful application in the total synthesis of various bryostatin analogues led us to 
pursue this remarkable process in the total synthesis of the bryostatin 1 itself.  
 Our first generation retrosynthesis of bryostatin 1 is shown in Figure 2.29. This 
approach utilizes a late stage functionalization of the B and C-rings to form a tricyclic 
macrolactone 2.143. The B-ring of the tricycle was envisioned to be constructed from a 
pyran annulation between the A-ring aldehyde 2.145 and C-ring silane 2.144. This 
synthetic plan was utilized in the synthesis of various bryostatin analogues.
28,29
 Although 
this plan was successful in the synthesis of bryopyran analogues, the late stage 
functionalization of the C-ring in tricyclic compound 2.143 posed a number of problems. 
Most notable of these is the aldol condensation of the ketone 2.143 with 
methylglyoxylate in order to install the C22-C34 -unsaturated ester. This reaction was 
problematic due to the simultaneous aldol reaction on the C7 acetate. The other problem 
is the low selectivity during the reductiuon of the C20 ketone in the advanced substrates. 
Moreover, this synthetic plan was more linear and would require a longer linear number 
of steps to reach bryostatin 1 than the one that would use a fully functionalized C-ring. 
However, the full functionalization of the silane 2.144 or similar glycal were not 
successful and even if it would have worked, that would add too many steps in this piece 
and would make the synthesis even more linear. Therefore we redesigned our synthesis 
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Figure 2.29. First Generation Retrosynthesis of Bryostatin 1 
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Our new retrosynthetic analysis of bryostatin 1 is shown in Figure 2.30. This new 
diagonal disconnection divides the bryostatin into two parts of almost equal complexity, 
the C-ring aldehyde 2.146 and A-ring-hydroxy allylsilane 2.147. The highly convergent 
assembly of these two fully functionalized fragments would construct the B-ring of the 
bryostatin with desired stereochemistry in the C11 and C15 position. In addition, the 
process would also install an exocyclic olefin handle for the installation of the methyl 
enoate moiety on C13 position. Once the B-ring is formed, the other end of these two 






The allylsilane moiety on the A-ring was to be constructed by the addition of 
trimethylsilyl methylmagnesium bromide to the methylester 2.147 (Figure 2.31). 
Formation of the A-ring and installation of the C9 stereocenter would be achieved from 
the ketalization/equilibrium of the corresponding keto-alcohol derived from the acyclic 
precursor 2.148. The 1,3 antirelationship between the C5 and C7 alcohol would allow the 
use of a chelation controlled addition of stannane 2.149 on the aldehyde 2.150 and set C7 
the stereocenter. This reaction would also install the gem-dimethyl group on the C8 
position. Thus the acyclic precursor 2.148 could be constructed via a highly convergent 
union of stannane 2.149 and aldehyde 2.150. The stannane 2.149 would be generated via 
stannylation of the mesylate of an alcohol ultimately derived from ester 2.151. The gem-
dimethyl group on ester 2.151 was envisioned to be installed by an aldol condensation of 
the ester 2.153 with acetone. The C11 stereocenter was expected to be installed by a 
catalytic asymmetric allylation (CAA) reaction of corresponding aldehyde. Since C5 and 
C3 stereocenter also have an antirelationship, they could be constructed via another Lewis 
acid mediated 1,3 chelation controlled addition reaction of thioketene acetal 2.155 on 
aldehyde 2.154. The C5 stereocenter would come from the CAA reaction of the 
corresponding aldehyde.  
In C-ring, the exocyclic methyl enoate would be installed by an aldol 
condensation of the ketone 2.156 with methyl glyoxylate (Figure 2.32). The C19 
stereocenter would be installed by the methanolysis of the glycal followed by 
equilibration. The C20 stereocenter of the fully functionaliozed C-ring aldehyde 2.146 
was thought to arise from the reduction of the reduction of the corresponding ketone. The 
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cyclization. A highly convergent union of carboxylic acid 2.159 and alcohol 2.160 would 
be used to synthesize compound 2.158. The alcohol 2.160 was prepared in six steps from 
commercially available R-isobutyl lactate during which the C23 and C25 stereocenters 
were installed  through a series of 1,3 and 1,2 chelation controlled allylation reactions. 
The carboxylic acid piece 2.158 would be formed in four steps from commercially 
availavle methyl isobutyrate.  
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First Generation Approach Towards A-ring Silane  
 Our studies towards the first generation synthesis of the A-ring silane 2.147 was 
carried out by Dr. Dennie Welch (Figure 2.33).
31
 The synthesis commenced with the 
installation of the C11 stereocenter using CAA reaction on commercially available 
aldehyde 2.161.
32
 While the usual CAA reaction takes few days to complete, this 
particular CAA took only 12 h. This could be rationalized due to the highly electrophilic 
nature of the aldehyde due to the presence of electron withdrawing group in conjugation 






the olefin under Semmelhack‟s condition provided the ester 2.153 in good yield.33 An 
aldol reaction of the ester 2.153 with acetone provided the diastereomeric mixture of 
adduct 2.164 which was eliminated yielding terminal olefins.  Migration of the terminal 
olefin to more substituted position followed by full reduction of the ester provided the 
alcohol 2.165. The alcohol was converted into mesylate and in situ displacement with 
tributyltin lithiate provided the desired stannane 2.149. The synthesis of the aldehyde  
2.150 has been discussed in the synthesis of the bryostatin analogues in Chapter 1. 
With both stannane 2.149 and aldehyde 2.150 in hand, the crucial coupling was 
attempted (Figure 2.34). Activation of the aldehyde using five equivalents of dimethyl 
aluminium chloride followed by addition of the stannane 2.149 provided the alcohol as a 
single diastereomer. Use of Lewis acids such as MgBr2•OEt2 or TiCl2(OiPr)2 failed to 
promote the addition whereas use of toluene instead of dichloromethane as a solvent 
dramatically improved the selectivity. With the successful establishment of the C7 
stereocenter and installation of the gem-dimethyl group, the alcohol was converted into 
an acetate which is present in the natural product. Attempts to cleave both terminal and 
internal olefins simultaneously using ozone or OsO4/NaIO4 were complicated due to 
various side reactions and failed. Thus a selective osmylation and oxidative cleavage of 
the terminal olefin followed by Pinnick oxidation provided the carboxylic acid which was 
converted into its methyl ester using trimethysilyldiazomethane. The PMB group was 
removed under oxidative condition providing the alcohol 2.169. Ozonolysis and reductive 
cleavage of the remaining olefin led to the formation of the keto alcohol which, when 
treated with acidic methanol, provided the cyclic methyl ketal with concomitant 






Temporary protection of the alcohol as a TMS ether prepared the A-ring methyl 
ester 2.170 for the crucial Bunnelle allylsilane forming reaction (Figure 2.35).
34
 Addition 
of 15 equivalent of TMS-methylene Grignard reagent to the methyl ester 2.171 in the 
presence of excess anhydrous Cerium chloride did not provide any desired product. In 
fact the Grignard reagent did not even react with potentially labile groups such as the 






group was deprotected was fully recovered without any by products.  The reaction was 
also attempted under reflux condition with or without cerium chloride and still the 
starting material was left intact. The possibility of the fact that Grignard reagent might be 
bad was ruled out by preparing fresh batches of the reagent every time and testing it with 
simple methyl esters such as methyl benzoate. While the model substrate provided the 
desired allylsilane in high yield, the ester 2.171 gave no desired product under the 
identical conditions.  
Failure to form the desired allylsilane from the ester 2.171 led us to assume that 
steric factors could be keeping the ester from reacting with the Grignard reagent. One 
such sterically hindering group could be the TMS ether. With this in mind, the reaction 
was attempted with a methylester 2.170 with free alcohol in the beta position. In fact one 
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mole of the Grignard reagent reacted with the methyl ester and the resulting TMS 
methylene ketone was isolated. Subjection of the ketone to excess Grignard reagent did 
not yield any desired product. It was hypothesized that the cyclized A-ring might be 
imposing the steric hindrance for the addition of the Grignard reagent. To test this 
hypothesis, the open chain methylester 2.172 in which the TBS group was switched for a 
TMS group was subjected to Bunnelle reaction (Figure 2.36). Once again, the reaction 
did not provide any desired product but the starting material. However, the methylester 
with free alcohol gave the TMS-methylene ketone which failed to react further. At this 
point, it is not known which factor is responsible for the inherent inertness of the methyl 
ester but the steric hindrance caused by the gem-dimethyl group coupled with various 






An Alternative Synthesis of A-ring Silane  
Since the formation of the desired A-ring hydroxyallylsilane from the methyl 
ester 2.171 was found impossible to work, alternative routes to such silane were sought. 
One such route involved a CAA reaction of the trimethylsilyl methylallylstannane to an 
aldehyde to construct the -hydroxyallylsilane. The A-ring aldehyde 2.173 was prepared 
in multigram quantities and was successfully used in the synthesis of various bryostatin 
analogues. A catalytic asymmetric allylation (CAA) reaction on such aldehyde would set 
the C11 stereocetner as well as install the allylsilane moiety (Figure 2.37). Unfortunately, 
when the reaction was attempted using various CAA conditions such as high catalyst 
loading, warming to room temperature etc. and no desired product but starting material 
was isolated. As the substrate is highly oxygenated, it was suspected that the catalyst 
might undergo competitive binding with these functionalities and thus not activate the 
aldehyde enough for nucleophilic addition. Addition of super stoichiometric amount of 
BITIP catalyst did not have any effect and only starting material was recovered. Use of 
Lewis acids such as MgBr2•OEt2 was found to be ineffective whereas stronger Lewis 






As the asymmetric synthesis of the hydroxy allylsilane 2.147 directly from 
aldehyde 2.173 failed, an alternative approach was undertaken (Figure 2.38). Thus a 
thermal addition of the trimethylsilyl methallyl tributylstannane to the aldehyde 2.173 
produced the 1:1 mixture of hydroxyallylsilane 2.174. Initial attempts to separate the 
mixture of diastereomers using silica gel column chromatography under numerous 
solvent systems failed. Although it was found that the mixture could be separated using 
preparative thin layer chromatography eluting with with 1% EtOAc in benzene, the 
separation proved to be impractical on large scale. Alternatively, the mixture of alcohols 
was oxidized to ketone 2.175 and was envisioned to asymmetrically reduce to an alcohol 
either using a chiral reagent or using substrate directed reduction. Use of a external chiral 
reagent such as the CBS catalyst was ineffective.
35
 Despite the absence of any literature 
precedence, it was anticipated that the pyran oxygen could direct a 1,3  chelation assisted 
reduction of the ketone. Samarium iodide is known for 1,3 anti or sometimes syn 
reduction to beta keto alcohols and has been successfully used in the total synthesis of 
Epothilone.
36
 Unfortuantely, the ketone 2.175 was completely inert to samarium iodide 
reduction. Application of Evans-Saksena reaction did not provide any product and the 
starting material was recovered.
37
 A metal hydride with stronger chelating ability such as 
ZnBH4 was also ineffective. Other hydrides such as LiBH4, DIBAL-H and LiAlH4 
resulted in the formation of 1:1 diastereometic mixture of alcohols along with reduction 
of the thioester and acetates.  
The metal hydrides used thus far were either not able to reduce the ketone or also 
reduced the esters with no selectivity in either case. However, when the reduction was 
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Figure 2.38. Alternative Synthesis of A-ring Silane 2.147 
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Cerium chloride is an additive known to chelate the ketone in the Luche reduction 
of -unsaturated ketones and it was thought that it could probably chelate with both the 
pyran and ketone oxygens.
38
 In the event, we were astonished to find that reduction of the 
ketone 2.175 under Luche condition in fact afforded the alcohol in good yield with 
moderate selectivity. Attempts to improve the selectivity of the reduction by maintaining 
the reaction temperature at -78°C or -42°C did not have any effect and the reaction did 
not go to completion. At the present moment, the origin of the selectivity of the ketone 
reduction under Luche condition is not fully understood, but the chelation of both pyran 
and ketone oxygen by cerium and an intermolecular hydride delivery from the beta face 
seems to be the most logical explanation. 
With the successful reduction of the ketone, verification of the stereochemistry of 
the alcohol 2.147 using a chemical method was addressed next (Figure 2.39). The A-B-
ring compound 2.177 had been prepared and characterized previously (Figure 2.39-a).
39
 
A pyran annulation of the hydroxy allylsilane 2.147 with the aldehyde 2.178 would give 
the same compound 2.178 and their NMR could be compared. Unfortunately, the reaction 
with aldehyde 2.178 failed and no desired product was isolated. Therefore, a similar 
approach was adjusted whereby the diastereomerically pure bispyran compound 2.180 
was prepared using a pyran annulation reaction between the aldehyde and a known silane 
2.179. Another pyran annulation using the 4:1 mixture of hydroxyallylsilane 2.147 and 
hydrocinnamaldehyde 2.181 provided the compound 2.182. It should be noted that 
although the compound 2.182 has two unknown stereocenters with a possibility of 4 
diastereomers, only two isomers can result in which both substituents at 2 and 4 positions 
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C NMR of the major isomer of bispyran 2.182 matched with that of authentic 
compound 2.180 thus confirming that the major isomer of the alcohol 2.147 had the 
desired stereochemistry. The synthesis of A-ring hydroxy allylsilane 2.147 was thus 
completed in 17 steps (longest linear sequence) from aldehyde 2.173. The synthesis is 
based on the substrate controlled generation of stereocenters and required only one chiral 
material to install the C5 stereocenter. All remaining four stereocenters were installed 
with the help of the C5 stereocenter in a highly substrate controlled manner.  
 
A Convergent Synthesis of C-ring Aldehyde 
With the preparation of the A-ring hydroxyallylsilane 2.147 accomplished, we 
focused our attention toward the synthesis of the C-ring aldehyde 2.146 (Figure 2.40). 
This required the preparation of glycal 2.157 which could be derived from the thioester 
2.184 used during the synthesis of bryostatin analogues. Although the glycal 2.157 could 
be prepared in gram scale, frequent requirement of this material in multigram quantities 
for all bryostatin projects demanded a more concise synthesis. The only real drawback in 
the route to the dihydropyran 2.157 was the linear nature of its synthesis. Thus any 
improvement in the existing route would require a convergent approach for the synthesis 
of this material. 
The presence of the glycal moiety in the intermediate 2.157 led us to consider its 
formation by a more direct method instead of the existing route that involves the 
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Figure 2.40. Comparison of Two Routes Towards Glyca12.157 (a) old, (b) new 
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methods used to generate the cyclic enol ether is the Takai-Utimoto ester olefin 
cyclization and has been successfully used during the total synthesis of various natural 
products.
40 
An important modification to the original Takai-Utimoto reaction was 
developed by Professor Jon D. Rainier at the University of Utah in which they use 
dibromoethane instead of dibromomethane.
41 
Use of this alternative halide dramatically 
increased the ratio of cyclic versus acyclic enol ether products. If we could apply this 
Rainier metathesis reaction in the synthesis of the dihydropyran 2.157, this would make 
use of ester 2.158 as a precursor. Such an ester could be easily generated by a convergent 
esterification using a relatively simple alcohol and acid. Moreover, the alcohol fragment 
2.160 was prepared in just six steps during the synthesis of bryostatin analogues. This 
new approach would not only signigicantly reduce the number of steps to achieve glycal 
2.157, but also make the synthesis highly convergent.  
Approach towards the synthesis of glycal 2.157 was developed by another 
graduate student Thomas J. Cummins and by the author.
42
 Briefly, the acid fragment 
2.159 was synthesized in four steps from commercially available methyl isobutyrate 
2.185 (Figure 2.41). Alkylation of the ester 2.185 followed by a free radical bromination 
provided the allyl bromide 2.186 . The bromine was displaced with t-
butyldimethylsilanol in the presence of silver triflate. Basic hydrolysis of the methyl ester 
furnished the acid fragment 2.159 which was esterified with the previously known 
alcohol 2.160. The olefin was subjected to hydroboration/oxidation reaction and the 
resulting alcohol was oxidized to an aldehyde. A one carbon homologation of the 
aldehyde using Wittig reaction prepared the olefin. Subjection of the ester olefin 2.158 to 






Difficulties associated with the late stage functionalization of the C-ring in 
tricyclic compound during the synthesis of bryostatin analogous led us to consider 
functionalization of it before pyran annulation. Of the most difficult reactions during 
analogue synthesis was the aldol reaction between the C-ring ketone and methyl 
glyoxylate (Figure 2.42). This was due to a competitive aldol reaction taking place on the 






on a C-ring compound prior to coupling with A-ring silanes. Such an early 
functionalization would also make the synthesis highly convergent. Thus the epoxidation 
of the glycal 2.157 using MMPP followed by in situ opening with methanol furnished a 
methoxy alcohol compound which was immediately oxidized to a ketone using Ley 
oxidation (Figure 2.43).
43
 An aldol condensation between the ketone 2.156 and freshly 
distilled methylglyoxyolate provided the ,-unsaturated ester 2.193 as single 
geometrical isomer in excellent yield. The ketoester 2.193 possessed a characteristic 
bright yellow color and was found to be unstable for long term storage or for carrying this 





Luche condition providing the alcohol as single diastereomer which was also found 
unstable for purification using silica gel chromatography. This required the protection of 
the alcohol with some protecting group. Conversion of the alcohol into an ester having 
the ,-unsaturated bryostatin side chain was not applicable because it could not be  
differentiated from the B-ring olefin for the oxidative cleavage step that would be 
required. Attempted conversion of the alcohol into a silyl ether using TBSCl was 
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unsuccessful whereas use of TESOTf provided a low yield of the desired product due to 
the sensitive nature of the alcohol starting material. Use of protecting groups such as 
trifluoroacetate or chloroacetate provided the desired esters but the esters turned out to be 
unstable for subsequent transformations. Hoping that the C20 and C7 acetate could be 
differentiated later in the synthesis, the C20 alcohol was converted into its acetate. 
Removel of the TBS group under standard condition followed by oxidation of the 
resulting alcohol completed the synthesis of fully functionalized aldehyde in 18 steps 
(longest linear sequence). 
During the synthesis of Merle 32 it was observed that the basic methanolysis of 
the C7 acetate was slow and took 6 h to complete, but occured without any side reactions 
such as transesterification of the macrolactone ester (Figure 2.44). When the acetate 
2.194 was subjected to the same reaction condition, interestingly, the acetate group was 
removed in just 1 h indicating that the C20 acetate was at least five times more reactive 
than the C7 acetate. The difference in the reactivity of these two acetates is presumably 
due to the activation of the C20 acetate by an inductive effect of the surrounding groups. 
Thus the conversion of C20 alcohol into its acetate might permit its selective removal in 
the presence of the C7 acetate for the synthesis of bryostatin 1 (vide infra). Moreover, 
both the acetates could be kept for the synthesis of bryostatin 7. If this selective removal 
of C20 acetate is successful, this would allow the synthesis of other members of the 
bryostatin family that have acetate at C7 position and different esters at the C20 position. 








Coupling of the A and the C-ring and the Completion of Bryostatin 1 
With both fragments in hand, A-ring hydroxyallylsilane 2.147 and and C-ring 
aldehyde 2.146 were subjected for the crucial pyran annulations (Figure 2.45). The 
reaction provided the tricyclic compound 2.199 in good yield. Along with the usual side 
reactions such as TMS protection of the hydroxyl group and protodesilation of the 
allylsilane, few other side reactions were noticed. The major by product was found to 
result from an inramolecular cyclization of the hydroxy allylsilane to the C9 position 
leading to the formation of a spirocyclic compound. Attempts to isolate this side product 
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Figure 2.45. Attempted Preparation of the Seco Acid 
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spectrum. Efforts to eliminate the intramolecular cyclization of the allylsilane by 
concentrating the reaction mixture or increasing the number of equivalents of the 
aldehyde partner were fruitless. Partial decomposition of the aldehyde 2.146 and silane 
2.147 was also noticed if the temperature of the reaction was increased to 40 °C or above. 
 Advancement of the tricycle 2.199 required the regioselective cleavage of the 
exocyclic B-ring olefin in the presence of an internal olefin and the exocyclic olefin on 
the C-ring. Studies during the synthesis of bryostatin analogue Merle 30 showed that 
ozonolysis or osmylation were unselective for these two olefins. However, the exocyclic 
olefin could be cleaved selectively by carefully treating the bisolefin with a solution of 
ozone followed by dimethyl sulfide.
29
 When these conditions were applied to bisolefin 
2.199, the reaction was completely unselective. It should be noted that the major 
difference between those two substrates is the presence of an extra methoxy group at the 
C9 position and a full functionalized C-ring in 2.199. The reason for the failure to 
selectively ozonize the exocyclic olefin in the compound 2.199 is not fully understood 
but it is most likely due to the blockage of the exocyclic olefin by the C9 methoxy group. 
However, it was later found that the C13-C30 olefin could be selectively oxidized to a diol 
using Sharpless reagent.
44
 Thus, the regioselective dihydroxylation of the B-ring under 
Sharpless condition followed by oxidative cleavage provided the ketone 2.200 in good 
yield. Either AD mix- or AD mix-were equally effective for the dihydroxylation 
reaction. Removal of the PMB group under oxidative conditions provided the alcohol 
2.201. Subjection of the thioester 2.201 to hydrolysis conditions using mCPBA in 
THF/water gave a complex mixture of products which lacked the S-tBu signal in the 
1
H- 
NMR. The proton NMR also showed the absence of the C9 methoxy group indicating that 
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the hydrolysis of the methylketal had also occurred. Attempts to convert the mixture of 
products into a single compound and to restore the C9 methylketal using PPTS/MeOH or 
CSA/MeOH led to complete decomposition. 
 Since the hydrolysis of the thioester under slightly acidic conditions using 
mCPBA in THF/H2O was unsuccessful, an alternative route towards the seco acid was 






discovered that LiOH/H2O2 mediated thioester hydrolysis could be carried out in the 
presence of other esters and the C9 methylketal in the presence of free C3 alcohol.
28
 Thus, 
the BPS group at C3 position as removed using buffered HF•py in THF/methanol. Use of 
methanol during the BPS deprotection was necessary to avoid the hydrolysis of C9 and 
C19 methylketals. Hydrolysis of the thioester 2.202 took place smoothly using 
LiOH/H2O2 providing the hydroxy acid intermediate. Treatment of such hydroxy acid 
with TESCl protected both the alcohol and the carboxylic acid and selective removal of 
the TES ester occurred during workup and silica gel column chromatography providing 
the carboxylic acid 2.203. The PMB group was removed using DDQ providing the seco 
acid which was subjected to Yamaguchi esterification furnishing the macrolactone 2.204.  
With the macrolactone in hand, Sharpless asymmetric dihydroxylation of the 
bisolefin regioselectively provided the exocyclic diol which was oxidatively cleaved to 
ketone 2.205 (Figure 2.47). An asymmetric Horner-Wadsworth-Emmons reaction on the 
ketone using Fuji‟s chiral BINOL phosponate 2.206 provided a 4:1 mixture of Z:E ,-
unsaturated methyl esters in favor of the desired isomer.
45
 The geometric isomers were 
easily separated using preparative thin layer silica gel chromatography using 10% EtOAc 
in benzene and eluting  twice. When the bisacetate 2.207 was subjected to K2CO3/MeOH, 
we were pleased to find that the selective methanolysis of the C20 acetate occurred in just 
45 min providing the desired alcohol, which proved to be unstable for purification and 
characterization. Threfore, it was immediately esterified with (2E,4E)-octa-2,4-dienoic 
anhydride providing protected bryostatin 1. When the protected bryostatin 1 2.208 was 
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methyketals and a TES group were removed in just 1 h.
46
 Further heating the mixture for 
12 h removed the BOM group leaving the other five esters untouched and provided 
bryostatin 1 in 72% yield. 
 The synthetic bryostatin 1 was found identical to the natural bryostatin 1 in 






C DEPT, high resolution mass and the 
optical rotation. As seen in the literature
47
 and by us, the NMR of the bryostatins is highly 
concentration dependent, presumably due to hydrogen bonding with the solvent. The 
concentration effect is more prominent especially when any amount of H2O or D2O is 
present in the NMR solvents. Thus the comparison of the NMR of synthetic and natural 
bryostatins was carried out under similar concentrations (Figure 2.48 and 2.49). 
In addition to bryostatin 1, our route is also applicable for the synthesis of other 
members of the bryostatin family (Figure 2.50). A global deprotection of the bisacetate 
2.207 using LiBF4 would provide bryostatin 7. Since the C20 acetate can be selectively 
removed in the presence of the C7 acetate, other bryostatins having different esters at C20 
positions can be prepared. For example, esterification of the C20 alcohol with propanoic 
anhydride and subsequent deprotection would provide bryostatin 9. Similarly, 
Esterification of 2.210 with the C20 alcohol followed by global deprotection would 




Current route to bryostatin can also be applied in the synthesis of B and C-ring 
diversified bryostatin analogues (Figure 2.51). The ketone 2.505 is suitably placed for 
independent functionalization on the B and the C-ring. Moreover, conversion of C20 
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K2CO3/MeOH. If successful, this would lead to the synthesis of A-ring diversified 
analogues as well. 
 
Conclusions 
The first total synthesis of bryostatin 1 was accomplished in 30 steps (longest 
linear sequence, 55 total steps) from the R-isobutyl lactate 2.183. The preparation of the 
A-ring hydroxy allylsilane was completed in 17 steps whereas the C-ring aldehyde was 
made in 18 steps. Thus both of these fragments of similar complexity were prepared in 
almost the same number of steps. A highly convergent union of these two fragments 
constructed the macrocycle which after 11 chemical transformations furnished bryostatin 
1.  
Our synthesis of bryostatin is distinct from other existing syntheses in many 
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aspects, most notable of these being the assembly of the B-ring pyran of the bryostatin 
through a highly convergent union of fully functionalized A and C-ring fragments. This 
represents one of the most complex pyran annulation reactions to date. The gem-dimethyl 
group on the A-ring was installed through the addition of a novel stannane reagent in a 
stereoselective fashion. The synthesis is heavily based on stereoselective carbon-carbon 
bond formation utilizing substrate mediated 1,2 or 1,3 chelation controlled reactions. All 
11 sp
3
 stereocenters were installed using only two chiral reagents, highlighting the highly 
substrate controlled nature of the synthesis.  
 
Graphical Summary of Total Syntheses of Bryostatins 
A graphical summary of the total syntheses of various bryostatins is shown in 
Figure 2.52, 2.53, 2.54, 2.56 and 2.57. Our total synthesis of bryostatin 1 utlizes a 
convergent coupling of fully functionalized A- and the C-ring to construct the B-ring. On 
the other hand, Masamune, Evans and Yamamura use the same basic disconnection in 
which the A-B ring system is connected to the C-ring using Julia coupling. Trost‟s 
synthesis of bryostatin 16 is based on the alkane-alkyne coupling to construct the B-and 
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General Experimental Procedures, Materials and Instrumentation 
Solvents were purified according to the guidelines in Purification of Common 
Laboratory Chemicals (Perrin, Armarego, and Perrin, Pergamon: Oxford, 1966).
48
 
Diisopropylamine, diisopropylethylamine, pyridine, triethylamine, EtOAc, MeOH, and 
CH2Cl2 were distilled from CaH2.  The titer of n-BuLi was determined by the method of 
Eastham and Watson.
49
 All other reagents were used without further purification.  Yields 
were calculated for material judged homogenous by thin layer chromatography and 
nuclear magnetic resonance (NMR).  Thin layer chromatography was performed on 
Merck Kieselgel 60 Å F254 plates or Silicycle 60Å F254 eluting with the solvent indicated, 
visualized by a 254 nm UV lamp, and stained with an ethanolic solution of 12-
molybdophosphoric acid, or 4-anisaldehyde.  Flash column chromatography was 
performed with Silicycle Flash Silica Gel 40 – 63 µm or Silicycle Flash Silica Gel 60 – 
200 µm, slurry packed with 1% EtOAc/hexanes in glass columns. Preparative thin layer 
chromatography was performed on Silicycle 60Å F254 20 cm × 20 cm × 250 μm plates. 
Glassware for reactions was oven dried at 125 C and cooled under a dry nitrogen 
atmosphere prior to use.  Liquid reagents and solvents were introduced by oven dried 
syringes through septum-sealed flasks under a nitrogen atmosphere.  Nuclear magnetic 
resonance spectra were acquired at 500 MHz for 
1
H and 125 MHz for 
13
C.  Chemical 
shifts for proton nuclear magnetic resonance (
1
H NMR) spectra are reported in parts per 
million relative to the signal of relative to the signal of residual CHCl3 at 7.27 ppm.  
Chemical shifts for proton nuclear magnetic resonance (
1
H NMR) spectra are reported in 
parts per million relative to the signal residual CDCl3 at 7.27 ppm .  Chemical shifts for 
carbon nuclear magnetic resonance (
13
C NMR and DEPT) spectra are reported in parts 
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per million relative to the center line of the CDCl3 triplet at 77.23 ppm. Chemical shifts 
of the unprotonated carbons („C‟) for DEPT spectra were obtained by comparison with 
the 
13
C NMR spectrum.  The abbreviations s, d, apd, dd, ddd, dddd, t, td, tt, q, dq, and m 
stand for the resonance multiplicity singlet, doublet, apparent doublet, doublet of 
doublets, doublet of doublet of doublets, doublet of doublet of doublet of doublets, 
doublet of doublet of doublets of doublets, triplet, triplet of doublets, triplet of triplets, 
quartet, doublet of quartets, and multiplet, respectively.  Optical rotations (Na D line) 
were obtained using a microcell with 1 dm path length.  Specific rotations ([] , Unit: 
°cm
2
/g)  are based on the equation  = (100·)/(l·c)  and are reported as unit-less 
numbers where the concentration c is in g/l00 mL and the path length l is in decimeters.  
Mass spectrometry was performed at the mass spectrometry facility of the Department of 
Chemistry at The University of Utah on a double focusing high resolution mass 
spectrometer. Compounds were named using using ChemDraw 12.0. 
 
Experimental Procedures and Analytical and Data  
 Preparation of ((2S,4S,6S)-6-((R)-2-((tert-
butyldiphenyl silyl)oxy) -4-(tert-butylthio)-4-oxobutyl)-2-(2-hydroxy-4-
((trimethylsilyl)methyl) pent-4-en-1-yl)-2-methoxy-3,3-dimethyltetrahydro-2H-
pyran-4-yl acetate (2.174): To a solution of aldehyde 2.173 (320 mg, 0.48 mmol, 1 
equiv) in toluene (1 mL) in a 4 mL vial was added trimethyl(2-
tributylstannylmethyl)allylsilane (407 mg, 0.97 mmol, 1 equiv) via syringe. The mixture 
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was heated at reflux for 12 h at which time TLC analysis showed the reaction was 
complete. The reaction mixture was allowed to cool to rt and the solvent was removed 
under reduced pressure. Purification was accomplished by flash column chromatography 
using a 2  10 cm silica gel column, eluting with 5% EtOAc/hexanes, collecting 4 mL 
fractions. The product containing fractions (23-66) were combined and concentrated 
under reduced pressure to provide alcohol 2.174 (325 mg, 85%) as a 1:1 mixture of 
diastereomers and as colorless oil. Rf = 0.6 (20% EtOAc/hexanes);   20D  +15 (c = 1.5, 
CHCl3); 500 MHz 
1
H NMR (CDCl3) δ 7.70-7.65 (m, 4H), 7.44-7.36 (m, 6H), 5.06-5.01 
(m, 1H), 4.65-4.61 (m, 2H), 4.28-4.19 (m, 1H), 4.10-3.88 (m, 1H), 3.49-3.44 (m, 1H), 
3.13-3.11 (m, 1H), 3.01 (s, 3H), 2.75-2.57 (m, 2H), 2.21-2.13 (m, 1H), 2.02 (s, 3H), 2.00-
1.47 (m, 9H), 1.44-1.43 (m, 9H), 1.03 (s, 9H), 0.90-0.82 (m, 6H), 0.04-0.03 (m, 9H); 125 
MHz 
13
C NMR (CDCl3) δ 197.7, 197.6, 173.1, 170.6, 170.5, 144.6, 144.3, 136.0, 135.9, 
134.0 (2), 133.7, 133.6, 129.9 (3), 127.8 (3), 110.3 (2), 105.3, 104.8, 73.3, 73.2, 
68.8, 68.5, 67.0, 66.8, 66.3, 66.2, 52.5, 52.2, 49.0, 48.3 (2), 48.1, 46.6, 46.1, 43.8, 43.6, 
42.4, 42.0, 39.5, 37.9, 32.7, 31.7, 29.9 (2), 27.1, 27.0, 26.9, 21.4, 20.6, 20.4, 19.5 (2), 
17.5, 16.8, -1.12, -1.14; 125 MHz DEPT 
13
C NMR (CDCl3) CH3 δ 51.3, 50.3, 32.2 (2), 
29.4, 23.6, 22.8, 22.6, 19.8, 19.1, -1.14; CH2 δ 112.6 (2), 54.7, 54.5, 48.8, 48.4, 46.1, 
45.9, 41.8, 40.1, 35.0, 29.3, 29.2, 25.1; CH0 δ 138.3, 138.2, 132.2, 130.1, 75.6, 75.4, 71.0, 
70.8, 69.3, 69.1, 68.6, 68.5; IR (neat) 3071, 2956, 2858, 1742, 1680, 1472, 1427, 1364, 
1246, 1111, 1074, 1027, 976, 849, 739, 703 cm
-1
; HRMS (ESI/APCI) calcd for 




 Preparation of (2S,4S,6S)-6-((R)-2-((tert-
butyldiphenylsilyl)oxy)-4-(tert-butylthio)-4-oxobutyl)-2-methoxy-3,3-dimethyl-2-(2-
oxo-4-((trimethylsilyl) methyl)pent-4-en-1-yl)tetrahydro-2H-pyran-4-yl acetate 
(2.175): To a stirring solution of alcohol 2.174 (325 mg, 0.414 mmol, 1.0 equiv) in 
CH2Cl2 (4 mL) in a 15 mL rb flask at -15 C, was added freshly distilled N,N-
diisopropylethylamine (504 µL, 2.8 mmol, 7.0 equiv), dropwise via syringe. After 10 min 
at -15 C, dimethyl sulfoxide (293 µL, 4.1 mmol, 10.0 equiv) was added to the reaction 
mixture via syringe and the solution was allowed to stir for an additional 10 min. Sulfur 
trioxide pyridine complex (263 mg, 1.6 mmol, 4.0 equiv) was then added in one portion. 
The reaction was allowed to proceed for 1 h at -15 C, after which time TLC analysis 
indicated complete consumption of starting material. The reaction mixture was diluted 
with EtOAc (10 mL) and quenched by the addition of saturated aqueous NaHCO3 
solution (10 mL). The layers were separated and the aqueous layer was extracted with 
EtOAc (2 10 mL). The combined organic layers were washed with brine (2  10 mL), 
dried over MgSO4, filtered, and concentrated under reduced pressure. Purification was 
accomplished by flash column chromatography on a 2  8 cm column, eluting with 5% 
EtOAc/hexanes, collecting 4 mL fractions. The product containing fractions (16-26) were 
combined and concentrated under reduced pressure to give the ketone 2.175 (301 mg, 
93% yield) as a white foam.  Rf = 0.37 (10% EtOAc/hexanes);   20D  +8 (c = 1.0, 
CHCl3); 500 MHz 
1
H NMR (CDCl3) δ 7.69-7.65 (m, 4H), 7.45-7.36  (m, 6H), 4.99 (dd, J 
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= 11.7, 5.1 Hz, 1H), 4.70 (s, 1H), 4.67 (s, 1H), 4.23 (q, J = 6.4 Hz, 1H), 3.55 (dddd, J = 
9.9, 6.7, 6.7, 3.3 Hz, 1H), 3.15-3.07(m, 3H), 3.07 (s, 3H), 2.77 (d, J = 13.5, 2H), 2.68 (dd, 
J = 14.6, 6.5 Hz, 1H), 2.61 (dd, J = 14.2, 5.1 Hz, 1H), 2.14 (d, J = 16.9 Hz, 2H), 2.01 (s, 
3H), 1.79-1.73 (m, 1H), 1.52 (d, J = 2.5 Hz, 2H), 1.44 (s, 9H), 1.03 (s, 9H), 0.94 (s, 3H), 
0.80 (s, 3H), 0.03 (s, 9H) ; 125 MHz 
13
C NMR (CDCl3) δ 206.1, 197.6, 170.5, 141.2, 
136.1, 135.9, 134.2, 133.6, 129.9, 129.8, 127.8(2), 112.3, 104.4, 73.1, 68.8, 66.2, 54.3, 
52.6, 49.2, 48.2, 44.3, 43.6, 42.5, 32.6, 29.9, 27.1, 26.6, 21.3, 20.6, 19.5, 17.4, -1.1 ; 125 
MHz DEPT 
13
C NMR (CDCl3) CH3 δ 49.2, 29.9, 27.1, 21.4, 20.6, 17.4, -1.1; CH2 δ 
112.3, 54.3, 52.6, 44.3, 43.6, 32.6, 26.6; CH1 δ 136.1, 136.0, 130.0, 129.9, 127.8 (2), 
73.1, 68.8, 66.2,; CH0 δ 206.1, 197.6, 170.5, 141.2, 134.2, 133.6, 129.8, 104.4, 73.1, 48.2, 
42.5, 19.5; IR (neat) 3049, 2956, 2858, 1740, 1679, 1631, 1472, 1427, 1389, 1365, 1246, 
1111, 1074, 1028, 996, 849, 759, 703, 611 cm
-1
; HRMS (ESI/APCI) calcd for 
C43H66NaO7SSi2 (M+Na): 805.3966, found: 805.3965. 
 Preparation of (2S,4S,6S)-6-((R)-2-((tert-
butyl diphenylsilyl)oxy)-4-(tert-butylthio) -4-oxobutyl)-2-((S)-2-hydroxy -4-
((trimethylsilyl) methyl) pent-4-en-1-yl)-2-methoxy-3,3-dimethyltetrahydro-2H-
pyran-4-yl acetate (2.147): To a stirring solution of ketone 2.175 (206 mg, 0.263 mmol, 
1.0 equiv) in MeOH (26 mL, 0.01 M) in a 50 mL rb flask at rt was added CeCl3·7H2O 
(1.9 g, 5.3 mmol, 20 equiv). The mixture was stirred until all the CeCl3·7H2O was 
completely dissolved.  The mixture was then cooled to -42 ºC and stirred for 10 min, and 
then NaBH4 (100 mg, 2.63 mmol, 10.0 equiv) was added. Stirring continued for 5 h at       
305 
 
-42 ºC after which the reaction was warmed to 0 ºC and stirred for an additional 1 h, then 
quenched by the slow addition of saturated aqueous NH4Cl solution (5 mL) and diluted 
with 40% EtOAc/hexanes (10 mL). The layers were separated and the aqueous layer was 
extracted with 40% EtOAc/hexanes (2  10 mL). The organic phase was washed with 
brine (5 mL), then dried over Na2SO4, filtered and concentrated under reduced pressure. 
Purification was accomplished by flash column chromatography on a 2  7 cm column, 
eluting with 5% EtOAc/hexanes, collecting 4 mL fractions. The products containing 
fractions (21-48) were combined and concentrated under reduced pressure to give the 
alcohol 2.147 (171 mg, 82% yield) as a 4:1 mixture of diastereomers as measured by 
NMR. For analytical purpose, a small portion of the mixture of diastereomers was further 
purified using preparative thin layer chromatography eluting with 1% EtOAc in benzene 
to give the pure desired major isomer as a colorless oil: Rf = 0.3 (10% EtOAc/hexanes); 
  20D  +16.7 (c = 1.1, CHCl3); 500 MHz 
1
H NMR (CDCl3) δ 7.70-7.64 (m, 4H), 7.45-
7.36  (m, 6H), 5.04 (dd, J = 11.7, 4.8 Hz, 1H), 4.66-4.61 (m, 2H), 4.25 (q, J = 5.8 Hz, 
1H), 4.07 (q, J = 7.3 Hz, 1H), 3.46 (dddd, J = 10.3, 8.3, 5.4, 3.5 Hz, 1H), 3.13(s, 1H), 
3.01 (s, 3H), 2.73 (dd, J = 14.6, 6.3, 1H), 2.63 (dd, J = 14.6, 6.3 Hz, 1H), 2.18 (dd, J = 
13.6, 5.8 Hz, 1H), 2.02 (s, 3H), 1.94 (dd, J = 13.1, 6.8 Hz, 1H), 1.81-1.76 (m, 4H), 1.54 
(d, J = 1.4 Hz, 2H), 1.44 (s, 9H), 1.03 (s, 9H), 0.90 (s, 3H), 0.82 (s, 3H), 0.04 (s, 9H) ; 
125 MHz 
13
C NMR (CDCl3) δ 197.0, 170.6, 144.4, 136.1, 136.0, 134.0, 133.7, 130.0, 
129.9, 127.8(2), 110.3, 104.8, 73.2, 68.8, 67.1, 66.3, 52.5, 49.0, 48.3, 46.1, 43.8, 42.0, 
39.5, 32.8, 29.9, 27.1, 21.4, 20.4, 19.5, 17.6, -1.1; 125 MHz DEPT 
13
C NMR (CDCl3) 
CH3 δ 49.0, 29.9, 27.1, 21.4, 20.4, 17.6, -1.1; CH2 δ 110.3, 52.5, 46.1, 43.8, 39.5, 32.8, 
29.9; CH1 δ 136.1, 136.0, 130.0(2), 127.9(2), 73.2, 68.8, 67.1, 66.3; CH0 δ 197.8, 
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170.6, 144.4, 134.0, 133.7, 104.8, 48.3, 42.0, 19.5; IR (neat) 2956, 2858, 1742, 1680, 
1427, 1366, 1246, 1111, 1074, 1027, 849, 703 cm
-1
; HRMS (ESI/APCI) calcd for 
C43H68NaO7SSi2 (M+Na): 807.4122, found: 807.4120. 
Verification of stereochemistry at the C11 position of the compound 2.147: In 
order to verify the stereochemistry of the C11 alcohol, a pyran annulation was carried out 
between the silane 2.147 and hydrocinnamaldehyde using TMSOTf to furnish the 
compound 2.182 (Figure 2.57). On the other hand, an authentic compound 2.180 with 
known stereochemistry at C11 was prepared independently using a different pyran 
annulation between the aldehyde 2.173 and the known silane 2.179. Since the pyran 
annulation takes place with retention of configuration at the alcohol center and the NMR 






CDCl3 and C6D6. This verifies that the hydroxyl group at the C11 position of the major 
isomer of compound 2.147 has the desired configuration.  
 Preparation of (2S,4S,6S)-6-((R)-2-((tert-butyl 
diphenylsilyl)oxy)-4-(tert-butylthio)-4-oxobutyl)-2-methoxy-3,3-dimethyl-2-(((2S,6S)-
4-methylene-6-phenethyltetrahydro-2H-pyran-2-yl)methyl)tetrahydro-2H-pyran-4-
yl acetate (2.180): To a stirring solution of aldehyde 2.173 (21 mg, 0.032 mmol, 1.0 
equiv) and hydroxyallylsilane 2.179 (8 mg, 0.032 mmol, 1.0 equiv) in Et2O (460 µL) in a 
flame dried 5 mL vial at -78 ºC was added a solution of TMSOTf in Et2O (38 μL of 1.0 
M,, 0.038 mmol, 1.2 equiv) via syringe. After 3 h at -78 ºC, the reaction mixture was 
quenched by the addition of N,N-diisopropylethylamine, followed by the addition of 
saturated aqueous NaHCO3 solution. The mixture was warmed to rt, the phases were 
separated, and the aqueous phase was extracted twice with Et2O. The organic phases 
were combined, dried over Na2SO4 and concentrated under reduced pressure. Purification 
was accomplished by flash column chromatography eluting with hexanes/EtOAc (7:3) to 
provide the pyran 2.180 (16 mg, 61%) as a white foam.  Rf = 0.4 (10% EtOAc/hexanes); 
  20D  +18 (c = 1.1, CHCl3); 500 MHz 
1
H NMR (CDCl3) δ 7.70-7.65 (m, 4H), 7.44-
7.18 (m, 11H), 4.97 (dd, J = 11.7, 4.8 Hz, 1H), 4.68 (dd, J = 7.8, 1.9 Hz, 2H),  4.26 (sep, 
J = 3.9 Hz, 1H), 3.42 (dddd, J = 7.4, 5.4, 3.4, 1.9 Hz, 1H), 3.21-3.17 (m, 1H), 2.98(s, 
3H), 2.85 (ddd, J = 14.1, 10.7, 5.3 Hz, 1H), 2.76 (dd, J = 14.6, 4.3 Hz, 1H), 2.71 (dd, J = 
14.6, 7.3 Hz, 1H), 2.58 (ddd, J = 13.6, 10.2, 6.3 Hz, 1H), 2.23 (d, J = 13.1 Hz, 1H), 2.15 
(d, J = 13.1 Hz, 1H),  2.01 (s, 3H), 1.99-1.86 (m, 3H), 1.84-1.64 (m, 5H), 1.45 (s, 9H), 
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1.43 (d, J = 1.9 Hz, 1H), 1.32-1.26 (m, 2H), 1.02 (s, 9H), 0.93 (s, 3H), 0.87 (s, 3H); 125 
MHz 
13
C NMR (CDCl3) δ 198.1, 170.7, 145.0, 142.6, 136.1, 136.0, 134.4, 133.6, 129.9, 
129.8, 128.6, 128.5, 127.8, 127.7, 125.8, 108.6, 104.0, 77.5, 74.6, 73.9, 69.5, 66.0, 53.2, 
48.2(2), 43.7, 42.4, 41.9, 40.8, 39.2, 38.6, 32.8, 32.2, 30.0, 27.1, 21.4, 20.8, 19.5, 16.9; 
125 MHz DEPT 
13
C NMR (CDCl3) CH3 δ 48.2, 30.0, 27.1, 21.4, 20.8, 16.9; CH2 δ 108.6, 
53.2, 43.7, 42.4, 40.8, 39.2, 38.6, 32.8, 32.2; CH1 δ 136.1, 136.0, 129.9, 129.8, 128.6, 
128.5, 127.8, 127.7, 125.9, 77.5, 74.6, 73.9, 69.5, 66.0; CH0 δ 198.1, 170.7, 145.0, 142.6, 
134.6, 133.6, 104.0, 48.2, 41.9, 19.5; IR (neat) 3050, 2932, 2858, 1742, 1682, 1455, 
1427, 1364, 1243, 1110, 890, 822, 739, 701, 611cm
-1
; HRMS (ESI/APCI) calcd for 
C49H68NaO7SSi (M+Na): 851.4353, found: 851.4362. 
 Preparation of (2S,6S)-6-((2R,3R)-3-((benzyloxy) 
methoxy)-2-((4-methoxybenzyl)oxy)butyl)-2-((E)-5-((tert-butyldimethylsilyl)oxy)-2-
methylpent-3-en-2-yl)-2-methoxydihydro-2H-pyran-3(4H)-one (2.156): To a stirring 
solution of dihydropyran 2.157 (100 mg, 0.16 mmol, 1.0 equiv) in CH2Cl2 (1.6 mL) at 0 
°C was added MeOH (0.8 mL). Powdered NaHCO3 (34 mg, 0.4 mmol, 2.5 equiv) was 
added in one portion and the solution was stirred at 0 °C for 10 min. Magnesium 
monoperoxyphthalate (80%, 197 mg, 0.32 mmol, 2.0 equiv) was added slowly and the 
mixture was stirred for 1 h at 0 °C. The reaction mixture was then quenched by the 
addition of saturated aqueous NaHCO3 solution (5 mL), diluted with EtOAc (5 ml) and 
the layers were separated. The aqueous layer was extracted with EtOAc (3  5 mL). The 
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combined organic layers were washed with water (5 mL), and with brine (5 mL), then 
dried over Na2SO4, filtered, concentrated, and taken into the next step without further 
purification. 
 To this intermediate alcohol in CH2Cl2 (3 mL), at rt, were added 4 Å molecular 
sieves (200 mg), TPAP (6 mg, 0.016 mmol, 0.1 equiv), and 4-methylmorpholine-N-oxide 
(56 mg, 0.48 mmol, 3.0 equiv). The mixture was stirred at rt for 1 h and then diluted with 
EtOAc (10 mL). The mixture was then filtered through a small plug of Florisil
®
 and 
washed with copious amounts of EtOAc. The solvent was removed under reduced 
pressure and purification was accomplished by flash column chromatography, using a 2  
7 cm silica gel column, eluting with 15% EtOAc/hexanes, collecting 4 mL fractions. The 
product containing fractions (14-27) were combined and concentrated under reduced 
pressure to provide methoxyketone 2.156 (74 mg, 68% over 2 steps) as a colorless oil.  Rf 
= 0.4 (10% EtOAc/hexanes);   20D  +10.3 (c = 1.1, CHCl3); 500 MHz 
1
H NMR 
(CDCl3) δ 7.37-7.20 (m, 7H), 6.85-6.83 (m, 2H), 5.97 (dt, J = 15.6, 1.9 Hz, 1H), 5.49 (dt, 
J = 16.1, 4.8 Hz, 1H), 4.85 (d, J = 6.8 Hz, 1H), 4.83 (d, J = 7.3 Hz, 1H), 4.66 (s, 2H), 
4.62 (d, J = 11.2 Hz, 1H), 4.44 (d, J = 10.7 Hz, 1H), 4.14 (dd, J = 5.3, 1.4 Hz, 2H), 4.12-
4.06 (m, 2H), 3.87 (ddd, J = 10.2, 4.8, 1.9 Hz, 1H), 3.79 (s, 3H), 3.22 (s, 3H), 2.42 (dd, J 
= 8.5, 5.6 Hz, 2H),  1.99-1.85 (m, 3H), 1.65 (ddd, J = 13.1, 10.2, 2.9 Hz, 1H), 1.21 (d, J = 
6.3 Hz, 3H), 1.13 (s, 3H), 1.09 (s, 3H), 0.90 (s, 9H), 0.06 (s, 3H), 0.05 (s, 3H); 125 MHz 
13
C NMR (CDCl3) δ 207.6, 159.3, 138.0, 136.1, 130.7, 129.4, 128.6, 128.0, 127.9, 127.8, 
114.0, 104.2, 93.5, 77.3, 72.6, 72.1, 70.1, 69.6, 64.2, 55.4, 52.3, 44.1, 37.7, 36.4, 30.2, 
26.1, 22.9, 22.1, 18.5, 14.9, -4.9; 125 MHz DEPT 
13
C NMR (CDCl3)  CH3 δ 55.4, 52.3, 
26.1, 22.9, 22.1, 14.9, -4.9; CH2 δ 93.5, 72.1, 69.6, 64.2, 37.7, 36.4, 30.2; CH δ 136.1, 
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129.4, 128.6, 127.9, 127.8, 127.7, 113.9, 77.3, 72.6, 70.1; CH0 δ 207.6, 159.3, 138.0, 
130.7, 104.2, 44.1, 18.5. IR (thin film) 2953, 2856, 1723, 1612, 1513, 1462, 1382, 1249, 
1112, 1042, 836, 777, 737, 698 cm
-1
; HRMS (ESI) calcd for C38H58NaO8Si (M+Na) 
693.3799, found 693.3802. 
Preparation of (E)-methyl 2-((2S,6S)-6-((2R,3R)-3-
((benzyloxy) methoxy)-2-((4-methoxybenzyl)oxy)butyl)-2-((E)-5-((tert-butyldimethyl 
silyl)oxy)-2-methylpent-3-en-2-yl)-2-methoxy-3-oxodihydro-2H-pyran-4(3H)-
ylidene) acetate (2.193): To a stirring solution of ketone 2.157(237 mg, 0.35 mmol, 1.0 
equiv) in MeOH (3.5 mL) at rt were added K2CO3 (243 mg, 1.76 mmol, 5 equiv) and a 
solution of freshly distilled methyl glyoxylate in THF (590 µL of 3M, 1.76 mmol, 5 
equiv). The mixture was stirred for 1 h, during which time the color of the solution 
changed to yellow, then quenched by pouring into saturated aqueous NH4Cl solution (10 
mL). Ether (10 mL) was added, the phases were separated, and the aqueous phase was 
extracted with Et2O (3  10 mL). The combined organic phases were dried over Na2SO4, 
filtered and concentrated under reduced pressure. Purification was accomplished by flash 
column chromatography, using a 2  7 cm silica gel column, eluting with 15% 
EtOAc/hexanes, collecting 4 mL fractions. The product containing fractions (6-18) were 
combined and concentrated under reduced pressure to provide enoate 2.193 (210 mg, 
80% ) as a bright yellow oil. Rf = 0.3 (10% Et2O/40% hexanes/50% CH2Cl2);   20D  -
24.1 (c = 1.2, CHCl3); 500 MHz 
1
H NMR (CDCl3) δ 7.37-7.16 (m, 7H), 6.83-6.80 (m, 
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2H), 6.53 (dd, J = 2.9, 1.4 Hz, 1H), 5.80 (td, J = 16.1, 1.4 Hz, 1H), 5.40 (td, J = 16.1, 4.8 
Hz, 1H), 4.85 (d, J = 6.8 Hz, 1H), 4.83 (d, J = 6.3 Hz, 1H), 4.66 (s, 2H), 4.60 (d, J = 10.7 
Hz, 1H), 4.40 (d, J = 11.2 Hz, 1H), 4.15-4.02 (m, 4H), 3.88 (ddd, J = 11.7, 3.9, 1.4 Hz, 
1H), 3.77 (s, 3H), 3.75 (s, 3H), 3.30 (td, J = 17.1, 1.9 Hz, 1H), 3.20 (s, 3H),  2.84 (ddd, J 
= 19.0, 12.6, 3.4 Hz, 1H), 1.95 (ddd, J = 14.6, 9.2, 1.9 Hz, 1H), 1.74 (ddd, J = 12.6, 9.7, 
2.4 Hz, 1H), 1.20 (d, J = 6.3 Hz, 3H), 1.10 (s, 3H), 1.04 (s, 3H), 0.89 (s, 9H), 0.04 (s, 
6H);  125 MHz 
13
C NMR (CDCl3) δ 197.7, 166.1, 159.3, 148.2, 138.0, 134.7, 130.6, 
129.2, 128.7, 128.6, 128.0, 127.8, 122.6, 113.9, 104.7, 93.5, 76.9, 72.3, 71.7, 69.6, 69.5, 
64.1, 55.3, 52.2, 51.8, 44.6, 36.1, 36.0, 26.1, 22.5, 22.0, 18.5, 14.6, -5.0;  125 MHz DEPT 
13
C NMR (CDCl3)  CH3 δ 55.3, 52.2, 51.8, 26.1, 22.5, 21.9, 14.6, -5.0; CH2 δ 93.5, 71.7, 
69.6, 64.0, 36.1, 36.0; CH δ 134.7, 129.2, 128.7, 128.6, 128.0, 127.8,122.6, 113.9, 76.9, 
72.3, 69.5; CH0 δ 197.7, 166.1, 159.3, 148.2, 138.0, 130.6, 104.7, 44.6, 18.5. IR (thin 
film) 2933, 2886, 2856, 1724, 1612, 1513, 1462, 1383, 1178, 835, 777, 739, 698 cm
-1
; 
HRMS (ESI) calcd for C41H60NaO10Si (M+Na) 763.3853, found 763.3856. 
 Preparation of (E)-methyl 2-((2S,3S,6S)-3-acetoxy-
6-((2R,3R)-3-((benzyloxy)methoxy)-2-((4-methoxybenzyl)oxy)butyl)-2-((E)-5-((tert-
butyldime thylsilyl)oxy)-2-methylpent-3-en-2-yl)-2-methoxydihydro-2H-pyran-
4(3H)-ylidene) acetate (2.194): To a stirring solution of ketone 2.103 (554 mg, 0.74 
mmol, 1.0 equiv) in MeOH (74 mL, 0.01 M) at rt was added CeCl3·7H2O (5.6 g, 14.9 
mmol, 20.0 equiv). The resulting mixture was stirred until all the CeCl3·7H2O was 
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completely dissolved. The mixture was then cooled to -42 ºC and stirred for 10 min, then 
NaBH4 (283 mg, 7.47 mmol, 10.0 equiv) was added. Stirring was continued for 1 h at -42 
ºC after which the reaction was quenched by the slow addition of saturated aqueous 
NH4Cl solution (20 mL) and diluted with 40% EtOAc/hexanes (30 mL). The layers were 
separated and the aqueous layer was extracted with 40% EtOAc/hexanes (3  30 mL). 
The organic phase was washed with water (20 mL), and with brine (2  20 mL), then 
dried over Na2SO4, filtered and concentrated under reduced pressure to provide the crude 
intermediate alcohol. The alcohol was found to be unstable for purification, and was thus 
carried directly to the next step without further purification. 
 To a stirring solution of this alcohol in CH2Cl2 (37 mL, 0.02 M) at 0 ºC were 
added pyridine (1.2 mL, 14.9 mmol, 20 equiv), DMAP (91 mg, 0.74 mmol, 1 equiv), and 
acetic anhydride (353 µL, 3.73 mmol, 5 equiv). The reaction mixture was stirred at 0 ºC 
for 3 h and then quenched by the addition of saturated aqueous NaHCO3 solution (20 
mL). The mixture was stirred vigorously for 10 min and was then diluted with 40% 
EtOAc/hexanes (50 mL). The phases were separated and the aqueous phase was extracted 
with 40% EtOAc/hexanes (2  20 mL). The combined organic phases were washed with 
brine (2  20 mL), dried over Na2SO4, filtered, and concentrated under reduced pressure. 
Purification was accomplished by flash column chromatography using a 3  8 cm silica 
gel column, eluting with 10% EtOAc/hexanes, collecting 6 mL fractions.  Fractions 21-
70 provided the desired product 2.194 as a single diastereomer (495 mg, 84% over 2 
steps) and as a colorless liquid.  Rf = 0.46 (30% EtOAc/hexanes);   20D -0.8 (c = 1.1, 
CHCl3); 500 MHz 
1
H NMR (CDCl3) δ 7.37-7.19 (m, 7H), 6.85-6.82 (m, 2H), 6.00 (dt, J 
= 15.6, 1.4 Hz, 1H), 5.88 (bs, 1H), 5.36 (dt, J = 16.1, 5.3 Hz, 1H), 5.37 (s, 1H), 4.87 (d, J 
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= 7.3 Hz, 1H), 4.84 (d, J = 7.3 Hz, 1H), 4.66 (d, J = 1.9 Hz, 2H), 4.61 (d, J = 10.7 Hz, 
1H), 4.42 (d, J = 10.7 Hz, 1H), 4.14-4.09 (m, 2H), 4.03 (dddd, J = 12.4, 9.2, 2.7, 2.7 Hz, 
1H), 3.89 (ddd, J = 9.7, 4.3, 1.9 Hz, 1H),  3.78 (s, 3H), 3.68 (s, 3H), 3.51 (dd, J = 15.6, 
8.5 Hz, 1H), 3.23 (s, 3H),  2.29 (ddd, J = 14.6, 11.4, 1.9 Hz, 1H), 2.03 (s, 3H), 1.92 (ddd, 
J = 14.6, 10.2, 2.4 Hz, 1H), 1.73 (ddd, J = 14.6, 10.2, 2.4 Hz, 1H), 1.22 (d, J = 6.3 Hz, 
3H), 1.10 (s, 6H), 0.89 (s, 9H), 0.05 (s, 6H);  125 MHz 
13
C NMR (CDCl3) δ 169.0, 166.2, 
159.0, 152.2, 138.0, 137.8, 130.3, 129.2, 128.3, 127.6, 127.5, 124.0, 117.3, 113.6, 102.5, 
93.1, 76.6, 72.1, 71.8, 71.7, 69.3, 68.3, 64.3, 55.0, 51.4, 50.9, 45.6, 36.2, 32.3, 25.1, 24.6, 
23.1, 21.1, 18.3, 14.5, -5.1 (2);  125 MHz DEPT 13C NMR (CDCl3)  CH3 δ 55.0, 51.4, 
51.0, 25.9, 24.6, 23.1, 21.1, 14.5, -5.1; CH2 δ 93.1, 71.7, 69.3, 64.3, 36.1, 32.3; CH δ 
138.1, 129.2, 128.3, 127.6 (2), 124.1, 117.3, 113.7, 76.6, 72.1, 71.8, 68.3; CH0 δ 169.0, 
106.2, 159.0, 152.2, 137.8, 130.3, 102.5, 45.6, 18.3. IR (thin film) 2952, 2886, 2856, 
1714, 1720, 1665, 1612, 1513, 1462, 1435, 1372, 1248, 1158, 1107, 943, 836, 777, 737, 
698 cm
-1
; HRMS (ESI) calcd for C43H64NaO11Si (M+Na) 807.4116, found 807.4129. 
Preparation of (E)-methyl 2-((2S,3S,6S)-3-acetoxy-
6-((2R,3R)-3-((benzyloxy)methoxy)-2-((4-methoxybenzyl)oxy)butyl)-2-((E)-5-
hydroxy-2-methylpent-3-en-2-yl)-2-methoxydihydro-2H-pyran-4(3H)-
ylidene)acetate (2.195): To a stirring solution of the TBS ether 2.194 (495 mg, 0.63 
mmol, 1.0 equiv) in a 5:4:1 THF/MeOH/ pyridine solution (13 mL, 0.05M) at 0 ºC in a 
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plastic bottle was added HF·py (13 mL of 20% in pyridine). The reaction mixture was 
stirred at 0 ºC for 10 min and then warmed to rt. Stirring was continued for 3 h and the 
reaction mixture was then quenched by pipetting it into a mixture of saturated aqueous 
NaHCO3 solution and 50% EtOAc/hexanes (30 mL of each). The layers were separated 
and the aqueous layer was extracted with 50% EtOAc/hexanes (3  30 mL). The 
combined organic layers were washed with brine (30 mL), dried over Na2SO4, filtered 
and concentrated under reduced pressure. Purification was accomplished using flash 
column chromatography with a 2  8 cm silica gel column, eluting with 30% 
EtOAc/hexanes, collecting 4 mL fractions. The product containing fractions (28-55) were 
combined and concentrated under reduced pressure to provide alcohol 2.195 (393 mg, 
93%) as a colorless oil: Rf = 0.3 (50% EtOAc/hexanes);   20D -5.9 (c = 1.1, CHCl3); 
500 MHz 
1
H NMR (CDCl3) δ 7.37-7.19 (m, 7H), 6.85-6.82 (m, 2H), 5.98 (dt, J = 15.6, 
1.6 Hz, 1H), 5.88 (bs, 1H), 5.49 (dt, J = 16.1, 5.8 Hz, 1H), 5.43 (s, 1H), 4.86 (d, J = 6.8 
Hz, 1H), 4.84 (d, J = 6.8 Hz, 1H), 4.67 (s, 2H), 4.61 (d, J = 10.7 Hz, 1H), 4.41 (d, J = 
11.2 Hz, 1H), 4.14 (dddd, J = 10.7, 6.3, 6.3, 3.7 Hz, 1H), 4.07-4.02 (m, 3H), 3.90 (ddd, J 
= 10.2, 4.3, 1.9 Hz, 1H),  3.78 (s, 3H), 3.69 (s, 3H), 3.46 (dd, J = 15.6, 2.4 Hz, 1H), 3.22 
(s, 3H),  2.34 (ddd, J = 14.1, 10.9, 1.4 Hz, 1H), 2.05 (s, 3H), 1.92 (ddd, J = 14.1, 9.7, 1.9 
Hz, 1H), 1.73 (ddd, J = 13.1, 10.2, 2.4 Hz, 1H), 1.45 (t, J = 6.2 Hz, 1H), 1.21 (d, J = 6.3 
Hz, 3H), 1.12 (s, 3H), 1.10 (s, 3H);  125 MHz 
13
C NMR (CDCl3) δ 169.1, 166.2, 158.9, 
152.1, 138.9, 137.7, 130.2, 129.1, 128.2, 127.5 (2), 124.6, 117.0, 113.5, 102.3, 93.0, 
76.3, 71.9, 71.8, 71.4, 69.2, 68.2, 63.5, 54.9, 51.1, 50.9, 45.7, 35.9, 32.4, 23.9, 23.6, 21.0, 
14.4;  125 MHz DEPT 
13
C NMR (CDCl3)  CH3 δ 54.9, 51.1, 50.9, 23.9, 23.6, 21.0, 14.4; 
CH2 δ 93.0, 71.4, 69.2, 63.5, 35.9, 32.4; CH δ 138.9, 129.1, 128.2, 127.5 (2), 124.6, 
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117.0, 113.5, 76.3, 71.9, 71.7, 68.2; CH0 δ 169.1, 166.2, 158.9, 152.1, 137.7, 130.2, 
102.3, 45.7; IR (thin film) 2911, 2360, 1744. 1719, 1664, 1612, 1513, 1255, 1436, 1328, 
1234, 1173, 846, 750, 698 cm
-1
; HRMS (ESI) calcd for C37H50NaO11 (M+Na) 693.3251, 
found 693.3248 . 
 Preparation of (E)-methyl 2-((2S,3S,6S)-3-
acetoxy-6-((2R,3R)-3-((benzyloxy)methoxy)-2-((4-methoxybenzyl)oxy)butyl)-2-
methoxy-2-((E)-2-methyl-5-oxopent-3-en-2-yl)dihydro-2H-pyran-4(3H)-ylidene) 
acetate (2.146): To a stirring solution of the alcohol 2.195 (390 mg, 0.58 mmol, 1 equiv) 
in CH2Cl2 (12 mL) at rt, were added 4 Å molecular sieves (400 mg), TPAP (20 mg, 0.05 
mmol, 0.1 equiv), and 4-methylmorpholine-N-oxide (204 mg, 1.74 mmol, 3.0 equiv).  
The mixture was stirred at rt for 1 h and then diluted with EtOAc (20 mL). The mixture 
was then filtered through a small plug of Florisil
®
 and washed with copious amounts of 
EtOAc. The solvent was removed under reduced pressure and purification was 
accomplished by flash column chromatography, using a 2.5  7 cm silica gel column, 
eluting with 25% EtOAc/hexanes, collecting 6 mL fractions. The product containing 
fractions (18-35) were combined and concentrated under reduced pressure to provide 
aldehyde 2.146 (354 mg, 91%) as a colorless oil.  Rf = 0.37 (40% EtOAc/hexanes); 
  20D -1.8 (c = 1.0, CHCl3); 500 MHz 
1
H NMR (CDCl3) δ 9.50 (d, J = 7.3 Hz, 1H), 
7.36-7.17 (m, 7H), 6.83-6.80 (m, 2H), 5.91 (dd, J = 16.1, 7.8 Hz, 1H), 5.86 (bs, 1H), 5.39 
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(s, 1H), 4.85 (d, J = 6.8 Hz, 1H), 4.82 (d, J = 6.8 Hz, 1H), 4.64 (s, 2H), 4.60 (d, J = 10.7 
Hz, 1H), 4.38 (d, J = 11.2 Hz, 1H), 4.15 (dddd, J = 6.3, 6.3, 6.3, 4.1 Hz, 1H), 4.07 (dddd, 
J = 12.6, 9.5, 2.9, 2.9 Hz, 1H), 3.87 (ddd, J = 10.2, 4.3, 1.9 Hz, 1H),  3.77 (s, 3H), 3.68 
(s, 3H), 3.51(dd, J = 16.1, 2.4 Hz, 1H), 3.23 (s, 3H),  2.34 (ddd, J = 14.1, 11.3, 1.4 Hz, 
1H), 2.03-2.02 (m, 1H), 1.95 (ddd, J = 14.1, 9.3, 1.9 Hz, 1H), 1.89 (s, 3H), 1.75 (ddd, J = 
13.1, 10.2, 2.9 Hz, 1H), 1.21 (d, J = 6.3 Hz, 3H), 1.13 (s, 3H), 1.11 (s, 3H);  125 MHz 
13
C NMR (CDCl3) δ 194.1, 168.4, 166.4, 165.8, 159.0, 151.0, 137.6, 130.0, 129.0, 128.2, 
127.4 (2), 126.5, 117.6, 113.5, 102.1, 93.1, 76.1, 71.7, 71.2, 71.0, 69.2, 68.8, 54.9, 51.1, 
50.9, 47.1, 35.8, 32.4, 23.6, 21.4, 20.9, 14.1;  125 MHz DEPT 
13
C NMR (CDCl3)  CH3 δ 
54.9, 51.1, 50.9, 23.6, 21.4, 20.9, 14.1; CH2 δ 93.1, 71.2, 69.2, 35.8, 32.4; CH δ 194.1, 
166.4, 129.1, 128.2, 127.4 (2), 126.5, 117.5, 113.5, 76.1, 71.7, 71.0, 68.8; CH0 δ 168.4, 
165.8, 159.0, 151.0, 137.6, 130.0, 102.1, 47.1. IR (thin film) 2911, 2836, 1749, 1718, 
1686, 1612, 1513, 1462, 1435, 1370, 1301, 1231, 1172, 1105, 1064, 904, 821, 752, 699 
cm
-1
; HRMS (ESI) calcd for C37H48NaO11 (M+Na) 691.3094, found 691.3094. 







dihydro-2H-pyran-4(3H)-ylidene)acetate (2.199): A flame dried 15 mL rb flask was 
charged with aldehyde 2.146  (101 mg, 0.151 mmol, 1.0 equiv) and hydroxyallylsilane 
2.147  (130 mg, 0.166 mmol, 1.1 equiv) and subjected to high vacuum for 1 h. To this 
mixture was added Et2O (2.1 mL) and the solution was cooled to -78 ºC with stirring 
under argon. To the stirring solution of aldehyde and silane was added a solution of 
TMSOTf in Et2O (181 μL of 1.0 M, 0.181 mmol, 1.2 equiv). After 5 h at -78 ºC, the 
reaction mixture was quenched by the addition of diisopropylethylamine (200 μL) and 
stirred for 15 min. The mixture was warmed to 0 ºC and saturated aqueous NaHCO3 
solution (5 mL) was added. The mixture was warmed to rt, diluted with 5 mL Et2O, and 
the phases were separated. The aqueous phase was extracted with Et2O (3  10 mL). The 
organic phases were combined, washed with brine (10 mL), dried over Na2SO4, and 
concentrated under reduced pressure. Purification was accomplished by flash column 
chromatography on a 2  7 cm silica gel column, eluting with hexanes/EtOAc (9:1), 
collecting 4 mL fractions. The product containing fractions (42-60) were combined and 
concentrated under reduced pressure to provide the pyran 2.199  (123 mg, 60%) as a 
white foam. Rf = 0.36 (30% EtOAc/hexanes);   20D  +8.9 (c = 1.0, CHCl3); 500 MHz 
1
H NMR (CDCl3) δ 7.70-7.65 (m, 4H), 7.44-7.29 (m, 11H), 7.21-7.19 (m, 2H), 6.84-6.82 
(m, 2H), 5.99 (dd, J = 16.1, 0.9 Hz, 1H), 5.88 (s, 1H), 5.44 (s, 1H), 5.35 (dd, J = 16.1, 
5.3 Hz, 1H), 4.95 (dd, J = 11.6, 4.8 Hz, 1H), 4.86 (d, J = 6.8 Hz, 1H), 4.84 (d, J = 6.8 
Hz, 1H), 4.69 (s, 1H), 4.66 (s, 2H), 4.61(d, J = 11.2 Hz, 1H), 4.42 (d, J = 10.7 Hz, 1H), 
4.27-4.23 (m, 1H), 4.13-4.05 (m, 2H), 3.88 (ddd, J = 9.7, 4.4, 1.9 Hz, 1H), 3.78 (s, 3H), 
3.68 (s, 3H), 3.66-3.62 (m, 1H), 3.47 (dd, J = 13.6, 2.4 Hz, 1H), 3.39-3.37 (m, 1H), 3.23 
318 
 
(s, 3H), 3.21-3.14 (m, 1H), 2.93 (s, 3H), 2.71-2.69 (m, 2H), 2.33 (ddd, J = 14.6, 12.1, 1.9 
Hz, 1H), 2.27-2.10 (m, 2H), 2.05 (s, 3H), 1.99 (s, 3H), 1.93-1.79 (m, 4H), 1.74-1.62 (m, 
4H), 1.44 (s, 9H), 1.32-1.26 (m, 2H), 1.21 (d, J = 6.3 Hz, 3H), 1.11 (s, 3H), 1.09 (s, 3H), 
1.02 (s, 9H), 0.87 (s, 3H), 0.82 (s, 3H); 125 MHz 
13
C NMR (CDCl3) δ 189.1, 170.6, 
169.4, 166.6, 159.3, 152.6, 144.6, 138.0, 137.8, 136.1, 136.0, 134.4, 133.6, 130.6, 129.9, 
129.8, 129.4, 128.6, 127.9 (2), 127.8, 127.7, 126.5, 117.2, 114.0 (2), 108.9, 104.0, 
102.7, 93.5, 78.5, 76.9, 74.8, 73.7, 72.5, 72.1 (2), 69.6, 69.4, 68.4, 66.0, 55.4, 53.1, 52.4, 
51.3, 48.2, 46.1, 43.7, 42.5, 40.5, 39.1, 36.5, 33.0, 32.7, 30.0, 27.1, 24.3, 23.9, 21.5, 21.4, 
20.7, 19.5, 16.7, 14.9; 125 MHz DEPT;   CH3 δ 55.4, 51.4, 51.3, 48.2, 29.9, 27.1, 24.3, 
23.9, 21.5, 21.4, 20.7, 16.7, 14.9; CH2 δ 108.8, 93.4, 72.1, 69.6, 53.1, 43.6, 42.5, 40.5, 
39.0, 36.5, 33.0, 32.7; CH δ 137.7, 136.1, 135.9, 129.9, 129.8, 129.4, 128.6, 127.9, 127.7 
(2), 126.4, 117.2, 113.9 (2), 78.5, 76.9, 74.8, 73.7, 72.5, 72.0, 69.3, 68.4, 66.0; CH0 δ 
189.1, 170.6, 169.4, 166.6, 159.3, 152.6, 144.6, 138.0, 134.4, 133.6, 130.6, 127.9, 104.0, 
102.7, 46.1, 42.0, 19.5; IR (neat) 2951, 1743, 1721, 1681, 1598, 1513, 1460, 1429, 1365, 
1246, 1163, 1109, 1040, 822, 755, 703 cm
-1
; HRMS (ESI/APCI) calcd for 
C77H106NaO17SSi (M+Na): 1385.6818, found:1385.6838. 






((benzyloxy)methoxy)-2-((4-methoxybenzyl) oxy) butyl) -2-methoxydihydro-2H-
pyran-4(3H)-ylidene)acetate (2.202): To a stirring solution of the BPS ether 2.199  (101 
mg, 0.07 mmol, 1.0 equiv) in a 5:4:1 THF/MeOH/pyridine solution (3.7 mL, 0.02M) at 0 
ºC in a 10 mL plastic centrifuge tube was added HF·py (1.6 mL of 20% in pyridine). The 
reaction mixture was stirred at 0 ºC for 1 h and then warmed to rt. Stirring was continued 
for 36 h and the reaction mixture was then quenched by pipetting it into a mixture of 
saturated aqueous NaHCO3 solution and EtOAc (5 mL of each). The layers were 
separated and the aqueous layer was extracted with EtOAc (3  5 mL). The combined 
organic layers were dried over Na2SO4, filtered and concentrated under reduced pressure. 
Purification was accomplished by flash column chromatography on a 2  7 cm silica gel 
column, eluting with 25% EtOAc in hexanes, collecting 4 mL fractions. The product 
containing fractions (11-49) were combined and concentrated under reduced pressure to 
provide the alcohol 2.202 (75 mg, 90%) as a white foam. Rf = 0.3 (40% EtOAc/hexanes); 
  20D  +17.3 (c = 1.2, CHCl3);  500 MHz 
1
H NMR (CDCl3) δ 7.36-7.34 (m, 5H), 7.21-
7.20 (m, 2H), 6.84-6.82 (m, 2H), 6.00 (dd, J = 16.1, 1.6 Hz, 1H), 4.78 (d, J = 7.5 Hz, 
1H), 5.88 (s, 1H), 5.43 (s, 1H), 5.39 (dd, J = 16.1, 4.8 Hz, 1H), 5.19 (dd, J = 11.2, 4.8 
Hz, 1H), 4.85 (d, J = 6.8 Hz, 1H), 4.70-4.68 (m, 2H), 4.67 (s, 2H), 4.61(d, J = 11.2 Hz, 
1H), 4.42 (d, J = 11.2 Hz, 1H), 4.33-4.32 (m, 1H), 4.11 (ddd, J = 8.7, 7.3, 2.4 Hz, 1H), 
4.08-4.05 (m, 1H), 3.96-3.92 (m, 1H), 3.89 (ddd, J = 10.5, 4.4, 2.2 Hz, 1H), 3.78 (s, 3H), 
3.68 (s, 3H), 3.53-3.46 (m, 2H), 3.24 (s, 3H), 3.22 (s, 3H), 2.63-2.61 (m, 2H), 2.37-2.30 
(m, 2H), 2.22-2.18 (m, 2H), 2.07 (s, 3H), 2.03 (s, 3H), 1.95-1.56 (m, 5H), 1.46 (s, 9H), 
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1.28-1.25 (m, 1H), 1.21 (d, J = 6.3 Hz, 3H), 1.11 (s, 3H), 1.10 (s, 3H), 1.01 (s, 3H), 0.91 
(s, 3H); 125 MHz 
13
C NMR (CDCl3) δ; 200.1, 170.8, 169.4, 166.6, 159.3, 152.5, 144.7, 
138.0, 137.7, 133.4, 130.6, 129.4, 128.6, 127.9, 127.8, 126.4, 117.2, 113.9, 108.8, 104.1, 
102.7, 93.5, 78.6, 76.9, 75.0, 74.1, 72.5, 72.0, 69.6, 68.3, 65.3, 64.9, 55.4, 51.5, 51.4, 
51.3, 48.5, 46.1, 42.4, 42.2, 41.9, 40.5, 39.2, 36.4, 32.9, 32.6, 29.9, 24.2, 24.1, 21.5, 21.4, 
20.7, 17.0, 14.9.125  MHz DEPT; CH3 δ; 55.4, 51.4, 51.3, 48.5, 29.9, 24.2, 24.1, 21.5, 
21.4, 20.7, 17.0, 14.9 CH2 δ; 108.8, 93.5, 72.0, 69.6, 51.5, 42.4, 41.9, 40.5, 39.2, 36.4, 
32.9, 32.7, CH δ; 137.7, 129.4, 128.6, 127.9, 127.8, 126.4, 117.3, 113.9, 78.6, 76.9, 75.0, 
74.1, 72.5, 72.1, 68.3, 65.3, 64.9 CH0 δ; 200.1, 170.8, 169.4, 166.6, 159.3, 152.5, 144.7, 
138.0, 133.4, 130.6, 104.1, 102.7, 46.1, 42.2; IR (neat) 2950, 2836, 1722, 1679, 1612, 
1513, 1435, 1366, 1246, 1160, 1105, 1041, 982, 900, 849, 755, 699 cm
-1
; HRMS 
(ESI/APCI) calcd for C61H88NaO17S (M+Na): 1147.5635, found:1147.5652. 
 




6-methoxy-5,5-dimethyltetrahydro-2H-pyran-2-yl)-3-((triethylsilyl) oxy) butanoic 
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acid (2.203): To a stirring solution of thiolester 2.202 (32 mg, 0.0284 mmol, 1.0 equiv) 
in THF (2.4 mL) in a 5 mL vial at 0 ºC were added water (0.6 mL), LiOH powder (14 
mg, 0.568 mmol, 20 equiv) and H2O2 (0.64 mL of 30%, 0.568 mmol, 20 equiv). The 
resulting solution was stirred at 0 °C for 1 h, then poured into a mixture of aqueous pH 6 
phosphate buffer solution and EtOAc (5 mL of each). The layers were separated and the 
aqueous layer was extracted with EtOAc (3  5 mL). The combined organic layers were 
dried over Na2SO4, filtered, and concentrated under reduced pressure to give the hydroxy 
acid as a sticky oil, which was taken into the next step without further purification.  
 To a stirring solution of this hydroxy acid in CH2Cl2 (1.4 mL) in a 5 mL vial at -
15 ºC was added DMAP (35 mg, 0.284 mmol, 10 equiv), followed by TESCl (23 µL, 
0.142 mmol, 5 equiv) via syringe. The solution was stirred at -15 ºC for 1 h, then poured 
into a mixture of aqueous pH 4 (acetic acid/sodium acetate) buffer and EtOAc (5 mL of 
each). The layers were separated and the aqueous layer was extracted with EtOAc (3  5 
mL). The combined organic layers were dried over Na2SO4, filtered, and concentrated 
under reduced pressure. Purification was accomplished using flash column 
chromatography with a 1  5 cm silica gel column, eluting with 30% EtOAc/hexanes, 
collecting 4 mL fractions. The product containing fractions (3-12) were combined and 
concentrated under reduced pressure to provide the carboxylic acid 2.203  (24.8 mg, 77% 
over 2 steps) as a white foam: Rf = 0.66 (5:4:1 hexanes: EtOAc:MeOH);   20D  +13 (c 
= 1.1, CHCl3); 500 MHz 
1
H NMR (CDCl3) δ 7.36-7.22 (m, 5H), 7.21-7.19 (m, 2H), 6.84-
6.82 (m, 2H), 6.00 (d, J = 14.6 Hz, 1H), 5.88 (s, 1H), 5.43 (s, 1H), 5.37 (dd, J = 16.1, 5.3 
Hz, 1H), 5.15 (dd, J = 11.7, 4.3 Hz, 1H), 4.85 (s, 2H), 4.71-4.68 (m, 2H), 4.66 (s, 2H), 
4.60 (d, J = 10.7 Hz, 1H), 4.42 (d, J = 10.7 Hz, 1H), 4.25-4.22 (m, 1H), 4.13-4.05 (m, 
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2H), 3.89 (ddd, J = 10.2, 4.8, 2.6 Hz, 1H), 3.77 (s, 3H), 3.68 (s, 3H), 3.52-3.46 (m, 1H), 
3.23 (s, 3H), 3.18 (s, 3H), 2.68 (dd, J = 15.1, 4.3 Hz, 1H), 2.52 (dd, J = 15.1, 6.8 Hz, 
1H), 2.35-2.27 (m, 2H), 2.21-2.11 (m, 2H), 2.07 (s, 3H), 2.03 (s, 3H), 1.96-1.61 (m, 9H), 
1.44-1.37 (m, 1H), 1.21 (d, J = 6.3 Hz, 3H), 1.11 (s, 3H), 1.09 (s, 3H), 1.00 (s, 3H), 0.94 
(t, J = 7.8 Hz, 9H), 0.91 (s, 3H), 0.60 (q, J = 7.8 Hz, 6H); 125 MHz 
13
C NMR (CDCl3) δ; 
170.9, 169.4, 166.6, 159.3, 152.5, 144.6, 137.9, 137.8, 129.4, 128.6, 127.9, 127.8, 126.5, 
117.2, 113.9, 108.8, 104.2, 102.7, 93.4, 78.7, 76.9, 74.8, 74.0, 72.5, 72.0, 69.6, 68.4, 68.0, 
67.8, 65.8, 55.4, 51.4, 51.3, 48.7, 48.4, 46.1, 44.2, 43.3, 42.4, 42.1, 40.6, 39.2, 36.4, 33.3, 
33.0, 24.2, 24.1, 23.9, 21.5, 21.4, 20.8, 17.2, 16.9, 14.8, 7.0, 5.2; 125  MHz DEPT; CH3 
δ; 55.4, 51.4, 51.3, 48.6, 48.4, 24.2, 23.9, 21.5, 21.4, 20.8, 16.9, 14.8, 7.0; CH2 δ; 108.7, 
93.3, 72.0, 69.6, 44.2, 43.3, 42.4, 40.6, 39.1, 36.4, 33.3, 33.0, 5.2; CH δ; 137.8, 129.4, 
128.5, 127.9, 127.8, 126.5, 117.2, 113.9, 78.7, 76.8, 74.8, 74.0, 72.5, 72.0, 68.4, 67.8, 
65.8; CH0 δ 170.9, 169.4, 166.6, 159.3, 152.5, 144.6, 137.9, 130.9, 130.6, 104.2, 68.0, 
46.1, 42.1, 24.1, 17.2; IR (neat)  2953, 2877, 1721, 1612, 1513, 1459, 1379, 1245, 1172, 
1081, 1041, 848, 740 cm
-1
; HRMS (ESI/APCI) calcd for C62H91NaO17Si (M+Na): 
1189.6107, found:1189.6110. 






diacetate (2.204): To a stirring solution of the PMB ether 2.203  (45.2 mg, 0.0397 mmol, 
1 equiv) in CH2Cl2 (3.2 mL) at 0 ºC was added pH 8 phosphate buffer (800 µL). DDQ 
(45 mg, 0.198 mmol, 5 equiv) was added in one portion and the reaction was stirred 
vigorously for 1.5 h. The reaction mixture was then poured into a mixture of CH2Cl2 and 
pH 4 acetate buffer (5 mL each), the layers were separated, and the aqueous layer was 
extracted with CH2Cl2 (3  5 mL). The combined organic layers were dried over Na2SO4, 
filtered, and concentrated. The crude product was quickly passed through a column of 
silica gel (1  7 cm) eluting with 30% EtOAc/hexanes, collecting 4 mL fractions. The 
product containing fractions 8-19 were combined and concentrated under reduced 
pressure to give the seco acid, partially mixed with DDQ byproducts, which was taken to 
the next step without further purification.  
 To a stirring solution of the seco acid in THF (1.3 mL) at 0 °C were added 
triethylamine (31 µL, 0.238 mmol, 6.0 equiv) and 2,4,6-trichlorobenzoyl chloride (18 µL, 
0.119 mmol, 3.0 equiv) via syringe. After 10 min, the reaction mixture was warmed to rt 
and stirring was continued for an additional 4 h.  The reaction mixture was then diluted 
with 3:1 toluene/THF (20 mL) and taken up into a 25 mL gas-tight syringe. This solution 
was added by syringe pump to a stirring solution of DMAP (97 mg, 0.795 mmol, 20.0 
equiv) in toluene (39 mL) at 40 °C over 12 h. The residual contents of the syringe were 
rinsed into the flask with toluene (0.5 mL) and stirring was continued for an additional 2 
h.  The reaction mixture was cooled to rt, diluted with 30% EtOAc/hexanes (30 mL), and 
washed with saturated aqueous NaHCO3 solution (10 mL) and with brine (10 mL). The 
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organic phase was dried over Na2SO4, filtered, and concentrated under reduced pressure. 
Purification was accomplished using flash column chromatography with a 1  8 cm silica 
gel column, eluting with 20% EtOAc/hexanes, collecting 4 mL fractions. The product 
containing fractions (5-12) were combined and concentrated under reduced pressure to 
provide macrolactone 2.204  as a white foam (28 mg, 71% over 2 steps).  Rf = 0.46 (30% 
EtOAc/hexanes);   20D  +54.4 (c = 1.0, CHCl3); 500 MHz 
1
H NMR (CDCl3) δ 7.37-
7.31 (m, 5H), 6.27 (d, J = 15.6 Hz, 1H), 5.95 (d, J = 1.9 Hz, 1H), 5.65 (dd, J = 10.2, 4.8 
Hz, 1H), 5.33 (dd, J = 16.1, 8.3 Hz, 1H),  5.20 (dd, J = 11.7, 4.8 Hz, 1H), 5.18 (s, 1H), 
4.85 (d, J = 6.8 Hz, 1H), 4.83 (d, J = 6.8 Hz, 1H), 4.72-4.71 (m, 2H), 4.67 (s, 2H), 4.45 
(ddd, J = 12.8, 9.4, 4.0 Hz, 1H), 3.99 (ddd, J = 10.5, 7.8, 2.1 Hz, 1H), 3.85 (dd, J = 5.8, 
4.8 Hz, 2H),  3.78-3.73 (m, 2H),  3.69 (s, 3H), 3.11 (s, 3H), 3.10 (s, 3H),  2.63 (dd, J = 
17.5, 3.4 Hz, 1H), 2.19 (dd, J = 17.5, 9.2 Hz, 2H), 2.18-2.08 (m, 4H), 2.06 (s, 3H), 2.02 
(s, 3H), 1.87-1.82 (m, 1H), 1.69-1.61 (m, 4H), 1.28-1.18 (m, 7H), 1.10 (s, 3H), 1.08 (s, 
3H), 0.94 (t, J = 6.8 Hz, 9H), 0.90-0.87 (m, 1H), 0.85 (s, 3H), 0.58 (dq, J = 7.3, 1.9 Hz, 
6H); 125 MHz 
13
C NMR (CDCl3) δ; 170.9. 170.7, 169.3, 166.9, 151.3, 145.1, 139.2, 
137.8, 128.7, 128.0 (2), 127.2, 119.5, 108.5, 103.1, 93.4, 79.8, 74.2, 74.0, 73.7, 73.4, 
70.8, 69.9, 66.8, 65.9, 64.6, 53.3, 51.4, 48.3, 45.4, 44.9, 43.5, 41.7, 41.4, 40.9, 40.2, 36.6, 
33.9, 30.9, 26.6, 21.6, 21.5, 20.5, 20.4, 17.6, 16.1, 7.2, 5.8, 1.2; 125  MHz DEPT; CH3 δ; 
53.3, 51.4, 48.3, 26.6, 21.6, 21.5, 20.4, 17.6, 16.1, 7.2, 1.2; CH2 δ; 108.5, 93.4, 69.9, 45.4, 
43.5, 41.4, 40.9, 40.1, 36.6, 33.9, 30.9, 5.8; CH δ; 139.3, 128.7, 128.0 (2), 127.2, 119.6, 
79.8, 74.2, 74.0, 73.7, 73.4, 70.8, 66.8, 65.9, 64.6; CH0 δ 170.9, 170.7, 169.3, 166.9, 
151.3, 145.1, 137.8, 103.1, 44.9, 41.7, 20.5; IR (neat)  2951, 2878, 1735, 1653, 1595, 
325 
 
1456, 1434, 1368, 1238, 1163, 1100, 1027, 890, 745 cm
-1
; HRMS (ESI/APCI) calcd for 
C54H81NaO15Si (M+Na): 1051.5426, found:1051.5442. 
 Preparation of (3S,7R,8E,11S,12S,13E,15S 
,17R,21R,23S,25S)-17-((R)-1-((benzyloxy)methoxy)ethyl)-1,11-dimethoxy-13-(2-
methoxy-2-oxoethylidene)-10,10,26,26-tetramethyl-5,19-dioxo-21-((triethylsilyl)oxy)-
18,27,28,29-tetraoxatetracyclo [21.3.1.13,7.111,15] nonacos-8-ene-12,25-diyl 
diacetate (2.205). To a stirring solution of olefin 2.204  (21.1 mg, 0.021 mmol, 1.0 
equiv) in t-butanol (0.5 mL) and water (0.5 mL) at rt was added AD mix- (29 mg, 1.4 
g/mmol olefin). The reaction was allowed to proceed for 24 h, after which time TLC 
analysis indicated completion of reaction. The reaction mixture was quenched by the 
addition of saturated aqueous sodium bisulfite solution (5 mL) and the resulting mixture 
was stirred for 30 min, then diluted with EtOAc (5 mL) and the layers were separated. 
The aqueous layer was extracted with EtOAc (2  5 mL). The combined organic layers 
were dried over Na2SO4, filtered, and concentrated under reduced pressure to give the 
diol as a colorless paste which was taken directly onto the next reaction without further 
purification.  
To a stirring solution of the crude diol in THF (0.75 mL) and 0.1 M pH 7 phosphate 
buffer (0.25 mL) at rt was added NaIO4 (23 mg, 0.105 mmol, 5 equiv). The mixture was 
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stirred vigorously at rt for 3 h, then diluted with EtOAc (5 mL) and quenched by the 
addition of saturated aqueous NaHCO3 solution (5 mL) and the layers were separated. 
The aqueous layer was extracted with EtOAc (3  5 mL).  The combined organic layers 
were washed with brine, dried over Na2SO4, filtered, and concentrated under reduced 
pressure. Purification was accomplished by flash column chromatography using a 1  5 
cm silica gel column, eluting with 30% EtOAc/hexanes, collecting 4 mL fractions. The 
product containing fractions (3-7) were combined and concentrated under reduced 
pressure to provide ketone 2.205  as a white foam (17.7 mg, 81% over 2 steps). Rf = 0.5 
(30% EtOAc/hexanes);   20D  +88.2 (c = 0.88, CHCl3); 500 MHz 
1
H NMR (CDCl3) δ 
7.37-7.26 (m, 5H), 6.35 (d, J = 15.6 Hz, 1H), 5.95 (d, J = 1.4 Hz, 1H), 5.62 (dd, J = 
10.7, 4.3 Hz, 1H),  5.35 (dd, J = 16.1, 7.8 Hz, 1H),  5.20 (dd, J = 10.2, 4.8 Hz, 1H), 5.20 
(s, 1H), 4.85 (d, J = 6.8 Hz, 1H), 4.82 (d, J = 6.8 Hz, 1H), 4.66 (s, 2H), 4.41-4.33 (m, 
2H), 4.10-4.06 (m, 1H), 3.84-3.81 (m, 2H), 3.75-3.71 (m, 1H), 3.70 (s, 3H), 3.66-3.60 
(m, 2H), 3.10 (s, 3H), 3.08 (s, 3H),  2.66 (dd, J = 17.5, 2.9 Hz, 1H), 2.40-2.16 (m, 7H),  
2.06 (s, 3H), 2.03 (s, 3H), 1.85-1.80 (m, 1H), 1.66-1.63 (m, 3H), 1.23 (s, 3H), 1.22 (s, 
3H), 1.10 (s, 3H), 1.08 (s, 3H), 0.98 (s, 3H), 0.93 (t, J = 8.3 Hz, 9H), 0.57 (q, J = 8.3 Hz, 
6H); 125 MHz 
13
C NMR (CDCl3) δ; 207.7, 170.8, 170.7, 169.3, 166.8, 151.1, 140.5, 
128.7, 128.0, 125.5, 119.6, 103.0, 102.9, 93.5, 78.4, 77.4, 74.4, 73.5, 72.2, 71.0, 69.9, 
66.8, 65.8, 64.7, 53.2, 51.4, 48.6, 48.0 (2), 45.1, 44.9, 43.1, 41.7, 39.9, 36.9, 33.8, 30.8, 
29.9, 26.7, 21.6, 21.5, 20.5, 20.3, 17.5, 16.4, 7.2, 5.8; 125  MHz DEPT; CH3 δ; 53.2, 
51.4, 48.0, 26.7, 21.6, 21.5, 20.5, 20.3, 17.5, 16.4, 7.2; CH2 δ; 93.5, 69.9, 48.6, 48.1, 45.1, 
43.1, 39.9, 36.9, 33.8, 30.8, 5.8; CH δ; 140.5, 128.7, 128.0, 125.5, 119.6, 78.4, 77.4, 74.4, 
74.0, 73.5, 72.2, 71.0, 66.8, 65.8, 64.7; CH0 δ 207.7, 170.8, 170.7, 169.3, 166.8, 151.1, 
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103.0, 44.9, 41.7, 36.9, 29.9; IR (neat)  2953, 2879, 1729, 1667, 1596, 1457, 1434, 1368, 
1239, 1163, 1097, 1027, 903, 751 cm
-1
; HRMS (ESI/APCI) calcd for C54H81NaO15Si 
(M+Na): 1053.5219, found:1053.5208 
 Preparation of (2Z,2'E)-dimethyl 2,2'-
((3S,7R,11S,12S,15S,17R,21R,23S,25S,E)-12,25-diacetoxy-17-((R)-1-((benzyloxy) 
methoxy)ethyl)-1,11-dimethoxy-10,10,26,26-tetramethyl-19-oxo-21-((triethylsilyl) 
oxy)-18,27,28,29- tetraoxatetracyclo [21.3.1.13,7.111,15] nonacos-8-ene-5, 13-
diylidene) diacetate (2.207). To a stirring solution of the R-BINOL phosphonate 2.206  
(70 mg, 0.174 mmol, 15 equiv) in THF (1 mL) in a 5 mL vial at -78 °C was added a 
solution of NaHMDS in THF (117 µL of 1.0 M, 0.116 mmol, 10 equiv) down the wall of 
the vial via syringe. The resulting solution was stirred at -78 °C for 30 min. The ketone 
2.205 (12 mg, 0.0116 mmol, 1 equiv) was dissolved in THF (100 µL) and added 
dropwise along the side of the vial via syringe and then rinsed in with THF (0.1 mL). The 
solution was stirred at -78 °C for 1 h then warmed to 0 °C and stirring was continued for 
48 h. The reaction was quenched by the dropwise addition of saturated aqueous NaHCO3 
solution (5 mL) and was then diluted with EtOAc (5 mL). The layers were separated and 
the aqueous layer was extracted with EtOAc (3  5 mL). The combined organic layers 
were dried over Na2SO4, filtered and concentrated under reduced pressure. Purification 
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was accomplished using flash column chromatography with a 1  5 cm silica gel column, 
eluting with 30% EtOAc/hexanes, collecting 4 mL fractions. The product containing 
fractions (3-6) were combined and concentrated under reduced pressure to provide the 
desired unsaturated ester as a 4:1 Z:E mixture of diastereomers. The E and Z 
diastereomers were separated using preparative thin layer chromatography eluting with 
10% EtOAc/benzene to afford 8.5 mg of the desired Z isomer 2.207 and 2.1 mg of the E 
isomer (combined yield 85%), both as colorless oils. Analytical data for the desired Z 
isomer: Rf = 0.39 (30% EtOAc/hexanes);   20D  +92.3 (c = 0.53, CHCl3); 500 MHz 
1
H 
NMR (CDCl3) δ 7.37-7.29 (m, 5H), 6.30 (d, J = 15.6 Hz, 1H), 5.95 (d, J = 1.4 Hz, 1H), 
5.69 (s, 1H), 5.62 (dd, J = 10.2, 4.3 Hz, 1H),  5.35 (dd, J = 15.6, 7.8 Hz, 1H), 5.19 (dd, J 
= 11.7, 4.8 Hz, 1H), 5.17 (s, 1H), 4.86 (d, J = 7.3 Hz, 1H), 4.83 (d, J = 6.8 Hz, 1H), 4.68 
(d, J = 11.7 Hz, 1H), 4.64 (d, J = 11.7 Hz, 1H), 4.40 (dddd, J = 9.7, 9.7, 2.7, 2.7 Hz, 
1H), 4.03 (ddd, J = 10.7, 7.8, 2.3 Hz, 1H), 3.88-3.72 (m, 5H), 3.69 (s, 3H), 3.69 (s, 3H),  
3.67-3.59 (m, 2H), 3.10 (s, 3H), 3.09 (s, 3H), 2.64 (dd, J = 17.5, 3.4 Hz, 1H), 2.37 (dd, J 
= 17.5, 9.7 Hz, 1H), 2.18-2.10 (m, 3H), 2.07 (s, 3H), 2.02 (s, 3H), 2.01-1.98 (m, 2H), 
1.92 (t, J = 12.6 Hz, 1H), 1.83 (t, J = 11.7 Hz, 1H), 1.67-1.62 (m, 4H), 1.24 (s, 3H), 1.23 
(d, J = 6.3 Hz, 3H), 1.15-1.14 (m, 1H), 1.11 (s, 3H), 1.08 (s, 3H), 0.95 (s, 3H), 0.93 (t, J 
= 7.8 Hz, 9H), 0.85 (s, 3H), 0.57 (dq, J = 16.1, 2.4 Hz, 6H); 125 MHz 
13
C NMR (CDCl3) 
δ; 170.9, 170.7, 169.3, 167.1, 166.9, 158.4, 151.3, 139.9, 137.8, 128.6, 128.0, 127.9, 
126.7, 119.5, 114.4, 103.1, 103.0, 93.6, 78.9, 74.5, 74.0, 73.7, 72.9, 71.0, 69.9, 66.8, 65.9, 
64.7, 53.3, 51.4, 51.1, 48.2, 45.2, 45.0, 43.3, 42.6, 41.7, 40.1, 37.0, 36.5, 33.9, 30.8, 26.5, 
21.6, 21.4, 20.5 (2), 17.5, 16.4, 7.1, 5.8; 125  MHz DEPT; CH3 δ; 53.3, 51.4, 51.1, 48.2, 
26.5, 21.6, 21.4, 20.4 (2), 17.5, 16.4, 7.1; CH2 δ; 93.6, 69.9, 45.2, 43.3, 42.6, 40.1, 37.0, 
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36.5, 33.9, 30.8, 5.8; CH δ; 139.9, 128.6, 128.0, 127.9, 126.7, 119.5, 114.4, 78.9, 74.5, 
74.0, 73.7, 72.8, 71.0, 66.8, 65.9, 64.7; CH0 δ 170.9, 170.7, 169.3, 167.1, 166.9, 158.4, 
151.3, 137.8, 103.1, 103.0, 47.7, 45.0; IR (neat)  2952, 1740, 1612, 1513, 1456, 1382, 
1249, 1173, 1107, 1039, 835, 739, 699 cm
-1
; HRMS (ESI/APCI) calcd for C57H86NaO18Si 
(M+Na): 1109.5481, found:1109.5493. 




[21.3.1.13,7.111,15]nonacos-8-ene-5,13-diylidene)diacetate (2.208) To a stirring 
solution of diacetate 2.207  (4.7 mg, 0.00432 mmol, 1.0 equiv) in MeOH (400 µL ) in a 4 
mL vial at rt was added K2CO3 (3 mg, 0.0216 mmol, 5 equiv) and the mixture was stirred 
for 45 min. The reaction mixture was quenched by the addition of saturated aqueous 
NH4Cl solution (5 mL) and was then diluted with CH2Cl2 (5 mL). The phases were 
separated and the aqueous phase was extracted with CH2Cl2 (3  5 mL). The combined 
organic phases were washed with brine (5 mL), dried over Na2SO4, filtered and 
concentrated under reduced pressure. This intermediate unstable alcohol was taken into 
the following reaction without further purification. 
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To a stirring solution of this alcohol in CH2Cl2 (400 µL, 0.001 M) in a 5 mL reaction 
vial at rt were added pyridine (17 µL, 0.21 mmol, 50 equiv), DMAP (5.0 mg, 0.043 
mmol, 10 equiv), and octadienoic anhydride (35 mg, 0.129 mmol, 30 equiv). The reaction 
mixture stirred at rt for 12 h and was then quenched by the addition of saturated aqueous 
NaHCO3 solution (5.0 mL). The mixture was stirred vigorously for 30 min and was then 
diluted with 40% EtOAc/hexanes (5 mL). The phases were separated and the aqueous 
phase was extracted with 40% EtOAc/hexanes (2  5 mL). The combined organic phases 
were dried over Na2SO4, filtered, and concentrated under reduced pressure. Purification 
was accomplished using flash column chromatography on a 1  3 cm silica gel column 
eluting with 10% EtOAc/hexanes (12 mL) followed by 30% EtOAc/hexanes, collecting 4 
mL fractions. Fractions 7-9 provided the desired product 2.208  as a pale yellow oil (3.6 
mg, 71% over 2 steps)  Rf = 0.46 (30% EtOAc/hexanes);   20D  +53.7 (c = 0.18, 
CHCl3); 500 MHz 
1
H NMR (CDCl3) δ 7.37-7.28 (m, 5H), 6.31 (d, J = 16.1 Hz, 1H), 
6.18-6.17 (m, 2H), 5.98 (d, J = 1.9 Hz, 1H), 5.78 (d, J = 15.1 Hz, 1H),  5.69 (s, 1H), 5.64 
(ddd, J = 11.7, 4.8, 1.7 Hz, 1H),  5.34 (dd, J = 16.1, 7.8 Hz, 1H), 5.26 (s, 1H), ), 5.20 
(dd, J = 11.7, 4.8 Hz, 1H), 4.87 (d, J = 7.3 Hz, 1H), 4.84 (d, J = 6.8 Hz, 1H), 4.68 (d, J = 
11.7 Hz, 1H), 4.65 (d, J = 11.7 Hz, 1H), 4.43-4.39 (m, 1H), 4.05-4.02 (m, 1H), 3.88-3.71 
(m, 6H), 3.68 (s, 3H), 3.63-3.61 (m, 2H),  3.10 (s, 3H), 3.10 (s, 3H), 2.64 (dd, J = 17.0, 
3.4 Hz, 1H), 2.38 (dd, J = 17.5, 9.7 Hz, 1H), 2.32-2.30 (m, 1H), 2.16-2.09 (m, 5H), 2.02 
(s, 3H), 1.95-1.81 (m, 3H), 1.66-1.62 (m, 3H), 1.50-1.43 (m, 3H), 1.25 (s, 3H), 1.23 (s, 
3H), 1.11 (s, 3H), 1.09 (s, 3H), 0.95-0.91 (m, 15H), 0.85 (s, 3H), 0.85 (s, 3H), 0.57 (dq, J 
= 18.0, 2.4 Hz, 6H); 125 MHz 
13
C NMR (CDCl3) δ; 170.9, 170.7, 167.1, 167.0, 158.5, 
151.6, 146.8, 145.9, 140.0, 137.8, 128.6, 128.5, 128.0, 127.9, 126.6, 119.4, 118.5, 114.3, 
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103.3, 103.0, 93.6, 78.9, 74.5, 74.1, 73.4, 72.9, 71.0, 69.9, 66.8, 66.0, 64.7, 53.3, 51.3, 
51.0, 48.2, 45.2, 45.1, 43.3, 42.6, 41.7, 40.1, 37.1, 36.5, 35.2, 34.5, 33.9, 31.0, 26.6, 22.0, 
21.4, 20.5, 20.4, 17.5, 16.4, 13.9, 7.1, 5.8; 125  MHz DEPT; CH3 δ; 53.3, 51.3, 51.1, 
48.2, 26.6, 21.4, 20.5, 17.5, 16.4, 13.9, 7.1; CH2 δ; 93.6, 69.9, 45.2, 43.3, 42.6, 40.1, 37.1, 
36.5, 35.2, 33.9, 30.9, 22.0, 5.8; CH δ; 146.8, 145.9, 140.0, 128.6, 128.5, 128.0, 127.9, 
126.6, 119.4, 118.5, 114.3, 78.9, 74.5, 74.0, 73.4, 72.8, 71.0, 66.8, 65.9, 64.7; CH0 δ; 
170.9, 170.7, 167.1, 167.0, 158.5, 151.6, 137.8, 103.3, 103.0, 45.1, 41.7, 34.5; IR (neat) 
2958, 2857, 1737, 1680, 1613, 1514, 1471, 1427, 1365, 1247, 1173, 1109, 834, 740, 704, 
611 cm
-1
; HRMS (ESI/APCI) calcd for C63H94NaO18Si (M+Na): 1189.6107, 
found:1189.6110. 
 
Preparation of Bryostatin 1: To a 4 mL 
reaction vial containing the protected bryostatin 1 29 (3.6 mg, 0.003 mmol, 1 equiv) was 
added a solution of LiBF4 in 25:1 CH3CN/water (550 µL of 0.25 M, 0.003 mmol, 45.0 
equiv). The reaction vial was sealed and the mixture was stirred at 80 ºC for 14 h. After 
cooling to rt, the reaction mixture was diluted with EtOAc (5 mL) and was quenched by 
the addition of saturated aqueous NaHCO3 solution (5 mL). The layers were separated 
and the aqueous phase was extracted with EtOAc (3  5 mL). The combined organic 
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phases were dried over Na2SO4, filtered and concentrated. Purification was accomplished 
using flash column chromatography with a 0.5  6 cm silica gel column, collecting 6  50 
mm test tube fractions, eluting with 20% EtOAc/hexanes for fractions from 1-10 
followed by 50% EtOAc/hexanes. The product containing fractions (21-40) were 
combined and concentrated under reduced pressure to provide bryostatin 1 (2.0 mg, 72%) 
as a white powder. Rf = 0.37 (60% EtOAc/hexanes).   20D  +11 (c = 0.20, CHCl3), 
natural   20D  +9 (c = 0.21, CHCl3), IR (neat) 2934, 1716, 1643, 1435, 1366, 1246, 
1160, 1099, 1003, 860, 812, 754, 733 cm
-1
; HRMS (ESI/APCI) calcd for C47H68NaO17 
(M+Na): 927.4354, found: 927.4355; 500 MHz 
1
H, 125 Mz 
13
C, and DEPT in CDCl3 are 






















Tabir 2.1. Comparison rJ:Prol"" I\'MR Cb=ical Shifts for BryoSUltin I 
Prot"" No NanraI (a) Nan.-aI (b) S~'OIbe1ic (b) 
1. 2.42 (del, J .. 12.2, 2.1 Hz Iii) lA5 (del, J = In. 2_0 Hz Iii) 2.45 (del, J = 12.2, 2.0 Hz Iii) 
1b 2.53 (del, J .. 12.2, 12.0 Hz Iii) 251 (deI,J = In. 10_2 Hz Iii) HI (del, J " 12.2, 10.2 Hz Iii) 
3 4.12 (m, Iii) 4.15 (m. Iii) 4. 16 (m, Iii) 
3-0H 4.24 (d.J = 12.0Hl, 11i) 4.24 (m. Iii) 4.l5(m, Iii) 
•• 1.55 (ddd,J '" 14.8, 3.6, 3.1 Hl, Iii) 1.58 (ddd, J = 14.6. 33. 3.0 Hz. IH) 1.57 (ddd,J " 15.1, 3.8, 3.1 Hl, Iii) 
4b 2.02 (m, Iii) 2.05 (m. Iii) 2.06 (m, Iii) 
, 4.21 (tt, J " 11 .6, 2.3 Hz, Iii) 4.22(tt, J = I L7.l.6 Hz. Iii) 4.23 (tt, J " 11.7, 1.5 Hz, Iii) 
~ 1.48 (q, J " 11.7 Hz, Iii) L47 (q. J = 10.7 Hz. Iii) 1.48 (q, J " 10.7 Hl, Iii) 
"" 
1.72 (ddd,J " 12.3, 4.6, 2.6 Hl, Iii) 1.7~ (!W. J = 12.7. H. 2.8 fu. IH) 1.75 (ddd, J .. 12.6, 4.9, 2.9 Hl, IH) 
7 5.19(m, 11i) 5.19(m. l li) 5.l9(m, 11i) 
9-0H 3.25 (br, Iii) 2.97 (br. Iii) 2.92 (br, Iii) 
10. 1.66 (d, J .. 14.9 Hz, Iii) 1.66 (d, J = 15.1 Hz. Iii) 1.67 (d, J .. 15.1 Hz, Iii) 
lOb 2.06(m, Iii) H)6(m. Iii) 2.06(m, 11i) 
11 3.% (ddd, J '" 11 .2, 7.5, 2.2 Hz, Iii) 3.86 (ddd, J = 10.2. 7.1. 2.3 Hz. IH) 3.86 (ddd, J .. 9.7, 7.1 , 1.8 Hz, IIi) 
12ax 2.22 (1,) .. 12 Hz, Iii) 2.21 (I.J = 12.2 Hz. IIi) 2.21 (I, J .. 12.2 Hz, Iii) 
12~q 2.IO(m, 11i) 2.IO(m.lIi) 2.10(m, IIi) 
l'n 1.87 (br, Iii) 1.88 (br. IIi) 1.88 (br, Iii) 
14~q 3.66 (m, 11i) 3.67 (m. IIi) 3.67 (m, Iii) 
I' 4.09(ddd, J " 11 .0, 8.5, 2.5 Hz, IIi) 4.09 (ddd, J = 10.,.8.1. 1.9 Hz. 11-1) 4.08 (ddd, J " 10.2, 7.6, 1.3 HZ, IIi) 
16 5.32 (del, J " 15.7, 8.5 Hz, lli) 5.32 (deI,J = 15.6. 8.3 Hz. IIi) D2 (del, J "' 15 .6, 8.3 Hz, Iii) 
17 5.78 (d, J .. 15.6 Hz, I Ii) 5.78 (d. J = 15.6 Hz. Iii) S.78(d,J .. 16.1 Hz, Iii) 
19-0H S.lS(s, Iii) 5.16(s, IIi) S.l6(s, 11i) 
10 S.18(s, 11i) 5.19 (s, Iii) S.19 (s, Iii) 
22"" 2.06 (m, Iii) 2_06 (m. IIi) 2.06 (m, Iii) 









TIII* 2_1_ COIlIimJM 
ProIIXl No Nannl{a) Naruni (b) S~'OIbe1ic (b) 
13 4.02 (n,J = I 1.3, 2.4 Hl,Iii) 4m (n, J = 11.2. 2_3 Hz. Iii) 4.02 (n, J = 11.2, 2. 1 Hl, Iii) 
14a 1.83 (ddd, J .. B .8, 11.6, 2.9 Hl, Iii) 1.83 (ddd, J = 14.4. 115. 2_7 Hz. Iii) 1.83 (ddd, J = IH, 11.3,3.2 Hz. Iii) 
14b 1.99 (III, I Ii) 1.98 (m. Iii) 1.97(111, Iii) 
" 
5.17 (111, Iii) 5_18 (m. Iii) 5.18 (III, Iii) 
26 3.78 (III, Iii) 3_79 (m. Iii) 3.78 (III, Iii) 
" 
1.24 (d, J .. 6.4 Hz) 1_24 (d.J = 63 Hz) 1.24 (d, J = 6.8 Hz) 
27-0H 3.7S (lI.d) (o_eL) (lI.d ) 
'" 
1.00(s, 31i) 1.0 1 ('. 31i) 1.01 (s, 31i) 
" 
0.96(s, 31i) 0_95 ('. 31i) 0.95 (s, 31i) 
30 5.68 (1, J .. 1.7 Hz, Iii) 5_68 ('. Iii) 5.68 (s, Iii) 
32 US (s, 3H) 1.15 ('. 31i) 1.16(s,31i) 
33 1.01 (s, 31i) 1.01 ('. 31i) 1.01 (s, 31i) 
34 6.oo(d,J=2.0Hz,11i) 6_oo(d. J = IA Hz.11i) 6.01 (s, IH) 
37 2.08 (s, 3H) 2.()6(,. 31i) 2.06 (s, 31i) 
3. 3.73 (s, 3H) 3_7 1 (' . 31i) 3.71 (s, 3H) 
40 5.81 (d, J " !s .2 Hz, IH) HI Cd. J = 15_6 Hz. Iii) 5.80 Cd, J .. IS.! Hz, IH) 
41 7.28 (del, J .. ISA, 10.2 Hz, lli) 7_28 em. Iii) 7.28 (m, IH) 
42 6.18 (m, IH) 6_18 Cm. Iii) 6.18 (m, IH) 
43 6.17(m, lH) 6_IiCm. 11i) 6.17(m,1H) 
44 2.16(m, 2H) 2_16 (m. 21i) 2.16 (m, 2H) 
45 lA7 (sat, J .. 7A Hl, 2H) 1.47 (sat. J = 7_3 Hz. 2H) l.47 (sat, J .. 7.6 Hz, 2H) 
46 0.92 (t, J .. 7A Hz, 3H) 0_93 (t, J = 7_3 Hz. 3H) 0.93 (t, J .. 7.3 Hl, 3H) 
47 
_ """""'-1 3_67 (' . 3H) 3.67 (s, 3H) 
(I) rakeo tram Mag. Res. Chern. 1991. 29. 366-3i4. 
(b) Measw-eci WIder sGWar CDIIC~ (2 ",,12351Jl. CDC13)_ 
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Table 2.2 Comparison of 
13
C NMR Chemical Shift for Bryostatin 1 
 
 
    Carbon                   Natural
a 
              Natural
b
                 Synthetic
b 
 
        C1 172.2                   172.2             172.2 
C2 42.2 42.3   42.3 
C3 68.4 68.4 68.4 
C4 39.8 39.9 39.8 
C5 65.7 65.7 65.7 
C6 33.3 33.3 33.3 
C7 72.9 72.8 72.8 
C8 41.0 41.0 41.0 
C9 101.8 101.8 101.8 
C10 41.9 41.9 41.9 
C11 71.5 71.5 71.5 
C12 44.1 44.2 44.1 
C13 156.8 156.7 156.7 
C14 36.4 36.4 36.4 
C15 79.1 79.1 79.1 
C16 129.5 129.4 129.4 
C17 139.1 139.2 139.2 
C18 44.8 44.9 44.9 
C19 99.0 99.0 99.0 
C20 74.0 74.1 74.0 
C21 151.9 151.9 152.0 
C22  31.3 31.3  31.3 
C23 64.7 64.7 64.7 
C24 35.9 35.9 35.9 
C25 73.6 73.7 73.6 
C26 70.1 70.2 70.2 
C27 19.7 19.8 19.8 
C28 16.8 16.8 16.8 
C29 21.0 21.1 21.1 
C30 114.2 114.3 114.3 
C31 166.7 166.7 166.7 
C32 24.6 24.6 24.6 
C33 19.7 19.7 19.8 
C34 119.5 119.5 119.6 
C35 167.0 167.0 167.0 
C36 171.0 170.9 170.9 
C37 21.1 21.2 21.1 
C38 51.0 51.1 51.1 
C39 165.5 165.5 165.6 
C40 118.6 118.6 118.6 
C41 146.3 146.3 146.4 
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Table 2.2 Continued 
 
 
    Carbon                   Natural
a 
              Natural
b
                 Synthetic
b 
 
C42 128.3 128.3 128.4 
C43 145.4 145.5 145.5 
C44 35.0 35.1 35.1 
C45 21.8 21.9 21.9 
C46 13.6 13.7 13.7 






































Table 2.3 .Comparison of 
13









C47 51.1 51.1 
C38 51.1 51.1 
C32 24.6 24.6 
C37 21.2 21.2 
C29 21.1 21.1 
C33 19.8 19.8 
C27 19.7 19.8 
C28 16.8 16.8 
C46 13.7 13.7 
CH2 
C12 44.1 44.1 
C2 42.3 42.3 
C10 41.9 41.9 
C4 39.9 39.8 
C14 36.4 36.4 
C24 35.9 35.9 
C44 35.1 35.0 
C6 33.3 33.3 
C22 31.5 31.3 
C45 21.9 21.9 
CH1 
C41 146.4 146.4 
C43 145.5 145.5 
C17 139.2 139.2 
C16 129.4 129.4 
C42 128.3 128.4 
C34 119.5 119.6 
C40 118.6 118.6 
C30 114.3 114.3 
C15 79.1 79.1 
C20 74.0 74.0 
C25 73.8 73.7 
C7 72.8 72.8 
C11 71.5 71.5 
C26 70.2 70.2 
C3 68.4 68.4 
C5 65.7 65.7 
C23 64.7 64.7 
 
CH0  
C1 172.2 172.2  
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C8 41.0 41.0  
C9 101.8 101.8  
C13 156.7 156.7  
C18 44.9 44.9  
C19 99.0 99.0 
C21 151.9 152.0  
C31 166.7 166.7  
C35 167.0 167.0   
C36 170.9 170.9  
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